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Abstract 
 
Introduction 
Regular assessment of patients’ health related quality of life (HRQoL) with feedback to 
clinicians can play an important role in patient-doctor communication, problem 
detection and monitoring.  Many cancer specific HRQoL instruments are available but 
their clinical utility in routine practice has not been systematically evaluated. The aim 
was to develop a HRQoL questionnaire for patients with advanced colorectal cancer 
(CRC) for use in routine practice and to explore ways to increase its’ clinical utility. 
Methods and results 
A comprehensive development strategy was used to create CRC specific questionnaire 
for clinical practice. The strategy involved exploration of issues discussed in 
consultations of 17 CRC patients (68 consultations), review of literature, interviews with 
7 oncologists and 10 patients, validation of the questionnaire in a sample of 155 CRC 
patients and validation in 448 patients as part of a wider study. A 55 item 
questionnaire, QuEST-Cr was created. 
Exploratory work was performed to examine the longitudinal impact of patient reported 
HRQoL collection with feedback using data from 198 patients’ oncology consultations 
over 4 consecutive visits. Impact of intervention on consultation content and 
communication preferences of patients and doctors were examined. Findings highlight 
lack of discussions about psychosocial issues even when patients reported poor 
functioning. Repeated assessment helped to maintain discussions of patients’ 
symptoms over time but not psychosocial issues.  
Training oncologists was considered a way of increasing the impact of patient reported 
HRQoL intervention. Review of literature identified barriers that needed to overcome. 
Conceptual models of adult learning guided the choice of teaching methods. 
Development of trigger DVDs provided valuable experiential learning opportunity.   
Conclusion: 
I developed and evaluated an instrument for screening and identifying the needs of 
CRC patients in routine clinical practice. I developed a training programme for 
oncologists which may help increase the clinical utility of patient reported HRQoL data.   
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Chapter 1 Introduction 
 
1.1 Health Related Quality of Life 
 
The term “Quality of life (QoL)” has become a familiar phrase in everyday language as 
well as in academic literature.  Although many people will have an intuitive 
understanding of what “Quality of Life” means to them, it may take on a different 
meaning to different people, depending on the context of the term being used.  
In healthcare research, the term “Health Related Quality of Life (HRQoL)” is often used 
to distinguish between “quality of life” in its more general meaning and to focus the 
attention on how a person’s life may be affected by disease or its treatment (Fayers, 
2007).  
Cancer remains one of the most common causes of death in the UK (Cancer Research 
UK).  Although there have been significant advances in diagnostics and treatments 
available for the disease leading to improvement in survival, cancer remains an 
incurable condition for many, if diagnosed at an advanced stage of the disease. Better 
understanding of how disease and its treatment impact on patients is important 
whatever the condition but this is particularly relevant for conditions which are chronic 
or incurable and for which treatment can have significant side effects. Cancer therefore 
provides a compelling model for examining the disease and its’ impact on patients’ 
lives. 
The earliest attempts to examine the non biological aspects of cancer patients’ 
functional performance was made by Karnofsky (Karnofsky, 1949), who developed a 
clinical scale to quantify patients’ ability to perform routine self care activities and their 
level of independent living. Improvement on the Karnofsky Performance Scale rating 
was used to determine the clinical effectiveness of nitrogen mustards as a palliative 
therapy for cancer (Karnowsky et al., 1948). The functional assessment of patients was 
very much focused on their physical abilities or their health status. Very little attention 
was given by clinicians and researchers on some of the early non-clinical literature of 
surveys to evaluate happiness and psychological well-being which had been published 
by psychologists (Prutkin and Feinstein, 2002). However, in 1976, Priestman and 
Baum described the use of Linear Analogue Self Assessment (LASA) Scale in patients 
receiving treatment for breast cancer (Priestman and Baum, 1976). They used a visual 
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analogue scale on a 10 centimetre line labelled with extreme “anchors” at each end, 
where patients placed a mark which corresponded with how they felt. There were 10 
questions in the scale ranging from feelings of well-being, pain and patients’ perception 
of treatment efficacy. The sum of the marks given became an overall measure of 
quality of life. They showed that their LASA Scale could be used to monitor the 
subjective benefit of treatment and to compare the subjective toxicities of different 
treatment regimens (Priestman and Baum, 1976). This type of instrument became 
popular tool for assessing quality of life in cancer patients; however, the next two 
decades saw the growth in the development of standardised instruments to measure 
quality of life in social sciences which became more widely used by researchers in the 
field of cancer medicine (Montazeri, 2008). 
HRQoL research in cancer has expanded enormously over the last three decades, in 
association with growing concerns for the high symptom burden and unmet 
psychosocial needs of cancer patients receiving treatment (Aaronson, 1987, Cella and 
Tulsky, 1990, Fayers, 2007).  The growth of HRQoL research has been seen 
particularly in clinical trials where quality of life end points are integrated into 
assessment of cancer therapies in addition to traditional endpoints such as tumour 
response or survival.  It aims to gain better understanding of patients’ experience of 
their illness and the impact of the disease and treatment may have on their lives, which 
cannot be captured by biomedical parameters alone.  
So what is meant by Health Related Quality of Life?  There is a broad consensus that 
HRQoL is a multi-dimensional construct (The WHOQOL Group, 1998), which includes 
the three domains stated in the World Health Organization’s definition of “health” as its 
core (World Health Organization, 1946).  These are physical functioning, psychological 
functioning and social well-being. However, the definitions of QoL or HRQoL have long 
been debated and there is no single definition that has been universally accepted.  
Many authors have proposed various definitions for the term, which also includes 
domains such as patient satisfaction, general health (Schumacher et al., 1991), 
physical symptoms and treatment related side effects (Aaronson et al., 1991), sexual 
functioning and existential issues. In addition, some authors have included indirect 
consequences of disease or treatment such as unemployment or financial difficulties 
(Fayers, 2007).  
 
When considering a patient faced with treatment decisions for their cancer, QoL may 
be considered as the cost of treatment (e.g. side effects of treatment/toxicity) against 
the benefit it may bring to the patient (e.g. response to treatment and possible resultant 
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prolongation of life) (Cella and Tulsky, 1993).  When the aim of the treatment is to cure 
the disease, then the decision to face potentially toxic therapy may be relatively straight 
forward, provided that the patient is well enough to receive the treatment.  However, 
when the aim of the treatment is palliative, then the decision making process may 
become more complex.  Patients will need to consider the potential benefit of the 
treatment against the impact the treatment may have on various aspects of their lives. 
Researchers have used various HRQoL models to guide their research due to the 
multi-dimensional construct of HRQoL. A conceptual model is a schematic 
representation of a theory that acts as a practical tool to provide a better understanding 
of a phenomenon, such as HRQoL, by illustrating relationships between concepts 
(Bakas et al., 2012).  
Wilson and Cleary have proposed a conceptual model for HRQoL (Wilson and Cleary, 
1995) which integrates both the “biomedical” model of health and the “quality of life” 
model of health (Fig. 1.1).  The “biomedical” model aims to better understand the 
disease processes in order to facilitate diagnosis and management of the disease and 
the “quality of life” model places its focus on the patients’ functioning and their overall 
well-being.  Their model includes five main domains; biological, symptoms, function, 
general health perceptions and overall HRQoL. They are arranged from left to right 
according to increasing biological, social and psychological complexity.  Their model 
also encompasses the characteristics of the patient, the social context in which the 
patient lives and any non medical factors which may impact on patients’ overall quality 
of life.  
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Figure 1-1 Wilson and Cleary’s model of health-related quality of life (Wilson and Cleary, 
1995) 
 
Cella and Tulsky have proposed a model for HRQoL among cancer patients (Cella and 
Tulsky, 1993).  Their model consists of four main domains; physical, functional, 
emotional and social (Fig. 1.2).  They also specify a number of important areas which 
are not exclusively captured by the four domains listed.  These are work, sexuality, 
leisure, spirituality and family functioning.  They state that these secondary domains 
may be associated with aspects of two or more of the four main domains.  For 
example, symptoms and side effects of the disease may impact on patients’ physical 
functioning and their ability to work. 
  
Many questionnaires or instruments have been developed which aims to measure 
HRQoL.  These instruments allow patients to self report their experiences of in relation 
to their disease and associated healthcare interventions.  This in turn allow researchers 
and healthcare professionals to gain insight into how the disease process impacts on 
patients’ physical, social and emotional functioning, as well as symptoms of disease 
and treatment side effects.   
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Figure 1-2 Cella’s model of quality of life (Cella and Tulsky, 1993) 
 
There is a broad consensus that HRQoL is subjective in that it derives from the 
individual patient and that it represents patients’ experience from their own perspective 
(Bottomley, 2002).  These patient self-reported measures have come to be known as 
Patient Reported Outcomes (PROs) and instruments used to obtain PROs as Patient 
Reported Outcome Measures (PROMs) or PRO instrument.  PROs have been defined 
as “any report of the status of a patient’s health condition that comes directly from the 
patient, without interpretation of the patient’s response by a clinician or anyone else” 
(Food and Drugs Administration, 2009). PROs can, therefore, relate to symptoms, 
signs, functional status and HRQoL.  It may also include broader concepts such as 
patients’ perceptions of satisfaction and preference. 
 
1.2 Measuring HRQoL 
 
There are now many HRQoL instruments which have been developed.  These 
instruments are usually questionnaires consisting of a number of items or questions, 
often with several items grouped into domains (e.g. physical function, emotional 
function and social function).  HRQoL instruments can be categorised broadly into two 
groups; generic and specific instruments.  Generic HRQoL instruments are designed to 
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be applicable across a wide range of populations and interventions, whereas specific 
HRQoL instruments are designed to be relevant to a specific group of patients (e.g. 
patients with cancer) or to particular interventions (Patrick and Deyo, 1989).  
Generic HRQoL includes Health Profiles and Utility Measures.  Health profiles are 
instruments which attempt to measure all important aspects of HRQoL. They provide a 
range of scores representing individual domains of HRQoL, which may be useful to 
clinicians and researchers trying to measure differential impact of conditions or 
treatment on various aspects of HRQoL.  Medical Outcomes Study 36-Item Short Form 
(SF-36) Health Survey (Ware and Sherbourne, 1992) is an example of a Health Profile.  
The SF-36 consists of eight sections which forms individual subscales within the 
questionnaire.  These eight sections are vitality, physical functioning, bodily pain, 
general health perceptions, physical role functioning, emotional role functioning, social 
role functioning and mental health. It also includes an item which provides a suggestion 
of perceived change in health.  Utility Measures of HRQoL, sometimes referred to as 
preference based measures, reflects patients’ preferences for treatment process and 
outcome.  These measures often provide a single number on a continuum of perfect 
health (1) to death (0), which is referred to as health index score.  Utility based 
measures are used in pharmaco-economic research, particularly in cost utility analysis 
(Coons et al., 2000). An example of Utility Measures is EuroQol Instrument, EQ-5D 
(EuroQoL Group, 1990). EQ-5D has five dimensions which are mobility, self care, 
usual activity, pain/discomfort and Anxiety/depression. The questionnaire also consists 
of an overall assessment of the respondents’ health on a visual analogue scale.   
Specific HRQoL instruments focuses on aspects of health status that are specific to the 
area of primary interests. The instruments may be specific to the disease (such as 
cancer), to a certain function (such as emotional function) or to a problem (such as 
pain) (Guyatt et al., 1993).  The EORTC QLQ-C30 (Aaronson et al., 1993) is an 
example of a disease specific HRQoL, which has been developed to measure HRQoL 
in cancer patients.  Similar to SF-36, EORTC QLQ-C30 consists of a number of 
functional domains which are physical function, emotional function, social function, role 
function and cognitive function.  It also contains items addressing some of the common 
symptoms and side effects attributable to the underlying disease and its treatment, 
such as pain, nausea and vomiting, diarrhoea and constipation.  Disease specific 
instrument such as EORTC QLQ-C30 allows comparisons to be made across the 
cancer population.  However, it may fall short of addressing issues or symptoms which 
are specific to those with particular types of cancer (Sprangers et al., 1993).  The 
EORTC Quality of Life Group have therefore produced a number of cancer site specific 
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“modules” to complement the EORTC QLQ-C30 in order to improve relevance to 
particular type of cancer.  The EORTC QLQ-CR38 (Sprangers et al., 1999) is an 
example of a colorectal cancer site specific questionnaire which is used in conjunction 
with the EORTC QLQ-C30.  This approach of using the core questionnaire with primary 
disease site specific module can complement each other by retaining some 
generalisability across the cancer population whilst also ensuring that issues specific to 
the primary cancer site are also addressed (Sprangers et al., 1993, Bottomley and 
Aaronson, 2007). 
Many HRQoL instruments have pre-defined set of domains.  This means that domains 
which may be important for individual patient may be missing, while at the same time 
including domains that may be of less importance to that individual. Individualised 
measures have been developed which allows the individual respondent to choose the 
most important domains to be evaluated (McGee et al., 1991, Ruta et al., 1994). One of 
the commonly used individualised measures is the Schedule for Evaluation of 
Individual Quality of Life – Direct Weighting (SEIQoL-DW) (Hickey et al., 1996), an 
abbreviated form of SEIQoL (O'Boyle et al., 1992). It uses semi-structured interviews to 
collect the data.  Participants are invited to nominate five domains they consider to be 
the most important in their life.  Then the person is asked to rate how he/she is doing in 
each of the domains they have nominated on a visual analogue scale.  In the third 
stage, the person is asked for the relative importance of each area, represented by five 
differently coloured areas on a pie chart with the greatest importance assigned to the 
largest pie area on the chart. 
These instruments can be used in a number of applications; majority of these 
instruments have been developed for use in clinical trials and economic evaluations. 
However, there are some instruments which have been developed to assist healthcare 
professionals in caring for individual patients.  Selection of HRQoL instrument may be 
based on a number of criteria including psychometric properties of the instruments 
such as reliability and validity, but also more general considerations such as the 
appropriateness of the instrument for a given application (Fitzpatrick et al., 1998). 
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1.3 Use of HRQoL in cancer clinical trials 
 
Application of HRQoL assessment in cancer has been seen predominantly in the 
setting of clinical trials investigating the impact of variety of healthcare interventions, 
such as new anticancer therapies.  
Development of reliable and valid self reported HRQoL questionnaires have allowed 
assessment of HRQoL to be increasingly incorporated into cancer clinical trials over 
the last four decades.  This is reflected by growing recognition for the need to assess 
cancer treatments more broadly in addition to traditional endpoints, such as tumour 
response and survival. Measuring HRQoL can help to better understand the impact of 
various types of cancer and how the treatment may impact on patients’ lives. HRQoL 
endpoints are particularly important when the intervention being investigated is 
palliative therapy for incurable cancer.  In these situations, quality of survival may be 
just as important as the duration of survival (Joly et al., 2007). Assessment of HRQoL 
is now considered very much an integral part of the cancer clinical trial protocol. 
Clinical trial organizations such as EORTC and National Cancer Institute, all have 
designated quality of life working group, facilitating the integration of HRQoL 
assessments in clinical trials (Bottomley et al., 2005). 
The HRQoL data derived from clinical trials or population based studies may be utilized 
in a number of ways.  It may allow better understanding of the characteristics of the 
patient population of interest and enable comparisons to be made between different 
groups of patients (Osoba et al., 2005).  Longitudinal assessment of HRQoL may 
provide how the intervention being investigated impacts on patients over time and 
provide insight into the patients’ experiences. Many investigators are now utilising 
modular approach in measuring HRQoL (Aaronson et al., 1988, Sprangers et al., 1998, 
Brady et al., 1997).  Several instruments have been developed specifically for a 
particular disease group, thus allowing more detailed assessment of the impact of a 
given intervention in a defined group of patients. 
HRQoL data from clinical trials may also have an impact on clinical decision making.  If 
there are different treatment options with similar efficacies, HRQoL data may help 
patients and oncologists choose the treatment which may have less detrimental impact 
on patients’ functioning and symptoms (Osoba, 1999).  HRQoL information may also 
assist involving patients in their decision making when there are trade-offs between 
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treatment efficacy and toxicities. It may also improve detection of impaired 
psychosocial functioning among patients (Lipscomb et al., 2005). 
HRQoL measures, in conjunction with patients’ clinical data, have also been shown to 
be prognostic indicator for survival in a number of studies (Gotay et al., 2008, Quinten 
et al., 2009, Montazeri, 2009). As HRQoL assessment includes multiple dimensions of 
patients’ physical, psychological and social functioning, they may provide more 
sensitive information over clinical parameters such as performance status. 
HRQoL data derived from clinical trials also play an important component of health 
technology assessment (European Medicines Agency, 2012).  For example, The 
National Institute for Health and Care Excellence (NICE) provides guidance to the NHS 
in England on the clinical and cost effectiveness of new and well established health 
technologies.  In the assessment of the cost effectiveness, HRQoL plays critical role in 
determining the Quality Adjusted Life Years (QALYs) of a medical intervention 
(National Institute for Health and Care Excellence, 2014), which can influence whether 
the intervention may be recommended and subsequently adopted as standard practice 
within the NHS. 
 
1.4 Use of HRQoL in routine clinical practice 
 
Increase in the integration of HRQoL assessments within cancer clinical trials has been 
associated with the greater appreciation for the importance of assessing the impact of 
cancer and its’ treatments on the physical, psychological and social functioning of the 
individual patient.  There is growing recognition that routine measurement of HRQoL in 
oncology practice has the potential to improve cancer care planning, monitoring and 
management of cancer patients (Donaldson, 2004). Routine assessment of patients’ 
HRQoL may increase healthcare professionals’ awareness of the issues which are 
important to their patients and facilitate delivery of a more patient-centred care, tailored 
to the needs of the individual patient (Boyes et al., 2006).  Measuring individual 
patient’s HRQoL routinely may allow patients to express their own experiences of their 
illness (Feldman-Stewart and Brundage, 2009), promote their involvement in medical 
decision making and enhance communication between patients and healthcare 
professionals (Greenhalgh and Meadows, 1999).  Regular assessment of patients’ 
health status may also help to identify adverse effects of cancer and its’ therapy 
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(Higginson and Carr, 2001) and help monitor effects of treatment response or disease 
progression and inform decisions about treatment plans (Lipscomb et al., 2007). 
 
1.4.1 Evidence for use of HRQoL in routine clinical practice 
 
Use and efficacy of patient reported outcomes in routine clinical practice have been 
explored in four reviews (Greenhalgh and Meadows, 1999, Espallargues et al., 2000, 
Marshall et al., 2006, Valderas et al., 2008) conducted between 1999 and 2008.  
Between these reviews, 13 to 35 randomised controlled trials were identified evaluating 
the use of patient reported outcome interventions in a wide variety of clinical settings, 
with majority of the studies conducted in primary care.  There was a trend, however, 
with more recent studies being conducted within the setting of specialist services, 
including cancer (Marshall et al., 2006). 
 
Greenhalgh et al (Greenhalgh and Meadows, 1999) found evidence that most clinicians 
had positive attitudes about feasibility and utility of patient reported health assessment 
in routine clinical practice. Clinicians found the information derived from the measures 
useful in making an overall assessment of the patient and having a positive impact on 
patient-doctor relationship.  There was a suggestion that patient reported measures 
improved detection of psychological issues although this did not necessarily translate 
into change in treatment or increased referral to other allied services.  Similar findings 
about increased detection of psychological problems were also observed by other 
reviewers (Espallargues et al., 2000, Marshall et al., 2006).  Most of the studies 
reviewed demonstrated effect of the patient reported outcome intervention on at least 
one aspect of the process of care when these were measured, such as patient 
education and counselling and increased detection of patient issues (Valderas et al., 
2008).  However, the impact of the interventions on more distal outcomes such as 
patients’ health status and satisfaction with care were less convincing.   
 
All of the reviews made remarks on the diversity of the interventions used in the studies 
identified; the clinical setting, instruments used, frequency of administration, unit of 
randomisation, mode of feedback to the healthcare professionals and the outcome 
measures of the studies.  This heterogeneity or lack of comparability across the studies 
has limited the likelihood of performing formal quantitative meta-analyses in order to 
evaluate the impact of patient reported outcome intervention within routine clinical 
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practice.  The reviews highlight the need for further research before patient reported 
outcome intervention is recommended for routine clinical practice.  In particular, they 
emphasize the importance of building theoretical knowledge base regarding the impact 
of the intervention on patient outcomes and addressing any barriers to implementing 
patient reported measures in routine clinical practice.    
 
1.4.2 Evidence for HRQoL in routine oncology practice 
 
Marshall et all (Marshall et al., 2006) identified 4 randomised controlled studies 
specifically in the oncology setting (Trowbridge et al., 1997, McLachlan et al., 2001, 
Detmar et al., 2002, Velikova et al., 2004).  Study by Trowbridge et al (Trowbridge et 
al., 1997) recruited patients with advanced or recurrent cancer from various primary 
sites including patients with haematological malignancies.  Their study specifically 
focused on a single symptom of pain.  Patients were asked to complete measures 
which described their experience of pain in the preceding 7 days, together with their 
satisfaction of their medication and the degree to which they provided pain relief.  
Patients whose doctors received the feedback of the questionnaire findings reported a 
lower incidence of pain at 4 week follow up.  In addition, they found different 
prescribing patterns for analgesia between the two groups, with doctors more likely to 
make changes to patients’ medications for patients in the intervention group.  No 
analysis was performed to investigate the relationship between changes in the 
prescribing patterns and pain relief to provide an indication of likely causality.    
 
McLachlan et al (McLachlan et al., 2001) evaluated self reported cancer needs, HRQoL 
and psychosocial information to screen for psychological distress in patients with 
different types of cancers.  The measures were collected on touch screen computers 
and the results of the patient reported measures were fed back in real time so that the 
results were made available to the doctor during the consultation for those patients 
randomised to the intervention arm.  Study utilized a designated care coordination 
nurse who was present during these consultations, who formulated an individualised 
management plan based on the issues raised in the patient reported measures. They 
found no significant differences between the two arms with respect to changes in 
cancer needs, HRQoL, or psychosocial functioning between baseline and follow up 
assessments, nor with respect to patients’ satisfaction with care.  However, for a 
subgroup of patients reporting moderate to severe emotional distress at baseline, there 
was a significant reduction in depression for the patients in the intervention group at 6 
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months follow up.  They made no comment on the evidence linking screening for 
psychological issues and changes in the referral to allied services or management.   
 
Detmar et al (Detmar et al., 2002) conducted a longitudinal study among patients 
receiving palliative chemotherapy treatment.  Patients were asked to complete a 
standardised HRQoL instrument, EORTC QLQ-C30 immediately before the 
consultation with their doctor with results being made available for the consultation.  
The unit of randomisation was the doctors in this study which used a cross over design 
thus doctors provided their own controls.  They found significant improvement in 
doctor-patient communication for those patients whose HRQoL questionnaire results 
were fed back to their oncologists with increased discussions of issues not commonly 
discussed, such as social functioning and fatigue.  There was evidence for the 
intervention having an impact on patient satisfaction but this was limited to perceptions 
of increased emotional support from their doctors. They acknowledged that the cross 
over design may have carried with it the risk of contamination effect with doctors who 
began in the experimental condition and subsequently crossed over to the control 
condition having been made more aware of patients’ HRQoL issues.   
 
Velikova et al (Velikova et al., 2004) also conducted a longitudinal study in oncology 
out-patients receiving treatment for their underlying cancer.  They aimed to examine 
the effects of regular HRQoL assessment, using standardised HRQoL measures with 
EORTC QLQ-C30 and HADS, on patient-doctor communication and patient well-being.  
As well as intervention and standard care arms, Velikova et al included an attention 
control arm in which patients completed the HRQoL measures but the results were not 
fed back to the doctors. The study found positive impact on patient-doctor 
communication and patient well-being for the patients in the intervention group.  The 
study also indicated regular completion of HRQoL measures alone without feedback to 
the doctors may have a positive impact on patient well-being.  The authors also 
acknowledged the possible contamination effect as the patients were the unit of 
randomisation and the same doctors saw patients from each of the study arms and 
doctors’ practices may have been influenced by the exposure to the patient reported 
outcome intervention during the study. 
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1.4.3 From research to clinical practice 
 
The above reviews of patient reported outcomes of HRQoL in routine clinical practice 
have highlighted that, whilst there has been some beneficial impact of patient reported 
outcomes on the processes of patient care, the anticipated benefits of the intervention 
on patient outcomes is yet to be realised.  
 
Although the concept of measuring HRQoL in order to improve the care and 
management of individual patients seem a logical progression from measuring HRQoL 
in clinical trials to gain better understanding of the impact of disease and treatment on 
patients at a group level, there are a number of significant differences between these 
two contexts as well as the HRQoL measures serving different functions within them. 
Some of the key differences are outlined in Table 1.1. 
 
Table 1.1 Different utility of HRQoL: Clinical research vs Clinical practice 
 Research setting Clinical practice 
Objectives Characterisation of patient groups Characterisation of individual 
patients 
Screening for patient problems 
Treatment decision guidance 
Status of HRQoL 
instruments used 
The descriptive capabilities (validity, 
reliability, responsiveness) of 
HRQoL measures are well 
established 
The definitive impact of HRQoL 
data fed back to clinicians on 
patient outcomes has not yet 
been demonstrated consistently 
Context Defined within the clinical trial 
protocols 
Routine patient care 
Target population Sampled/randomised/matched 
groups from the target population as 
appropriate to the study hypotheses 
and required power of the study 
Unselected population within the 
care system 
HRQoL instruments  Focused set of instruments 
determined by the trial protocol 
Determined by aim of intervention 
Instruments relevant to each 
individual patient’s clinical 
condition 
Frequency of 
HRQoL 
measurement 
Defined by the trial protocol Dependent on the aim of 
intervention: 
Single collection or longitudinal 
Analysis strategies Data collected and analysed at 
defined time-points within the study 
Real-time output needed for 
integration into clinical practice 
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1.4.4 HRQoL instruments for clinical practice 
 
HRQoL measures in the research setting perform a descriptive function of 
characterising a defined patient group.  The descriptive capabilities (e.g. validity and 
reliability) of the HRQoL instruments used in this setting have been rigorously tested.  
The instruments are administered in a highly controlled manner for a defined group of 
patients in order to answer a specific research question. 
 
HRQoL assessment within a routine clinical practice aims to characterise the 
experience of an individual patient and ultimately expect the process to change the 
behaviour of the patient and the healthcare professional.  Many of the studies which 
have utilized patient reported measures have used the intervention to screen for any 
problems patients may be experiencing so that these issues are brought to the 
attention of the healthcare professionals, in the anticipation that this would lead to 
change in the management of the patients to address these issues. 
 
There are several important considerations when choosing HRQoL instruments for 
clinical practice in terms of what kind of instruments should be used and what should 
be done to validate these tools further for use within the clinical practice (Arnould, 
2006).  Questionnaires which have been developed with the aim of making 
comparisons between different groups of patients within research setting may not 
necessarily be suitable for assessing patients on an individual basis (McHorney and 
Tarlov, 1995).   
 
There are a number of characteristics that instruments for clinical practice need to 
have. It has to be of acceptable length for the patients to complete in routine clinical 
practice to reduce patient burden (Kirkova et al., 2006, Snyder et al., 2012).  The 
instrument needs to be easy to use for the healthcare professionals. The scoring of the 
instruments need to be quick so that the results are readily available after patient has 
completed the questionnaire, unless technology for real time calculation of scores are 
available.  The instrument needs to ask relevant questions for the clinical practice and 
support a judgment or trigger an action.  It needs to address important issues for the 
patient, issues that patients would want assistance from the healthcare professionals 
and issues that healthcare professionals feel that they are able to offer their patients 
some help (Snyder et al., 2007).  The instrument needs to meet the specification for 
use in routine practice (Feinstein, 1992) and may require items based on clinical 
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judgment or relevant to the context, not necessarily in accordance with psychometric 
theory (Feinstein, 1983).  
 
Velikova et al conducted a focus group study in order to explore both patients and 
oncologists’ views on the use and content of HRQoL questionnaire for routine oncology 
practice (Velikova et al., 2007a). They identified four key themes which were 
considered important to be included in the HRQoL instruments for use in clinical 
practice by the patients and oncologists.  These were “common symptoms and 
problems”, “disease site specific issues”, “treatment specific issues” and “individual 
patient-specific issues”. This study suggested that questionnaires for use in clinical 
practice needed to contain items which addressed disease site specific issues as well 
as those issues which may be common across all tumour sites.  This is very similar to 
the approach already taken by the EORTC and FACT questionnaires, with a core set of 
items across all tumour sites with disease/condition specific modules. This study also 
suggested that a prompt list of issues may help patients to report any problems or 
concerns that they specifically wished to discuss, thus tailoring the instrument for 
individual patients.  
 
In summary, instruments for clinical practice need to serve different functions 
compared to clinical research.  New instruments may be necessary to meet the needs 
of clinical practice utility.  Within the oncology practice, the HRQoL assessment may be 
expected to serve a number of different functions/purpose.  First is to monitor common 
cancer and treatment related symptoms with patients’ self report providing consistent 
measurement over time. This may help to provide evidence of treatment response or 
disease progression and facilitate clinical decision making regarding treatment.  The 
second function is to screen or highlight any issues which may not be routinely 
addressed during consultations but are important and relevant to the patients, such as 
emotional distress, family/social issues and sexual functioning (Taylor et al., 2011, 
Anderson et al., 2008, Stead et al., 2003). 
   
1.4.5 Conceptual framework for HRQoL assessment in routine clinical 
practice 
 
Patient reported HRQoL information aims to convey their symptoms and functioning to 
the healthcare professionals in order to serve the functions as described above.  It can 
therefore be considered a method of communication between patients and clinicians. 
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Indeed, there is evidence to suggest that provision of patient reported HRQoL 
information to healthcare professionals can have an impact on patient–doctor 
communication (Greenhalgh and Meadows, 1999).  However, the mechanism by which 
this impact on communication leads to possible changes in patient outcomes is a 
complex staged process as illustrated below (Greenhalgh et al., 2005).  
 
 
Provision of information of health status measures to clinicians 
 
Changes to doctor-patient 
communication 
The provision of HRQoL information to clinicians will prompt them 
to discuss HRQoL issues with their patients. In doing so, the 
patient and clinician will come to develop a shared view of the 
goals of treatment. 
 
Monitor treatment 
response/detect 
unrecognised problems 
HRQoL information will enable clinicians to detect unrecognised 
problems and/or monitor the impact of treatment through the 
HRQoL measures alone or through further discussions prompted 
by the HRQoL data. 
 
Changes to clinicians 
management of patients 
On detecting a problem or a decrease in HRQoL in response to 
treatment, the clinician will intervene in some way to address this.  
(E.g. changes to treatment, referrals to other services, ordering 
further investigations or the provision of advice on how the patient 
might manage their problems). 
 
Changes to patient health 
behaviour 
The very act of monitoring responses to treatment, or through 
discussing the problem with their clinician or actual treatment 
changes (for example, to address side effects) may result from or 
lead to changes in patient behaviour 
 
Improved patient 
satisfaction/improved 
health outcomes 
Provision of HRQoL information may lead to improvements in the 
patient’s health status or satisfaction with their care 
 
Figure 1-3 Greenhalgh’s description of the possible impact of HRQOL assessment in 
clinical practice (Greenhalgh et al., 2005) 
 
19 
 
1.4.6 Barriers to implementation of HRQoL assessments in routine clinical 
practice 
 
Integration of HRQoL assessment in routine clinical practice has been slow compared 
to its adoption in clinical research.  Beyond the challenges of identifying the most 
appropriate instrument for use in routine clinical practice, a number of potential barriers 
have been proposed which may explain the relatively slow uptake of HRQoL 
assessment in this setting.  These have been broadly categorised into three groups;   
1) Healthcare professional/provider issues, 2) Healthcare delivery and organizational 
issues and 3) patient related issues (Deyo and Carter, 1992, Davis and Cella, 2002, 
McHorney and Earl Bricker, 2002).  
 
1.4.6.1 Healthcare professional issues 
 
Healthcare professionals’ endorsement for HRQoL assessment in routine clinical 
practice is essential for this intervention to be adopted into routine clinical practice 
(Davis and Cella, 2002).  Healthcare professionals’ lack of familiarity or experience with 
HRQoL assessments is considered to be one of the most important barriers for routine 
assessment of HRQoL (Morris et al., 1998a, Bezjak et al., 2001).  There is 
considerable discrepancy between clinicians’ perceptions of “usefulness” for routine 
HRQoL assessment and the reality of this assessment actually taking place within their 
practice (Taylor et al., 1996, Morris et al., 1998a, Bezjak et al., 2001).  
 
Healthcare professionals are unlikely to have received any formal training in the use 
and interpretation of HRQoL instruments (Donaldson, 2004), therefore they may find it 
difficult to choose the most appropriate instrument, when these should be administered 
and how often and at what stage in the patients’ disease trajectory such intervention 
would be most valuable.  In addition, unlike laboratory or radiological investigations 
results, they may find it difficult to interpret the HRQoL information and use the 
information to influence patient management (Sutherland and Till, 1993, Giesler, 2000).   
 
Another possible barrier is the healthcare professionals’ perception that assessment of 
patients’ HRQoL may unearth multiple problems to which the clinicians may not have 
effective solutions for.  This may result in longer consultations in an already busy 
practice.   
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Many of the studies investigating the use of HRQoL assessment in routine oncology 
practice have focused on oncologists as the recipient of the HRQoL information from 
patients.  However, clinical nurse specialists play an important role in supporting 
patients from diagnosis and through their treatment course and beyond (Taenzer et al., 
2000).  It may be that HRQoL information being made available to wider team 
members may be helpful in delivering the necessary care for the patients.  
 
1.4.6.2 Healthcare delivery and organizational issue 
 
Routine data collection from patients requires commitment of significant resources, if 
the infrastructure for conducting such intervention is not already present.  Unless the 
instrument is very short and easy to calculate the scores, it is likely that some form of 
technology will be necessary to assist with data collection and prompt scoring of the 
results so that it can be integrated into the normal work flow within the clinic.  This is 
likely to require a member of staff to assist patients in completing the questionnaire, 
answer any queries and trouble shoot any technical issues.  Such person may not be 
readily available.  There also needs to be a mechanism whereby the HRQoL 
information from patients are stored securely and potentially be made available to other 
members of the clinical team to view.  This will require robust mechanisms to ensure 
the patient reported information is linked with their case notes. 
 
Consideration also needs to extend to the likely impact of the implementation of routine 
HRQoL assessment on the allied health services, such as referral to the palliative care 
team for symptom management, psychological intervention for emotional distress and 
other resources within the community which patients may need to access (Donaldson, 
2004). 
 
1.4.6.3 Patient related issues 
 
Just as the patient reported outcome measure intervention needs to be acceptable for 
the healthcare professionals, it also needs to be acceptable to the patients and that 
they feel the intervention has some utility and relevance in their care (Donaldson, 
2004). Patient burden is a real concern for those with cancer diagnosis as some 
patients may be very ill and may not be able to complete a long questionnaire regularly.   
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Feasibility studies have shown that patients are willing and able to use a number of 
different devices for data input such as touch screen computers (Buxton et al., 1998, 
Goldman, 2000).  New measurement approaches such as computer adaptive testing 
may help to make the data collection more efficient and precise and reduce burden for 
patients (Hays et al., 2000). 
 
 
1.5 Training for healthcare professionals 
 
Training healthcare professionals in the use of patient reported HRQoL measures have 
been suggested as one of the ways of overcoming the barriers concerning healthcare 
professional related issues as described above (Greenhalgh, 2009, Luckett et al., 
2009).  In the two randomised controlled studies within oncology setting (Detmar et al., 
2002, Velikova et al., 2004), where training to the clinicians was provided, this was 
mainly on the explanation of the instruments used in the intervention and how they 
were scored. How the patient reported data was used, if at all, in the management of 
the patients was left to the clinicians’ discretion.   
 
For the routine assessment of patients’ HRQoL to become more widely adopted, the 
training of clinicians should not only focus on the instruments to be used but also on 
the potential benefits of the intervention in the management of their patients (Luckett et 
al., 2009).  The training would also provide opportunities to address clinicians’ 
concerns that HRQoL assessments may have a significant impact on the consultation 
length and their worries that it may highlight issues which they are not able to manage 
themselves.  There are a number of studies demonstrating that provision of patients’ 
HRQoL data in clinic consultation do not lengthen consultations where this has been 
measured objectively (McLachlan et al., 2001, Detmar et al., 2002, Velikova et al., 
2004). Moreover, there is suggestion that use of HRQoL information may make the 
consultations for effective and efficient (Newell et al., 1997, Velikova et al., 1999) by 
allowing the clinician to prioritise their discussions according to the patient reported 
information.  Training should therefore emphasize on the time efficiency as one of the 
goals of the intervention (Luckett et al., 2009).  In order for the clinicians to promptly 
manage issues reported by their patients, there needs to be a provision of guidelines 
and referral pathways so that patients may be given the necessary sign-posting 
(Rubenstein et al., Rosenbloom et al., 2007). Such guidelines should also be included 
as part of the training for the clinicians.  The training should also highlight the evidence 
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for the reliability of the data generated by HRQoL assessment compared with other 
clinical measures (Hahn et al., 2007). The patient reported data may also help to 
augment the deficiency in the clinicians’ awareness of their patients experience of 
cancer and its’ treatment. 
 
1.6 Summary 
 
There are now many validated HRQoL instruments available, which have facilitated 
HRQoL assessments to be routinely incorporated in clinical trials in cancer.  HRQoL 
assessments in routine clinical practice may be useful to facilitate communication 
between doctors and patients and help monitor individual patients symptoms and side 
effects.  This may lead to improvement in patient care by allowing detection of 
problems which may not otherwise be realised, leading to improved outcomes for 
patients and their satisfaction with their care.  However, evidence for the more distal 
outcomes of routine HRQoL assessment is still limited.    
A number of barriers to implementing HRQoL assessments in routine clinical practice 
have been highlighted.  One of these barriers is the potential lack of suitable 
instruments for this purpose.  Existing instruments which have been developed for 
clinical trials may not be wholly suitable for use in clinical practice as they have not 
been developed with this use in mind.  Instruments may need to be developed or 
adapted so that they are more suitable to be used in clinical practice for the 
assessment of individual patient. In addition, the instrument needs to be relevant to the 
clinical practice and address issues which are specific to the disease and treatment in 
order to increase the clinical utility.   
Another key area for implementing routine assessment of HRQoL is the need for 
training for the clinicians in how to use the patient reported HRQoL information during 
their consultations with their patients and to highlight the potential benefits of using this 
information so that assessment of patients’ HRQoL can become integral to routine 
clinical practice. 
With my background in Medical Oncology, I felt I was well placed to focus my thesis on 
issues of clinician training and to develop a training programme for clinicians to 
facilitate the integration of routine HRQoL assessment in oncology practice.  
In order to address the issues of using the most suitable measures for HRQoL 
assessment in clinical practice I have chosen to work in colorectal cancer (CRC), as it 
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is one of the most common cancers diagnosed in the UK, affecting both men and 
women, with recent expansion in systemic treatments, causing high symptom burden 
and psychological impact.  Selecting one cancer type would allow me to explore 
relevant issues that affect this particular group of patients. 
 
1.7 Colorectal Cancer 
 
1.7.1 Incidence 
 
Colorectal cancer is the fourth most common cancer diagnosed in the UK, accounting 
for 13% of all new cancer diagnosis.  It is the third most common cancer in both men 
(after prostate and lung cancers) and women (after breast and lung cancers) 
separately (Cancer Research UK). 
In 2011, there were 41,581 new cases of colorectal cancer in the UK; 23,171 (56%) in 
men and 18,410 (44%) in women (Cancer Research UK).  Colorectal cancer is a 
disease of older age with approximately 43% colorectal cancer cases diagnosed in 
patients over the age of 75 years and over, and 95% of all cases were diagnosed in 
those aged 50 years and over. Incidence rates are significantly higher for men than in 
women in adults aged 45 years and over. 
 
1.7.2 Mortality 
 
Colorectal cancer is the second most common cause of death in the UK, accounting for 
10% of all deaths from cancer.  There were 16,187 deaths from colorectal cancer in UK 
in 2012 (Cancer Research UK). 
Like many cancers, survival for colorectal cancer is dependent on the stage of disease 
at diagnosis; those presenting at stage I having the best chance of survival.  Patients 
with stage IV disease or those with metastatic disease are incurable in majority of 
cases, with 5 year survival of 7%.  There has, however, been a significant improvement 
in survival for patients with colorectal cancer over the last 40 years.  One year age-
standardised net survival for colorectal cancer has increased from 46% during 1971-
1972 to 76% during 2010-2011 in England and Wales.  This is likely due to advances in 
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surgical techniques, improvements in pre-operative radiological investigations and 
improvements in both adjuvant and palliative chemotherapy. 
 
1.7.3 Diagnosis of colorectal cancer 
 
Diagnosis of colorectal cancer is usually made on direct visualisation of the tumour by 
endoscopic (colonoscopy) examination, unless there are contraindications for 
performing this investigation.  Biopsy is then taken during the endoscopic examination 
in order to make a definitive histological diagnosis.  CT colonography may be used in 
centres where this is available or barium enema instead of colonoscopy.  However, if a 
suspicious lesion is detected on these radiological investigations colonoscopy and 
biopsy are usually performed, unless there are any contraindications (National Institute 
for Health and Care Excellence, 2011). 
 
1.7.4 Staging of colorectal cancer 
 
Staging of cancer is important as it helps to predict survival.  Staging also allows 
comparison of outcome in clinical trials and helps determine the most appropriate 
treatment for patients.  Patients will usually undergo a contrast enhanced computed 
tomography (CT) of chest, abdomen and pelvis to determine the extent of the disease.  
Patients with rectal cancer will also undergo magnetic resonance imaging (MRI) of 
pelvis in order to assess their risk of local recurrence, as determined by anticipated 
resection margin, tumour and lymph node staging, unless this investigations is 
contraindicated.  For patients who are unable to have MRI, endo-rectal ultrasound may 
be offered in order to obtain the necessary information (National Institute for Health and 
Care Excellence, 2011). 
Tumour (T), Node (N), Metastasis (M) staging classification is used in colorectal cancer 
staging.  T stage describes the extent of the primary tumour, N stage describes the 
involvement of loco-regional lymph nodes and M stage describes whether there is 
evidence of distant metastatic spread. Another staging classification commonly used by 
the doctors is the Dukes’ staging (Dukes, 1932). Since the Dukes’ staging has been 
proposed in 1932, it has undergone a number of modifications (Astler and Coller, 1954, 
Gabriel et al., 1935, Turnbull et al., 1967) as has the TNM staging, which is currently 7th 
edition (Edge, 2010).  There are four stages in Dukes’ classification; A, B, C and D.  In 
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simplistic terms, Dukes’ stage A means that the cancer is confined in the mucosa, 
Dukes’ B means that the cancer has invaded the muscularis propria but no loco-
regional lymph nodes are involved, Dukes’ C means that the cancer has invaded the 
muscularis propria and loco-regional lymph nodes are involved and Dukes’ D means 
that the cancer has spread to other part of the body such as liver.  
 
1.7.5 Treatment 
 
1.7.5.1 Management of local disease 
 
Primary surgical therapy for colon cancer 
 
Standard therapy for patients with localised colon cancer has been open surgical 
resection of the primary and regional lymph nodes.  However, laparoscopic surgery or 
laparoscopic assisted surgery is increasingly used which has been shown to be as 
effective as open surgery in a selected group of patients.  (Clinical Outcomes of 
Surgical Therapy Study Group, 2004, Weeks et al., 2002) .   
Primary surgical therapy for rectal cancer 
 
The management of rectal cancer differs slightly from that of colon cancer due to the 
increased risk of local recurrence and a poorer overall prognosis.  Differences include 
the surgical technique, and use of preoperative radiotherapy or chemo-radiotherapy 
(Berho et al., 2015, Sauer et al., 2012, Roh et al., 2009), depending on the risks for 
local recurrence as determined by the findings of staging MRI pelvis.  There is also 
important consideration regarding therapeutic issues related to the maintenance or 
restoration of normal sphincter, genitourinary and sexual functions (Balch et al., 2006, 
Baxter and Garcia-Aguilar, 2007). The management of rectal cancer requires a 
multidisciplinary team approach in order to ensure best possible outcome for the 
patients (Berho et al., 2015). 
The primary treatment for patients with localised rectal cancer is surgical resection of 
the tumour.  The surgical approach used may vary according to the location of the 
tumour, stage of the disease, presence or absence of high risk features (positive 
margins, lymphovascular invasion and poorly differentiated histology). Types of 
surgical resection include polypectomy, transanal local excision, total mesorectal 
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excision with autonomic nerve preservation via low-anterior resection or total 
mesorectal excision via abdomino-perineal resection for patients who are not 
candidates for sphincter preservation, leaving patients with a permanent end-colostomy 
(Guillem and Cohen, 1999, Balch et al., 2006, Baxter and Garcia-Aguilar, 2007). 
 
1.7.5.2 Adjuvant chemotherapy 
 
Patients who have undergone potentially curative resection of their colon cancer may 
be offered adjuvant chemotherapy, aimed at reducing the risk of recurrence.  Prior to 
2000, 5-Fluorouracil was the only cytotoxic chemotherapy available in the adjuvant 
setting.  There is evidence to suggest that patients with stage III colon cancer are the 
group of patients most likely to derive benefit from adjuvant chemotherapy (Laurie et 
al., 1989, Moertel et al., 1990, Wolmark et al., 1993, International Multicentre Pooled 
Analysis of Colon Cancer Trials (IMPACT) investigators, 1995). Subgroups of patients 
with stage II colon cancer may be at higher risk for recurrence (e.g. those with tumour 
adherence to neighbouring structures, perforation and obstruction) (Merkel et al., 
2001), however, evidence for 5-Fluorouracil based adjuvant chemotherapy leading to 
improved overall survival for patients with stage II colon cancer is inconsistent (Moertel 
et al., 1995). 
Capecitabine is an oral fluoropyrimidine that undergoes multiple enzymatic conversions 
to 5-Fluorouracil. Adjuvant Capecitabine provides equivalent outcome to intravenous   
5-Fluorouracil and folinic acid (Twelves et al., 2005).  More recently, addition of 
Oxaliplatin to the 5-Fluorouracil based chemotherapy regimen in the adjuvant setting 
has lead to improvement in the overall survival of patients with stage III colon cancer 
(Andre et al., 2004, Andre et al., 2009) and has now become the standard adjuvant 
chemotherapy regimen for many. 
Unlike colon cancer, role of adjuvant chemotherapy with 5-Fluorouracil based 
chemotherapy in patients with rectal cancer is less well defined and more research is 
needed to identify patient group that may derive benefit from adjuvant chemotherapy 
(Petersen et al., 2012). 
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1.7.5.3 Treatment of metastatic or recurrent colorectal cancer 
 
Surgical resection of local recurrence for both colon and rectal carcinoma may be 
feasible.  In cases of rectal cancer, local recurrence alone after initial attempted 
curative resection, aggressive local therapy may lead to long term disease free survival 
(Ogunbiyi et al., 1997, Vermaas et al., 2007).  Use of primary chemo-radiotherapy for 
previously non-irradiated rectal cancer patients with locally advanced pelvic recurrence 
may increase respectability and allow preservation of sphincter function (Lowy et al., 
1996).  
Patients with limited liver and pulmonary metastasis may be considered for surgical 
resection in highly selected patients (Coppa et al., 1985, Gayowski et al., 1994, Jaeck 
et al., 1997, Girard et al., 1996, Headrick et al., 2001). However, in majority of cases, 
patients with metastatic colorectal cancer are treated with palliative chemotherapy with 
the aim of reducing the volume of disease, alleviating some of the cancer related 
symptoms and prolong survival.  
 
1.7.5.4 Chemotherapy drugs for the treatment of metastatic colorectal cancer 
 
For many years, 5-Fluorouracil was the only active chemotherapy drug in the treatment 
of colorectal cancer.  Studies have shown response to treatment and prolongation of 
the time to progression (TTP) of disease (Petrelli et al., 1989), as well as improved 
survival and quality of life for patients receiving chemotherapy compared with best 
supportive care (Scheithauer et al., 1993, Nordic Gastrointestinal Tumor Adjuvant 
Therapy Group, 1992, Buyse et al., 2000).  Several trials have explored various 
regimens using different doses and schedules of 5-Fluorouracil.  They have shown 
similar results in terms of median survival of the order of 12 months (Leichman et al., 
1995). 
As previously discussed, Capecitabine is an oral fluoropyrimidine drug which 
undergoes a number of conversions to become 5-Fluorouracil. Prior to the advent of 
multi-agent chemotherapy, two randomised controlled studies demonstrated equivalent 
efficacy between Capecitabine and 5-Fluorouracil given in a regimen called Mayo 
Clinic regimen (Van Cutsem et al., 2001, Hoff et al., 2001). 
In addition to 5-Fluorouracil and Capecitabine, there are now two additional 
chemotherapy drugs available for the treatment of advanced colorectal cancer.  These 
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are Irinotecan and Oxaliplatin.  Randomised controlled studies in patients with 
advanced colorectal cancer have demonstrated improved response rates, 
progressions-free survival (PFS) and overall survival (OS) when Irinotecan or 
Oxaliplatin was combined with 5-Fluorouracil and folinic acid. (Saltz et al., 2000, de 
Gramont et al., 2000, Douillard et al., 2000, Braun et al., 2003).  Two studies compared 
infusional 5-Fluorouracil regimens in combination with either Irinotecan or Oxaliplatin 
(Tournigand et al., 2004, Colucci et al., 2005).  In both of these studies, patients were 
allowed to cross over upon progression of first line therapy. These trials showed no 
difference in the progression free survival and overall survival between the treatment 
arms.   
Randomised studies have addressed the equivalence of substituting Capecitabine for 
infusional 5-Fluorouracil in combination with Oxaliplatin (Diaz-Rubio et al., 2007, 
Porschen et al., 2007).  These studies have shown similar progression free survival 
between the two regimens.  The Bolus, Infusional, or Capecitabine with Camptosar-
Celecoxib (BICC-C) trial evaluated several different Irinotecan-based regimens in 
patients with advanced colorectal cancer in the first line treatment setting (Fuchs et al., 
2007).  Patients who received Irinotecan with infusional 5-Fluorouracil had better 
progression free survival compared to those who received Irinotecan with bolus 5-
Fluorouracil or Irinotecan with Capecitabine.  Patients who received Irinotecan with 
Capecitabine had the highest rates of toxicities (Fuchs et al., 2007). 
Therefore, chemotherapy with 5-Fluorouracil based chemotherapy in combination with 
either Irinotecan or Oxaliplatin may be considered valid first line chemotherapy 
regimens for patients with advanced colorectal cancer, who are fit enough to have 
combination chemotherapy. 5-Fluorouracil may be substituted by Capecitabine for 
combination with Oxaliplatin but infusional 5-Fluorouracil is preferred when combined 
with Irinotecan. Patients may be offered Irinotecan based chemotherapy as second line 
treatment after Oxaliplatin based chemotherapy and vice versa.  
Infusional 5-Fluorouracil with folinic acid or Capecitabine chemotherapy may be 
considered first line therapy for those patients who are not considered fit enough for 
combination chemotherapy.  However, a randomised study has shown that 
combination chemotherapy with Oxaliplatin and either infusional 5-Fluorouracil or 
Capecitabine, if dose modified, may be feasible in elderly patients with borderline 
performance status.  However, this study did not show overall survival benefit for those 
patients receiving combination chemotherapy (Seymour et al., 2007) 
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1.7.5.5 Side Effects of Colorectal Cancer Chemotherapy 
 
Toxicity of 5-Fluorouracil changes significantly when the drug is used in different doses 
and schedules (Macdonald, 1999). The difference is particularly observed when bolus 
schedules are compared to infusional schedules (Levy et al., 1998). Bolus single agent 
of 5-Fluorouracil was, in the past, the standard method of administration for this drug in 
the treatment of colorectal cancer however, infusional regimens are favoured for their 
side effect profile.  Bolus 5-Fluorouracil was associated with significant 
myelosuppresion.  Major toxicities caused by infusional 5-Fluorouracil include 
mucositis, diarrhoea and palmar-plantar erythrodysesthesia, more commonly known 
and “hand-foot syndrome” (Levy et al., 1998). Infusional treatment requires patients to 
have indwelling central venous catheters which may cause additional problems for 
patients, such as thrombosis and infections.  
Capecitabine has similar profile of toxicities as 5-Fluorouracil, which is not surprising 
given that it is ultimately converted to 5-Fluorouracil.  Incidence of mucositis, diarrhoea 
and nausea are less common among patients receiving Capecitabine compared to 
those patients on bolus 5-Fluorouracil.  However, incidence of hand-foot syndrome is 
significantly higher among patients on Capecitabine compared to bolus 5-Fluorouracil 
(Cassidy et al., 2002).  
Rare side effects of 5-Fluorouracil and Capecitabine include their cardiac toxicities.  
These side effects include acute coronary syndrome, cardiomyopathy and arrhythmias 
(Sorrentino et al., 2012).   
Irinotecan may be associated with a number of serious side effects.  These include 
myelosuppresion, diarrhoea which can be severe, and hair loss (Fuchs et al., 2007).  
Oxaliplatin is also associated with risk of myelosuppresion but its’ main troublesome 
side effect is sensory peripheral neuropathy (Saif and Reardon, 2005).  
 
1.7.5.6 Biological treatments for colorectal cancer 
 
The last decade has seen a number of biological treatments with activities in the 
treatment of colorectal cancer in combination with chemotherapy or as single agents.  
These include Bevacizumab, Cetuximab, Panitumomab, Aflibercept and Regorafenib.   
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Many of these treatments are currently not readily available within the National Health 
Service in the UK, although oncologists in England can apply for funding for some of 
these drugs via the Cancer Drugs Fund (NHS England).   
 
1.7.6 HRQoL in colorectal cancer patients 
 
Patients diagnosed with cancer will go through a number of stages during the course of 
their illness.  Each stage of the disease trajectory will pose different challenges for the 
patients and impact on their HRQoL.   
Diagnosis with a potentially life threatening disease is likely to instill fear and 
uncertainty for patients diagnosed with any cancer, including colorectal cancer.  There 
is evidence to suggest that significant proportion of patients with colorectal cancer 
suffer from anxiety and depression (Strong et al., 2007). There is indication to suggest 
that younger patients with the disease are more like to have psychological distress 
compared to older patients (Cohen et al., 2014). It has been suggested that this may 
be in part due to younger patients potentially bearing more work and family related 
strains as a consequence of their cancer diagnosis (Arndt et al., 2004).  On the other 
hand, older patients may have different expectations of life and of the future.  They may 
anticipate developing various diseases as part of the aging process (Cohen et al., 
2014, Phipps et al., 2008).   Studies have indicated that those patients who have 
anxiety or depression at baseline are more likely to have on-going psychological issues 
long term (Chambers et al., 2012). 
Surgical intervention for the primary cancer can have significant impact on patients, 
particularly for those patients diagnosed with rectal cancer.  Patients with rectal cancer 
are more likely to receive pre-operative treatment such as radiotherapy or chemo-
radiotherapy.  These treatments can cause additional toxicities and higher rate of 
surgical complication for patients (Marijnen et al., 2002) and may result in long term 
sequelae in terms of bowel and sexual dysfunction (Birgisson et al., 2007).  Rectal 
cancer patients are more likely to undergo surgical procedure which results in the 
formation of a permanent stoma.  This can have an impact, not only on patients’ bowel 
function, but also on how the patients adjust their life around managing the stoma and 
on their body image (Sprangers et al., 1995, Jansen et al., 2010). Rectal cancer 
patients are more likely than patient with colon cancer to report body image issues and 
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sexual dysfunction long term (Downing et al., 2015, Traa et al., 2012, Brown and 
Randle, 2005).   
Chemotherapy treatment can cause a wide range of side effects as discussed earlier.  
Patients undergoing treatment will not only experience these toxicities but regular 
hospital visits to receive these treatments will undoubtedly have impact on their day to 
day activities.  If the treatment is palliative for those with incurable disease then 
patients may have other symptoms attributable to their underlying disease as well as 
the treatment side effects.  They are also more likely to have other health issues and 
concerns compared to those patients receiving the treatment as adjuvant therapy to the 
surgery with the aim of increasing the chance of cure. Fear of recurrence and 
uncertainty may be a significant on-going concern for those patients who may have 
received treatment with curative intent (Jansen et al., 2010, Downing et al., 2015).  In 
addition, colorectal cancer affects older population; therefore these patients may have 
other significant co-morbidities which may have additive burden on their daily lives 
(Downing et al., 2015). 
 
1.7.7 HRQoL instruments in colorectal cancer 
 
A wide range of HRQoL instruments have been used in the assessment of HRQoL 
among colorectal cancer patients.  These include both generic and cancer specific 
questionnaires but many studies employed colorectal cancer specific modules in order 
to capture issues which are specific to this group of patients. Review of the HRQoL 
instruments will be presented in Chapter 3 as part of the questionnaire development. 
 
1.7.8 Summary 
 
Colorectal cancer and its’ treatments can pose significant symptom and psychosocial 
burden among patients.  Evaluation of existing HRQoL instruments is necessary to 
examine if any of the existing measures are suitable for use in clinical practice. 
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1.8 Training programme for integration of patient reported HRQoL in 
routine consultations 
 
The clinical consultation remains the foundation of all medical practice.  During the 
course of a professional lifetime, most doctors will conduct between 160,000–300,000 
medical interviews (Lipkin, 1996).  Effective doctor-patient communication is a 
fundamental component in the delivery of high quality healthcare. It can facilitate 
positive effects for both patients and doctors, which include improved accuracy and 
understanding of patients’ problems (Maguire et al.); patient satisfaction with their care 
and better understanding of their diagnosis/problems leading to adherence to therapy 
(Silverman et al., 2005); improved doctor-patient relationship and improved doctors’ 
well-being (Fallowfield, 1995, Ramirez et al., 1995). 
Communication is a skill which may be taken for granted.  Some doctors are much 
better natural communicators than others.  However, medical consultation requires 
skills which are different to how we may interact with other people socially.   Different 
patients require different approaches and doctors need to be able to adjust their 
communication skills to meet the needs of the patient accordingly.   
Good communication skills are particularly relevant in cancer medicine.  Consultations 
about cancer may involve many difficulties, including breaking bad news about the 
diagnosis of cancer, or recurrence; treatment failure/disease progression and 
prognosis.  Oncology consultations may also involve discussion of complex information 
about treatments and informed consent and participation into clinical trials.   
The goal of effective communication between patients and doctors is to ensure patients 
receive the most optimal care.  Communication needs of patients and doctors are 
therefore invariably linked to this goal.  Optimal care for the patients includes not only 
the best medical management of the underlying cancer, but also optimal management 
of the patients’ psychosocial adjustments in response to their disease. Eliciting these 
issues during the consultations, however, requires skill which not all clinicians may 
have. 
Patient reported HRQoL would be expected to facilitate improved patient-doctor 
communication by providing clinicians with rich information about their patients, which 
can be used in a number of beneficial ways such as detection of problems and 
monitoring of patients’ progress over time.  However, adoption of patient reported 
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HRQoL collection in routine clinical practice has been slow due to a number of barriers 
described previously.   
Training healthcare professionals has been suggested as one of the ways which may 
help overcome healthcare professional related barriers to implementation of routine 
patient reported HRQoL collection  (Greenhalgh, 2009, Luckett et al., 2009).  These 
barriers relate to clinicians’ lack of expertise with the HRQoL assessments for 
individual patients (Morris et al., 1998a) and their concerns about the HRQoL 
highlighting problems for which clinicians feel unequipped to deal with (Donaldson, 
2004).  Another barrier may also be their reluctance for change (Locklear et al., 2014).  
Descriptions of training provided to healthcare professionals within published studies of 
patient reported outcome interventions are brief where this information has been 
provided (Greenhalgh and Meadows, 1999).  These training tended to focus on the 
HRQoL instruments used within the study and how these instruments were scored, 
without guidance on how healthcare professionals might use the data (Detmar et al., 
2002, Velikova et al., 2004). Training, therefore, need to address these barriers so that 
doctors can respond to patient reported data in the way that would influence patient 
management. 
In order to develop this training programme, I have explored the training methods used 
in the communication skills training to see if similar strategies may be feasible, as the 
patient reported outcomes intervention aims to impact on the communication between 
the patient and the healthcare professionals. 
This developmental process will be discussed in detail in Chapter 6.  
 
1.9 Research Hypothesis  
 
 
My research hypothesis is that HRQoL questionnaires that have been developed 
primarily for assessing HRQoL of a group of patients (for example in clinical trials) may 
not wholly be suitable for use in clinical practice to assess individual patients. It may be 
possible to adapt existing questionnaires to ensure the instrument addresses all key 
areas relevant to the patient within the routine clinical practice setting. Training 
oncologists on how to integrate patient reported HRQoL data would further enhance 
the intervention by providing the oncologists with skills to incorporate patient data to 
assist clinical decision making. 
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My expectation is that a questionnaire developed specifically for use in clinical practice 
together with training for the doctors would serve the following functions: 
 
1. Enhance doctor-patient communication; active involvement of patients’ views 
and facilitating collaborative working relationship between the two parties. 
2. Provide a reliable assessment of colorectal cancer specific physical symptoms 
and treatment toxicities.  This may provide a way of monitoring treatment 
response and toxicities over time and help support clinical decision making. 
3. Screen for and identify problems which are not always addressed by healthcare 
professionals, such as emotional distress and impact of treatment on daily 
activities. Training will allow doctors to respond to patient concerns more readily 
and integrate patient views during their clinic consultations. 
 
My work on the questionnaire development was specifically for patients with colorectal 
cancer.  However, it is important to have a consistent approach across different cancer 
sites in assessing patients’ HRQoL.  Therefore, questionnaire developmental 
processes were undertaken simultaneously with similar questionnaire developments in 
other cancer sites (breast and gynaecological). The training for the doctors was generic 
and intended for all oncologists with different cancer site expertise. 
. 
1.9.1 Aims of thesis and outline of chapters 
 
The main aim of my thesis was to develop (or adapt) a HRQoL questionnaire, 
specifically for patients with colorectal cancer to be used in routine clinical practice.  
The questionnaire was intended to facilitate patient care, based on the current 
colorectal cancer practice, available literature on HRQoL assessment in clinical 
practice, oncologists and patient opinions. 
I have utilized a mixed methods approach which included review of literature, 
qualitative interviews with both oncologists and patients, and quantitative statistical 
methods.  Methods used in this thesis are presented and discussed in detail in Chapter 
2. 
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Objectives of my thesis and outline of the chapters are presented below: 
Chapter 3: The details of the questionnaire developmental process are described in 
Chapter 3.  This Chapter explored issues commonly discussed in real 
life clinic consultations of colorectal cancer patients.  Review of the 
literature of questionnaires used to evaluate HRQoL of colorectal cancer 
patients was performed. This was followed by comparison of issues 
raised in clinic consultations and in the questionnaires. Further opinions 
were sought from oncologists specialising on colorectal cancer 
treatment and from their patients to assess relevance to routine clinical 
practice and also usability of the questionnaires. 
Chapter 4: In this Chapter, I have tested the psychometric properties of the newly 
developed/adapted colorectal cancer specific questionnaire by 
administering it to a group of patients. The statistical analysis used 
helped to identify subscales and helped to reduce the number of items 
included in the questionnaire. 
Chapter 5: In this Chapter, I have conducted exploratory analyses of the previous 
randomised controlled study conducted by the Leeds Psychosocial 
Oncology and Clinical Practice Research Group (Velikova et al., 2004).  
The aims of these analyses were to investigate what impact patient 
reported HRQoL had on doctor-patient communication and to explore 
whether the severity of patient reported symptoms and functions had 
any bearing on whether these issues were discussed during the clinic 
consultation.  These analyses were aimed at identifying elements of the 
intervention that could be improved through training of the doctors. 
Chapter 6: In this Chapter, conceptual models of knowledge acquisition and 
learning styles were explored which informed the structure of 
communication skills training in cancer.  Teaching interventions used in 
communications skills training were reviewed to see what teaching 
methods would be suitable for training oncologists in using patient 
reported HRQoL data.  This chapter also describes the developmental 
processes of “trigger” tapes used in the training programme to provide 
experiential learning opportunity for the oncologists. 
Chapter 7 In this Chapter, I have described the Pilot Study of Doctor Training 
which aimed to evaluate the possible impact of doctor training. The 
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actual conduct of the study and patient recruitment were performed by 
the members of Leeds Psychosocial Oncology and Clinical Practice 
research Group (POCPRG). 
 
1.9.2 Function of the thesis within a context of broader research 
programme 
 
Cancer Research UK funded programme of research (C7775/A7424, 2008 – 2012) 
called Quality of Life, Enhanced Staff Training (QuEST), aimed to maximise the impact 
of patient reported HRQoL assessment on processes of patient care and outcomes.   
 
The research programme consisted of two strands of work which were developed in 
parallel; these strands were questionnaire development and doctor training. 
 
Questionnaire development strand aimed to evaluate and enhance existing HRQoL 
instruments by active engagement with both healthcare professionals and patients in 
making sure that issues relevant and important for patients were included in the 
questionnaire.  It aimed for the questionnaires to be suitable for use within clinical 
practice. 
 
The aim of the doctor training strand was to develop a training programme to assist 
healthcare professionals in responding to and facilitate integration of patient reported 
HRQoL information into clinic consultations in the way that patient reported data would 
play an active role in clinical decision making process. 
 
In addition to these two strands within the Cancer Research UK funded programme of 
research, Leeds POCPRG are working on technology that enabled information 
collected from questionnaires completed on touch screen computers to be 
automatically scored and uploaded on to patients’ electronic record system used in 
Leeds called the Patient Pathway Manager (PPM). This integrated system allowed 
results from questionnaire to be scored and presented in a graphical format 
immediately so that these results could be viewed by the oncologists during the clinic 
consultation. 
 
As the questionnaire results were integrated into the patients’ notes, they became part 
of the work flow for the oncologists, which enabled the clinicians to process the 
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information efficiently.  The format of result presentation included graphs which were 
colour coded in traffic light schema according to cut off points to provide indication for 
more serious problems. 
 
As part of the Cancer Research UK funded programme of research, three cancer site 
specific questionnaires for colorectal (QuEST-Cr), breast (QuEST-Br) and 
gynaecological cancers (QuEST-Gy) were adapted simultaneously.  I was responsible 
for the adaptation processes for the development of QuEST-Cr.  I was responsible for 
managing the recruitment of most of the colorectal cancer patients for the validation of 
the questionnaire items.  Statistical analyses were conducted in parallel with other 
cancer sites but I was responsible for the analysis of the colorectal cancer patients’ 
data. In order to create consistent function scales across the three cancer sites, group 
decisions were made on certain items which are described in detail in Chapter 4. 
I was the key person in leading the development of doctor training programme.  I 
explored the conceptual models of adult learning and learning styles to inform the types 
of teaching methods needed.  I reviewed the teaching methods used in advanced 
communication skills training and used this as the framework on which the doctor 
training can be built on. I developed the “trigger tapes” to use as facilitation aid during 
the training to provide alternative experiential learning opportunity instead of role play. 
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Chapter 2 Methodology 
 
2.1 Introduction 
 
Various methodologies were employed in order to address the aims of this thesis.  
Mixed methods approach, in which both quantitative and qualitative methods are 
combined, allows making the most of their respective strengths (Curry et al., 2009).  
Quantitative methods alone may not be sufficient in measuring complex aspects of how 
a medical care intervention may impact on patient outcomes. Qualitative methods are 
more exploratory in nature which may help to uncover beliefs and values of study 
participants which underpin their health behaviour (Malterud, 2001, Eccles et al., 2003, 
Green and Britten, 1998).  The data generated from both methods may provide more 
complete data, thus offering supporting or complimentary information to facilitate better 
understanding of the research subject and provide broader perspective on the overall 
research question (Curry et al., 2009, Creswell JW, 2003).   
 
Following methods were applied: 
1. Evidence synthesis through structured review of literature 
2. Qualitative methodology including semi structured interviews analysed using 
framework/thematic analysis 
3. Quantitative methodology including descriptive statistics, regression analysis 
and psychometric methods 
 
The thesis can be divided into the following key stages 
1. Identifying the issues pertinent to patients with advanced colorectal cancer for 
inclusion in a colorectal cancer specific questionnaire package 
2. Reviewing the questionnaire package with patients and oncologists 
3. Refining the questionnaire package to facilitate its utility in the routine clinical 
oncology practice 
4. Exploring the barriers for patient reported outcomes to be employed routinely in 
clinical practice 
5. Developing training programme for oncologists to assist them in using the 
patient reported HRQoL data 
6. Pilot study to test the potential benefits of doctor training 
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This chapter describes each of these key stages with references to available 
methodologies for data collection and analyses to meet their objectives, and the 
reasons behind decisions made regarding choice of methodologies utilized in this 
thesis.   
 
2.2 Identifying relevant issues and topics for inclusion in the 
colorectal cancer specific questionnaire  
 
One of the aims of this thesis was to explore whether existing health related quality of 
life (HRQoL) questionnaires, which have been developed for the purpose of capturing 
patients’ quality of life in a specific group of patients/population (for example, in a 
clinical trial) would meet the needs of capturing such data for each individual patient 
within routine oncology practice.    
 
It was envisaged that the questionnaire specific for colorectal cancer patients would 
address their symptoms, side effects of treatments and functional concerns.  There 
would also be an additional concerns checklist which allowed patients to indicate 
whether they wished to discuss any specific issues. 
 
It was expected that there would be some sections within the questionnaire which were 
generic to all cancers such as assessment of patients’ physical function, emotional 
function and concerns checklist. 
 
2.2.1 What topics are discussed in routine oncology clinic consultations? 
 
In order to begin to answer the above question, it seemed natural to explore what 
topics or issues are actually raised and discussed in routine oncology clinic 
consultations.   
 
There are a number of methods to gather such information.  One method would be to 
review the patients’ medical notes and document the issues written in the notes or in 
clinical correspondence.  The problem with this method is that the doctor may not have 
written down all of the issues that were discussed.  Doctors often summarise the 
consultation and document what was perceived to be the most pertinent issue from 
their perspective.  Therefore, this method may not necessarily reflect the patients’ 
viewpoint as the data would be obtained from documentation produced by the doctors.   
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Other methods include researchers making notes in real time during the consultation or 
using audio-visual equipment to capture such data.  However, these methods can be 
considered intrusive and may potentially disrupt the flow of the clinic consultation.   
The most suitable method was considered to be the use of digital dictation devices. 
These are very small and can be left on the doctors’ desk during the consultation.  
Leeds POCPRG has a wealth of experience in audio recording of clinic consultations 
and this was considered to be the favoured approach. 
 
There are a number of methods for analysing patient-doctor communication and their 
interactions during a clinical encounter.  Comprehensive consultation coding systems 
such as Roter Interaction Analysis System (RIAS) (Roter and Larson, 2002) or Medical 
Interaction Process System (MIPS) (Ford et al., 2000) can both provide detailed 
information about the complexity of patient-doctor interactions, through coding each 
utterance (any meaningful section of speech) during the consultation.  These coding 
systems not only examine the discussion topics of the consultation but they also allow 
examination of the contributions made by the doctor and the patient and how they fulfill 
the purpose of the medical interview; gathering information and understanding the 
patient’s problems, providing education and counseling, building a rapport and 
responding to patients’ emotions and managing any problems identified.  However, 
application of these coding systems can be very time consuming.   
 
An alternative method is to use a simpler content analysis as a systematic analysis of 
the topics covered during patient-doctor interaction during the medical consultations.  
This method of analysis can be applied to a wide range of data, including text, videos 
and audio-recordings.  It is a way of studying and analysing communication in a 
methodical, objective and quantitative manner for the purpose of measuring variables 
(Kerlinger, 1986).  Content analysis has successfully been utilized in studies of patient-
doctor communication in the oncology setting (Detmar et al., 2002, Fagerlind et al., 
2008, Velikova et al., 2004) with good inter-rater reliability (Fagerlind et al., 2008).   
 
As the aim of this part of the study was to capture the topics of discussion during a 
routine oncology clinic consultation, it was felt that the most suitable method of 
analysing the data was content analysis. 
 
Leeds POCPRG has already conducted many studies utilising audio-recording of clinic 
consultations.  Rather than collecting new audio-recording of clinic consultations, 
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previously recorded consultations of colorectal cancer patients were used for the 
purpose of this part of the study. 
 
2.2.2 Examining the issues covered in existing quality of life 
questionnaires. 
 
HRQoL questionnaires are developed by exploring issues which are relevant to the 
group of patients under investigation.  This may be achieved by gathering such 
information directly from the patients.  Another method used to generate items for 
inclusion in questionnaire is to conduct a review of literature to identify common 
symptoms and quality of life issues that are pertinent to the specified patient group 
(Johnson et al., 2011). Structured literature review of HRQoL instruments was 
performed to explore which topics or issues were already addressed by these existing 
instruments.   
 
The finding from the above content analysis of consultation audio-recordings were 
compared to the findings of the review of the literature, in order to generate a 
comprehensive list of topics and issues relevant to the colorectal cancer patients. 
 
 
2.3 Reviewing the questionnaire items with oncologists and patients 
 
The aim of this stage of the project was to review the items of the questionnaire 
generated from measures described above, to ensure that the items were relevant to 
what is required for routine clinical practice and also to make sure that they reflected 
patients’ experiences.  This was also an opportunity to review the wording of the 
questions with healthcare professionals and patients and to rationalise which items 
should be included in the questionnaire. 
 
There are both quantitative and qualitative methods available in achieving the aim of 
this stage of the study.  The quantitative method would involve asking the healthcare 
professionals to provide their rating of each item according to how useful they find each 
item in routine clinical practice.  Patients can also answer the questionnaire items 
which may provide indication as to the prevalence of the issue and to assess whether 
the questionnaire items are relevant to them. However, quantitative methods alone 
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may not address some of the other aims such as making sure that the wording of the 
items is appropriate. 
 
Qualitative methods that may be applied here are interviews and focus group 
discussions.  Interviews are among the most common methods for collecting qualitative 
data. They can be categorised into unstructured, semi-structured and structured 
(Fontana and Frey, 1994).  Semi-structured interview is the most commonly used 
method in qualitative research.  The interviewer will have a framework of the themes or 
topics to be explored but the questions can be left relatively open, allowing the 
interviewee to talk more openly about their experiences and thus enabling new ideas to 
be brought up.  
 
Focus group discussions are a form of group interview (Kitzinger, 1995) in which a 
group of participants gather to discuss a specified topic to generate data.  During focus 
group discussions, participants are encouraged to communicate with one another; 
asking questions and exchanging their experiences, allowing exploration of peoples’ 
knowledge and experiences.  The researcher acts more as a “moderator”, rather than 
an “interviewer” in focus groups to keep the discussions flowing.  Focus groups can 
involve a single group of participants meeting on a single occasion or it can involve 
many groups with repeated meetings.  Typically, focus group discussions consist of 
four to eight participants but this number may vary (Wilkinson, 2004). The 
disadvantages of focus group discussions include the possibility that some of the 
participants may be hesitant to express their honest views if their thoughts oppose the 
views of others. There is also a risk that the discussion may become dominated by one 
or two people within the group, leading to bias. In addition, some participants may find 
it difficult to discuss sensitive topics amongst a group of people. 
 
Using both quantitative and qualitative methods was considered the most appropriate 
approach for this part of the study.  Oncologists specialising in the treatment of 
colorectal cancer patients were asked to go through the list of questionnaire items and 
provide their evaluation according to how useful they considered each item to be. This 
was coupled with a semi-structured interview around the questionnaire items, which 
also explored their views about using such questionnaires within routine clinical 
practice and how that may impact on patient care. Patients were also asked to 
complete the questionnaire items, which was then followed by a semi-structured 
interview.  This helped to clarify whether the items were relevant to their experience 
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and also to check any issues around the wording of the items. Patients’ views on using 
such questionnaire were also explored. 
 
Semi-structured interviews were chosen over focus group discussions due to practical 
reasons of difficulties in arranging a convenient time for oncologists and patients to 
meet.  Patient interviews were conducted when they attended for their planned out-
patient appointments in order to avoid additional visits to the hospital. 
 
Quantitative data generated from oncologists rating of the items and patients 
completing the questionnaire were analysed using descriptive statistics to explore the 
oncologists’ assessment of the items and also to evaluate the prevalence of the issues 
amongst patients.   
 
All of the semi-structured interviews conducted were audio-recorded and later 
transcribed prior to analysis.   
 
Qualitative data analysis involves processes which converts the collected data into 
some form of explanation, understanding or interpretation of the subjects and situation 
being investigated.  There are two main approaches for analysis; deductive and 
inductive approaches.  The main difference between the two approaches is that 
deductive approach is aimed at testing a theory whilst inductive approach is concerned 
with generation of new theory or new phenomena emerging from the data. 
 
Inductive analysis is the most common approach used to analyse qualitative data 
(Thomas, 2006).  There are various analysis methods described associated with 
specific approaches or traditions, such as narrative analysis (Cortazzi, 2014), 
phenomenology (Giorgi, 1997), discourse analysis (Kinneavy, 1971) and grounded 
theory (Strauss and Corbin, 1994). More recently, some researchers have described 
more generic analysis methods for qualitative data collectively referred to as “general 
inductive approach” or framework/thematic analysis (Thomas, 2006). 
 
Thematic content analysis is the most commonly used analysis method in qualitative 
research.  It focuses on examining themes within the data.  A theme represents a 
pattern of response or meaning from the data that is related to the research questions. 
Coding is the primary process for developing themes within the raw data by 
recognising important moments in the data and encoding it prior to interpretation 
(Braun and Clarke, 2006). This analysis method is strongly influenced by the data 
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rather than the researcher’s preconceptions and theories about what themes may 
emerge.   There are six key stages of thematic analysis: 1) familiarising yourself with 
the data; 2) generating initial codes; 3) searching for themes; 4) reviewing themes; 5) 
defining and naming themes and 6) producing the final report. The method allows 
relatively non technical way for analysing large volume of qualitative data in a 
comprehensive manner (Braun and Clarke, 2006). 
 
Qualitative thematic analysis has therefore been used in analysing the data obtained 
through the semi-structured interviews conducted in this part of the study.  The findings 
from the interviews were combined with the quantitative ratings for the items in order to 
gain a more complete understanding of the data.  
 
 
2.4 Refining the questionnaire package  
 
One of the most important steps in the development of questionnaires is the validation 
process, which consists of a series of procedures to determine the quality of the 
instrument as a tool for measurement.  This would ensure that the questionnaire is 
valid and reliable. 
 
Validity refers to how well the instrument measures what it is supposed to measure.  
Reliability refers to the degree to which an instrument produces repeatable or 
consistent results. In order to test the validity and reliability of the questionnaire, it 
needs to be tested in a group of patients for whom the questionnaire has been 
developed. 
 
The main aim of this part of the study was to refine the questionnaire and to ensure its’ 
suitability for use within routine clinical practice. Secondary aim of this study was to try 
and reduce the number of items within the questionnaire in order to reduce burden for 
patients completing the questionnaire but also to assist the healthcare professionals in 
interpreting the results.  
 
There are two main theories leading the development and validation of rating scales 
and questionnaires: the classical test theory and the item response theory. 
The main purpose of classical test theory within psychometric testing is to understand 
and improve the reliability of the instrument.  Classical test theory assumes that any 
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score obtained from an instrument (the “observed” score) is composed of both the 
“true” score, which is unknown, and “error” in the measurement process (DeVellis, 
2006).  Errors can occur through a number of variables.  These include the individuals 
completing the questionnaire, the items within the questionnaire and the timing of 
administering the questionnaire. The goal in classical test theory is to estimate errors in 
measurement and to suggest ways of improving the instrument so that errors are 
minimized.   As there is no way to directly observe or calculate the “true” score, a 
variety of methods are used to estimate the reliability of a test.  These include: 
 
1. Test-retest reliability is a measure of reliability obtained by administering the 
same test to a group of individuals twice over a short period of time (when no 
change in status/scores is expected).  The scores from Time 1 and Time 2 can 
then be correlated in order to evaluate the test for stability over time 
2. Parallel forms reliability is a measure of reliability obtained by administering 
different versions of an assessment tool (both versions contain items that probe 
the same construct) to the same group of individuals.  The scores from the two 
versions can then be correlated in order to evaluate the consistency of results 
across alternate versions.  
3. Inter-rater reliability is a measure of reliability used to assess the degree to 
which different judges or raters agree in their assessment decisions.   
4. Internal consistency reliability assesses the consistency of results across 
items within a test. The most common internal consistency measure is 
Cronbach's alpha 
 
The classical test theory encompasses a number of methods which can be used to 
reduce the number of items within a questionnaire.  Frequently employed methods 
include factor analysis, correlations and Cronbach’s alpha statistics per scale, or 
stepwise regression (Coste et al., 1997).  
 
Factor analysis identifies the number of latent constructs and underlying structure of a 
set of variables. Items that measure the same construct should load onto the same 
factor which helps to form a sub-scale. Factor loading is based on correlation between 
items and range from -1 to 1. -1 indicates a negative correlation and 1 indicates a 
positive correlation, a score of 0 means that there is no correlation at all between the 
items. 
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Sub-scales identified through factor analysis can then be evaluated further by checking 
the internal consistency using Cronbach’s alpha.  The value of Cronbach’s alpha 
ranges from 0 to 1.0; the closer the value of alpha to 1.0, the more reliable the scale. 
Cronbach’s alpha may sometimes be improved by removing item(s) from the subscale, 
which may also assist in item reduction. 
 
A number of limitations of classical test theory have been described.  One of these is 
that the sample characteristics and test or instrument characteristics cannot be 
separated; each can only be interpreted in the context of the other. Classical test 
theory also assumes that there is equal measurement of error exists amongst the 
sample population.  The classical test theory places its emphasis on the test score 
properties of the instrument rather than on the item parameters and it provides no basis 
for predicting the likelihood of a given response of a sample to a given test item, based 
on the response to other items (DeVellis, 2006). 
 
Item response theory (IRT) is a more modern theory which was first proposed in the 
field of psychometrics for the purpose of ability assessment in education. It continues to 
be widely used in education setting to calibrate and evaluate items in tests, 
questionnaires, and other instruments and to score subjects on their abilities, attitudes, 
or other latent traits.  The theory describes studies of test and item scores on 
assumptions concerning the mathematical relationship between abilities (or other 
hypothesized latent traits) and item responses (Hambleton et al., 1991). 
 
The purpose of IRT is to provide a framework for evaluating how well assessments 
work and how well the individual items on assessments work, leading to more precise 
measurements.  This allows IRT to construct scales that are short but still reliable and 
valid.  IRT also enables applications such as computer adaptive testing (CAT), in which 
questions can be successively selected, based on the previous response given by the 
person completing the test/questionnaire. This tailored question selection can result in 
greater precision with only a relatively small number of questions (Gershon, 2005).  
 
Disadvantages of IRT include the need for a large sample size for analysis (>500) for 
questions with multiple response options, such as the Likert scale (Reeve and Fayers, 
2005).  Other disadvantages include the need for standalone computer programmes to 
conduct the analyses, which are often complex, compared to the analysis methods 
used in classical test theory  (Streiner, 2010).  
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For the colorectal cancer specific questionnaire presented in this thesis, classical test 
theory methodologies were applied.  These are well established methods for 
questionnaire development outside of the education context (Aaronson et al., 1993, 
Trask et al., 2008) and analyses can be performed on smaller sample sizes 
(Hambleton and Jones, 1993).  Future research may utilize item response theory 
methodologies to the classical test theory approach in order to enhance the instrument 
further.  
 
 
2.5 Longitudinal analysis from the previous Randomised Controlled 
Trial 
 
A previously conducted randomised control trial by the Leeds POCPRG demonstrated 
that regular feedback of patient reported outcomes of HRQoL to oncologists during 
cancer treatment led to improved doctor-patient communication and patient well being 
(Velikova et al., 2004).  However, the impact observed was small.  The published 
results were derived from pre-planned analysis of doctor-patient communication at a 
single time point, due to time and resource restrictions.  Following the publication of the 
study, the members of the group continued to analyse all of the audio-recordings of the 
out-patient consultations collected as part of this study, resulting in the formation of a 
rich longitudinal dataset of doctor-patient communication in oncology.  The 
consultations had been analysed using content analysis, employing a study specific 
framework.  The analysis focused on the topics of discussion and dynamics of the 
communication (who initiated discussion of a specific topic).  Approximately 75% of 
patients in the trial completed HRQoL questionnaire over time (4 consecutive 
consultations) and their consultations were audio-recorded and content analysed. 
 
I was given access to this rich dataset in order to perform exploratory analysis of 
doctor-patient communication and how the completion and feedback to oncologists of 
HRQoL influenced the content of the discussions that took place during the 
consultations. The aim of the exploratory analysis was to identify elements of the 
questionnaire intervention which may be acted upon in order to enhance the process.  
 
Regression analysis is a statistical method for investigating relationships between a 
dependent variable and one or more independent variables.  Regression analysis is 
widely used for prediction or forecasting and can infer causality between the variables. 
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As the exploratory analysis was going to involve investigating the impact of 
questionnaire administration to various outcomes in doctor-patient communication 
during the consultations, regression analysis was considered to be the most 
appropriate approach. 
 
The dataset obviously consisted of data collected from patients repeatedly over time 
(i.e. longitudinal data).  One of the aims of the analysis was to investigate the impact of 
the questionnaire intervention on doctor-patient communication over time.  There are a 
number of statistical methods available for analysing repeated measures. One method 
is repeated measures analysis of variance (ANOVA). It is used to compare three or 
more group means where the participants are the same in each group.  The analysis 
requires a number of conditions to be met.  One is that the dependent variable should 
be measured at a continuous level and this should be distributed normally. Another 
condition is the independent variable should consist of at least two categorical, 
“related” groups.  This means that the same subjects are present in both groups. 
Another is the variances of the differences between all combinations of related groups 
must be equal (known as sphericity).  
 
Another method is the mixed effects model.  The model can accommodate both fixed 
effects and random effects within the model. Fixed effects represent population 
parameters, assumed to be the same each time data is collected. Estimating fixed 
effects is the traditional domain of regression modeling. Random effects, by 
comparison, are sample-dependent random variables. Mixed effects model offers 
flexible framework by which to model the sources of variation and correlation that occur 
from grouped data. There are a number of advantages to using mixed effects models.  
One advantage is the mixed effects model can handle missing data much better within 
the model compared to ANOVA. Another benefit of mixed effects model is that time can 
be incorporated as a truly continuous effect, whereas in ANOVA time is considered as 
a categorical variable.  Mixed effects can also integrate any other important predictor 
variable that may change with time within the model. 
 
Mixed effects method was chosen over the ANOVA method as it allowed better 
modeling of various variables including time as a continuous variable. 
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2.6 Development of doctor training 
 
In order to develop the doctor training programme, it was necessary to explore 
conceptual models of knowledge acquisition and teaching methodologies to inform the 
structure and the content of the training programme.  As the training was aimed 
primarily at facilitating oncologists to incorporate patient reported HRQoL information 
into their clinic consultations and impacting on patient-doctor communication, training 
methods used in advanced communication skills were reviewed and used as the 
framework for the training programme. 
 
2.7 Pilot study to test the potential impact of doctor training 
 
The objective of the pilot study was to gain an estimate of the impact of the doctor 
training programme on patient-doctor communication. There are a number of study 
designs that can be used to evaluate the impact of the doctor training.  These designs 
vary in the extent to which they allow the observed effects to be attributed to the 
intervention. These study designs can be broadly grouped into 3 main categories; 
experimental, quasi-experimental or non-experimental. 
 
Experimental designs or randomised experiments are considered to be the most 
rigorous and scientific approach to evaluating effectiveness of an intervention. 
Randomised controlled study is often considered as the “gold standard”. Quasi-
experimental designs shares similarities with the experimental design but lack the 
random assignment to treatment or control.  Quasi-experimental study designs are 
therefore commonly used in the evaluation of interventions when random assignment is 
not possible or practical.  The non-experimental design only has an intervention group 
and lacks a control or comparison group, making it the weakest study design 
(Grimshaw et al., 2000). 
 
Although randomised controlled study is the most rigorous study design to measure the 
impact of the doctor training, conducting a randomised study can be costly and time 
consuming.  As the aim of the pilot study was to obtain an estimate of the impact of the 
training which would help inform sample size calculation for the future study 
investigating the combined effect of the cancer site specific questionnaires and doctor 
training, quasi-experimental pre-test/post-test design was considered most feasible 
study design for the pilot study.   
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Chapter 3 Questionnaire Development 
 
3.1 Introduction 
 
3.1.1 Aim 
 
The aim of this part of the study was to develop a HRQoL questionnaire (QuEST-Cr) 
for patients with advanced colorectal cancer, undergoing chemotherapy treatment, 
using a comprehensive development plan.  The questionnaire was aimed specifically 
for use in routine clinical practice. 
 
The plan included  
1. Exploration of topics/issues discussed during clinic consultations of colorectal 
cancer patients 
2. Literature review of existing HRQoL, including generic HRQoL, generic cancer 
HRQoL and colorectal cancer specific HRQoL instruments 
3. Interviews with oncologists specialising in the treatment of colorectal cancer 
and with patients undergoing treatment for colorectal cancer 
 
3.2 Questionnaire development 
 
Many validated questionnaires have been developed with the aim of capturing patients’ 
perspectives on how their illness and healthcare interventions impact on their lives 
(Ware, 1995, Fitzpatrick et al., 1998) 
 
The process of developing a questionnaire usually involves several key stages.  These 
have been described in a number of guidelines (Johnson et al., 2011, Food and Drugs 
Administration, 2009).  Before the questionnaire development can begin, a conceptual 
framework must be formulated so that there is a clear description of the research 
question and the population for which the questionnaire is being developed.   
 
The guidelines published by the EORTC Quality of Life Group describe four phases in 
the questionnaire development. This guidance specifically refers to the development of 
tumour site specific or disease distribution specific (e.g. patients with brain metastasis) 
modules.  The four phases described are: 
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Phase 1. Generation of quality of life issues 
Phase 2. Construction of item list 
Phase 3. Pre-testing 
Phase 4. Field-testing 
 
During phase 1, quality of life issues that cover the area of interest are compiled from 
literature review, patients with relevant condition and healthcare professionals with 
clinical expertise within the specified area of interest. These quality of life issues are 
then presented as items or questions to be included in the questionnaire during phase 
2. The EORTC Quality of Life Group has a bank of previously validated items from 
which they can select items to match the identified topic of interest. They also provide 
guidance on how item should be constructed when new items are required. The 
guidance recommends that the item list generated should be reviewed by healthcare 
professionals (ideally those that were not involved in the phase 1 of the questionnaire 
development) with clinical expertise of the target population or those with knowledge of 
questionnaire development prior to pre-testing phase with patients, in order to check for 
clarity of wording, removal any duplication and also to check the breadth of coverage. 
The pre-testing of the questionnaire is performed with a small group of patients to 
identify and solve any issues concerning administration of the questionnaire.  This is 
followed by structured interviews with each of the patients to ensure completeness and 
questionnaire acceptability. The questionnaire is further refined by incorporating any 
modifications prior to field testing in a large group of patients. 
 
The phases described in the EORTC guidelines were used as the framework for the 
development of the questionnaire within this study. Table 3.1 illustrates the comparison 
between the EORTC development phases and the methods used within this study. 
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 Table 3.1 EORTC module development phases vs QuEST-Cr development stages 
EORTC module development phases 
 
QuEST-Cr development stages 
Phase 1: Generation of QoL issues: 
Literature review 
Views of patients and healthcare 
professionals 
Stage 1. Generation of QoL issues: 
Review of issues raised in routine 
oncology consultations 
Literature review 
Phase 2: Construction of item list: 
Matching QoL issues generated 
from phase 1 to relevant items 
from EORTC Item Bank. New 
items created if existing item was 
not available. 
Stage 2. Construction of item list: 
Matching QoL issues generated 
from stage 1 to existing EORTC 
questions.  New items were 
created if existing items were not 
available. 
Stage 3. Interviews with health 
professionals 
Review of item list of items to 
check wording, remove 
duplications and check breadth of 
topic coverage 
Phase 3. Pre-testing: 
Small number of patients to 
complete the questionnaire, 
followed by interviews to check 
any issues with administration of 
questionnaire, check acceptability 
and relevance 
Stage 4. Pre-testing 
Small number of patients to 
complete the questionnaire, 
followed by interviews to check 
any issues with administration of 
questionnaire, check acceptability 
and relevance 
Phase 4. Field-testing: 
Psychometric testing of reliability, 
validity and sensitivity to change of 
the questionnaire 
Stage 5. Validation: 
To test the questionnaire in a large 
group of patients to perform 
psychometric testing of reliability 
and validity of the questionnaire 
  
 
Many questionnaires have been successfully developed using the above EORTC 
guidelines. However, the ultimate aim of the questionnaires developed in this manner 
has been for its use within clinical trials to compare groups of patients rather than in 
routine clinical practice for individual patients.  In addition, some of the disease specific 
modules developed by the EORTC Quality of Life Group have been developed to 
assess patients’ symptoms across a range of treatment modalities including surgery, 
radiotherapy and chemotherapy.  As the aim within this study was to develop a 
questionnaire for use in chemotherapy review clinics, investigation of issues discussed 
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in such clinics for colorectal cancer patients was considered as useful starting point for 
the development of the questionnaire.  This process has been used to substitute the 
interviews with patients and healthcare professionals described in the first phase of the 
EORTC guidelines.  
 
Interviews were conducted later in the developmental stages.  The interviews with the 
healthcare professionals were conducted in order to gather feedback regarding the 
items and their views on the usefulness of the individual items and questionnaire as a 
whole.  This process also helped to ensure that the questionnaire had the necessary 
breadth of coverage of the topics. In addition, healthcare professionals were asked to 
comment on the wording of the items and to remove any redundant or duplicate items.  
Interviews with patients not only evaluated the questionnaire items but also tested any 
administrative issues as the questionnaire was delivered on touch screen computer.  
 
Interviews were chosen over focus groups as interviews suited the process needed for 
this particular stage of the questionnaire development but also for practical reasons; 
difficulty in organising a convenient time for a group of healthcare professionals to meet 
and also preventing any additional hospital visit for patients.  In addition, the 
questionnaire included items which were potentially sensitive or embarrassing for 
patients to discuss in a group setting and was considered better addressed on an 
individual basis. 
 
Processes undertaken in the development of the colorectal cancer specific 
questionnaire, QuEST-Cr, for use in routine oncology practice is detailed in this 
chapter.  The methods ensure all the issues important and relevant for the target 
population are included.  This chapter details stages 1-4 of the developmental process 
(as presented in table 3.1) and stage 5 is presented in chapter 4. 
 
3.3 Methods 
 
3.3.1 Stage 1. Generation of quality of life topics 
 
3.3.1.1 Review of issues discussed in colorectal cancer patient consultations 
 
The analysis was performed on a dataset previously collected by the Leeds POCPRG 
as part of a randomised controlled study which will be referred to as attention control 
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study (Velikova et al., 2008).  The concept of this study arose from the previous 
randomised controlled study, which demonstrated that patients completing HRQoL 
questionnaires and feeding back the results from these questionnaires to the 
oncologists had a positive impact on patient well-being (Velikova et al., 2004).  This 
study also demonstrated a trend for improved patient well-being within the attention 
control group, where patients completed the HRQoL questionnaires but the results 
were not feedback to the oncologists.  The attention control study was conducted to 
further explore whether completing of HRQoL questionnaire alone had an impact on 
patients’ well being. The patients were randomised to either the intervention group 
(completion of HRQoL questionnaires with no feedback to the oncologists) or control 
group (standard care).  The two main outcomes of the study were patient well being 
and patient-doctor communication. A summary of the key elements of this study is 
shown in Table 3.2. 
 
Table 3.2 Summary of attention control study 
Study sample Patients with various cancer diagnoses 
Commencing chemotherapy treatment and 
expected to attend at least three more times 
Study setting Out-patient clinics in Leeds cancer centre and 
two district general hospitals in Yorkshire 
Study design Randomised controlled trial with two arms: 
Intervention arm (completion of HRQoL 
questionnaire, EORTC QLQ-C30, prior to each 
out-patient consultation) 
Control arm (standard care) 
Study measures Audio-recording of consultations 
Patients: 
FACT-G questionnaire 
Preferences and 
perceptions of 
communication (PPC) 
questionnaire 
Demographics 
Doctors: 
Preferences and 
perceptions of 
communication (PPC) 
questionnaire 
Demographics 
 
The results of the HRQoL questionnaires completed by the patients were not fed back 
to the doctors within this study, which may have had an impact on the content of the 
consultation discussion.  The audio-recordings collected from the study were subjected 
to content analysis.  This was performed by the members of the Leeds POCPRG, 
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using a study specific proforma that was devised in analysing the consultations.  One 
of the key areas of this content analysis was investigating the topics or issues raised 
during the clinic consultations and the person initiating the subject (patient/relative or 
doctors).  The content analysis proforma mapped onto the symptoms and quality of life 
domains of the questionnaire used within the study (EORTC QLQ-C30). Any other 
issues or symptoms raised which were outside of the questionnaire domains were also 
noted. 
 
Review of the topics discussed in out-patient chemotherapy review consultations for 
colorectal cancer patients was considered a helpful starting point in the development of 
the questionnaire. This part of the study was assisted by Dr Sally Taylor, a member of 
the Leeds POCPRG, who was involved with the analysis of the attention control study, 
who was very familiar with the study database.   
 
3.3.1.2 Literature review 
 
In order to explore HRQoL issues concerning patients with colorectal cancer, a 
literature search was performed.  The literature search was conducted in PubMed 
using Medical Subject Headings (MeSH).  The search terms used were “Intestinal 
Neoplasm” AND “Quality of Life” AND “Questionnaires”.  References published up to 
end of 2012 were included. Non English references were removed.  References 
concerning patients only with inflammatory bowel disease and those concerning 
genetic screening of hereditary condition increasing the risk of developing bowel 
cancer were also removed.  Generated references were reviewed to see whether the 
study involved administration of patient self reported questionnaire in colorectal cancer 
patients. List of questionnaires was complied and reviewed to explore relevant issues 
for colorectal cancer patient population.   
 
Comparing topics of discussion from consultation and HRQoL questionnaire items 
The topics of discussions identified from the analysis of clinic consultation audio-
recordings were tabulated.  The questionnaires identified from the review of the 
literature were examined to see how well each of the questionnaires covered the topics 
identified from the clinic consultations and to see if there was a suitable existing 
questionnaire which covered these issues adequately.  Review of the existing 
questionnaires also helped to identify any important or relevant issues which may not 
have been raised in the clinic consultations. 
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3.3.2 Stage 2. Construction of item list 
 
Items from existing HRQoL questionnaires were mapped onto the topics identified from 
the clinic consultation analysis.  Access to the items from EORTC Item Bank 
(Bottomley et al., 2002) was granted following request submitted by Prof Velikova.  
These items were used to augment any issues/topics which were not adequately 
addressed by items from questionnaires derived from above literature review. EORTC 
Item Bank holds many well validated items which have been tested by large patient 
population.  Access to this resource helped to bridge any perceived gaps in the 
coverage of topics by existing instruments, resulting in the formation of a 
comprehensive list of items to be put forward towards the final questionnaire.  
Original response options were maintained for each item depending on the 
questionnaire they had originated from.  Majority had Likert responses with four 
response options, ranging from “not at all” to “very much”. 
 
Previous focus group feedback from patients and oncologists (Velikova et al., 2007a) 
have indicated the need for questionnaire items to encompass issues concerning 
functional impact of cancer.  This included impact on patients’ daily activities, family life 
and sexuality.  Items encompassing these topics were also sought from the EORTC 
item bank if these were not already covered by the existing questionnaires. 
 
3.3.3 Stage 3. Interview with healthcare professionals 
 
The aims of the interview with the healthcare professional were 1) to evaluate which of 
the items they considered useful as part of patient assessment in routine clinic review 
of patients, 2) to ensure the breadth of coverage of relevant topics and 3) to check the 
wording of items and to remove any overlapping items. The list of items was grouped 
into a number of sections.  First section consisted of items concerning patients’ 
physical functioning, second section focused on symptoms and third section consisted 
on items addressing psychosocial issues.  The list of items presented to the healthcare 
professionals is presented in Appendix 1. 
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3.3.3.1 Study sample and procedure 
 
A list of oncologists working in Leeds Cancer Centre, specialising in the treatment of 
patients with colorectal cancer was compiled.  All relevant consultant medical 
oncologists and their specialist registrars, and consultant clinical oncologists who 
treated colorectal cancer patients with chemotherapy were approached by an invitation 
letter. Arrangements were then made for the interview to take place at a convenient 
time for the oncologists.  Clinical nurse specialists for bowel cancer patients are based 
in the surgical department and are not directly involved in oncology out-patient clinics 
at Leeds Cancer Centre.  Therefore, the interviews were conducted only with doctors. 
Interviews were carried out by two researchers, so that one of the two researchers was 
able to make notes during the interview.   
 
3.3.3.2 Data collection 
 
The interviews were semi-structured according to a predefined interview schedule 
prepared around the questionnaire items.  All questionnaire items were presented on 
paper. Firstly, oncologists were asked to comment about the physical functioning items 
and asked for their preference out of number of items listed.  The oncologists were 
then asked to review the items in the questionnaire and to provide their rating on 
whether they considered each of the items “useful”, “somewhat useful” or “not useful” in 
the assessment of patients undergoing chemotherapy treatment in their clinics. For the 
purpose of the analysis, the ratings were scored 1-3, with 1 indicating “not useful”.  
They were asked to comment the reasoning behind their rating selection.  The 
interview was audio-recorded and relevant sections were later transcribed. 
 
3.3.3.3 Analysis 
 
Rating provided by the oncologists for the questionnaire items were analysed using 
descriptive statistics.  This helped to illustrate their level of endorsement for each item.  
This assisted with decisions about removal of items.  Any discussions around items 
concerning psychosocial issues were transcribed verbatim from the audio-recordings of 
the interviews and analysed qualitatively using thematic analysis 
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3.3.4 Stage 4. Interview with patients 
 
3.3.4.1 Study sample and procedure 
 
The aims of the interviews with patients were 1) to address any administrative 
problems with the questionnaire, 2) to ensure items in the questionnaire were relevant 
to their experience and 3) to check clarity of wording.  Interviews with patients not only 
served the purpose of the pre-testing of the questionnaire as described in the EORTC 
questionnaire development guidelines, but also provided opportunities for them to 
suggest any additional issues not already addressed in the item list presented to them. 
Eligible patients were those with advanced colorectal cancer, attending oncology out-
patient clinics at Leeds Cancer Centre, undergoing chemotherapy treatment.  Patients 
were purposively selected to ensure both gender were represented and to encompass 
patients on different chemotherapy treatment which may have different toxicity profiles.  
 
The plan was to interview around 10 patients as suggested by the EORTC guidelines 
(Johnson et al., 2011) for this stage of the questionnaire development. The study was 
approved by the NHS Ethics Committee and written informed consent was obtained 
from all participating patients. 
 
All consenting patients were interviewed on the days when they were scheduled to 
attend the hospital in order to minimize additional visits. 
 
3.3.4.2 Data Collection 
 
Interviews conducted were semi-structured using a predefined interview schedule 
prepared around the questionnaire items. All participating patients were initially asked 
to complete the questionnaire items on touch screen computer and respond to the 
questions according to their own experience.  The questionnaire was uploaded and 
accessed through the Patient Pathway Manager (PPM), an electronic notes system 
used in the Leeds Cancer Centre.  PPM has a research management module which 
allows recording of patient involvement in research studies within the oncology 
department. The questionnaire was devised so that patients did not have the option to 
return to the previous questions; therefore they were unable to change their response 
once entered.  
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Any issues regarding the use of touch screen was noted. Following completion of the 
questionnaire, patients were asked to comment about the questionnaire items and any 
issues concerning wording of the items using paper copies of the questionnaire they 
had just completed.  They were also asked to provide suggestions for any issues not 
included in the questionnaire. All interviews were audio-recorded and later transcribed 
verbatim.  
 
3.3.4.3 Analysis 
 
The scores derived from the completion of the questionnaire items were analysed 
using descriptive statistics.  Majority of the questionnaire items had a Likert response, 
with four response options ranging from “not at all”, “a little”, “quite a bit” to “very much” 
scoring 1-4 respectively.  Items with different response options were analysed 
individually. This provided indication as to the prevalence of the issue questioned and 
severity of any problems experienced by the study participants.  A symptom/issue was 
considered to be present if the patient had responded to anything other than “not at all” 
or equivalent response.  The results from the quantitative analysis were later used to 
assist decisions regarding item removal.  
 
The interview transcripts were analysed qualitatively using thematic analysis to explore 
patients’ views on the questionnaire items, particularly in relation to their own 
experiences.  
 
3.4 Results 
 
3.4.1 Review of issues discussed in colorectal cancer patient 
consultations 
 
17 patients with colorectal cancer took part in the attention control study.  12 patients 
(70.6%) were men and 5 patients (29.4%) were women with median age of 67 years 
(range 47 – 86 years). 15 patients (88.2%) were receiving palliative chemotherapy for 
metastatic or locally advanced colorectal cancer, whereas 2 patients (11.8%) were 
receiving adjuvant chemotherapy following surgical resection of high risk colorectal 
cancer. 9 patients (53%) were receiving oral single agent Capecitabine and 4 patients 
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(24%) were receiving combination chemotherapy with either Oxaliplatin or Irinotecan 
with 5-Fluorouracil and folinic acid.  
 
There were total of 68 clinic consultations involving these 17 patients.  Data from all 68 
consultations was utilized in order to take full advantage of this valuable consultation 
data. The topics or issues raised during the consultation are listed in Table 3.3 in the 
order of frequency of discussion. Similar issues were grouped together, for example 
discussion of “weight” encompassed all discussions about weight including weight gain 
and loss.  
 
Table 3.3 Topics raised in oncology consultations 
 Topic raised in consultation Frequency % 
1 Overall functioning 62 91.2 
2 Bowel function 47 69.1 
3 Fatigue 40 58.8 
4 Nausea 33 48.5 
5 Pain 33 48.5 
6 Social functioning 33 48.5 
7 Sore mouth/tongue/ulcers 29 42.6 
8 Appetite 26 38.2 
9 Neuropathy 22 32.4 
10 Infection - cough/catarrh/cold 22 32.4 
11 Physical functioning 20 29.4 
12 Sore hands 19 27.9 
13 Skin - rash/dry/sore 18 26.5 
14 Weight 16 23.5 
15 Role functioning 15 22.1 
16 Emotional functioning 10 14.7 
17 Sleep 8 11.8 
18 Stomach - bloated/upset 8 11.8 
19 Dyspnoea 7 10.3 
20 Sore eyes/watery eyes 7 10.3 
21 Finance 6 8.8 
22 Hair loss 5 7.4 
23 Indigestion 5 7.4 
24 Taste 4 5.9 
25 Voice 4 5.9 
26 Dizziness 4 5.9 
27 Nose 4 5.9 
28 Swallowing 3 4.4 
29 Swollen legs/feet 3 4.4 
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30 Rectal bleeding 3 4.4 
31 Temperature - feeling hot/cold 3 4.4 
32 Throat issues 3 4.4 
33 Cognitive functioning 2 2.9 
34 Bleeding - general 2 2.9 
35 Headache 2 2.9 
36 Feet problems 2 2.9 
37 Bladder function 2 2.9 
38 Haemorrhoids 2 2.9 
39 Rectal discharge 1 1.5 
40 Genital discharge 1 1.5 
41 Flatulence 1 1.5 
42 Drinking 1 1.5 
43 Chest tightness 1 1.5 
 
3.4.2 Literature review 
 
The literature search returned 211 references.  There were 24 non English references 
which were excluded from review.  Further 24 references were removed as these 
specifically concerned patients with inflammatory bowel disease or they were 
concerned about genetic screening. Of the remaining 163 references, 42 specifically 
involved patients with rectal carcinoma, majority of these addressing the impact of 
surgical intervention for the disease. There were total of 34 questionnaires used in 
these references, which included a variety of questionnaires; some assessing general 
quality of life issues but others specifically focusing on a particular function such as 
continence. 64 references utilized the EORTC QLQ-C30 (Aaronson et al., 1993) 
together with EORTC QLQ-CR38 (Sprangers et al., 1999) as their quality of life 
instruments.  They were by far the most commonly utilized instruments. 
 
There were seven colorectal cancer specific questionnaires or questionnaires relevant 
to patients with colorectal cancer.  These instruments were: 
1. EORTC QLQ-CR38 (Sprangers et al., 1999) 
2. EORTC QLQ-CR29 (Whistance et al., 2009) 
3. FACT-C (Ward et al., 1999) 
4. EORTC QLQ-LMC21 (Blazeby et al., 2009) 
5. City of Hope Quality of Life – Ostomy (Grant et al., 2004) 
6. Stoma Quality of Life Scale (Baxter et al., 2006) 
7. Gastrointestinal Quality of Life Index (GIQLI) (Eypasch et al., 1995) 
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The items from these questionnaires were compared to the list of symptoms/issues 
raised during the routine clinic consultations as described above.  City of Hope Quality 
of Life – Ostomy and Stoma Quality of Life Scale was excluded from this part of the 
analysis as the questions within these questionnaires were specifically in relation to 
patients having a stoma. 
 
Table 3.4 lists the symptoms and issues discussed in routine clinic consultations and 
explores which questionnaires had the best coverage of these issues. 
The combination of EORTC QLQ-C30 the disease specific modules provided the best 
coverage.  EORTC QLQ-C30 plus QLQ-CR38, QLQ-CR29 and QLQ-LMC21 covered 
21, 22 and 17 symptoms/issues respectively. There were some differences in the 
issues covered across these questionnaires but overall, EORTC QLQ-C30 plus above 
three modules covered 24 symptoms/issues. Table 3.4 illustrates how well the 
instruments covered the topics identified from consultation analysis. Therefore, it was 
felt that the EORTC instruments were most suited to be used as the core structure for 
the development of the colorectal cancer specific questionnaire, QuEST–Cr. 
 
Table 3.4 Comparison between topics raised in 68 oncology consultations and topics 
covered in existing questionnaires 
Topic raised in consultation Freq (%) 
QLQ-C30 
+CR38 
QLQ-C30 
+CR29 
QLQ-C30 
+LMC21 
FACT-
C 
GIQLI 
Overall functioning 62 (91.2) x x x x x 
Bowel function 47 (69.1) x x x x x 
Fatigue 40 (58.8) x x x x x 
Nausea 33 (48.5) x x x x x 
Pain 33 (48.5) x x x x  
Social functioning 33 (48.5) x x x x x 
Sore mouth/tongue/ulcers 29 (42.6)   x   
Appetite 26 (38.2) x x x x x 
Neuropathy 22 (32.4)   x   
Infection - cough/catarrh/cold 22 (32.4)      
Physical functioning 20 (29.4) x x x x x 
Sore hands 19 (27.9)      
Skin - rash/dry/sore 18 (26.5)      
Weight 16 (23.5) x x x x  
Role functioning 15 (22.1) x x x x  
Emotional functioning 10 (14.7) x x x x x 
sleep 8 (11.8) x x x x  
Stomach - bloated/upset 8 (11.8) x x  x x 
Dyspnoea 7 (10.3) x x x   
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sore eyes/watery eyes 7 (10.3)      
Finance 6 (8.8) x x x   
hair loss 5 (7.4) x x    
Indigestion 5 (7.4)     x 
Taste 4 (5.9) x x    
Voice 4 (5.9)      
Dizziness 4 (5.9)      
Nose 4 (5.9)      
Swallowing 3 (4.4)     x 
Swollen legs/feet 3 (4.4)      
Rectal bleeding 3 (4.4) x x   x 
Temperature - feeling hot/cold 3 (4.4)      
Throat issues 3 (4.4)      
Cognitive functioning 2 (2.9) x x x   
Bleeding - general 2 (2.9)      
Headache 2 (2.9)      
Feet problems 2 (2.9)      
Bladder function 2 (2.9) x x    
piles 2 (2.9)      
rectal discharge 1 (1.5)  x    
Genital discharge 1 (1.5)      
flatulence 1 (1.5) x x   x 
drinking 1 (1.5)      
chest tightness 1 (1.5)      
Total number of topics covered   21 22 17 13 13 
 
3.4.3 Construction of the item list 
 
The questionnaires identified from the literature review included important topics which 
were not raised during the routine consultations analysed above.  As the aim of the 
colorectal cancer specific questionnaire was to raise any issues that patients may be 
having problems with, it was felt that these issues needed to be addressed. 
 
3.4.3.1 Stoma function 
 
Some patients with colorectal cancer may have undergone an operation which may 
have resulted in a formation of a stoma. Having a stoma can have an impact on the life 
of a patient in a number of ways (Brown and Randle, 2005).   Patients often require 
both psychological and social adjustments following a formation of a stoma (Brown and 
Randle, 2005).  Although stoma function or issues were not raised in the content 
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analysis of the consultations, it was felt important that this topic was included in the 
colorectal cancer questionnaire, QuEST-Cr. 
 
There were several questions related to stoma function from the questionnaires 
examined above. Items from QLQ-CR38, QLQ-CR29 and FACT-C were included in the 
list of items for review in the interview study. In addition to the questionnaires identified 
in the literature review, the comprehensive health assessment (CHA) questionnaires 
from Medical Research Council (MRC) FOCUS 2 Trial (Seymour et al., 2011) were 
reviewed. This study specifically looked at efficacy of modified dose palliative 
chemotherapy for patients with advanced colorectal cancer.  This study specifically 
involved patients who were older and had borderline performance status.  The CHA 
within this trial consisted on a number of questionnaires including Mini Mental Test 
examination (Folstein et al., 1975), Charlson Co-Morbidity Index (Charlson et al., 
1987), EQ5D (EuroQoL Group, 1990), Nottingham Extended Activities of Daily Living 
Scale (Nouri and Lincoln, 1987) and some items from EORTC QLQ-C30.  The authors 
had added their own stoma related questions and these were also included in the item 
list for review in the interview study. Questionnaires specifically looking at stoma 
related quality of life (City of Hope Quality of Life – Ostomy (Grant et al., 2004) and 
Stoma Quality of Life Scale (Baxter et al., 2006)) were considered too detailed to be 
included in QuEST-Cr. 
 
3.4.3.2 Sexual functioning and body image 
 
Treatment of colorectal cancer may involve a combination of surgery, radiotherapy and 
chemotherapy.  Treatment for rectal cancer patients in particular, often involves a type 
of surgery which may result in a formation of temporary or permanent stoma. Additional 
treatment with radiotherapy in combination with surgery may have a significant impact 
on patients’ bowel, bladder and sexual functioning (Sprangers et al., 1995, Reese et 
al., 2014, Ho et al., 2011). Despite this, sexual dysfunction remains understudied and 
often not discussed in clinic consultations (Flynn et al., 2012). Body image disturbance 
may be an issue, particularly for those patients with a stoma.  Presence of body image 
disturbance may be linked to higher prevalence of anxiety and depression among such 
patients (Sharpe et al., 2011). 
 
All of the colorectal cancer specific questionnaires identified from the review of 
literature included questions on sexual functioning. QLQ-CR38, QLQ-CR29, FACT-C 
65 
 
and the two stoma specific questionnaires contained items concerning body image. As 
I had chosen to use the EORTC questionnaires as my core list of questionnaire items, I 
decided to retain the relevant items from the EORTC modules regarding these topics. 
 
3.4.3.3 Physical functioning 
 
Physical function is a topic covered in many questionnaires identified in the review of 
literature.  It is one of the most commonly discussed functions in the oncology 
consultations as it can provide an indication as to how the patient may be responding 
to treatment, which may in turn have an impact on decisions about investigations and 
treatment. 
 
Physical function has been defined as “the performance of or capability to perform a 
variety of physical activities normal for people in good health” (Stewart and Kamberg, 
1992).  This encompasses activities of daily living (ADL) and instrumental activities of 
daily living (IADL).  ADL are basic tasks that we normally do such as self care, feeding 
ourselves and walking.  IADL are tasks which allow a person to live independently such 
as preparing meals, house work, managing money and shopping. 
 
World Health Organization (WHO) performance status is commonly used within clinical 
trials to describe the characteristics of patients’ physical ability and oncologists often 
use this as a surrogate measure of patients’ physical functioning in routine clinical 
practice.  Definition of WHO performance status is shown in Table 3.5. Karnofsky 
Performance Status Scale (Karnofsky, 1949) is another measure used by the clinicians 
to rate patients physical ability.  This scale is used less frequently compared to the 
WHO performance status but it also describes the patients’ physical ability using a 0-
100 scale; 100 indicating the best possible physical ability. 
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Table 3.5 WHO Performance Status 
Grade Explanation of activity 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up 
and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
 
As indicated in the review of literature, EORTC QLQ-C30 is one of the most commonly 
used HRQoL questionnaire used in oncology setting.  In the previous focus group study 
(Velikova et al., 2007a), oncologists made suggestions that physical functioning and 
other items within the QLQ-C30 could be made more useful for use in clinical practice 
so that patients could rate their physical function in the way that would match with 
oncologists’ assessments such as the WHO performance status. With this suggestion 
in mind, the WHO performance status was adapted into patient self report format to be 
presented to the oncologists for their view. 
 
Physical function assessments are included in many HRQoL instruments. Rotterdam 
Symptom Checklist (RSCL) (de Haes et al., 1990) is another HRQoL instrument 
developed for assessment of QoL in cancer patients.  This instrument also contains a 
physical function scale which encompasses activities of daily living (ADL) and 
instrumental activities of daily living (IADL) tasks. Unlike the EORTC QLQ-C30, RSCL 
items cover IADL tasks well such as patients’ ability of perform housework and 
shopping.  It was decided to retain physical function items from RSCL as well as those 
from the EORTC QLQ-C30 and the WHO performance status in patient self report 
format to be presented to the oncologists for review. They were separated from other 
functions and symptoms to specifically draw oncologists’ attention during the interview. 
These three physical function items were presented to healthcare professionals as part 
of the questionnaire development plan across the three cancer sites within the wider 
research programme. 
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3.4.3.4 Other issues  
 
There were several symptoms related to chemotherapy toxicities which were not 
covered by the existing questionnaires.  These were “Infection”,” Sore hands”,” skin 
problems”,” sore eyes” and “indigestion”. Questionnaire items relating to these 
symptoms were identified from the EORTC Quality of Life Group Item Bank (Bottomley 
et al., 2002) and also from FOCUS 2 Comprehensive Health Assessment 
questionnaires (Seymour et al., 2011). 
 
Chemotherapy treatment can cause lowering of the white blood cells which can make 
patients vulnerable to infection.  Therefore, an additional item was created specifically 
asking whether the patient had experienced an infection episode. 
 
Whilst discussing the items for consideration for the QuEST questionnaires with other 
researchers as part of the wider research programme, additional items were included 
from the EORTC Item Bank (Bottomley et al., 2002) concerning impact of the cancer 
treatments and patients’ future perspectives. 
 
The resulting item list is shown below (Table 3.6) with details of where the items have 
originated from. This list of questionnaire items was taken forward for the interview with 
the oncologists.  The first section consisted of physical function scales from EORTC 
QLQ-C30, Rotterdam Symptom Checklist (RSCL) and WHO performance status in 
patient self report format.  This was followed by items concerning toxicities of treatment 
or disease related symptoms, which also included stoma related items from EORTC 
QLQ-CR38, QLQ-CR29, FACT-C and FOCUS 2 for comments from the oncologists. 
Next section consisted of items concerning psychosocial issues and functioning.   
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Table 3.6 QuEST-Cr items and their origin (Full names of questionnaires with their 
references are presented in Appendix 2) 
Item Source 
Physical Function  
Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag 
or a suitcase? 
QLQ-C30 
Do you have any trouble taking a long walk? QLQ-C30 
Do you have any trouble taking a short walk outside of the house? QLQ-C30 
Do you need to stay in bed or a chair during the day? QLQ-C30 
Do you need help with eating, dressing, washing yourself or using the toilet? QLQ-C30 
A number of activities are listed below.  We do not want to know whether you actually do 
these, but only whether you are able to perform them presently.  Would you please mark 
the answer that applies most to your condition of the past week? 
 
Care for myself 
Walk about the house 
Light housework/household jobs 
Climb stairs 
Heavy housework/household jobs 
Walk out of doors 
Go shopping 
Go to work 
 
RSCL 
Please select one of the following items that best describes your current level of physical 
ability 
 
0 -  I am fully active and more or less as I was before my illness 
1 – I cannot carry out heavy physical work, but can do anything else 
2 – I am up and about more than half the day; I can look after myself, but not well 
enough to work  
3 – I am in bed or sitting in a chair for more than half the day; I need some help in self 
care 
4 – I am in bed or a chair all the time and need a lot of looking after 
 
WHO PS 
(adapted from 
CRUK Cancer 
Help website) 
Infection  
Have you had any infection since your last cycle of chemotherapy? New 
Have you been bothered by fevers or chills? QLQ-HDC29 
Chemotherapy toxicity/disease related symptoms  
Have you had sore mouth or tongue? QLQ-LMC21 
Have you had dry mouth? QLQ-CR29 
Have you had problems with sense of taste? QLQ-CR29 
Did food and drink taste different from usual? QLQ-CR38 
Have you lacked appetite? QLQ-C30 
Have you had trouble with eating? QLQ-LMC21 
Have you felt full up too quickly after beginning to eat? QLQ-LMC21 
Have you worried about losing weight? QLQ-LMC21 
Have you had indigestion or heartburn? QLQ-OV28 
Have you felt nauseated? QLQ-C30 
Have you vomited? QLQ-C30 
Have you been constipated? QLQ-C30 
Did you have bloated feeling in your abdomen? QLQ-CR29 
Were you troubled by passing wind/gas/flatulence? QLQ-OV28 
Have you had diarrhoea? QLQ-C30 
Have you blood in your stools? QLQ-CR29 
Have you had mucus in your stools? QLQ-CR29 
Have your skin or eyes been yellow (jaundiced)? QLQ-LMC21 
Have you had soreness or redness of your hands or feet? FOCUS2 
Have you had any other skin problems (e.g. itching, dryness, sensitivity to sun)? QLQ-OV28 
Have you had tingling or numbness in your hands or feet? 
QLQ-CR29 
modified 
Are you concerned by any changes in your hearing? 
QLQ-OV28 
modified 
Have you lost your hair as a result of your treatment? QLQ-CR29 
Have you been upset by hair loss? QLQ-OV28 
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Stoma  
Do you have a stoma?  
 Yes      No 
 
If yes, have you had any problems with it (for example soreness of skin, increased 
frequency, leakage)? 
FOCUS2 
Do you have a stoma? 
 Yes      No 
 
Only for patients WITHOUT a stoma 
Did you have frequent bowel movements during the day? 
Did you have frequent bowel movements during the night? 
Did you feel the urge to move your bowel movements without actually producing any 
stools? 
Have you had any unintentional release of stools? 
Have you had any blood in your stools? 
Have you had any difficulty in moving your stools? 
Have your bowel movements been painful? 
 
Only for patients WITH a stoma 
Were you afraid that other people would be able to hear your stoma? 
Were you afraid that other people would be able to smell your stoma? 
Were you worried about possible leakage from the stoma? 
Did you have problems caring for your stoma? 
Was your skin around the stoma irritated? 
Did you feel embarrassed because of your stoma? 
Did you feel less complete because of your stoma? 
 
QLQ-CR38 
Do you have a stoma bag (colostomy/ ileostomy)? Please circle the correct answer. 
 Yes      No 
 
Answer these questions ONLY IF YOU HAVE A STOMA BAG 
Have you had unintentional release of gas/flatulence from your stoma bag? 
Have you had leakage of stools from your stoma bag? 
Have you had sore skin around your stoma? 
Did frequent bag change occur during the day? 
Did frequent bag change occur during the night? 
Did you feel embarrassed because of your stoma? 
Did you have problems caring for your stoma? 
 
Answer these questions ONLY IF YOU DO NOT HAVE A STOMA BAG 
Have you had unintentional release of gas/flatulence from your back passage? 
Have you had leakage of stools from your back passage? 
Have you had sore skin around your anal area? 
Did frequent bowel movements occur during the day? 
Did frequent bowel movements occur during the night? 
Did you feel embarrassed because of your bowel movement? 
QLQ-CR29 
Do you have an ostomy appliance? 
 Yes      No 
 
If yes, please answer the next two items: 
I am embarrassed by my ostomy appliance 
 
Caring for my ostomy appliance is difficult 
FACT-C 
Fatigue  
Have you had trouble sleeping? QLQ-C30 
Did you need to rest? QLQ-C30 
Have you felt weak? QLQ-C30 
Were you tired? QLQ-C30 
Have you been less active than you would like to be? QLQ-LMC21 
Have you felt slowed down? QLQ-LMC21 
Have you felt lacking in energy? QLQ-LMC21 
Pain  
Have you had pain? QLQ-C30 
Did pain interfere with your daily activities? QLQ-C30 
Did you have abdominal pain? QLQ-CR29 
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Have you had pain in your stomach area? QLQ-LMC21 
Have you had discomfort in your stomach area? QLQ-LMC21 
Did you have pain in your buttocks/anal area/rectum? QLQ-CR29 
Have you had pain in your back? QLQ-LMC21 
Bladder function  
Did you urinate frequently during the day? QLQ-CR29 
Did you urinate frequently during the night? QLQ-CR29 
Have you had any unintentional release (leakage) of urine? QLQ-CR29 
Did you have pain when you urinated? QLQ-CR29 
Others  
Were you short of breath? QLQ-C30 
Were your eyes painful, irritated or watery? QLQ-Br23 
Did you feel ill or unwell? QLQ-Br23 
Emotional/Cognitive Function  
Have you had difficulty in concentrating on things, like reading the newspaper or 
watching television? QLQ-C30 
Did you feel tense? QLQ-C30 
Did you worry? QLQ-C30 
Did you feel irritable? QLQ-C30 
Did you feel depressed? QLQ-C30 
Have you had difficulty remembering things? QLQ-C30 
Have you had trouble talking about your feelings to your family and friends? QLQ-LMC21 
Have you felt stressed? QLQ-LMC21 
Have you felt less able to enjoy yourself? QLQ-LMC21 
Body Image  
Have you felt physically less attractive as a result of your disease or your treatment? QLQ-CR29 
Have you been feeling less feminine/masculine as a result of your disease or your 
treatment? QLQ-CR29 
Have you been dissatisfied with your body? QLQ-CR29 
Sexual Function  
Has the disease or treatment affected your sex life (for the worse)? QLQ-LMC21 
To what extent were you interested in sex? (Men) QLQ-CR29 
Did you have difficulty getting or maintaining an erection? (Men) QLQ-CR29 
To what extent were you interested in sex? (Women) QLQ-CR29 
Did you have pain or discomfort during intercourse? (Women) QLQ-CR29 
Coping and Future Perspectives  
How much has your disease been a burden to you? QLQ-OV28 
How much has your treatment been a burden to you? QLQ-OV28 
How much has your chemotherapy treatment interfered with your normal daily activities? FOCUS2 
Have you worried about your health in the future? QLQ-LMC21 
Were your worried about your family in the future? QLQ-LMC21 
Did you feel uncertain about the future? QLQ-BN20 
Were the side effects of treatment worse than you expected? QLQ-HDC45 
Were you concerned about disruption of family life? QLQ-BN20 
Role and Social Function  
Were you limited in doing either your work or other daily activities? QLQ-C30 
Were you limited in pursuing your hobbies or other leisure time activities? QLQ-C30 
Has your physical condition or medical treatment interfered with your family life? QLQ-C30 
Has your physical condition or medical treatment interfered with your social life? QLQ-C30 
Has your physical condition or medical treatment caused you financial difficulties? QLQ-C30 
Have you had trouble having social contact with friends? QLQ-LMC21 
Treatment Worth  
Since you started chemotherapy, how worthwhile do you think your treatment has been? 
 
FOCUS2 
 
Three physical function scales, four sets of stoma related items and 79 items 
encompassing symptoms and various functions were presented to the oncologists for 
review. 
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3.4.4 Interview with healthcare professionals 
 
7 oncologists participated in the study. (Male=5).  4 were consultants and 3 were 
specialist registrars. As the target population for this questionnaire is patients with 
advanced colorectal cancer, receiving palliative chemotherapy, the interviews were 
conducted predominantly with Medical Oncologists who normally treat such cases in 
Leeds.  However, one Clinical (or Radiation) Oncologist was invited to participate as 
her practice provides palliative chemotherapy for significant number of patients with 
advanced colorectal cancer. The median age of oncologists interviewed was 37 years 
(range 29–47 years) with varied length of experience in oncology practice (mean 9.6 
years; range 2–18 years). 
 
All oncologists were presented with the above list of questionnaire items on paper and 
asked to rate individual questionnaire item according to how useful they would find the 
responses from the questionnaire items in routine clinical practice. They had three 
response options, “not useful”, “somewhat useful” and “useful” 
 
It was apparent that oncologists were able to provide rating for many of the symptom 
related questions with relative ease.  However, regarding items concerning 
psychosocial issues, they often preferred to describe their thoughts and views about 
these issues rather than providing a rating as such. 
 
3.4.4.1 Physical function 
 
All oncologists felt that the items in this section were simple for their patients to 
respond to. They were asked to choose their preference between EORTC QLQ-C30 
and RSCL items; 4 preferred EORTC QLQ-C30 items and 3 preferred the RSCL items. 
One of the doctors commented that the QLQ-C30 items mirrored the WHO 
performance status to some extent. Doctors who preferred the RSCL commented that 
the activities listed were more relevant to their patients. Two of the doctors commented 
on the preamble of the RSCL, which asks patients whether they are able to carry out 
the tasks listed rather than whether they actually perform them.  They felt that this may 
add a layer of complexity for the patients when they respond. In addition, they also 
commented that most of their patients are retired and “go to work” was irrelevant for 
their patients. Most of the doctors felt that WHO performance status would be a useful 
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addition to the physical function scale although some commented that this should be 
documented in the notes routinely anyway. 
 
Decisions made following the interview 
 
All three physical function scales were retained for review by the patients. RSCL 
preamble was removed and each task was made into a question format. For example, 
“Care for myself” was changed to “Are you able to care for yourself?” 
 
3.4.4.2 Chemotherapy toxicities and disease related symptoms 
 
There were 47 items in this section of the item list, covering treatment side effects and 
disease related symptoms.  The highly endorsed items were those relating to 
chemotherapy toxicities; sore mouth, nausea, vomiting, bowel function, sensory 
neuropathy, hand foot syndrome, pain and eye problems. Table 3.7 lists the items in 
the order of oncologists’ endorsement as indicated by the mean score derived from 
their rating. 
 
Table 3.7 Oncologist rating of colorectal cancer symptom items sorted by mean rating  
Symptoms mean 
1. Have you had sore mouth or tongue? 3.00 
2. Have you felt nauseated? 3.00 
3. Have you vomited? 3.00 
4. Have you been constipated? 3.00 
5. Have you had diarrhoea? 3.00 
6. Have you had soreness or redness of your hands or feet? 3.00 
7. Have you had tingling or numbness in your hands or feet? 3.00 
8. Have you had pain? 3.00 
9. Were your eyes painful, irritated or watery? 3.00 
10. Have you had indigestion or heartburn? 2.86 
11. Did food and drink taste different from usual? 2.71 
12. Have you lacked appetite? 2.71 
13. Have you had trouble sleeping? 2.71 
14. Did pain interfere with your daily activities? 2.71 
15. Have you had any infection since your last cycle of chemotherapy? 2.57 
16. Were you short of breath? 2.57 
17. Were you tired? 2.50 
18.  Have you been upset by hair loss? 2.43 
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19. Did you feel ill or unwell? 2.43 
20. Have you been less active than you would like to be? 2.33 
21. Have you been bothered by fevers or chills? 2.14 
22. Have you worried about losing weight? 2.14 
23. Did you have bloated feeling in your abdomen? 2.14 
24. Were you troubled by passing wind/gas/flatulence? 2.14 
25. Have you blood in your stools? 2.14 
26. Have you had any other skin problems (e.g. itching, dryness, sensitivity to sun)? 2.14 
27. Did you need to rest? 2.14 
28. Have you had trouble with eating? 2.00 
29. Have you felt full up too quickly after beginning to eat? 2.00 
30. Have you had mucus in your stools? 2.00 
31. Have you felt weak? 2.00 
32. Have you felt slowed down? 2.00 
33. Have you felt lacking in energy? 2.00 
34. Did you have pain in your buttocks/anal area/rectum? 2.00 
35. Did you have pain when you urinated? 2.00 
36. Have you had dry mouth? 1.86 
37. Have your skin or eyes been yellow (jaundiced)? 1.86 
38. Are you concerned by any changes in your hearing? 1.86 
39. Have you had pain in your back? 1.86 
40. Have you had problems with sense of taste?  1.71 
41. Did you have abdominal pain? 1.71 
42. Have you had discomfort in your stomach area? 1.71 
43. Have you had any unintentional release (leakage) of urine? 1.71 
44. Have you had pain in your stomach area? 1.57 
45. Did you urinate frequently during the day? 1.57 
46. Did you urinate frequently during the night? 1.57 
47. Have you lost your hair as a result of your treatment? 1.29 
Scoring:1="Not useful", 2="Somewhat useful", 3="useful" 
 
 
Items with oncologists’ mean rating score ≤ 2.0 were reviewed. Oncologists felt that 
pain was an important disease related issue to be raised during the consultation.  
However, they did not feel that enquiry about the specific sites of pain was necessary 
as this would be discussed in the consultation. Items directly relating to the primary 
tumour were considered perhaps less useful such as “blood and mucus in the stool”. 
Items on micturition were considered unnecessary but if the question was to be raised 
then they suggested reducing to one question. Items such as jaundice and hair loss 
would be apparent when the doctor sees that patient so these were considered 
unnecessary. However, impact of hair loss was considered worth asking, although not 
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many chemotherapy regimens used in the treatment of colorectal cancer caused total 
hair loss.  
 
Many oncologists agreed that fatigue is important to assess.  However, they felt there 
were too many questions presented covering this topic and recommended item 
reduction.  Infection was important as chemotherapy treatment can cause 
myelosuppresion making patients vulnerable to potentially serious infection.  “Fevers 
and chills” question was considered non-specific and direct question about infection 
was thought to be more useful. Asking specifically whether the patient received 
antibiotics may be helpful in determining the severity of the infection episode. Enquiry 
about whether the patient has been admitted to hospital during a treatment cycle might 
be helpful as this may have been due to treatment toxicity. This may have impact on 
decisions about treatment. 
 
Decisions made following the interview 
 
Two items concerning antibiotics and hospital admission were created following 
comments by the oncologists. Items which scored less than or equal to 2.0 were 
removed, except for two items concerning “fatigue” and one item concerning “taste” 
which were retained for patients’ views. Items regarding problems with micturition/ 
bladder function were replaced by “Have you had any problems with your water works” 
as suggested by the oncologists. Two items were removed despite oncologists' mean 
score being >2.0 because of the comments they had made during the interviews 
(“troubled by wind/gas/flatulence” and “blood in stools”). 
 
3.4.4.3 Stoma questions 
 
Oncologists interviewed estimated that approximately 10-30% of their patients had a 
stoma. They all acknowledged that having a stoma may have wider implications for 
patients and that this topic should be covered in the questionnaire. Many considered 
items from QLQ-CR38 and QLQ-CR29 were too long and burdensome for patients.  
However, several doctors liked two items from QLQ-CR38; “Did you feel embarrassed 
because of your stoma?” and “Did you feel less complete because of your stoma?”  
They felt that these two items captured the body image issues experienced by the 
patients in relation to the stoma. In addition, some of the oncologists thought “Were you 
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afraid that other people would be able to smell your stools?” might be a genuine 
concern for patients. Of the two remaining sets of questions, all of the oncologists 
interviewed preferred the items from FOCUS2.  
 
Decisions made following the interview 
 
The stoma questions from FOCUS2 and the three items described above were 
retained to take forward to patient interviews. 
 
3.4.4.4 Psychosocial issues 
 
Although many oncologists provided some rating for the questions covering 
psychosocial issues, they provided their broader views about questionnaires raising 
issues listed in the item list. Audio-recording of this section of the interviews were 
transcribed verbatim and analysed using qualitative thematic analysis. 
The discussions took place around the questionnaire items which were grouped 
according to the relevant topics such as emotional functioning, body image, sexual 
functioning and treatment impact on patients’ social and role functioning. The key 
themes that have emerged from the analysis of the interviews were: 
 Implications of raising issues through questionnaire 
 Oncologists’ beliefs about the relevance of questions 
 Recommendations for the questionnaire including suggestions for 
wording/rephrasing of items 
 
3.4.4.5 Emotional functioning 
 
Implications of raising issues through questionnaire 
 
All oncologists recognised the importance of assessing emotional functioning of their 
patients.  Many welcomed routine assessment although two of the specialist registrars 
were concerned about how they may respond to a patient whose questionnaire scores 
indicated significant problems. They stated that they would welcome a specific 
guidance in managing such patients and having a defined pathway for further 
assessments by Psycho-Oncology team. One of the registrars stated that he would 
have a sense of patients’ emotional state when you meet them in clinic and from their 
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general demeanour, particularly if there had been a previous encounter with that 
patient.  He stated that questionnaire scores indicating poor emotional functioning, 
especially if this is observed repeatedly over time, may help support decisions about 
formal referral to allied services.    
 
Oncologists’ beliefs about relevance of questions 
 
Many oncologists were not convinced that their patients may relate to some of the 
items listed, in particular, many did not like the word “depressed” as they felt that there 
was a significant stigma attached to this word. Majority felt that their patients would 
better relate to phrases such as “feeling low in mood”. 
  
Decisions made following the interview 
 
Following the interview with the oncologists, it was decided to retain the QLQ-C30 
emotional function scale so that patients’ views can be obtained on these items.  
Additional items were added to encompass comments made by the oncologists.  The 
MHI-5 (Berwick et al., 1991) is a 5 item measure of emotional distress which has been 
shown to be a useful screening tool (Cull et al., 2001). The MHI-5 utilizes everyday 
language such as ‘downhearted and low” which may allow patients to better relate to 
the questions. The MHI-5 items were therefore included in the questionnaire to be 
presented to the patients in the interviews. In addition, two further items were added.  
These were “have you been bothered by mood changes?” and “Have you felt tearful?” 
It was felt that these may also be appropriate and relevant to the patients in describing 
their emotional state. 
 
3.4.4.6 Cognitive function 
 
Implications of raising issues through questionnaire 
 
There were two items addressing patients’ cognitive function.  Majority of the 
oncologists liked the question concerning “concentration” as it linked with specific 
activities “reading the newspaper” or “watching the television”.  They all felt that 
patients would be able to relate to this question. 
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Oncologists generally considered cognitive function assessment to be important 
although they indicated that colorectal cancer patients are generally older and there 
may be a number of reasons for why their cognitive function may be impaired.  There 
was a suggestion that perhaps they would not know what to do if the patient had 
reported poor cognitive functioning.  
 
3.4.4.7 Body Image 
 
Implications of raising issues through questionnaire 
 
Oncologist commented that they did not discuss about body image with their patients.  
They felt that body image is more likely to be a concern when patients are in follow up 
rather than when they are undergoing chemotherapy treatment when the focus of their 
clinic attendance would naturally be on managing and supporting patients through 
treatment. Some of the oncologists felt that there needed a specific referral pathway for 
patients if a problem was identified as asking the question would raise patients’ 
expectations. 
 
Oncologists’ beliefs about relevance of questions 
 
Several oncologists commented that many of the colorectal cancer patients are older 
men and body image issues are not as prevalent as other disease groups such as 
breast cancer. They felt that “attractive” or “less feminine or masculine” did not really 
capture body image issues which may be present among this group of patients. 
 
Recommendations for the questionnaire 
 
Some of the doctors felt that this topic should ideally be covered in a format where 
patients can specifically indicate whether they wished to discuss this topic with them. 
Phrases such as “feeling less complete”, “embarrassed” and “disfigured” may be more 
suitable for this group of patients, particularly for those who have undergone a surgery 
which may have resulted in a formation of a stoma. It was also suggested that patients 
should be given the option not to respond to these questions.  
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Decisions made following the interview 
 
The EORTC body image items were retained for discussion with patients.  Two items 
“Feeling less complete” and “embarrassed” were retained as part of the stoma function 
assessments as described previously. Option to allow patients to skip these questions 
was implemented for the patient interview stage of the study. 
 
3.4.4.8 Sexual function 
 
Implications of raising issues through questionnaire 
 
Many doctors felt that impact on patients’ sexual function was an important issue for 
their patients.  Some of the specialist registrars admitted that they would feel 
embarrassed to raise or discuss the subject unless it was brought up by the patient.  
Many felt that questionnaire was a good way of raising the topic for discussion. 
However, many oncologists felt that they were ill equipped in dealing such problems 
and indicted they would like a clear guidance on how this issue can be managed, 
although they appreciated that any treatment recommendation would be dependent on 
the specific problems experienced by the patient.   
 
Oncologists’ beliefs about relevance of questions 
 
Some oncologists felt that many of their patients are probably not sexually active given 
the age of the population. In addition, oncologists suspected that their patients would 
not answer or respond to the questionnaire items concerning sexual function. However, 
many felt that this was a relevant topic particularly for patients with rectal carcinoma, 
who may have undergone surgical and/or radiotherapy treatments previously, which 
may have had significant impact on their sexual function. For those that are sexually 
active, oncologists felt that the questionnaire items presented were satisfactory. 
 
Recommendations for the questionnaire 
 
Oncologists suggested that patient should be given the option not to answer these 
questions on the touch screen computer.  Suggestions were made about having an 
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opening question enquiring whether the patient had any issues concerning their sexual 
function and depending on their response this opener, further items may be presented 
to explore specific concerns. It was considered more helpful if the patient was given the 
option to indicate whether they specifically wished to discuss this area. 
 
Decisions made following the interview 
 
All the sexual function items were retained for review by the patients; however, specific 
message was inserted on the touch screen computer indicating that patients may skip 
these items if they did not wish to respond to them.  
 
3.4.4.9 Treatment impact on patients’ social and role functioning and future 
perspectives 
 
Implications of raising issues through questionnaire 
 
Many oncologists were interested to know about patients’ expectations of 
chemotherapy and whether they had been adequately informed of all the possible 
toxicities. They also liked the item enquiring about the impact of treatment on patients’ 
“normal daily activities” though this may overlap with the physical function items.  They 
were also interested to know whether patients have found their treatment “worthwhile”, 
despite of all the toxicities and inconvenience associated with their treatment. Some felt 
that this may assist in making decisions about future treatment for patients, particularly 
if a patient had equivocal response on radiological evaluation from previous treatments. 
Item on “finance” was generally well received as this is not a topic often raised in 
oncology consultations, yet it may have a huge impact on patients’ day to day lives.  
Oncologists felt that referral to a social worker would be straight forward once any 
financial concerns are identified. 
 
Many oncologists felt the future perspective items were not very helpful, stating that all 
patients with incurable cancer would be facing uncertainties.  In particular the “worry 
about your future health” was not considered useful.  They were unsure how they might 
handle patients’ response to this question but considered this would link with 
discussions about prognosis. 
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Table 3.8 Comments made by oncologists during interviews 
Emotional Function 
Implications of raising 
issues 
“These are things that I don’t know how to deal with” 
Relevance of questions “(poor emotional functioning) can have a huge impact on how patients cope 
with their treatment” 
 
“it’s the sort of thing you want to ask every time (to monitor)” 
Recommendation for 
wording 
“Would use phrases like - have you been worrying about things?” 
 
“Low in mood better than depressed” 
 
“(depressed) has a stigma attached to it as a medical term” 
 
“need questionnaire to capture people who need help” 
Cognitive 
Implications of raising 
issues 
 
Relevance of questions “(Colorectal cancer  patients are) older population in general and forgetfulness 
is part of the aging process” 
Recommendation for 
wording 
 
Body Image/Sexual function 
Implications of raising 
issues 
“The obvious problem with these questions is when the answers come out, we 
need tools to intercede and a referral network in place” 
 
“I don’t particularly feel qualified to deal body image – all I could do is to get in 
touch with someone that can help with that – maybe that’s all I need to do”  
 
“Many patients feel embarrassed to talk about these things (sexual function) 
but it can really worry them so questionnaire can help to raise these issues” 
 
“I suspect it would be something that won’t take the consultation anywhere” 
Relevance of questions “Physical attractiveness has not been an issue anyone has raised with me” 
“attractive may not be relevant but they can still have body image issues” 
 
“I’m not sure that asking a 75 year old man whether he feels physically less 
attractive as a result of having colorectal cancer is appropriate or useful thing 
to do, quite frankly” 
 
“patients may live several years on palliative chemotherapy so sexual function 
may be important” 
Recommendation for 
wording 
“a general opening question to the topic (sexual function) might be useful as a 
screening tool” 
 
“you don’t want to be asking these questions every 2-3 weeks” 
 
“feeling embarrassed might be more relevant” 
Role, social coping 
Implications of raising 
issues 
“(side effects and treatment interfering with daily activities) are useful thing to 
ask as we never specifically ask this (though it may be inferred by going 
through other questions” 
 
“Worry about family – there are two stems to that. Hereditary cancer risk to 
your children and family as a broad concept”  
 
“it’s useful to know (treatment worth) as it might help make decisions about 
future treatment if patients feel they got much out of it (chemotherapy) despite 
side effects” 
Relevance of questions “not sure how useful this information is (role and social) as it probably won’t 
affect treatment decisions” 
 
“Anybody feels uncertain about their future.  It’s just the whole uncertainty 
when you’ve got cancer” 
 
“I would definitely keep the finance question” 
Recommendation for 
wording 
“better to say how has it (cancer and treatment)affected your life or  changed 
your life (rather than burden)” 
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Oncologists’ beliefs about relevance of questions 
 
Oncologists anticipated that chemotherapy treatment would inevitably have impact on 
patients’ social and role functions.  Although patient reported data may provide further 
insight into the impact of patients’ experience of their treatment, oncologists felt that 
this would not directly have an impact on decisions about treatment. 
Recommendations for the questionnaire 
 
There were several items covering similar topics within this section and suggestions 
were made to reduce the number of items.  Many oncologists did not like the word 
“burden” in the two items enquiring about treatment and disease impact.  
 
Decisions made following the interview 
 
5 items were removed which had the least support from the oncologists from their 
comments and were considered to be overlapping.  The role and social function items 
from EORTC QLQ-C30 were retained for patient interviews. Two items on future 
perspectives were retained for patient interviews for their opinion. All the changes 
made following the interviews with the oncologists are presented in Table 3.9. 
 
Table 3.9 Summary table of changes made after interview with oncologists 
Items Outcome after interview 
with oncologists 
Physical Function  
Do you have any trouble doing strenuous activities, like carrying a heavy 
shopping bag or a suitcase? 
 
Do you have any trouble taking a long walk? 
Do you have any trouble taking a short walk outside of the house? 
Do you need to stay in bed or a chair during the day? 
Do you need help with eating, dressing, washing yourself or using the 
toilet? 
A number of activities are listed below.  We do not want to know whether 
you actually do these, but only whether you are able to perform them 
presently.  Would you please mark the answer that applies most to your 
condition of the past week? 
 
Care for myself 
Walk about the house 
Light housework/household jobs 
Climb stairs 
Heavy housework/household jobs 
Walk out of doors 
Go shopping 
Go to work 
 
 
However, “Go to work” was 
removed. 
 
Questions were modified 
into question format for each 
item. (e.g. “Are you able to 
care for yourself?”) 
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Please select one of the following items that best describes your current 
level of physical ability 
 
0 -  I am fully active and more or less as I was before my illness 
1 – I cannot carry out heavy physical work, but can do anything else 
2 – I am up and about more than half the day; I can look after myself, but 
not well enough to work  
3 – I am in bed or sitting in a chair for more than half the day; I need some 
help in self care 
4 – I am in bed or a chair all the time and need a lot of looking after 
 
 
Infection  
Have you had any infection since your last cycle of chemotherapy?  
Were you admitted to hospital during your last cycle of chemotherapy? New 
Were you prescribed any antibiotics during your last cycle of 
chemotherapy? 
New 
Have you been bothered by fevers or chills? X 
Chemotherapy toxicity/disease related symptoms  
Have you had sore mouth or tongue?  
Have you had dry mouth? X 
Have you had problems with sense of taste?  
Did food and drink taste different from usual?  
Have you lacked appetite?  
Have you had trouble with eating? X 
Have you felt full up too quickly after beginning to eat? X 
Have you worried about losing weight? X 
Have you had acid indigestion or heartburn? Modified 
Have you felt nauseated (sick)? Modified 
Have you vomited?  
Have you been constipated?  
Did you have bloated feeling in your abdomen?  
Were you troubled by passing wind/gas/flatulence? X 
Have you had diarrhoea?  
Have you had blood in your stools? X 
Have you had mucus in your stools? X 
Have your skin or eyes been yellow (jaundiced)? X 
Have you had soreness or redness of your hands or feet?  
Have you had any other skin problems (e.g. itching, dryness, sensitivity to 
sun)? 
 
Have you had tingling or numbness in your hands or feet?  
Are you concerned by any changes in your hearing? X 
Have you lost your hair as a result of your treatment? X 
Have you been upset by hair loss?  
Stoma  
Do you have a stoma?  
 Yes      No 
 
If yes, have you had any problems with it (for example soreness of skin, 
increased frequency, leakage)? 
 
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Do you have a stoma? 
 Yes      No 
 
Only for patients WITHOUT a stoma 
Did you have frequent bowel movements during the day? 
Did you have frequent bowel movements during the night? 
Did you feel the urge to move your bowel movements without actually 
producing any stools? 
Have you had any unintentional release of stools? 
Have you had any blood in your stools? 
Have you had any difficulty in moving your stools? 
Have your bowel movements been painful? 
 
 
 
Only for patients WITH a stoma 
Were you afraid that other people would be able to hear your stoma? 
Were you afraid that other people would be able to smell your stoma? 
Were you worried about possible leakage from the stoma? 
Did you have problems caring for your stoma? 
Was your skin around the stoma irritated? 
Did you feel embarrassed because of your stoma? 
Did you feel less complete because of your stoma? 
 
Removed except for three 
items 
 Were you afraid that 
other people would be 
able to smell your 
stoma? 
 Did you feel 
embarrassed because 
of your stoma? 
 Did you feel less 
complete because of 
your stoma? 
 
Do you have a stoma bag (colostomy/ ileostomy)? Please circle the correct 
answer. 
 Yes      No 
 
Answer these questions ONLY IF YOU HAVE A STOMA BAG 
Have you had unintentional release of gas/flatulence from your stoma bag? 
Have you had leakage of stools from your stoma bag? 
Have you had sore skin around your stoma? 
Did frequent bag change occur during the day? 
Did frequent bag change occur during the night? 
Did you feel embarrassed because of your stoma? 
Did you have problems caring for your stoma? 
 
Answer these questions ONLY IF YOU DO NOT HAVE A STOMA BAG 
Have you had unintentional release of gas/flatulence from your back 
passage? 
Have you had leakage of stools from your back passage? 
Have you had sore skin around your anal area? 
Did frequent bowel movements occur during the day? 
Did frequent bowel movements occur during the night? 
Did you feel embarrassed because of your bowel movement? 
X 
Do you have an ostomy appliance? 
 Yes      No 
 
If yes, please answer the next two items: 
I am embarrassed by my ostomy appliance 
 
Caring for my ostomy appliance is difficult 
X 
Fatigue  
Have you had trouble sleeping?  
Did you need to rest?  
Have you felt weak?  
Were you tired?  
Have you been less active than you would like to be?  
Have you felt slowed down? X 
Have you felt lacking in energy?  
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Pain  
Have you had pain?  
Did pain interfere with your daily activities?  
Did you have abdominal pain? X 
Have you had pain in your stomach area? X 
Have you had discomfort in your stomach area? X 
Did you have pain in your buttocks/anal area/rectum? X 
Have you had pain in your back? X 
Bladder function  
Did you urinate frequently during the day? X 
Did you urinate frequently during the night? X 
Have you had any unintentional release (leakage) of urine? X 
Did you have pain when you urinated? X 
Have you had any trouble with your waterworks? New  
Others  
Were you short of breath?  
Were your eyes painful, irritated or watery?  
Have you felt ill or unwell? Modified 
  
Emotional/Cognitive Function  
Have you had difficulty in concentrating on things, like reading the 
newspaper or watching television? 
 
Did you feel tense?  
Did you worry?  
Did you feel irritable?  
Did you feel depressed?  
Have you had difficulty remembering things?  
Have you had trouble talking about your feelings to your family and 
friends? 
 
Have you felt stressed?  
Have you felt less able to enjoy yourself?  
Have you been tearful? New  
Have you been bothered by mood changed? New 
Have you felt calm and peaceful?  New (MHI-5) 
Have you felt downhearted and low? New (MHI-5) 
Have you been a happy person? New (MHI-5) 
Have you felt so down in the dumps that nothing could cheer you up? New (MHI-5) 
Have you been a very nervous person? New (MHI-5) 
Body Image  
Have you felt physically less attractive as a result of your disease or your 
treatment? 
 
Have you been feeling less feminine/masculine as a result of your disease 
or your treatment? 
 
Have you been dissatisfied with your body?  
Sexual Function  
Has the disease or treatment affected your sex life (for the worse)?  
To what extent were you interested in sex? (Men)  
Did you have difficulty getting or maintaining an erection? (Men)  
To what extent were you interested in sex? (Women)  
Did you have pain or discomfort during intercourse? (Women)  
Coping and Future Perspectives  
How much has your disease been a burden to you? X 
How much has your treatment been a burden to you? X 
How much has your chemotherapy treatment interfered with your normal 
daily activities?  
Have you worried about your health in the future? X 
Were your worried about your family in the future?  
Did you feel uncertain about the future?  
Were the side effects of treatment worse than you expected?  
Were you concerned about disruption of family life? X 
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Role and Social Function  
Were you limited in doing either your work or other daily activities?  
Were you limited in pursuing your hobbies or other leisure time activities?  
Has your physical condition or medical treatment interfered with your family 
life? 
 
Has your physical condition or medical treatment interfered with your social 
life? 
 
Has your physical condition or medical treatment caused you financial 
difficulties? 
 
Have you had trouble having social contact with friends? X 
Treatment Worth  
Since you started chemotherapy, how worthwhile do you think your 
treatment has been? 
 
 
: Item retained, X: item removed  
 
3.4.5 Interview with patients 
 
Thirteen patients were approached to take part in the study.  Three patients declined.  
Total of 10 patients completed the study; 6 were men and 4 were women.  Their 
median age was 64.5 years (rage 58 – 70).  9 out of 10 patients were retired.   
They all had metastatic (stage 4) colorectal cancer. 9 out of 10 patients had liver 
metastasis. Patients’ disease characteristics and treatment regimens are described in 
Table 3.10 
 
Table 3.10 Patient characteristics 
  Number 
Primary disease site Ascending colon 
Transverse colon 
Sigmoid colon 
Recto-sigmoid junction 
rectum 
1  
1 
5 
1 
2 
Extent of metastatic disease One organ 
Two organs or more 
3 
7 
Chemotherapy regimen Oxaliplatin and 5 Fluorouracil (OxMdG*) 
Oxaliplatin and Capecitabine 
Irinotecan and 5 Fluorouracil (IrMdG*) 
Single agent Irinotecan 
5 Fluorouracil (MdG*) + Cetuximab 
6 
1 
1 
1 
1 
*MdG: Modified de Gramont regimen 
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3.4.5.1 Feasibility of accessing and completing the questionnaire through Patient 
Pathway Manager (PPM) 
 
The questionnaire was easily accessible through PPM during the study.  Patients were 
presented with three physical function scales (EORTC QLQ-C30, RSCL and WHO 
performance status in patient self report format) which consisted of 13 items, 3 items 
on infection and hospital admission, 26 items on symptom/treatment side effects, 5 
items on stoma function and 32 items on psychosocial issues. 
 
Average time taken for the patients to complete the questionnaire was 13 minutes 
(range 7 to 18 minutes).  All patients found the touch screen computer (TSC) easy to 
use and stated that they would prefer to complete the questionnaire on TSC rather than 
on paper.  
 
One patient reported that they had selected a wrong response option for one of the 
questions from Mental Health Inventory (MHI-5) where there are 6 response options to 
choose from. 
 
There was a technical problem in accessing the results of the questionnaire on PPM for 
two patients who entered the study.  This was later rectified by consulting with the 
information technology personnel for PPM. However, data for these two patients were 
unfortunately lost. 
 
3.4.5.2 Physical functions and symptoms 
 
Quantitative Analysis 
 
Scores from patients’ questionnaire responses for each item were collated; mean 
scores for each item were calculated and ranked from highest (indicating many patients 
experienced a problem) to lowest (indicating many patients did not experience a 
problem). 
 
3 items on infection concerning hospital admission and antibiotic use were not included 
in this analysis as they had “yes” or “no” responses. WHO performance status item was 
also excluded as this item had a different format to all other questions. In addition, 
stoma items were excluded from this analysis as there were only responses from two 
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patients.  Sexual function items were analysed separately as some patients opted not 
to answer the question as they had the option to skip.   
 
Prevalence scores for each item was also calculated which indicated the presence of at 
least some degree of problem concerning a symptom/issue (i.e. any responses other 
than “not at all” or equivalent response). 
 
Table 3.11 Physical function 
 Mean  
Prevalence 
(%) 
EORTC QLQ-C30 
(Not at all = 1; A little = 2; Quite a bit = 3; Very much = 4) 
  
Do you have any trouble taking a long walk? 2.4 87.5 
Do you need to stay in bed or a chair during the day? 2.1 62.5 
Do you have any trouble doing strenuous activities, like carrying 
a heavy shopping bag or a suitcase? 
2.0 75 
Do you have any trouble taking a short walk outside of the 
house? 
1.6 37.5 
Do you need help with eating, dressing, washing yourself or 
using the toilet? 
1.0 0 
RSCL 
(Able without help = 1; Without help but with difficulty = 2; Only 
with help = 3; Unable = 4) 
  
Can you perform heavy housework/household jobs? 2.0 62.5 
Are you able to care for yourself? 1.5 25 
Can you perform light housework/household jobs? 1.4 25 
Are you able to do your shopping? 1.4 25 
Can you climb stairs? 1.3 25 
Are you able to walk outdoors? 1.1 12.5 
Are you able to walk about the house? 1.0 0 
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Table 3.12 Symptom and treatment toxicities 
Questions 
(Not at all = 1; A little = 2; Quite a bit = 3; Very 
much = 4) 
Mean 
score 
Prevalence 
(%) 
Mean 
oncologist 
rating* 
Have you had tingling or numbness in your hands or 
feet? 3.0 100.0 3.0 
Have you been less active than you would like to be? 2.9 87.5 2.3 
Were you tired? 2.5 100.0 2.5 
Have you felt lacking in energy? 2.5 100.0 2.0 
Have you had problems with sense of taste? 2.5 87.5 1.7 
Did food and drink taste different from usual? 2.5 87.5 2.7 
Have you felt weak? 2.4 100.0 2.0 
Have you had sore mouth or tongue? 2.4 87.5 2.3 
Did you need to rest? 2.3 87.5 2.1 
Have you had diarrhoea (watery stools)? 2.1 62.5 3.0 
Were you short of breath? 2.0 62.5 2.6 
Have you felt nauseated (sick)? 1.9 75.0 3.0 
Were your eyes painful, irritated or watery? 1.9 50.0 3.0 
Have you had soreness or redness of your hands or 
feet? 1.9 37.5 3.0 
Have you felt ill or unwell? 1.6 62.5 2.4 
Did you have bloated feeling in your abdomen? 1.6 50.0 2.1 
Have you had any other skin problems (e.g. itching, 
dryness, sensitivity to the sun)? 1.6 50.0 2.1 
Have you had acid indigestion or heartburn? 1.6 37.5 2.9 
Have you lacked appetite? 1.5 37.5 2.7 
Have you had pain? 1.5 37.5 3.0 
Have you been constipated? 1.4 25.0 3.0 
Have you had trouble sleeping? 1.4 25.0 2.7 
Have you vomited? 1.3 25.0 3.0 
Did pain interfere with your daily activities? 1.3 25.0 2.7 
Have you had any problems with your waterworks? 1.1 12.5 NA 
Have you been upset by hair loss? 1.1 12.5 2.4 
*1: ”not useful”, 2: ”somewhat useful” and 3: “useful” 
 
 
 
As expected, patients found more strenuous tasks difficult to perform.  In terms of 
physical symptoms, peripheral neuropathy was the most common and troublesome 
side effect as well as fatigue.  
 
Table 3.11 and Table 3.12 illustrate the mean scores and the prevalence of 
symptoms/issues among the study population. Table 3.12 also lists oncologists’ rating 
for each of the questionnaire items derived from interviews described above. 
 
  
89 
 
3.4.5.3 Review of comments on physical functions and symptoms made by patients 
during the interview 
 
Physical functioning 
 
All patients found items in this section easy to answer. Only 2 patients were able to 
state their preference for one set of items over another. All patients stated that they 
found it easy to identify own level of physical ability on WHO performance status scale. 
One patient suggested that WHO performance status question was not necessary in 
addition to the other physical function items. 
 
Decision made after the interviews 
 
All physical function items were retained for further evaluation. 
 
Symptoms and side effects of chemotherapy 
 
All the patients identified with most of the symptoms covered in this section and felt that 
it was a very comprehensive list.  One patient gave an account of a terrible time he had 
with severe vein pain and felt that this should be covered in the questionnaire.  No 
other suggestions were made for additional issues to be included. All patients stated 
that fatigue was one of the most troublesome symptoms they had. 
 
Decision made after the interviews 
 
One item on taste was removed as this was considered duplication. “Did food and drink 
taste different from usual?” was retained as this had better rating by the oncologists. 
Item on bladder function was also removed in view of low prevalence and comments by 
made by oncologists in the previous interview study. Additional item on vein pain was 
added following patient comment. 
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3.4.5.3 Psychosocial Issues 
 
Quantitative Analysis 
 
Same analysis was performed with that of physical function and symptoms with 
tabulation of patients’ mean scores for each item and the prevalence of the issue. MHI-
5 was analysed separately as it had different response options from the other items.  
Sexual function was also analysed separately as some patients skipped items. 
 
Table 3.13 Mean score and prevalence of psychosocial issues among patients 
interviewed 
Questions 
(Not at all = 1; A little = 2; Quite a bit = 3; Very much = 4) Mean score 
Prevalence 
(%) 
Were you worried about your family in the future? 2.9 87.5 
Did you feel uncertain about the future? 2.6 75.0 
How much has your treatment interfered with your normal daily 
activities? 2.3 87.5 
Were you limited in doing either your work or other daily 
activities? 2.3 87.5 
Has your physical condition or medical treatment interfered with 
your social life? 2.1 100.0 
Were you limited in pursuing your hobbies or other leisure time 
activities? 2.1 75.0 
Have you felt less able to enjoy yourself? 2.0 87.5 
Were the side effects of treatment worse than you expected? 2.0 62.5 
Did you feel tense? 1.9 87.5 
Did you feel irritable? 1.8 75.0 
Have you felt stressed? 1.8 62.5 
Have you had difficulty remembering things? 1.6 50.0 
Did you worry? 1.5 50.0 
Have you been tearful? 1.5 50.0 
Since you started chemotherapy, how worthwhile do you think 
your treatment has been? 1.5 25.0 
Have you had difficulty in concentrating on things, like reading 
the newspaper or watching television? 1.5 25.0 
Since your diagnosis, have you been dissatisfied with your 
body? 1.5 25.0 
Has your physical condition or medical treatment interfered with 
your family life? 1.4 37.5 
Did you feel depressed? 1.3 25.0 
Have you had trouble talking about your feelings to your family 
and friends? 1.3 25.0 
Since your diagnosis, have you felt physically less attractive? 1.3 12.5 
Has your physical condition or medical treatment caused you 
financial difficulties? 1.1 12.5 
Have you been bothered by mood changes? 1.0 0.0 
Since your diagnosis, have you been feeling less 
feminine/masculine? 1.0 0.0 
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As anticipated by the oncologists, many patients admitted to future concerns and 
uncertainties.  Many patients reported that their everyday lives had been impacted by 
their illness and treatment.  Table 3.13 illustrates the mean patient scores and 
prevalence of psychosocial issues raised and Table 3.14 illustrate the same results for 
MHI-5 items. 
 
Table 3.14 Mean and prevalence of emotional distress (MHI-5) 
Mental Health Inventory (MHI-5) 
(None of the time = 1, A little of the time = 2, Some of the 
time = 3, A good bit of the time = 4, Most of the time = 5, All 
of the time = 6) Mean score 
Prevalence 
(%) 
Have you felt calm and peaceful? (scores reversed) 2.4 75.0 
Have you felt downhearted and low? 1.8 62.5 
Have you been a happy person? (scores reversed) 1.8 62.5 
Have you felt so down in the dumps that nothing could cheer 
you up? 1.4 37.5 
Have you been a very nervous person? 1.3 25.0 
 
3.4.5.4 Sexual Function 
 
Available responses were from 5 men and 3 women.  1 patient skipped all the items in 
this section. 4 out of 7 patients stated that their sex life had been affected by their 
illness or their treatment and these 4 patients all indicated that they were “not at all” 
interested in sex.   From the responses from this small group of patients, erectile 
dysfunction did seem to be a relevant issue for the male patients. 
 
Table 3.15 Patient responses to sexual function items 
Questions 
(Not at all = 1; A little = 2; Quite a bit = 3; Very 
much = 4) 
Responses 
available 
No. 
skipped mean 
Prevalence 
(%) 
During the past 4 weeks, has the disease or 
treatment affected your sex life (for the worse)? 7 1 2 57.1 
During the past 4 weeks, to what extent were 
you interested in sex? (score reversed) 7 1 3.8 100.0 
During the past 4 weeks, did you have difficulty 
getting or maintaining an erection? (men) 4 1 3.25 100.0 
Did you have pain or discomfort during 
intercourse? (women) 1 2 1 0 
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3.4.6 Qualitative analysis of psychosocial issues 
 
All interviews were audio-recorded and transcribed verbatim. The interviews were 
conducted in a similar manner to that of those with the oncologists; where discussions 
took place around items covering relevant topics. Data from all 10 patients were 
available for this part of the analysis. Sections on psychosocial items were analysed 
using qualitative thematic analysis.  The main themes arising from the analysis were: 
 Relevance of the issues being questioned to themselves or to others with 
similar diagnosis 
 Opinions about questionnaire items including suggestions for 
wording/rephrasing of items 
 
Emotional Function 
 
Relevance of the issues 
 
Many patients admitted that they had occasions when they felt “low” or “down” at times 
but generally stated that they had positive attitudes which helped them to cope on a 
day to day basis. Several patients commented that support from family and friends 
were vital in getting them through each day and expressed concerns for those people 
who may be lacking such support. 
 
Opinions about the questionnaire items 
 
Many stated that they would identify better with feeling “low” or “down” rather than 
“depressed”.  Some stated that there was a negative connotation and stigma attached 
with this word. Some patients liked the MHI-5 items as there were more response 
options and also because some of the items were positively phrased. 
 
Decision made after the interviews 
 
Item on “mood changes” was removed as the MHI-5 contained an item on feeling 
“downhearted and low”. Other items were retained.  Although some of the oncologists 
and patients had made remarks about the item feeling “depressed”, this item was 
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retained for further testing, particularly because it formed a part of a scale within the 
EORTC QLQ-C30. 
 
Cognitive Function 
 
Relevance of the issues 
 
Not many patients made remarks on these items but those that did, commented that 
they have become aware of their memory being affected since starting chemotherapy 
and identified well with the items covering this issue. 
 
Decision made after the interviews 
 
Both items were retained. 
 
Body image 
 
Relevance of the issues 
 
Many patients stated that “body image” issues were irrelevant to them personally. 
Some stated that it may be more relevant to those who are younger. However, one 
patient was particularly troubled by a hernia and he felt very unhappy with his 
appearance. 
 
Opinions about the questionnaire items 
 
None of the patients were offended by the items in this section.  However, one patient 
specifically stated that “dissatisfied” did not seem the right word to describe body image 
issues but had no other suggestions. 
 
Decision made after the interviews 
 
All three items on body image were retained for further testing. 
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Sexual function 
 
Relevance of the issues 
 
Some patients very much welcomed sexual function being included in the 
questionnaire.  These patients had been experiencing various issues but felt 
embarrassed to raise it in clinic consultations. In addition, they stated that they felt very 
embarrassed about talking regarding these issues with doctors of opposite gender to 
them. Several patients stated that these issues were not relevant to them as they were 
not sexually active or because they did not have a partner. 
 
Opinions about the questionnaire items 
 
All patients felt that this was an important topic to be included in the questionnaire to 
allow patients to raise the issues. However, they all agreed that patients be given the 
option not to respond. One patient suggested that the questionnaire could ask more 
detailed questions about specific problems but appreciated that these issues may not 
necessary be relevant to everyone. 
 
Decision made after the interviews 
 
It was decided that there should be a screening question.  If the patient reports no 
issues with their sexual function then they would not be shown further questions.  If 
however, the patient reports an issue then they would be presented with further 
questions on the matter.  Additional items were added from EORTC OV28 (“sexually 
active”, “sex enjoyable”, “pain and discomfort” for men and “dry vagina” for women) to 
specify the problem they may be experiencing 
 
Treatment impact on patients’ social and role functioning and future perspectives 
 
Relevance of the issues 
 
Most patients admitted that treatment and associated hospital visits had a significant 
impact on their daily lives. Several patients stated they had given up their hobbies 
because of treatment side effects. Majority of the patients expressed overwhelming 
support from their family and friends, who in turn helped them cope with their cancer 
diagnosis and treatment.  Several patients expressed their concern for their family in 
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the future more than for themselves. One patient stated that he felt isolated as his 
immediate family lived far away.  
 
Opinions about the questionnaire items 
 
One patient stated that raising financial issues was important as he had been given 
advice about entitlement to benefits which was helpful. 
Decision made after the interviews 
 
All the items in this section were retained for further testing as there was no strong 
evidence for removal.  New items “have you felt lonely” and “have you had support 
from family and friends?” were added to identify patients who may be feeling socially 
isolated. 
 
Treatment worthwhile? 
 
Opinions about the questionnaire items 
 
Many patients did not feel that they could respond truthfully to the question “how 
worthwhile” their treatment had been, as this would depend on how effective the 
treatment has been in controlling their cancer 
 
Decision made after the interviews 
 
This item was retained but response option was modified by giving patients option to 
respond “I don’t know” 
 
3.4.5.5 Summary of results from the interviews with patients 
 
As a result of the interviews with patients, 7 new items were added while 3 items were 
removed. Some items were modified; changes to phrasing of questions, changes in 
response options and branching of questions dependent on the screening or opening 
question. Changes made are summarized in Table 3.17. Remaining 82 items were 
taken forward to the next stage of the development of QuEST-Cr. 
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Table 3.16 Comments made by patients during interviews 
Emotional Function 
Relevance of issue “I do tend to feel depressed and down, particularly when I am by me self” 
“I get tearful at times” 
Opinions about the 
item 
“(Depressed) seems to be a “bad” word” 
 
“Mood swings better than depressed” 
 
“(Questionnaire) can help to keep an eye on things. Doctors can pick things up if 
things are not going right” 
 
“Felling low is something I would identify with (rather than depressed)” 
“Have you been a nervous person is a very strange question” 
Cognitive Function 
Relevance of issue “Chemotherapy does make me lose my mind a little bit” 
“I need to write everything down, otherwise I forget what to tell the doctor” 
Opinions about the 
item 
 
Body Image and Sexual Function 
Relevance of issue “they are not really an issue for me” 
 
“it might be more of an issue for younger people” 
 
“I would talk to my GP about it (sexual function) rather than Dr  ...(Hospital 
doctor” 
 
“There are doctors that I would find it easier to talk to about these things” 
 
“I was talking to another patient and he had the same problem (with sexual 
function) as I did” 
 
“I’m not very happy with my body image at all. I feel very embarrassed (with a 
hernia)” 
 
“I always get the feeling that everybody is looking at me” 
 
“People can get embarrassed by their stoma and emotionally scarred by it” 
Opinions about the 
item 
“For some people (sexual function questions) would be very helpful – if doctors 
see it, they can respond” 
 
“(Sexual function questions) should definitely be in the questionnaire” 
“I think it’s good to be asked” 
 
“I am embarrassed to bring it up (about sexual function). This (Questionnaire) 
might help”  
 
“I’d like people to have a choice (of answering questions)” 
 
“(Questionnaire) gives opportunity for people to raise it” 
Role, Social and Coping 
Relevance of issue “You need a lot of support, or you can go down very easily” 
 
“(Treatment) really interferes with my social life. I don’t like to go out with my 
pump on”  
 
“I can’t pursue my hobbies” 
 
“I really worry about my family” 
 
“I miss my family and friends. I get a little bit feeling sorry for myself cos I’m long 
way from my family” 
Opinions about the 
item 
“I didn’t know I was entitled to disability living allowance. (Finance question) is a 
good thing to draw attention” 
 
“(Treatment worth) you don’t know until you’ve had your scan at the end of 
treatment” 
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Table 3.17 Changes made to QuEST-Cr following interviews with patients 
Items Outcome after interview 
with patients 
Physical Function  
Do you have any trouble doing strenuous activities, like carrying a heavy 
shopping bag or a suitcase? 
 
Do you have any trouble taking a long walk? 
Do you have any trouble taking a short walk outside of the house? 
Do you need to stay in bed or a chair during the day? 
Do you need help with eating, dressing, washing yourself or using the 
toilet? 
Are you able to care for myself  
Modified so that each task 
made into a question 
 
Are you able to walk about the house 
Can you perform light housework/household jobs 
Can you climb stairs 
Can you perform heavy housework/household jobs 
Are you able to walk out of doors 
Are you able to do your shopping 
Please select one of the following items that best describes your current 
level of physical ability 
 
0 -  I am fully active and more or less as I was before my illness 
1 – I cannot carry out heavy physical work, but can do anything else 
2 – I am up and about more than half the day; I can look after myself, but 
not well enough to work  
3 – I am in bed or sitting in a chair for more than half the day; I need some 
help in self care 
4 – I am in bed or a chair all the time and need a lot of looking after 
 
 
Infection  
Have you had any infection since your last cycle of chemotherapy?  
Were you admitted to hospital during your last cycle of chemotherapy?  
Were you prescribed any antibiotics during your last cycle of 
chemotherapy? 
 
Chemotherapy toxicity/disease related symptoms  
Have you had sore mouth or tongue?  
Have you had problems with sense of taste? X 
Did food and drink taste different from usual?  
Have you lacked appetite?  
Have you had acid indigestion or heartburn?  
Have you felt nauseated (sick)?  
Have you vomited?  
Have you been constipated?  
Did you have bloated feeling in your abdomen?  
Have you had diarrhoea?  
Have you had soreness or redness of your hands or feet?  
Have you had any other skin problems (e.g. itching, dryness, sensitivity to 
sun)? 
 
Have you had tingling or numbness in your hands or feet?  
Have you been upset by hair loss?  
Have your veins been sore or irritated? New 
Stoma  
Do you have a stoma?  
 Yes      No 
 
If yes, have you had any problems with it (for example soreness of skin, 
increased frequency, leakage)? 
 
Were you afraid that other people would be able to smell your stoma?  
Did you feel embarrassed because of your stoma?  
Did you feel less complete because of your stoma?  
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Fatigue  
Have you had trouble sleeping?  
Did you need to rest?  
Have you felt weak?  
Were you tired?  
Have you been less active than you would like to be?  
Have you felt lacking in energy?  
Pain  
Have you had pain?  
Did pain interfere with your daily activities?  
Bladder function  
Have you had any trouble with your waterworks? X 
Others  
Were you short of breath?  
Were your eyes painful, irritated or watery?  
Have you felt ill or unwell?  
Emotional/Cognitive Function  
Have you had difficulty in concentrating on things, like reading the 
newspaper or watching television? 
 
Did you feel tense?  
Did you worry?  
Did you feel irritable?  
Did you feel depressed?  
Have you had difficulty remembering things?  
Have you had trouble talking about your feelings to your family and friends?  
Have you felt stressed?  
Have you felt less able to enjoy yourself?  
Have you been tearful?  
Have you been bothered about mood changes? X 
Have you felt calm and peaceful? (scores reversed)  
Have you felt downhearted and low?  
Have you been a happy person? (scores reversed)  
Have you felt so down in the dumps that nothing could cheer you up?  
Have you been a very nervous person?  
Body Image  
Have you felt physically less attractive as a result of your disease or your 
treatment? 
 
Have you been feeling less feminine/masculine as a result of your disease 
or your treatment? 
 
Have you been dissatisfied with your body?  
Sexual Function  
Has the disease or treatment affected your sex life (for the worse)?  
To what extent were you interested in sex? (Men + Women)  
To what extent were you sexually active? (Men + Women) New 
To what extent was sex enjoyable for you? (Men + Women) New 
Did you have difficulty getting or maintaining an erection? (Men)  
Did you have pain or discomfort during intercourse? (Men + Women) New for men 
Did you have a dry vagina during sexual activity? (Women) New 
Coping and Future Perspectives  
How much has your chemotherapy treatment interfered with your normal 
daily activities? 
 
Were your worried about your family in the future?  
Did you feel uncertain about the future?  
Were the side effects of treatment worse than you expected?  
Have you felt lonely? New  
Have you had support from your family and friends? New 
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Role and Social Function  
Were you limited in doing either your work or other daily activities?  
Were you limited in pursuing your hobbies or other leisure time activities?  
Has your physical condition or medical treatment interfered with your family 
life? 
 
Has your physical condition or medical treatment interfered with your social 
life? 
 
Has your physical condition or medical treatment caused you financial 
difficulties? 
 
Treatment Worth  
Since you started chemotherapy, how worthwhile do you think your 
treatment has been? 
 
 
New response option “I 
don’t know” 
: item retained, X: item removed 
 
 
 
3.5 Discussion 
 
The aim of this chapter was to describe in detail the initial developmental phases of a 
questionnaire, QuEST-Cr, which intends to measure symptoms, toxicities of cancer 
therapy and their impact upon patients’ functioning within routine oncology practice to 
help support the care of patients with colorectal cancer.   
 
The processes undertaken were broadly guided by the framework outlined by the 
EORTC Quality of Life Group module development guidelines (Johnson et al., 2011). 
Interviews with patients and healthcare professionals in the in the first phase of 
“generating quality of life issues” were substituted by the content analysis of routine 
oncology consultations of patients with colorectal cancer. This ensured that commonly 
discussed issues or topics within real life consultations were included in the 
questionnaire; which helped to make the questionnaire relevant to clinical practice and 
specific to the patient group.  It was felt that this substitution was acceptable given that 
EORTC guidelines are aimed at developing a new questionnaire for a group of patients 
where there are no other comparable existing questionnaires. Brown et al (Brown et al., 
2001b) used similar approach in the development of their chemotherapy toxicity 
questionnaire for use in routine practice.  They had used an established questionnaire 
which explored chemotherapy toxicities and used this as the starting point in their 
questionnaire adaptation in order to develop a tool which was more relevant in 
everyday practice. Remainder of the questionnaire developmental phases followed the 
EORTC guidance and used similar strategies as other authors developing modular 
instruments (Chow et al., 2009)  
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Review of the literature identified 5 questionnaires which were considered relevant to 
patient with colorectal cancer, although only 3 of these were specific to colorectal 
cancer with one for patients with liver metastasis and the other for gastrointestinal 
diseases in general. There were differences among the instruments identified in terms 
of the number of symptoms and issues covered, with some covering extensive range of 
bowel related symptoms.  The EORTC QLQ-C30 plus QLQ-CR29 (Whistance et al., 
2009) provided the best coverage of the topics raised in the clinic consultations.  
However, there were several symptoms which were not included in the questionnaires 
which were commonly discussed in clinics such as “sore mouth”, “tingling and 
numbness in fingers and toes” and “sore and red hands and feet”.  This may in due to 
the fact that these symptoms are due to chemotherapy treatments which were not 
available at the time of questionnaire development. For example, Oxaliplatin, the 
common side effect of which is sensory peripheral neuropathy, was shown to prolong 
progression free survival when combined with 5-fluorouracil and folinic acid in a phase 
III study, which was published in 2000 (de Gramont et al., 2000). This study led to 
Oxaliplatin being used as standard chemotherapy regimen for patients with colorectal 
cancer. Similarly, Capecitabine was shown to have equivalent efficacy to 5 Fluorouracil 
and folinic acid in a phase III study, which was published in 2001 (Van Cutsem et al., 
2001). One of the common side effects of Capecitabine is hand foot syndrome, which 
manifests as sore and red swollen hands and feet. Capecitabine can cause more 
mucosal toxicities compared to 5-Fluorouracil and folinic acid which may increase 
patients experiencing sore mouth and indigestion (Van Cutsem et al., 2001).  
 
There are a number of biological treatments which are being incorporated into the 
treatment of colorectal cancer.  These agents have different side effect profile 
compared to cytotoxic chemotherapy.  It is likely that further modules will need to be 
developed or existing modules to be updated once these agents are incorporated into 
standard treatment algorithm for patients with colorectal cancer. 
 
Many doctors considered this questionnaire to provide a “trigger” for discussion of 
certain issues, particularly if the patients were experiencing problems.  They felt that 
this should, by no means, replace the conversation with the patients.  Questions about 
specific sites of pain, detailed bowel/abdominal and bladder symptoms were therefore 
considered unnecessary as these issues would be discussed with the patient. Many of 
these items were therefore removed following interview with oncologists. 
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Oncologists recognised that a diagnosis of an incurable cancer would have a 
significant impact on patients and their families’ lives.  They appreciated that patients 
may become emotionally distressed because of the diagnosis, which can in turn have 
an impact on how patients might cope with their treatment.  Emotional functioning was 
therefore considered an important issue to look out for.  Many oncologists felt that the 
questionnaire could act as a screening tool but wanted some guidance as to how best 
to manage the patient if he/she reports problems here. Oncologists suggested that 
patients had both good and bad days like all of us, and feeling “low” from time to time 
was probably quite common for their patients and wanted the questionnaire to be 
reasonably sensitive in identifying patients that needed further intervention. 
 
There were a number of issues which are routinely addressed in existing instruments 
but were not included in the consultation analysis (indicating lack of discussion of the 
topic).  These were body image, sexual function and stoma issues.  These issues are 
included in the questionnaires because some of the treatment for colorectal cancer, 
such as surgery, may lead to a formation of a stoma (Cunningham et al., 2010), which 
can lead to patients having to make adjustments both physically and psychologically 
(Brown and Randle, 2005).  In addition, surgical intervention together with other 
modalities of cancer treatment such as preoperative radiotherapy and chemo-
radiotherapy can have a direct impact on patients’ sexual functioning (Ho et al., 2011).  
There is a large body of evidence that colorectal patients do indeed experience these 
concerns (Sharpe et al., 2011, Sprangers et al., 1995, Bullen et al., 2012, Traa et al., 
2012), although they may not readily be brought up in a routine chemotherapy review 
consultations. Both oncologists and patients considered these issues, particularly 
sexual function, to be important for this group of patients. 
 
Although many of the oncologists interviewed recognized sexual function was probably 
important for their patients, their sexual health care needs were poorly understood. 
Some felt uncomfortable or embarrassed to raise these topics during the consultations. 
This sentiment was echoed by the patients.  Oncologists expressed concerns about 
what should be done when a problem might be identified through the questionnaire and 
the impact such discussions may have on the consultation length.  These are well 
recognized barriers to discussing these topics (Traa et al., 2014, Park et al., 2009). 
Some oncologists commented using a questionnaire would give them permission to 
ask about these issues and allow more open discussion with patients. In addition, it can 
make patients realize that these are relevant and appropriate issues for them to 
discuss in outpatient clinics (Flynn et al., 2012, Traa et al., 2014). This may help to 
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determine the scale of the need among the patients, which can lead to developing any 
additional services required.  
 
Existing instruments also covered issues about the uncertainty and the future 
perspectives.  These issues were again not identified in the consultation analysis.  
However, these issues are likely to be particularly relevant when patients receive the 
outcome of tests to assess response to treatment.  The consultations used in the 
content analysis may not have captured discussion of these issues due to the timing of 
the audio-recording. During the interview with the oncologists, many indicated that 
items concerning future perspectives are not helpful as patients with incurable cancer 
would inevitably be faced with many uncertainties.  Nevertheless, it was felt important 
to retain items addressing these concerns. 
 
Many oncologists wanted the questionnaire to be able identify when patient specifically 
wished to discuss certain topics.  Additional concerns checklist was considered very 
helpful, particularly in addressing issues such as body image, sexual function and 
discussion about future and prognosis.  
 
There were a number of limitations to this study.  Although 68 consultations were 
analysed, these came from 17 patients, rather than 68 different patients.  If a patient 
was experiencing a particular symptom or an issue then this may have been repeated 
several times over the four visits, potentially distorting the prevalence of the problem.  
In addition 9 patients were in the attention control group of the study from which the 
consultations have been obtained. One of the aims of this study was to see whether 
patients completing the EORTC QLQ-C30 were more likely to raise issues covered by 
this questionnaire.  Therefore, patients in the attention control group may have raised 
more symptoms and function issues addressed in QLQ-C30, although independent 
samples t-tests confirmed that patients in the attention-control arm were no more likely 
to discuss symptoms and functions covered by the EORTC QLQ-C30 questionnaire 
items. 
 
Another limitation is the relatively small number of oncologists and patients interviewed. 
In addition, these oncologists and patients were all recruited from one hospital. 
However, the numbers were largely in line with the recommendations from the 
guideline used in this process (Johnson et al., 2011).  Although saturation was not 
reached in terms of generation of quality of life issues, both oncologists and patients 
were discussing similar issues during the interviews.  
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Furthermore, the interviews with healthcare professionals were limited to oncologists 
as they do not have a clinical nurse specialist based in their department in Leeds.  A 
nurse may have provided a different perspective and opinions about the questionnaire 
items and inform the issues patients report to them as opposed to oncologists. Further 
limitation was the loss of questionnaire data from 2 patients, although audio-recording 
of the whole interview were available, which may have skewed the mean and 
prevalence of the symptoms and issues covered in the questionnaire. 
 
3.6 Summary 
 
This chapter has described and presented the key stages of the development of 
QuEST-Cr, a colorectal cancer specific questionnaire for routine clinical practice.  
QuEST-Cr at this stage consisted of 82 items; 13 items on physical function, 3 items on 
infection/hospital admission, 25 items on symptoms and side effect of treatment, 5 
items on stoma, 3 items on body image, 6 items (for both men and women with 5 items 
common to both gender), and 27 items on other psychosocial issues. Items on Physical 
function and some of the symptoms/treatment toxicity items were common to all three 
cancer sites as part of the questionnaire development within the wider programme of 
research. 
 
For QuEST-Cr to be useful in everyday clinical practice, it needs to be quick and easy 
to administer, collect relevant information from patients and easily interpreted by the 
recipient of the questionnaire results.  This was not possible with an 82 item 
questionnaire and QuEST-Cr needed further refinement.  
  
The next chapter describes the testing of QuEST-Cr for its validity and reliability, using 
psychometric techniques. The QuEST-Cr has been administered to a large number of 
patients to collect the necessary data for the analysis.  Results from psychometric 
analysis and interviews will be used to further improve QuEST-Cr  
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Chapter 4 Questionnaire Validation Study 
 
4.1 Introduction 
 
The aim of this chapter was to assess the psychometric properties of the colorectal 
cancer specific questionnaire, QuEST-Cr, in a larger patient population, using classical 
psychometric theory.  In order to achieve this, individual item performance, 
measurement properties (including scale structure), reliability and clinical validity of the 
questionnaire were tested.  Attempts were made to reduce the number of items 
included in the questionnaire in the analysis process to improve its clinical utility.  In 
order to make the questionnaire useful for healthcare professionals to use the patient 
reported information in their clinical decision making, cut off score analysis was also 
performed. 
Previous chapter described the development of a questionnaire which consisted of 82 
items, which included assessment of physical function, emotional function and 
symptoms and issues specific to patients with colorectal cancer. It was envisaged that 
QuEST-Cr would include subscales in addition to single items, as seen in the EORTC 
questionnaires on which the QuEST-Cr was based. The aim was to develop a 
questionnaire with strong psychometric properties but also one that was clinically 
useful. 82 item questionnaire is a long questionnaire to be used in routine clinical 
practice.  It was, therefore, necessary to reduce the number of items included in the 
questionnaire to decrease patient burden in completing the questionnaire but also for 
the clinicians to be able to interpret the information efficiently. Several key issues were 
considered in order to improve the psychometric properties of the questionnaire whilst 
ensuring its utility in the clinical context.  These were reliability, validity, assessment of 
subscales and item reduction. 
 
4.1.1 Psychometric analysis 
A number of different measurement theories have been developed to test the 
psychometric properties of assessment instruments such as questionnaires; these 
include classical test theory (DeVellis, 2006) and item response theory (Hambleton et 
al., 1991).  Key concepts within the classical test theory are reliability and validity.  A 
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reliable measure is one that measures a construct consistently across time, individuals 
and situations.  A valid measure is one that measure what is intended to measure. 
There are different types of reliability assessments. The most relevant in terms of 
subscale development is internal consistency reliability, which assesses the 
consistency of results across items within a test.  One of the most common ways to 
demonstrate internal consistency reliability is Cronbach’s alpha statistics (Cronbach, 
1951), which uses inter-item correlations to determine whether the constituent items 
within the questionnaire or individual subscales are measuring the same concept 
(Edgar, 1998).  
There are three main types of validity; these are content, criterion and construct 
validity.  Content validity (or face validity) refers to expert opinion concerning whether 
the items within the test or the scale represents the concept the questionnaire is 
intended to measure.  For QuEST-Cr, this is addressed during the questionnaire 
development stages detailed in chapter 3, which included review of content of oncology 
consultations, review of the literature and interviews with patients and oncologists.  
Criterion validity compares the test with other measures or outcomes already 
considered to be valid. Therefore, criterion validity assessment involves comparing the 
new instrument with existing questionnaires which measure a similar concept and 
evaluate whether they produce similar results. Construct validity refers to how well a 
test measures the constructs that it was designed to measure. Construct validity often 
divided into three types; known groups validity, convergent validity and discriminant 
validity.  Known groups validity is based on the assumption that certain specified 
groups of subjects may be expected to score differently from other groups. Convergent 
validity refers to how well a test agrees with other previously validated tests that 
measure the same construct and discriminant validity refers whether constructs or 
measurements that are supposed to be unrelated are indeed unrelated. Multi-trait 
analysis can be performed to investigate this concept. 
 
4.1.2 Clinimetrics 
 
Psychometric approaches require multiple items to measure a single construct or 
domain. Therefore developing a questionnaire which aims to capture multiple 
dimensions of an individual’s HRQoL can result in a long questionnaire with multiple 
items. This can present as a challenge for implementation in a routine clinical practice, 
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where such assessments need to be made in a relatively short time to keep both 
patients and healthcare professionals engaged. Another approach used for developing 
a clinically useful instrument is to apply principles of clinimetrics (Feinstein, 1983), 
which includes selection of items based on clinical rather than statistical criteria; 
scoring to be simple and readily interpretable; and easy for clinicians to use (Feinstein, 
1983).  The clinimetric method aims to ensure clinical validity of measures which 
quantify patient experiences, such as symptoms and severity of illness. Example of 
clinimetric instrument includes the Apgar score (Apgar, 1953), which was developed to 
assess the health status of the newborn. The Apgar score is determined by evaluating 
five simple criteria, (appearance, pulse rate, reflex, activity and respiratory effort) on a 
scale of zero to two and summating the scores. Scales commonly used to describe 
performance status of an individual, such as the WHO performance status (Oken et al., 
1982) and Karnofsky performance scale (Karnofsky, 1949) both utilize clinimetric 
approach.  However, many clinimetric instruments consist of single items, which may 
fail to communicate the complexity behind the domain being measured. Therefore, 
there are calls for integration of psychometric and clinimetric approaches for 
developing patient outcome measures (Maruish, 2014).  
 
Development of QuEST-Cr planned to use both psychometric and clinimetric approach 
to ensure its utility within the clinical setting. The questionnaire was anticipated to 
consist of subscales and individual symptom items which would complement each 
other and provide broad assessment of patients’ HRQoL. Individual item performance 
was planned to be assessed using descriptive data obtained as part of the validation 
study as well as using the data collected during the interviews with the oncologists. 
 
4.1.3 Cut off score analysis 
 
In order to make the questionnaire useful in the clinical setting, it is necessary for the 
clinicians to be able to use the data derived from the patients in their clinical decision 
making. For example, results derived from laboratory test usually have reference 
ranges which assist clinicians to interpret the data and help them decide whether the 
results need acting upon.  However, the meaning of the (changes in) scores from 
health status questionnaires may not be inquisitively apparent to clinicians (Juniper et 
al., 1994). There is a need to define (changes in) scores which can represent clinical 
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relevance in order to assist clinicians to interpret the data.  This is referred to as the 
minimally important change (MIC) of health status questionnaires (Jacobson and 
Truax, 1991).  
Different approaches to determine the MIC on the scale of health status instruments 
have been proposed and includes distribution based and anchor based methods 
(Lydick and Epstein, 1993, Crosby et al., 2003). Distribution based methods are based 
on distributional characteristics of the sample, and express the observed change to 
some form of variation to obtain a standardised metric.  Examples are the effect sizes 
(ES) which relate observed change to the sample variability, or standardised response 
mean (SRM) which relate observed change to the variability of change. Another 
distribution based measure is the standard error of measurement (SEM), which links 
the reliability of the instrument to the standard deviation of the population (Crosby et 
al., 2003). The disadvantage of the distribution based methods is that they do not 
provide a good indication of the importance of the observed change. 
Anchor based methods uses an external measure, or anchor (which should correlate 
with the health status instrument being studied), to determine clinical important 
improvement or deterioration. The advantage of this approach is that “minimal 
importance” is explicitly defined and incorporated. However, the limitation of the anchor 
based method is that they do not take into account the variability of the instrument or 
the sample (Crosby et al., 2003). It is therefore recommended that both approaches 
are considered.  
These approaches were explored to evaluate the optimum cut off scores for the 
subscales within QuEST-Cr. 
 
4.2 Methods 
4.2.1 Study sample and procedure 
 
This was a cross sectional survey study.  Eligible patients were those with colorectal 
cancer (CRC), attending oncology clinics at Leeds Cancer Centre, who were currently 
receiving chemotherapy or had received chemotherapy in the past three months. 
Patients were approached to take part in the study at their planned out-patient clinic 
appointments.  Consenting patients completed the questionnaire on touch screen 
computer either on the day or whilst receiving chemotherapy. Paper questionnaires 
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were offered to minority of patients if they were unable to stay to complete the 
questionnaire during their hospital visit or if there were no plans for them to return to 
clinic within few weeks. Paper questionnaires were returned either by post or at their 
next clinic visit.  
Participating patients were asked to complete the CRC specific questionnaire QuEST-
Cr, followed by FACT-G (Cella et al., 1993), the Hospital Anxiety and Depression Scale 
(HADS) (Zigmond and Snaith, 1983) and Distress Thermometer (Roth et al., 1998) as 
validated measures of cancer-related quality of life and anxiety/depression 
respectively. Participating patients were also asked to complete a socio-demographics 
questionnaire which included their age, gender, marital status, education and 
employment status.  Patients’ clinical details including current extent of disease and 
chemotherapy regimens were collected from their medical notes. The project was 
approved by the Local NHS Research Ethics Committee. Written informed consent was 
obtained from patients and their oncologists to approach their patients. 
 
4.2.1.1 Study Measures 
QuEST-Cr 
 
The colorectal cancer specific questionnaire QuEST-Cr at this stage consisted on 82 
items, which covered symptoms and side effects of treatment specific to this group of 
patients as well as broader functional and psychosocial issues.  The questionnaire is 
presented in table 4.1.  The items within QuEST-Cr can be divided into the following 
broad categories: physical function (13 items), infection (3 items); symptoms and side 
effects (25 items); stoma (5 items); body image (3 items); sexual function (6 items each 
for men and women); and psychosocial functioning 27 items).  Response options from 
the original questionnaires were used, from which the items were derived. Response 
options for the majority of the items were: not at all; a little; quite a bit; very much. 
Response option of “don’t know” was added for the item about patients’ perception of 
treatment worth. 7 items in the physical function category had response options: 
unable; only with help; alone but with difficulty; alone easily. 5 items in the emotional 
function (from MHI-5) had response options: None of the time; a little of the time; some 
of the time; a good bit of the time; most of the time; all of the time. Patients were asked 
to consider their experience over the past week when responding to the questions. 
Appearance and body image items asked patients to reflect on their experience since 
their diagnosis and the sexual function items over the past 4 weeks. Patients were 
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given option to skip all body image and sexual function items.  Patients were presented 
with an opening question to the sexual function section which asked whether their sex 
life had been affected for the worse.  If the patient reported no issues then they were 
screened from the remaining questions.  
As the study allowed patients who had received chemotherapy within the past 3 
months to participate, an additional item “Have you had chemotherapy in the last 4 
weeks?” was added. The questionnaire items were numbered in such a way that some 
of the sexual function items were separated between men and women as shown in 
Table 4.1.  
Table 4.1 QuEST-Cr questionnaire 
Question No 
 
Questionnaire Item 
 
Q01 
Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag 
or a suitcase? 
Q02 Do you have any trouble taking a long walk? 
Q03 Do you have any trouble taking a short walk outside of the house? 
Q04 Do you need to stay in bed or a chair during the day? 
Q05 Do you need help with eating, dressing, washing yourself or using the toilet? 
Q06 Are you able to care for yourself? 
Q07 Are you able to walk about the house? 
Q08 Can you perform light housework/household jobs? 
Q09 Can you climb stairs? 
Q10 Can you perform heavy housework/household jobs? 
Q11 Are you able to walk outdoors? 
Q12 Are you able to do your shopping? 
Q13 
Please place a tick in the box next to the statement that best describes your current level 
of physical ability  
 □ I am fully active and more or less as I was before my illness 
 □ I cannot carry out heavy physical work, but can do anything else 
 □ I am up and about more than half the day; I can look after myself, but not well 
enough to work 
 □ I am in bed or sitting in a chair for more than half the day; I need some help in self 
care 
 □ I am in bed or a chair all the time and need a lot of looking after 
  
Q14 Have you had chemotherapy in the past 4 weeks? 
Q15 Have you had any infection during your last cycle of chemotherapy? 
Q16 Were you admitted to hospital during your last cycle of chemotherapy? 
Q17 Were you prescribed any antibiotics during your last cycle of chemotherapy? 
  
Q18 Have you felt ill or unwell? 
Q19 Have you had sore mouth or tongue? 
Q20 Did food or drink taste different from usual? 
Q21 Have you lacked appetite? 
Q22 Have you had indigestion or heartburn? 
Q23 Have you felt nauseated (sick?) 
Q24 Have you vomited? 
Q25 Have you been constipated? 
Q26 Did you have a bloated feeling in your abdomen? 
Q27 Have you had diarrhoea (or watery stools)? 
Q28 Were you short of breath? 
Q29 Have you had tingling or numbness in your hands or feet? 
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Q30 Have you had soreness or redness of your hands or feet? 
Q31 Have you had any other skin problems (e.g. itching, dryness, sensitivity to the sun)? 
Q32 Were your eyes painful, irritated, or watery? 
Q33 Have you been upset by hair loss? 
Q34 Have you had pain? 
Q35 Did pain interfere with your daily activities? 
Q36 Have your veins been sore or irritated? 
  
Q37 Do you have a stoma? 
Q38 
Have you had any problems with it (for example, soreness of skin, increased frequency, 
leakage)? 
Q39 Were you afraid that other people would be able to smell your stools? 
Q40 Did you feel embarrassed because of your stoma? 
Q41 Did you feel less complete because of your stoma? 
  
Q42 Have you had trouble sleeping? 
Q43 Did you need to rest? 
Q44 Have you felt weak? 
Q45 Were you tired? 
Q46 Have you been less active than you would like to be? 
Q47 Have you felt lacking in energy? 
Q48 
Have you had difficulty in concentrating on things, like reading the newspaper or 
watching television? 
Q49 Did you feel tense? 
Q50 Did you worry? 
Q51 Did you feel irritable? 
Q52 Did you feel depressed? 
Q53 Have you been a very nervous person? 
Q54 Have you felt so down in the dumps that nothing could cheer you up? 
Q55 Have you felt calm and peaceful? 
Q56 Have you felt downhearted and low? 
Q57 Have you been a happy person? 
Q58 Have you felt stressed? 
Q59 Have you had difficulty remembering things? 
Q60 Have you felt lonely? 
Q61 Have you had support from family or friends? 
Q62 Have you had trouble talking about your feelings to family or friends? 
Q63 Have you felt less able to enjoy yourself? 
Q64 Have you been tearful? 
  
Q65 Have you felt physically less attractive? 
Q66 Have you been feeling less feminine/masculine? 
Q67 Have you been dissatisfied with your body? 
  
Q68 Has the disease or treatment affected your sex life (for the worse)? 
Q69 To what extent were you interested in sex? 
Q70 To what extent were you sexually active? 
Q71 (men) To what extent was sex enjoyable for you? 
Q72 (men) Did you have difficulty getting or maintaining an erection? 
Q73 (men) Did you have pain or discomfort during intercourse? 
Q74 (women) To what extent was sex enjoyable for you? 
Q75 (women) Did you have a dry vagina during sexual activity? 
Q76 (women) Did you have pain or discomfort during intercourse? 
  
Q77 How much has your treatment interfered with your normal daily activities? 
Q78 Were the side effects of your treatment worse than you expected? 
Q79 Were you worried about your family in the future? 
Q80 Did you feel uncertain about the future? 
Q81 Were you limited in doing either your work or other daily activities? 
Q82 Were you limited in pursuing your hobbies or other leisure time activities? 
Q83 Has your physical condition or medical treatment interfered with your family life? 
Q84 Has your physical condition or medical treatment interfered with your social activities? 
Q85 Has your physical condition or medical treatment caused you financial difficulties? 
Q86 Since you started chemotherapy, how worthwhile do you think your treatment has been? 
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FACT-G 
 
FACT-G (Cella et al., 1993) is a quality of life instrument intended for use in a variety of 
chronic illness conditions, which was originally validated in a general cancer 
populations.  It has four scales: Physical well-being (FWB), Social/family well-being 
(SFWB), Emotional well-being (EWB) and Functional well-being (FWB).  A total score 
or individual subscale score can be calculated.  There are five response options to 
each item within the questionnaire: not at all, a little, somewhat, quite a bit or very 
much, scoring 0 – 4 respectively. Subscale scores range from 0-24 or 0-28 depending 
on the number of items within the subscale. Higher scores indicate better functioning. 
FACT-G has been validated in various cancer populations and has been shown to be 
reliable across many studies which have used this instrument (Victorson et al., 2008). 
 
Hospital Anxiety and Depression Scale (HADS) 
 
The HADS (Zigmond and Snaith, 1983) is a 14 item self report scale which consists of 
a depression and an anxiety scale, each with 7 items.  The scale was designed to 
screen for mood disorders in general (non-psychiatric) medical outpatients. It focuses 
on subjective disturbances of mood rather than physical signs and aims to distinguish 
depression from anxiety. There are four response options for each item scored on 0-3 
scale. Scores range from 0-42 with higher scores indicating greater anxiety or 
depression.  Score for each subscale range from 0-21. A score of 0-7 is considered 
normal, 8-10 mild, 11-14 moderate and 15-21 severe anxiety or depression (Zigmond 
and Snaith, 1983). The measure has been tested and shown to be valid and reliable in 
cancer patients (Vodermaier et al., 2009). 
 
Distress Thermometer (DT) 
 
DT (Roth et al., 1998) consists of a single item self report measure of psychological 
distress, followed by a symptom/problem checklist which was added by the National 
Comprehensive Cancer Network (NCCN) (National Comprehensive Cancer Network, 
2003). Patients grade the level of distress they have experienced on 0 (No distress) – 
10 (Extreme distress) visual analogue scale. The symptom/problem list consists of 39 
items which are divided into 5 groups (practical problems, family problems, emotional 
problems, physical problems, spiritual/religious concerns).  Cut off score of 4 is 
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suggested to be most sensitive and specific in cancer patients (Jacobsen et al., 2005, 
Gessler et al., 2008). 
 
4.3 Analysis 
 
The analysis had 5 key stages 
1. Individual item performance 
2. Principal axis factoring 
3. Internal consistency reliability 
4. Assessment of construct validity 
5. Cut off score analysis 
Item performance analysis included patient responses in terms of mean score, 
prevalence and spread of responses together with rating of items by the oncologists 
were tabulated to formulate evidence to support removing or retaining items.  
Comments made by patients and oncologists were reviewed prior to any decisions 
about item removal. The analyses performed were iterative and exploratory in nature 
with various stages of principal axis factor and reliability analysis being performed 
before definitive decisions being made about item inclusion/removal. Subscales 
strength were examined by comparing with validated questionnaires (FACT-G, HADS 
and DT). 
 
4.3.1 Sample size 
 
The sample size was calculated as part of a larger study validating breast, colorectal 
and gynaecological cancer site specific questionnaires, conducted by the Leeds 
POCPRG. There were 72 items common across the three disease site specific 
questionnaires and 9 items specific to colorectal cancer questionnaire and 2 items 
which were common with either breast or gynaecological cancer questionnaire. 
For multivariate analysis, a sample size of at least 200 participants or a subject to item 
ratio of 5-10 participants per item is typically recommended (Tabacknick and Fidell, 
2007).  With a ratio of 5 patients per item, it was estimated that a sample size of 370 
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patients would be required to analyse the 72 core (common across all questionnaires) 
items.  It was anticipated that between the three tumour groups, this target will be met.  
The planned sample size for the colorectal cancer questionnaire was 120 patients, 
which would also allow the measurement properties of the CRC specific items to be 
explored. 
 
4.3.2 Data preparation 
 
The data from the questionnaires were automatically imported from Patient Pathway 
Manager (PPM) into a Microsoft Access database for those patients who completed the 
questionnaires on touch screen computer.   Data from patients who completed the 
paper questionnaires were entered into the Microsoft Access database manually. 
Majority of the questionnaire items had 4 point response scale.  Data were recoded to 
avoid ‘0’ categories and to reflect high scores as universally indicating worse outcomes 
where necessary. Any items which did not have the standard 4 point response scale, 
such as the MHI5 questions which had 6 point response scale, were transformed to a 
1-4 scale so that they can be compared equally with other items during the analysis. 
Final dataset was imported into SPSS (PASW Statistics 17 for Windows, IBM 
Corporation, NY, USA).  
 
4.3.3 Individual item performance  
 
Descriptive statistics was applied to the data collected from the current study to 
calculate the mean, prevalence scores (proportion of patients who reported having 
problems) and spread of patient responses for each item. Items were considered to 
have problem distributions if  
1. Mean scores displaying floor or ceiling effect (mean score <1.5 or >3.0 respectively) 
2. Prevalence of experiencing at least some problem/symptom in question was <20% 
or >80% 
3. At least two response categories contained fewer than 10% of responses, indicating 
poor spread. (An item was considered to have “fair” spread of responses if one 
category included less than 10% of patient responses) 
114 
 
The descriptive analysis data was tabulated alongside ratings provided by the 
oncologists (Chapter 3). Items with oncologists’ mean ratings of less than 2.5 were 
considered poor (mean score of 3 indicates an item is useful and mean score of 1 
indicates an item is not useful).  Any other comments made by patients and oncologists 
during the interview studies were also considered as part of the assessment of item 
performance.  
 
4.3.4 Exploratory factor analysis 
 
The measurement properties of the CRC questionnaire were studied using exploratory 
factor analysis. Questionnaire items were initially reviewed in order to select most 
appropriate items for this analysis. Several items were excluded during this initial item 
selection.  These were 1) Items requiring clinical information from patients (questions 
concerning infection and antibiotic use); 2) Questions which contained branching items 
that filtered respondents according to “null” responses (stoma and sexual functioning 
questions) and 3) Items that were considered to be important clinical question (toxicity 
questions) which should be retained as single items.  The remaining items were 
broadly divided into “Physical” and “Psychosocial” items. Although physical and 
psychosocial issues were considered to be two separate concepts, physical symptoms 
may also have a causal relationship with psychosocial issues.  For example, “trouble 
sleeping” may be manifestation of underlying depressive illness.  Any items which were 
uncertain as to whether they were physical symptoms or psychosocial issues were 
included in both groups of analyses. 
Principal axis factoring (PAF) was used for the analysis.  PAF is a type of exploratory 
factor analysis, which is directed at understanding the correlations among variables by 
understanding the constructs that underlie them, whereas other forms of factor 
analysis, such as principal components analysis (PCA), is directed at reduction of 
variables to summarise the data (Costello and Osborne, 2005). PAF is considered to 
provide a more accurate reflection of the population factors compared to other types of 
factor analysis (Snook and Gorsuch, 1989). Promax rotation was applied as this allows 
the factors to correlate with other items within that factor (Costello and Osborne, 2005). 
Various factor models were examined iteratively and items were removed at different 
stages.  Physical issues and psychosocial issues were analysed separately, although 
there were items included in both analyses as described above. Standard diagnostic 
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tests were performed in order to ensure appropriateness for factor analysis.  These 
were Kaiser-Meyer-Olkin Measure of Sampling Adequacy and Bartlett's test of 
sphericity. The number of factors extracted by the models was restricted to those with 
Kaiser-Guttman Eigenvalue of >1.  Factors identified were given appropriate labels.  
Item loading values (>  0.3) were tabulated and variance accounted for by each factor 
was recorded. 
 
4.3.5 Internal consistency and reliability 
 
The scales identified by the exploratory factor analysis and previously existing 
subscales (from their validated questionnaires) were explored for optimal item 
reduction. The internal consistency and reliability of the hypothesised subscales was 
examined using Cronbach’s alpha correlation coefficients.  Alpha value between 0.7 
and 0.9 is generally considered acceptable (Fitzpatrick et al., 1998). Reliability analysis 
was performed in conjunction with principal axis factor analysis in order to identify the 
best fit model. 
 
4.3.6 Assessment of construct validity 
 
Multi-trait scaling analysis was performed to explore item convergent and discriminate 
validity. To ensure item convergent validity an item should have a correlation of 0.4 or 
greater with its own scale (Howard and Forehand, 1962) Item discriminate validity was 
confirmed if an item did not correlate higher with another scale. 
Known groups analysis was conducted using one-way between groups analysis of 
variance (ANOVA) to explore the subscales’ ability to differentiate between particular 
demographic and clinical characteristics of patients; and to see how they performed 
with respect to patients’ responses to HADS and FACT-G questionnaires. Patients 
were divided into groups according their gender, disease stage, age (three equal 
tertiles), HADS total score (divided into four groups using the cut scores provided by 
the developers of this instrument (Snaith and Zigmond, 1994)) and FACT-G total score 
quartiles. Quartiles were used for the FACT-G as there are no published cut-points for 
this instrument. 
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4.3.7 Cut off score analysis 
 
4.3.7.1 Distribution based methods 
 
Percentage of study population 
 
Score for each subscale identified from the above exploratory factor analysis and 
reliability analysis were calculated.  Lowest scores of the 10% and 25% (values chosen 
after discussion with the statistician of Leeds POCPRG) of patients with the poorest 
scores were calculated to represent severe and moderate impairment respectively.  
Minimally important change (MIC) 
 
Mean score differences corresponding to small, medium and large effect sizes were 
calculated by scaling the standard deviation of each scale by the effect size.  The 
standard errors of measurement (SEM) was calculated as a function of the function of 
the standard deviation and reliability () of each subscale.  The SEM provides an 
indication of the expected range of a patient’s true score. 
 
Anchor based methods 
 
FACT-G, HADS, and WHO performance status were used as anchors for the 
questionnaire subscales.  Specific anchors were chosen a priori, based on which 
measures were expected to be related. Previously published cut points for the anchors 
were identified where possible, otherwise distribution based cut points were derived. 
Each of the chosen anchors was used to predict the questionnaire subscale in question 
using linear regression.  The regression formula was applied to calculate equivalent cut 
off scores and accuracy of such grouping was assessed. Receiver Operator 
Characteristics curve analysis was also performed using the same anchors.  The best 
cut off score was derived which gave sensitivity above 0.8 or nearest for each of the 
subscales. Results from the above analyses were compared and most optimal cut off 
scores for each subscale were selected. 
Statistical analyses were guided by the POCPRG statistician, Miss Ada Keding.  
However, all analyses were performed by myself.  All statistical analyses were 
performed using SPSS (PASW Statistics 17 for Windows, IBM Corporation, NY, USA). 
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4.4 Evaluation of the CRC questionnaire as part of the POCPRG 
programme of research 
 
This study was a part of a wider study conducted by the POCPRG as part of their 
programme of research, evaluating cancer site specific questionnaires for breast and 
gynaecological cancer, as well as colorectal cancer (Harley et al., 2012). 
 
4.5 Results 
4.5.1 Patient characteristics 
 
Of the 168 eligible colorectal cancer patients, 159 patients (92%) consented to take 
part in the study.  However, 4 patients failed to return the paper questionnaires.  
Therefore, 155 colorectal cancer patients who had recently received or were currently 
receiving chemotherapy treatment completed the study.  97 were male (62.6%) and 58 
were female (37.4%).  Their median age was 64 years (range 31 – 88; SD 10.37).  100 
patients were receiving the chemotherapy with palliative intent, 51 patients were 
receiving chemotherapy as adjuvant therapy following potentially curative resection of 
their disease and 4 patients were receiving the chemotherapy as primary or neo-
adjuvant therapy to with the intention of down-staging their disease with the aim of 
definitive surgery.   
 
4.5.1.1 Chemotherapy regimens 
All the chemotherapy agents known to be active in the treatment of bowel cancer were 
represented in the study population.  These are Oxaliplatin, Irinotecan, 
Fluoropyrimidines (5 Fluorouracil and Capecitabine) and Mitomycin. Most common 
chemotherapy regimen was Oxaliplatin with 5 Fluorouracil and folinic acid (45.8%), 
followed by Oxaliplatin with Capecitabine (14.8%) and single agent Capecitabine 
(11%). 113 patients (72.9%) in the study were receiving intravenous chemotherapy; 17 
patients (11.0%) were on oral chemotherapy and 25 patients (16.2%) were on 
combination of intravenous and oral chemotherapy.  
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4.5.2 Feasibility of questionnaire completion 
 
131 patients (84.5%) completed the questionnaire on touch screen computer (TSC) 
and 24 patients (15.5%) completed on paper.  None of the patients reported difficulty in 
completing or understanding the questionnaires.  Missing data was minimal as majority 
of patient completed the questionnaire on TSC where they were not given the option to 
“skip” questions, except for the body image and sexual function items. There were 28 
items with at least 1 missing response (excluding body image and sexual function 
items).  This was due to one of the patients who completed paper questionnaire 
returning it with multiple missing responses.  There were only 4 items which had more 
than one missing data.   
 
2 patients reported that they selected the wrong response option when completing the 
MHI5 emotional function questions on the touch screen computer. This is likely to have 
occurred as the wording for these items are different to the standard 4 point responses. 
As there were only 2 patients who reported this, no specific changes were made to the 
questionnaire, in particular, option to return to previous items was not instituted. 
 
No specific comments were made for the inclusion of sexual functioning items.  129 
patients (83.2%) responded at least to the first item concerning general sexual function.  
24 patients (15.5%) responded to all of the items in this section. 
 
4.5.3 Item distributions 
 
4.5.3.1 Descriptive statistics 
 
Questionnaire responses were summarised in terms of mean, prevalence and spread.  
Items with problem distribution were identified according to the criteria set a priori. 
Questionnaire items with distribution issues is shown in Table 4.2 and summarised in 
Table 4.3. 
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Table 4.2 Questionnaire items with distribution issues 
Item 
No.  
 Floor 
effect 
(mean) 
Ceiling 
effect 
(mean) 
Low 
prev 
% 
High 
prev 
% 
Poor 
spread 
3 Do you have any trouble taking a short walk 
outside of the house? 
1.38    
 
5 Do you need help with eating, dressing, washing 
yourself or using the toilet? 
1.19  13.5  
 
6 Are you able to care for yourself? 1.45     
7 Are you able to walk about the house? 1.14  9.7   
8 Can you perform light housework/household 
jobs? 
1.40    
 
9 Can you climb stairs? 1.25  18.1   
11 Are you able to walk outdoors? 1.26  19.4   
12 Are you able to do your shopping?      
13 Please place a tick in the box next to the 
statement that best describes your current level 
of physical ability 
a. I am fully active and more or less as I 
was before my illness 
b. I cannot carry out heavy physical work, 
but can do anything else 
c. I am up and about more than half the 
day; I can look after myself, but not well 
enough to work 
d. I am in bed or sitting in a chair for more 
than half the day; I need some help in 
self care 
e. I am in bed or a chair all the time and 
need a lot of looking after 
 
1.19     
15 Have you had any infection during your last cycle 
of chemotherapy? 
  13.7   
16 Were you admitted to hospital during your last 
cycle of chemotherapy? 
  12.1   
19 Have you had sore mouth or tongue?      
21 Have you lacked appetite?      
22 Have you had indigestion or heartburn?      
24 Have you vomited? 1.14  11.6   
25 Have you been constipated? 1.41     
28 Were you short of breath?      
30 Have you had soreness or redness of your hands 
or feet? 
1.37     
31 Have you had any other skin problems (e.g. 
itching, dryness, sensitivity to the sun)? 
    
 
32 Were your eyes painful, irritated, or watery? 1.47     
33 Have you been upset by hair loss? 1.22  18.1   
34 Have you had pain?      
35 Did pain interfere with your daily activities? 1.37     
36 Have your veins been sore or irritated? 1.18  16.1   
38 Have you had any problems with it (for example, 
soreness of skin, increased frequency, leakage)? 
(stoma) 
    
 
43 Did you need to rest?    83.1  
45 Were you tired?    87.7  
46 Have you been less active than you would like to 
be? 
   83.1  
47 Have you felt lacking in energy?    85.6  
50 Did you worry?      
52 Did you feel depressed?      
53 Have you been a very nervous person?      
54 Have you felt so down in the dumps that nothing 
could cheer you up? 
    
 
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55 Have you felt calm and peaceful?    89.0  
56 Have you felt downhearted and low?      
57 Have you been a happy person?    80.6  
58 Have you felt stressed?      
60 Have you felt lonely? 1.30     
61 Have you had support from family or friends? 1.24  1.9   
62 Have you had trouble talking about your feelings 
to family or friends? 
1.42    
 
64 Have you been tearful?      
65 Have you felt physically less attractive?      
66 Have you been feeling less feminine/masculine?      
67 Have you been dissatisfied with your body?      
69 To what extent were you interested in sex?  3.22    
70 To what extent were you sexually active?  3.59    
71 To what extent was sex enjoyable for you? (Men)   6.7   
73 Did you have pain or discomfort during 
intercourse? (Men only) 
    
 
74 To what extent was sex enjoyable for you? 
(Women) 
  18.8   
77 How much has your treatment interfered with 
your normal daily activities? 
   83.9  
80 Did you feel uncertain about the future?    81.3  
84 Has your physical condition or medical treatment 
interfered with your social activities? 
   82.6  
86 Since you started chemotherapy, how worthwhile 
do you think your treatment has been? 
 3.07   
 
 
 
Table 4.3 Summary of items with distribution issues 
Characteristics of distribution 
issues 
Number of items with identified distribution issues  
(Total number of items 86 – sexual function items divided 
according to gender) 
Items with floor effect (mean <1.5) 18 
Items with ceiling effect  (mean >3.0) 3 
Items with low prevalence (<20%) 12 
Items with high prevalence (>80%) 9 
Poor item response spread 37 
Total number of items with some score 
distribution concerns 
53 
 
The distribution properties were used as a decision aid for item inclusion/exclusion 
following further analyses. 
.   
4.5.4 Exploratory factor analysis 
 
Table 4.4 illustrates the initial questionnaire item categorization prior to exploratory 
factor analysis. The following items were excluded from the analysis at the outset; 
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these were; items concerning infection which required clinical information and 
branching items (stoma and sexual function items). Remaining items were broadly 
divided into “Physical” and “Psychosocial” groups.  Item concerning treatment worth 
was also excluded from the factor analysis as it did not fit in with either category. 
Table 4.4 Categorisation of questionnaire items in preparation for exploratory factor 
analysis 
Question 
number 
 
Abbreviated question Item category 
Q01 strenuous activities Phys 
Q02 long walk Phys 
Q03 short walk Phys 
Q04 in bed Phys 
Q05 eat/wash/dress Phys 
Q06 self care Phys 
Q07 walk about the house Phys 
Q08 light housework Phys 
Q09 stairs Phys 
Q10 heavy housework Phys 
Q11 walk outdoors Phys 
Q12 shopping Phys 
Q13 physical activity (WHO) Phys 
Q14 chemo Clinical 
Q15 infection Clinical 
Q16 hospital Clinical 
Q17 antibiotics Clinical 
Q18 ill / unwell Phys 
Q19 sore mouth Phys 
Q20 taste Phys 
Q21 appetite Phys 
Q22 indigestion / heartburn Phys 
Q23 nauseated Phys 
Q24 vomited Phys 
Q25 constipated Phys 
Q26 bloated Phys 
Q27 diarrhoea Phys 
Q28 short of breath Phys 
Q29 hand/feet tingling Phys 
Q30 hand/feet sore Phys 
Q31 skin problems Phys 
Q32 painful eyes Phys 
Q33 hair loss upset Phys/Psych 
Q34 pain  Phys 
Q35 pain interference Phys 
Q36 sore veins Phys 
Q37 stoma Stoma 
Q38 stoma - problems Stoma 
Q39 stoma - smell stools Stoma 
Q40 stoma - embarrassment Stoma 
Q41 stoma - feeling complete Stoma 
Q42 sleep Phys/Psych 
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Q43 rest Phys/Psych 
Q44 weak Phys/Psych 
Q45 tired Phys/Psych 
Q46 less active Phys/Psych 
Q47 lacking energy Phys/Psych 
Q48 concentration Phys/Psych 
Q49 tense Psych 
Q50 worry Psych 
Q51 irritable Psych 
Q52 depressed Psych 
Q53 nervous Psych 
Q54 down in dumps Psych 
Q55 calm Psych 
Q56 downhearted Psych 
Q57 happy Psych 
Q58 stressed Psych 
Q59 memory Phys/Psych 
Q60 lonely Psych 
Q61 family support Psych 
Q62 talk about feelings Psych 
Q63 enjoyment Psych 
Q64 tearful Psych 
Q65 attractive Psych 
Q66 feminine/masculine Psych 
Q67 body dissatisfaction Psych 
Q68 sex life Sexual 
Q69 sex interest Sexual 
Q70 sexually active Sexual 
Q71/Q74 enjoyable men / women Sexual 
Q72 erection Sexual 
Q75 dry vagina Sexual 
Q73/Q76 intercourse discomfort men/women Sexual 
Q77 treatment and daily activities Phys/Psych 
Q78 side effects Phys/Psych 
Q79 family future Psych 
Q80 uncertain future Psych 
Q81 limited work or activities Phys/Psych 
Q82 hobbies Phys/Psych 
Q83 family life - interference Phys/Psych 
Q84 social activities Phys/Psych 
Q85 financial difficulties Psych 
Q86 treatment worthwhile Psych 
Phys: Physical; Psych: Psychosocial 
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4.5.4.1 Initial factor analysis - Physical items 
 
Round 1 
 
46 items belonging to the “physical” category were subjected to principal axis factoring. 
The Keyser-Meyer-Olkin value was 0.853 exceeding required levels (Tabacknick and 
Fidell, 2007) and Bartlett’s Test of Sphericity was significant (p<.05). The principal axis 
factoring revealed 13 factors with Eigenvalues above 1, which accounted for 60.4% of 
the variance (Table 4.5). 12 of these factors were logical and could be given meaning 
names.  These were: Treatment impact, everyday tasks, fatigue, strenuous activities, 
pain, toxicity, constipation, hands and feet, eyes, hair loss and sore mouth. 
  
  
 
1
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Table 4.5 Round 1 factor analysis of physical items. Dark grey indicates which factor the item correlates most highly with and light grey indicates 
which factors the item co-loads with (>0.3 or within 0.1 of the highest loading item). 
 
Treatment 
impact 
Everyday 
tasks 
Fatigue 
Strenuous 
activities 
Pain Toxicity Constipation 
Cognitive 
function 
Hands and 
feet 
Eyes Hair loss  12 
Sore 
mouth 
Strenuous 
activities 
.563 .501 .557 .801 .420 .286   .527 .350 .229 .235 .376 -.370 
Long walk .548 .577 .505 .709 .298 .247   .451 .337 .266 .224 .416 -.314 
Short walk .501 .822 .500 .555 .362 .301   .362 .373 .225   .467 -.449 
Stay in bed/chair .468 .493 .650 .430 .349 .254   .335 .121 .177   .381 -.389 
Help with 
eating/dressing 
.354 .744 .369 .434 .497 .153   .348 .192     .186 -.282 
Care for yourself .360 .647 .220 .367 .289     .129 .139   .111 .433   
Walk about the 
house 
.297 .696 .256 .133 .309       .135   -.127 .273   
Light housework .493 .627 .482 .622 .277 .162   .385 .322     .643 -.204 
Stairs .277 .766 .338 .509 .147 .166   .348 .231 .100 .201 .285 -.183 
Heavy 
housework 
.586 .515 .518 .837 .232 .205   .249 .181   .262 .509 -.190 
Walk outdoors .442 .782 .384 .584 .329 .352   .368 .308 .224 .433 .419 -.425 
Shopping .498 .625 .453 .714 .298 .274   .301 .284 .135 .191 .442 -.302 
WHO PS .594 .454 .621 .536 .315 .218   .351 .185     .455 -.158 
Ill or unwell .508 .316 .515 .347 .416 .677 .144 .459 .356 .263 .347 .466 -.315 
Sore mouth 
tongue 
.175   .141 .156   .203   .271 .269 .349 .166 .154 .364 
Taste different .358   .223 .107   .359 .290 .331 .271 .277 .184 .457 .142 
Lacked appetite .426 .216 .416 .364 .259 .370 .240 .345 .230 .246 .332 .580 -.211 
Indigestion .102 .123 .301   .114 .292 .387   .307     .382 .132 
Nausea .172   .293     .792 .271 .239   .291 .108 .215   
Vomiting           .567 .149   .120   .127   -.112 
Constipated         .237 .225 .630   .159     .183 .104 
Bloated abdo .211   .188 .133 .182 .285 .876 .221 .220   .227 .223   
Diarrhoea .192 .106 .191 .144   .225       .145   .222 .119 
Short of breath .511 .418 .538 .301 .471 .466   .451 .464 .352 .159 .335 -.360 
Numb 
hands/feet 
.216 .119 .101 .140     .161   .784   .138 .221 .138 
Sore hands feet               .180 .333 .204 -.145     
other skin probs     .137   .147 .127 .149 .303   .149       
Eyes painful .109   .119 .130   .183   .246 .102 .759 .141 .165   
  
 
1
2
5
 
Upset hair loss       .107       .102   .101 .544 .117   
Pain .392 .354 .393 .277 .871 .223 .157 .354 .159 .148   .281 -.211 
Pain interfere 
with activities 
.430 .464 .445 .358 .911 .236 .150 .418 .247 .167   .245 -.316 
Veins sore .295   .171 .104 .104 .140   .134 .101         
Trouble sleeping .360   .330   .234 .146 .314 .118 .299 -.106   .325 .297 
Need to rest .543 .283 .839 .324 .341 .327   .413 .280 .177   .342   
Felt weak .677 .384 .819 .583 .317 .403 .180 .514 .416 .185 .411 .599 -.327 
Tired .605 .294 .850 .513 .315 .345 .120 .515 .249 .145 .255 .470 -.133 
Less active .714 .431 .718 .627 .311 .220   .383 .340   .296 .600 -.271 
Lacking in 
energy 
.732 .421 .844 .659 .398 .336   .503 .338 .106 .412 .587 -.349 
Concentrating .558 .362 .553 .483 .323 .228 .112 .628 .259   .227 .473 -.281 
Difficulty 
remembering 
.363 .214 .364 .297 .257 .149   .661 .238 .162 .174 .277 -.123 
Treatment 
interfere with 
daily activities 
.824 .407 .582 .478 .324 .127   .335 .252   .168 .504   
Treatment side 
effects 
.577 .264 .371 .467 .264 .347 .186 .381 .303 .166 .277 .300 -.277 
Limited in work .781 .391 .562 .475 .353 .128   .371 .202 .148   .415   
Limited in  
hobbies 
.793 .481 .487 .540 .335 .169   .386 .239 .102 .163 .547   
Interfere with 
family life 
.748 .209 .500 .343 .286 .252   .222 .274   .118 .394 -.221 
Interfere with 
social activities 
.834 .444 .556 .464 .303 .194   .361 .367   .143 .407 -.164 
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Round 2 
 
The questionnaire items were reviewed with members of the Leeds POCPRG as part 
of the process of developing cancer site specific questionnaires across three different 
disease groups to see whether any of the items which did not fit in well with the named 
factor were considered clinically useful single items rather than item within a subscale. 
For example, item on sensory peripheral neuropathy would be considered important 
chemotherapy toxicity question, which can have an impact on clinical decision making.  
Therefore, items on sensory neuropathy, sore eyes and sore veins were removed from 
subsequent subscale analysis and retained as clinically meaningful single items. 
Principal axis factoring with remaining 43 items revealed 11 factors with Eigenvalues 
above 1, which accounted for 59.3% of the variance. The Keyser-Meyer-Olkin value 
was 0.87 and Bartlett’s Test of Sphericity was significant (.000). The factors could each 
be given meaningful names, which were: everyday tasks, fatigue, treatment impact, 
nausea and vomiting, pain, constipation, strenuous activities, appetite, sore mouth, skin 
and hair loss. 
Round 3 
 
Further review of the items was carried out following the above analysis.  
Gastrointestinal symptoms are of particular relevance for patients receiving 
chemotherapy treatment, especially for those with colorectal cancer.  Constipation and 
diarrhoea were both considered to be important clinically important individual items.  In 
addition, the WHO performance status was also removed as this item did not correlate 
well with other physical function items.  The WHO performance status item is also 
different from other items in a sense that it tries to capture the overall physical ability of 
a patient in one question, rather than exploring a particular side effect or ability to 
perform a specific activity. Remaining 40 items were subjected to principal axis 
factoring. The Keyser-Meyer-Olkin value was 0.87 and Bartlett’s Test of Sphericity was 
significant (.000). Principal axis factoring revealed 10 factors with Eigenvalues above 1 
which accounted for 58.5% of the variance.  The factors were each given names, which 
were: everyday tasks, impact on activities, fatigue, strenuous activities, nausea and 
vomiting, pain, non-specific bowel symptoms, skin/cognitive function, sore mouth and 
hair loss. The result of this factor analysis is shown in Table 4.6. 
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Table 4.6 Round 3 factor analysis of physical items (six items removed). Dark grey indicates which factor the item correlates most highly with and 
light grey indicates which factors the item co-loads with (>0.3 or within 0.1 of the highest loading item). 
 
Everyday 
tasks 
Impact on 
activities 
Fatigue 
Strenuous 
activities 
Nausea/ 
vomiting 
pain 
Non-
specific GI 
symptoms 
Skin/ 
cognitive 
Sore 
mouth 
Hair loss 
Strenuous activities     .126 .809   .187     .134 -.102 
Long walk .255 .106   .553     -.222   .195   
Short walk .725       .129   -.131 .116   -.101 
Stay in bed/chair .224   .527       -.148   -.241   
Help with eating/dressing .631         .251   .103     
Care for yourself .705 .130 -.173   -.225   .171     .115 
Walk about the house .859 .183   -.405     .116 -.222     
Light housework .454     .332 -.101     .222   -.268 
Stairs .815 -.251   .141   -.128   .106 .162   
Heavy housework .170 .132   .821       -.341     
Walk outdoors .721   -.146 .116 .130         .250 
Shopping .397     .568       -.176     
Ill or unwell   .201     .509 .133   .119   .155 
Sore mouth or tongue       .176 .143     .208 .778 .199 
Taste different   .294 -.158   .195 -.235 .237 .360 .239   
Lacked appetite       .111     .244 .168 -.139 .104 
Indigestion .184 -.261 .268 -.125 .198   .542       
Nausea         .836   .159 -.102 .171 -.131 
Vomiting       .106 .731     -.315     
Bloated abdomen     -.126     .101 .625   -.169   
Short of breath .162 .171 .150 -.135 .277 .109   .224     
Sore hands or feet .106 -.136   -.109       .434 .213 -.156 
other skin problems   -.211   -.192 -.110 .194   .547     
  
 
1
2
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Upset by hair loss       -.131         .228 .804 
Pain       .131   .739   .141     
Pain interfere with activities       .190   .801   .168     
Trouble sleeping   .293 .127 -.187   .167 .452   .178   
Need to rest     .860 -.152       .105 .131   
Felt weak     .542 .105     .137     .129 
Tired -.130   .880 .187         .103   
Less active   .294 .413 .278       -.128 -.109   
Lacking in energy   .155 .624 .233         -.116   
Concentrating   .128 .192   -.207   .138 .394 -.150   
Difficulty remembering     .106   -.217   -.116 .713 .137   
Treatment interfere with daily 
activities 
  .817     -.102           
Treatment side effects   .432 -.164 .251 .128           
Limited in work   .732     -.108           
Limited in pursuing hobbies .146 .748 -.104 .174         .112   
Interfere with family life -.179 .982   -.129     -.123 -.122 -.167   
Interfere with social activities   .895         -.113       
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4.5.4.2 Reliability analysis – Physical items 
 
Reliability analysis was performed for each of the subscales identified from the factor 
analysis using Alpha reliability statistics. The results from this analysis are shown in 
Table 4.7. 10 factors emerged from the final principal axis factoring. Name given to 
each factor is written in bold at the top of each section and below are the individual 
items which formed that factor. The loading column describes the correlations each 
item had within the factor. If any of the items co-loaded with another factor then this is 
detailed in the “co-loader”. The best alpha column indicates which items combined to 
create the best possible alpha. The initial alpha score and the percentage of variance 
explained by the factor or presented below the list of items for each factor. 
Each of the subscales was analysed individually to determine whether the alpha could 
be improved by removal of items.  The reliability statistics were repeated until the best 
alpha was achieved. For example, removing “Treatment side effects” and “Interfere 
with family life” improved the alpha for the impact on activities subscale. 
 
Table 4.7 Reliability analysis for physical items. 
Factor 1 Everyday Tasks       
 Initial Items Loading Co-Loader? Best α 
 short walk 0.725 n 
 Help with eating/dressing 0.631 n  
 Care for yourself 0.705 n  
 Walk about the house 0.859 -.405 strenuous activities  
 Light housework 0.454 .332 strenuous activities  
 Stairs 0.815 n  
 Walk outdoors 0.721 n  
Cronbach's α  0.871   0.871 
% Variance 
explained 
31.7       
     
Factor 2 Impact on Activities       
 Initial Items Loading Co-Loader? Best α  
 Treatment interfere 0.817 n  
 Treatment side effects 0.432 n X 
 Limited in work 0.732 n  
 Limited pursuing hobbies 0.748 n  
 Interfere with family life 0.982 n X 
 Interfere with social activities 0.895 n  
Cronbach's α 0.888   0.902 
% Variance 
explained 
6.6       
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Factor 3 Fatigue      
 Initial Items Loading Co-Loader? Best α  
 Stay in bed/chair 0.527 n X 
 Need to rest 0.860 n  
 Felt weak 0.542 n  
 Tired 0.880 n  
 Less active 0.413 n  
 Lacking energy 0.624 n  
Cronbach's α 0.910   0.914 
% Variance 
explained 
4.4       
     
Factor 4 Strenuous Activities       
 Initial Items Loading Co-Loader? Best α  
 Strenuous activities 0.809 n  
 Long walk 0.553 n  
 Heavy housework 0.821 -.341 skin/cognitive  
 Shopping 0.568 .397 everyday tasks  
Cronbach's α 0.856   0.856 
% Variance 
explained 
2.9      
     
Factor 5 Nausea & Vomiting       
 Initial Items Loading Co-Loader? Best α  
 Ill / unwell 0.509 n  
 Nausea 0.836 n  
 Vomiting 0.731 -.315 skin/cognitive  
 Short of breath 0.277 .224 skin/cognitive  
Cronbach's α 0.684   0.684 
% Variance 
explained 
3.5       
     
Factor 6 Pain       
 Initial Items Loading Co-Loader? Best α  
 Pain  0.739 n  
 Pain  interfere with activities 0.801 n  
Cronbach's α 0.886   0.886 
% Variance 
explained 
2.5      
     
Factor 7 Non-specific GI symptoms       
 Initial Items Loading Co-Loader? Best α  
 Lacked appetite 0.244 .168 skin/cognitive  
 Indigestion 0.542 n  
 Bloated abdomen 0.625 n  
 Trouble sleeping 0.452 n  
Cronbach's α 0.556   0.556 
% Variance 
explained 
2.2       
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Factor 8 Skin / Cognition       
 Initial Items Loading Co-Loader? Best α  
 Taste different 0.360 4 co-loaders X 
 Sore hands or feet 0.434 n X 
 Other skin problems 0.547 n X 
 Concentrating 0.394 n  
 Difficulty remembering 0.713 n  
Cronbach's α 0.512   0.603 
% Variance 
explained 
1.8       
     
Factor 9 Sore Mouth       
 Initial Items Loading Co-Loader? Best α  
 Sore mouth or tongue 0.778 n - 
Cronbach's α -   - 
% Variance 
explained 
1.5       
     
Factor 10 Hair Loss       
 Initial Items Loading Co-Loader? Best α  
 Upset by hair loss 0.804 n - 
Cronbach's α -   - 
% Variance 
explained 
1.4       
 
4.5.4.3 Secondary factor analysis 
 
Everyday tasks, impact on activities, fatigue, strenuous activities and pain all formed 
reliable subscales in the initial factor analysis as described above.  These items were 
removed from the factor analysis model for the physical and symptom items and further 
factor analysis was performed on the remaining 15 items.  These items were subjected 
to principal axis factoring. The Keyser-Meyer-Olkin value was 0.742 and Bartlett’s Test 
of Sphericity was significant (.000). Principal axis factoring revealed 6 factors with 
Eigenvalues above 1 which accounted for 41.9% of the variance. The result of this 
analysis is shown in Table 4.8. Four of the factors were logical and could be given 
names, which were: nausea and vomiting, mouth problems, hair loss and skin 
problems. 
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Table 4.8 Factor analysis of leftover physical items. Dark grey indicates which factor the 
item correlates most highly with and light grey indicates which factors the item co-loads 
with (>0.3 or within 0.1 of the highest loading item). 
 
1 
Nausea/ 
vomiting 
3 
Mouth 
problems 
Hair loss 
Skin 
problems 
Ill or unwell .501 .387         
Sore mouth or tongue -.122     .701 .146 .210 
Taste different .185     .624   -.182 
Lacked appetite .420   .112 .117 .100 -.207 
Indigestion -.151   .636     .138 
Nausea   .717   .182 -.108   
Vomiting   .712   -.127     
Bloated abdo .133   .651 -.196     
Shortness of breath .537 .173         
Sore hands or feet     .119 .159   .367 
other skin problems .163   .166     .301 
Upset by hairloss       .101 .700   
Trouble sleeping   -.101 .462 .148   .202 
Concentrating .660 -.118         
Difficulty remembering .749 -.102 -.188     .279 
 
Physical activity items were also explored individually as the initial factor analysis and 
reliability analyses did not reduce the number of items within the subscale significantly, 
particularly for the subscale “Everyday tasks”.  The 12 physical activity items were 
subjected to principal axis factoring. The Keyser-Meyer-Olkin value was 0.897 and 
Bartlett’s Test of Sphericity was significant (.000). The items separated into 2 factors 
with Eigenvalues above 1, which accounted for 55.5% of the variance. The result from 
this analysis is shown in Table 4.9. 
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Table 4.9 Factor analysis of physical activity items. Dark grey indicates which factor the 
item correlates most highly with and light grey indicates which factors the item co-loads 
with (>0.3 or within 0.1 of the highest loading item). 
 
Strenuous 
activities 
Everyday 
tasks 
Strenuous activities .962 -.228 
Long walk .782 
 
Short walk .361 .523 
Stay in bed/chair .399 .181 
Help with eating/dressing .157 .598 
Care for yourself 
 
.667 
Walk about the house -.305 .917 
Light housework .525 .267 
Stairs .228 .558 
Heavy housework .839 
 
Walk outdoors .314 .542 
Shopping .641 .17 
 
The factors could broadly be described as “strenuous activities” and “everyday tasks” 
although “stay in bed/chair” and “light housework” both loaded onto the factor which 
generally described activities which required more effort. In the previous factor 
analysis, “stay in bed/chair” loaded onto the factor which described symptoms of 
fatigue and “light housework” co-loaded between “everyday tasks” and “strenuous 
activities” (Table 4.5). 
 
 4.5.4.4 Secondary reliability analysis 
 
The reliability analysis of the 15 remaining physical and symptoms items (nausea and 
vomiting, mouth problems and skin problems) did not demonstrate good reliability.  
These subscales were disregarded but they were retained for decision whether they 
should be considered as single items. For example, nausea and vomiting are both 
important toxicity symptoms of chemotherapy and therefore they were retained as 
clinically meaningful question as part of this questionnaire 
The strenuous activity scale had a reliability of 0.870.  Two items “stay in bed/chair” 
and “light housework” were removed as they were considered not to fit in conceptually 
with “strenuous activity scale”.  The reliability was not significantly affected with alpha 
of 0.86 for the remaining four items in the subscale.  
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The everyday tasks scale had best reliability of 0.871 if all seven items, including “light 
housework” was included in the scale.  Conceptually, “short walk” and “walk about the 
house” seemed to encompass similar activity.  Removal of “walk about the house” had 
little impact on the alpha, which was 0.863; removal of “short walk” resulted in alpha of 
0.838. Similarly, “care for yourself” and “help with eating/washing and dressing” 
seemed to address similar activities.  Removal of “care for yourself” improved the alpha 
to 0.868. 
 
4.5.4.5 Final decisions made regarding physical items with wider programme of 
research in mind 
 
Regular meetings took place with other members of the Leeds POCPRG so that 
common subscales can be developed for questionnaires across the three cancer sites.   
The analyses of factor analyses and reliability analyses were reviewed and 
occasionally changes were made to produce the best combination of items for the 
three cancer groups. . For example, inclusion of “walk about the house” improved the 
alpha of the “everyday tasks” subscale for the breast and gynaecological cancer 
questionnaires over “short walk”.  This did not impact significantly on the alpha of the 
colorectal questionnaire, which was still 0.815. Table 4.10 illustrates the final decision 
made on the physical items. 
Table 4.10 Final decisions about physical items 
Abbreviated item description 
Decisions made 
(scale, single item, 
remove) 
Reasons 
short walk 
Remove Similar item within everyday task scale 
No detriment to alpha 
walk about the house 
Everyday Tasks Included to streamline with other 
questionnaires 
light housework Remove Good reliability 
stairs Everyday Tasks Good reliability 
walk outdoors Everyday Tasks Good reliability 
eat/wash/dress Everyday Tasks Good reliability 
strenuous activities Strenuous activities Good reliability 
long walk Strenuous activities Good reliability 
heavy housework Strenuous activities Good reliability 
shopping Strenuous activities Good reliability 
rest Fatigue Best alpha 
weak Fatigue Best alpha 
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tired Fatigue Best alpha 
less active Fatigue Best alpha 
lacking energy Fatigue Best alpha 
treatment and daily activities 
Impact on Activities Removed to streamline with other 
questionnaires 
limited work or activities Impact on Activities Good reliability 
hobbies Impact on Activities Good reliability 
family life - interference Impact on Activities Good reliability 
social activities Impact on Activities Good reliability 
pain  Pain Best alpha 
pain interference Pain Best alpha 
in bed 
Remove Did not fit conceptually with strenuous 
activities 
self care 
Remove Better reliability if removed.  
Similar to another item in everyday 
tasks  
ill / unwell Remove Poor doctor rating, too generic 
skin problems Remove Not specific enough 
concentration Single item Of clinical interest 
memory Single item Of clinical interest 
side effects 
Remove Question is good, but more about 
managing expectations 
physical activity (who) Single item Of clinical interest 
sore mouth Single item Of clinical interest 
taste Single item Of clinical interest 
appetite Single item Of clinical interest 
indigestion / heartburn Single item Of clinical interest 
nauseated Single item Of clinical interest 
vomited Single item Of clinical interest 
constipated Single item Of clinical interest 
bloated Single item Of clinical interest 
diarrhoea Single item Of clinical interest 
short of breath Single item Of clinical interest 
hand/feet tingling Single item Of clinical interest 
hand/feet sore Single item Of clinical interest 
hair loss upset 
Remove Not often applicable in colorectal 
cancer 
sore veins Single item Of clinical interest 
painful eyes Single item Of clinical interest 
sleep Single item Of clinical interest 
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4.5.4.6 Initial factor analysis – Psychosocial Items 
 
The 36 psychosocial items were subjected to principal axis factoring. The Keyser-
Meyer-Olkin value was 0.911 exceeding required levels and Bartlett’s Test of Sphericity 
was significant (p<.000) supporting the use of this type of analysis. Principal axis 
factoring revealed 8 factors with Eigenvalues above 1 which accounted for 58.7% of 
the variance.  The result from the principal axis factoring is shown in Table 4.11.  The 
names given to the 8 factors were: emotional functioning, impact on activities, fatigue, 
body image, future worries, depression, support and hair loss. 
There were 15 items which overlapped between physical and psychosocial items. 
These items generally fell into the same factors as previously identified during the 
exploratory factor analysis of the physical items. 
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Table 4.11 Initial factor analysis of psychosocial items. Dark grey indicates which factor the item correlates most highly with and light grey 
indicates which factors the item co-loads with (>0.3 or within 0.1 of the highest loading item). 
 
Emotional 
functioning 
Impact on 
activities 
Fatigue Body image 
Future 
worries 
depression support Hair loss 
Upset by hairloss -.124 -.289 .220 .181   -.179   .651 
Trouble sleeping           .724   -.253 
Need to rest -.126   .729     .342 .156   
Felt weak     .820         .284 
Tired -.101   .943           
Less active   .374 .538           
Lacking in energy   .242 .682         .182 
Concentrating .271 .160 .434     -.169 -.191   
Feel tense .527 -.170 .280     .239 -.227   
Worry .888       .112   -.263 -.125 
Irritable .394   .188     .174   .268 
Depressed .772 .144 -.109   -.174     .203 
Nervous person .490 -.141       -.141 .146 -.261 
Down in the dumps .802 -.204 .146     -.134 .351   
Calm and peaceful .477           .127 .220 
Downhearted and low .761               
Happy person .447 .171   -.176     .223 .221 
Felt stressed .500 -.116     .187 .262     
Difficulty remembering .456   .205           
Felt lonely .836             -.284 
Support from family and friends         -.159   .558   
Trouble talking about feelings .237         .216 .248 -.131 
  
 
1
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Less able to enjoy .398 .257 .363     -.129   -.126 
Tearful .177         .478     
Physically less attractive       .969       .123 
Less feminine/masculine .106 .244   .552         
Dissatisfied with body   .117   .671   .146   .205 
Treatment interfere with daily 
activities 
  .764 .192         -.121 
Treatment side effects .171 .524             
Worried about family -.122       .959   -.174   
Uncertain about future .207 .211 -.179   .608     .146 
Limited in work -.134 .749 .161   .100 .133   -.232 
Limited in pursuing hobbies   .849   .160 -.126     -.110 
Interfere with family life   .743     .150       
Interfere with social activities   .773 .131   .103     -.186 
Finance   .235     .240 .190   -.176 
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4.5.4.7 Initial reliability analysis 
 
In a similar manner to the physical items, reliability analysis was performed on each of 
the 8 subscales identified from the factor analysis.  The result is shown in Table 4.12.  
Table 4.12 Reliability analysis of psychosocial items 
Factor 1 Emotional functioning       
 Initial Items Loading Co-Loader? Best α  
 tense 0.527 n 
  worry 0.888 n 
 irritable 0.394 n 
 depressed 0.772 n 
 nervous 0.490 n X 
 down in the dumps 0.802 0.351 Support 
 calm and peaceful 0.477 n 
 downhearted 0.761 n 
 happy person 0.447 n 
 felt stressed 0.500 n 
 memory 0.456 n  
 lonely 0.836 n X 
 less able to enjoy 0.398 0.363 Fatigue  
      
Cronbach's 
α  
0.910   0.915 
% Variance 
explained 
36.3       
Factor 2  Impact on activities       
 Initial Items Loading Co-Loader? Best α  
 treatment interfere with daily activities 0.764 n  
 Treatment side effects 0.524 n X 
 limited in work 0.749 n  
 limited in hobbies 0.849 n  
 interfere with family life 0.743 n X 
 interfere with social activities 0.773 n  
     
Cronbach's 
α  
0.888   0.902 
% Variance 
explained 
6.7       
  
140 
 
 
Factor 3 Fatigue       
 Initial Items Loading Co-Loader? Best α  
 need to rest 0.729 0.342 Depression 
 felt weak 0.820 n 
 tired 0.943 n 
 less active 0.538 0.374 Impact of activities 
 lacking in energy 0.682 n 
 concentrating 0.434 n X 
     
Cronbach's 
α  
0.911   0.914 
% Variance 
explained 
4.7       
Factor 4 Body image       
 Initial Items Loading Co-Loader? Best α  
 less attractive 0.969 n 
 less feminine/masculine 0.552 n 
 dissatisfied with body 0.671 n 
 
   
 
Cronbach's 
α  
0.870   0.870 
% Variance 
explained 
3.0       
Factor 5 Future worries       
 Initial Items Loading Co-Loader? Best α  
 worried about family 0.959 n 
 uncertain about future 0.608 n 
 finance 0.240 0.235 Impact on activities X 
     
Cronbach's 
α  
0.728   0.814 
% Variance 
explained 
2.9       
Factor 6 Depression       
 Initial Items Loading Co-Loader? Best α  
 sleep 0.724 n 
 tearful 0.478 n 
     
Cronbach's 
α  
0.578   0.578 
% Variance 
explained 
1.9       
Factor 7 Support       
 Initial Items Loading Co-Loader? Best α  
 family support 0.558 n 
 talk about feelings 0.248 2 co-loaders 
 
   

Cronbach's 
α  
0.292   0.292 
% Variance 
explained 
1.7       
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Factor 8 Hair loss       
 Initial items Loading Co-Loader? Best α  
 upset by hair loss 0.651 n 
 
   

Cronbach's 
α  
 -   
% Variance 
explained 
1.6       
 
The emotional distress scale initially consisted of 13 items with Cronbach alpha 
reliability of 0.910.  After removal of two items, this could be improved to 0.915.  
However, 11 items within the subscale was considered too lengthy. Further reliability 
analyses were performed to examine how far the number of items within the subscale 
could be reduced, whilst maintaining acceptable reliability ( >0.8). It was possible to 
reduce the scale to 5 items (Feel tense, worry, irritable, depressed and stressed) and 
still retain reliability of 0.902. These items, with the exception of “stressed” derives from 
EORTC QLQ-C30 (Aaronson et al., 1993). Reliability of the four emotional functioning 
items from EORTC QLQ-C30 was found to be 0.889 and reliability of five items from 
MHI-5 (Berwick et al., 1991) was 0.756.   
Items for “impact on activities” and “Fatigue” formed reasonable subscales, as found 
from previous factor analyses of “physical” items. The three body image items showed 
good reliability with alpha of 0.870. 
 
4.5.4.8 Secondary factor analysis – Psychosocial items 
 
Principal axis factoring was performed on the remaining psychosocial items after items 
on “impact on activities”, “fatigue” and “body image” were removed as they had formed 
subscales with good reliability. The emotional function items were retained in the 
analysis. This analysis, however, failed to show any new meaningful factor which had 
not been identified previously. 
 
4.5.4.9 Final decisions made regarding psychosocial items with wider programme of 
research in mind 
 
In a similar manner to the decisions made for the “physical” items, regular meetings 
were held with other members of the Leeds POCPRG so that common subscales can 
be developed for the three cancer sites. Table 4.13 illustrates the decisions made on 
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the psychosocial items. There were two additional subscales identified which have 
been retained for the QuEST-Cr questionnaire; emotional distress and body image.  
The emotional functioning items from the MHI-5 was retained over the EORTC QLQ-
C30 emotional functioning subscale, despite the latter having better reliability, as the 
interview study suggested that both clinicians and patients did not necessarily feel that 
the wording from the EORTC QLQ-C30 items reflected patients’ experiences. 
Although two items concerning “uncertain about future” and “worried about family in the 
future” seemed to form a subscale according to the factor analysis, these items were 
considered to address different issues. These items were removed as clinicians 
considered “uncertainty about future” was something that they expected their patients 
to experience and not a helpful question for the purpose of this questionnaire. 
Table 4.13 Final decisions about psychosocial items 
Abbreviated 
item 
description 
Decisions 
made 
(scale, single 
item, remove) 
Reasons 
attractive 
Body Image Best alpha 
feminine/masc
uline Body Image 
Best alpha 
body 
dissatisfaction Body Image 
Best alpha 
nervous Emotional 
Distress 
MHI-5 items, good scale for clinical management 
down in 
dumps 
Emotional 
Distress 
MHI-5 items, good scale for clinical management 
calm Emotional 
Distress 
MHI-5 items, good scale for clinical management 
downhearted Emotional 
Distress 
MHI-5 items, good scale for clinical management 
happy Emotional 
Distress 
MHI-5 items, good scale for clinical management 
family future Family/ Future 
Worries 
Though good alpha with “uncertain future”, these were 
considered two separate issues 
rest 
Fatigue Best alpha 
weak 
Fatigue 
Best alpha 
tired 
Fatigue 
Best alpha 
less active 
Fatigue 
Best alpha 
lacking energy 
Fatigue 
Best alpha 
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uncertain 
future Future Worries 
Though good alpha with “family future”, these were 
considered two separate issues 
limited work or 
activities 
Impact on 
Activities 
Good reliability 
hobbies Impact on 
Activities 
Good reliability 
family life - 
interference 
Impact on 
Activities 
Good reliability 
social 
activities 
Impact on 
Activities 
Good reliability 
tense 
Remove 
Potential Anxiety question, but due to poor factoring of 
emotional items MHI-5 instead 
worry 
Remove 
Potential Anxiety question, but due to poor factoring of 
emotional items MHI-5 instead 
irritable 
Remove 
Potential Anxiety question, but due to poor factoring of 
emotional items MHI-5 instead 
depressed 
Remove 
Potential Depression question, but due to poor factoring of 
emotional items MHI-5 instead 
stressed 
Remove 
Potential Anxiety question, but due to poor factoring of 
emotional items MHI-5 instead 
lonely 
Remove Did not fit well into any emotional construct 
family support 
Remove Did not fit well into any emotional construct 
talk about 
feelings Remove Did not fit well into any emotional construct 
enjoyment 
Remove 
Potential Depression question, but due to poor factoring of 
emotional items MHI-5 instead 
tearful 
Remove 
Potential Depression question, but due to poor factoring of 
emotional items MHI-5 instead 
future health 
Remove Did not fit well into any emotional construct 
treatment and 
daily activities Remove Good question but data only for colorectal questionnaire 
side effects 
Remove Question is good, but more about managing expectations 
hair loss upset 
Remove 
Of clinical interest for breast and gynae, did not fit well with 
other items 
sleep 
Single Item Of clinical interest, did not fit well with other items 
concentration 
Single Item Of clinical relevance 
memory 
Single Item Of clinical relevance 
financial 
difficulties Single Item 
Anticipated to be single item, did not group meaningfully with 
other items 
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Table 4.14 summarises the final subscales derived from the above factor analyses of 
physical and psychosocial items and single items retained for QuEST-Cr. 
 
Table 4.14 Subscales derived from factor analyses and retained single items for QuEST-
Cr 
Strenuous activities 
Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a 
suitcase? 
Do you have any trouble taking a long walk? 
Can you perform heavy housework/household jobs? 
Are you able to do your shopping? 
 
Everyday Tasks 
Do you need help with eating, dressing, washing yourself or using the toilet? 
Are you able to walk about the house? 
Can you perform light housework/household jobs? 
Can you climb stairs? 
Are you able to walk outdoors? 
 
Pain 
Have you had pain 
Did pain interfere with your daily activities? 
 
Fatigue 
Did you need to rest?  
Have you felt weak? 
Were you tired? 
Have you been less active than you would like to be? 
Have you felt lacking in energy? 
 
Impact on activities 
Were you limited in doing either your work or other daily activities? 
Were you limited in pursuing your hobbies or other leisure time activities? 
Has your physical condition or medical treatment interfered with your family life? 
Has your physical condition or medical treatment interfered with your social activities? 
 
Emotional Distress (MHI-5) 
Have you been a very nervous person? 
Have you felt so down in the dumps that nothing could cheer you up? 
Have you felt calm and peaceful? 
Have you felt downhearted and low? 
Have you been a happy person? 
 
Body Image 
Have you felt physically less attractive? 
Have you been feeling less feminine/masculine? 
Have you been dissatisfied with your body? 
 
Single Items 
Have you had sore mouth or tongue? 
Did food or drink taste different from usual? 
Have you lacked appetite? 
Have you had indigestion or heartburn? 
Have you felt nauseated (sick?) 
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Have you vomited? 
Have you been constipated? 
Did you have a bloated feeling in your abdomen? 
Have you had diarrhoea (or watery stools)? 
Were you short of breath? 
Have you had tingling or numbness in your hands or feet? 
Have you had soreness or redness of your hands or feet? 
Have your veins been sore or irritated? 
Were your eyes painful, irritated, or watery? 
Have you had trouble sleeping? 
Has your physical condition or medical treatment caused you financial difficulties? 
 
4.5.4.10 Sexual function and stoma items 
 
Items for sexual function and stoma issues were retained as they were without any 
alterations in the QuEST-Cr as it was not feasible to analyse these items in the similar 
way as the other times in the questionnaire.  
 
4.5.5 Assessment of construct validity 
 
4.5.5.1 Multi-trait scaling analysis 
 
Table 4.15 illustrates the multi-trait scaling analysis performed to explore the item 
convergent validity, which was above 0.4 for all subscales. No item discriminate scaling 
errors were identified.  
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Table 4.15 Multi-trait scaling analysis. (Figures in bold represent item convergent 
validity) 
 
strenuous 
activities 
everyday 
tasks 
pain fatigue 
impact on 
activities 
emotional 
distress 
(MHI-5) 
body 
image 
Strenuous  
activities 
0.847 0.548 0.465 0.601 0.511 0.318 0.298 
Long walk 0.805 0.581 0.345 0.531 0.490 0.293 0.271 
Heavy  
housework 
0.876 0.582 0.294 0.586 0.543 0.301 0.350 
Shopping 0.822 0.678 0.372 0.492 0.454 0.216 0.279 
Help with 
eating/dressing 
0.512 0.777 0.491 0.365 0.366 0.136 0.223 
Walk about the 
house 
0.283 0.643 0.228 0.210 0.317 0.028 0.063 
Light  
housework 
0.659 0.768 0.361 0.516 0.493 0.243 0.278 
Stairs 0.558 0.817 0.220 0.352 0.262 0.190 0.223 
Walk outdoors 0.631 0.818 0.390 0.445 0.393 0.266 0.278 
Pain 0.374 0.363 0.950 0.362 0.350 0.173 0.334 
Pain interfere with 
activities 
0.450 0.475 0.945 0.431 0.402 0.150 0.301 
Need to rest 0.403 0.336 0.350 0.807 0.541 0.391 0.362 
Felt weak 0.603 0.474 0.359 0.873 0.599 0.430 0.423 
Tired 0.519 0.378 0.363 0.886 0.561 0.405 0.330 
Less active 0.644 0.489 0.329 0.844 0.644 0.380 0.383 
Lacking in energy 0.645 0.513 0.411 0.919 0.651 0.484 0.411 
Limited in work 0.527 0.429 0.366 0.619 0.864 0.352 0.386 
Limited in pursuing 
hobbies 
0.577 0.499 0.371 0.583 0.860 0.333 0.445 
Interfere with family 
life 
0.388 0.248 0.285 0.528 0.788 0.434 0.403 
Interfere with social 
activities 
0.522 0.468 0.316 0.629 0.876 0.407 0.454 
Nervous person 0.210 0.195 0.003 0.154 0.123 0.564 0.160 
Down in the dumps 0.215 0.202 0.092 0.434 0.333 0.806 0.384 
Calm and peaceful 0.299 0.193 0.191 0.361 0.386 0.734 0.421 
Downhearted and 
low 
0.188 0.152 0.172 0.416 0.373 0.725 0.338 
Happy person 0.269 0.122 0.136 0.369 0.375 0.748 0.262 
Physically less 
attractive 
0.307 0.247 0.265 0.356 0.389 0.367 0.933 
Less 
feminine/masculine 
0.420 0.324 0.353 0.479 0.526 0.417 0.852 
Dissatisfied with 
body 
0.245 0.216 0.288 0.348 0.425 0.391 0.886 
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4.5.5.2 Known groups analysis 
 
Results of the one-way between groups analysis of variance are presented in Table 
4.16. There was a statistically significant difference (p <.05) for all the subscales when 
evaluated against the HADS and FACT-G total scores. Poorer scale scores from 
QuEST-CR corresponded with poorer scores on both HADS and FACT-G.  
Age did not have significant impact on the subscales, apart from body image with 
younger patients reporting more problems. Female patients reported more problems 
with strenuous activities than male patients but otherwise gender impact was not 
observed. There was a trend for younger patients reporting body image issues. No 
significant differences were seen between patients with different stages of disease, 
although the number of patients with early stage disease (stages 1 to 3) was small.  
 
  
 
1
4
8
 
 
 
Table 4.16 Differences in subscale scores by disease stage, HADS and FACT-G Total score groups, age and gender 
 Disease Stage (Total n=155) p HADS Total Score  
(Total n=154) 
p FACT-G Total Score  
(Total n=155) 
p Age  
(Total n=155) 
p Gender  
(Total n=155) 
p 
 1 2 3 4  0-7 8-10 11-
15 
16-
42 
 108-
90 
89-
80 
79-
69 
68-0  31-
60 
61-
68 
69-
88 
 Male Fem
ale 
 
n=2 n=9 n=34 n= 
110 
 n=84 n=17 n=24 n=29  n=39 n=40 n=38 n=38  n=54 n=52 n=49  n=97 n=58  
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
 Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
 Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
 Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
 Mean 
(SD) 
Mean 
(SD) 
 
                       
Strenuous 
Activities 
2.38 
(1.94) 
2.19 
(0.75) 
1.88 
(0.68) 
2.10 
(0.91) 
.524 
1.76 
(0.78) 
2.33 
(0.78) 
2.41 
(0.81) 
2.45 
(0.92) 
.000 
1.37 
(0.44) 
1.86 
(0.73) 
2.48 
(0.80) 
2.57 
(0.85) 
.000 
1.96 
(0.81) 
2.10 
(0.86) 
2.13 
(0.94) 
.564 
1.91 
(0.83) 
2.3 
(0.88) 
.006 
                       
Everyday 
Tasks 
1.00 
(0.00) 
1.25 
(0.66) 
1.15 
(0.30) 
1.23 
(0.45) 
.750 
1.11 
(0.30) 
1.26 
(0.51) 
1.22 
(0.38) 
1.44 
(0.64) 
.004 
1.02 
(0.12) 
1.08 
(0.18) 
1.31 
(0.5) 
1.44 
(0.6) 
.000 
2.06 
(0.87) 
1.18 
(0.38) 
1.19 
(0.41) 
.598 
1.19 
(0.43) 
1.22 
(0.45) 
.653 
                       
Pain 
1.00 
(0.00) 
1.28 
(0.44) 
1.32 
(0.49) 
1.53 
(0.77) 
.293 
1.32 
(0.57) 
1.38 
(0.76) 
1.48 
(0.52) 
1.88 
(0.97) 
.003 
1.17 
(0.37) 
1.26 
(0.42) 
1.63 
(0.79) 
1.80 
(0.9) 
.000 
1.53 
(0.63) 
1.44 
(0.82) 
1.41 
(0.65) 
.673 
1.47 
(0.71) 
1.44 
(0.70) 
.768 
                       
Fatigue 
2.20 
(0.28) 
2.42 
(0.59) 
2.22 
(0.67) 
2.25 
(0.77) 
.911 
1.92 
(0.56) 
2.25 
(0.73) 
2.68 
(0.68) 
2.89 
(0.65) 
.000 
1.65 
(0.45) 
2.05 
(0.52) 
2.37 
(0.57) 
2.99 
(0.65) 
.000 
2.26 
(0.70) 
2.31 
(0.70) 
2.20 
(0.76) 
.727 
2.22 
(0.74) 
2.30 
(0.73) 
.536 
                       
Emotional 
Distress 
2.32 
(0.34) 
1.65 
(0.55) 
1.68 
(0.51) 
1.77 
(0.55) 
.352 
1.46 
(0.38) 
1.72 
(0.31) 
1.93 
(0.34) 
2.45 
(0.47) 
.000 
1.38 
(0.37) 
1.55 
(0.34) 
1.80 
(0.5) 
2.29 
(0.46) 
.000 
1.84 
(0.52) 
1.71 
(0.58) 
1.60 
(0.51) 
.287 
1.73 
(0.55) 
1.77 
(0.53) 
.638 
                       
Body 
Image 
1.67 
(0.94) 
1.67 
(0.47) 
1.49 
(0.63) 
1.78 
(0.86) 
.343 
1.33 
(0.48) 
1.94 
(0.88) 
2.07 
(0.76) 
2.35 
(0.95) 
.000 
1.25 
(0.42) 
1.49 
(0.63) 
1.75 
(0.66) 
2.36 
0.95 
.000 
1.94 
(0.84) 
1.63 
(0.77) 
1.52 
(0.75) 
.022 
1.65 
(0.84) 
1.80 
(0.73) 
.234 
                       
Impact on 
Activities 
2.13 
(0.18) 
2.17 
(0.81) 
2.12 
(0.80) 
2.24 
(0.81) 
.638 
1.81 
(0.62) 
2.40 
(0.78) 
2.71 
(0.66) 
2.81 
(0.77) 
.000 
1.58 
(0.54) 
1.96 
(0.56) 
2.25 
(0.56) 
3.07 
(0.68) 
.000 
2.33 
(0,81) 
2.16 
(0.78) 
2.13 
(0.82) 
.386 
2.15 
(0.79) 
2.31 
(0.82) 
.240 
                       
3
Sexual 
Function 
n=2 n=7 n=30 n=89  n=67 n=14 n=23 n=24  n=31 n=31 n=33 n=33  n=48 n=43 n=37  n=83 n=45  
 2.00 
(1.41) 
2.71 
(1.11) 
1.87 
(1.01 
2.31 
(0.29) 
.243 
1.85 
(1.13) 
2.50 
(1.16) 
2.61 
(1.27) 
2.75 
(1.23) 
.003 
1.68 
(0.98) 
2.00 
(1.25) 
2.27 
(1.23) 
2.91 
(1.18) 
.000 
2.35 
(1.18) 
2.21 
(1.23) 
2.08 
(1.32) 
.598 
2.22 
(1.31) 
2.24 
(1.09) 
.904 
*One person did not complete the HADS questionnaire therefore excluded from known groups analysis using HADS. 
1
HADS Total Score: range of scores 0-42, higher scores represent greater 
emotional distress; 
2
FACT-G Total Score: range of scores 0-108, lower scores represent poorer functioning; 
3
Sexual Function: only the first item in the scale was evaluated in order to maximize the 
responses available  
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4.5.6 Cut off score analysis 
 
4.5.6.1 Distribution base methods 
Percentage of study population 
 
Score for the subscale identified from the above factor analyses were calculated for the 
whole study population.  As majority of patients (83.2%) responded to the screening 
question concerning impact on their sexual function, this was included in the cut score 
analysis.  
The lowest score of the 10% and 25% (values chosen after discussion with the wider 
research group to represent severe and moderate impairment, respectively) of patients 
with the poorest scores is shown in Table 4.17. 
Table 4.17 Top percent of patients with worse scores 
Subscale (Mean Raw Score) 25% Cut off 
(Moderate Approximation) 
10% Cut off 
(Severe Approximation) 
Strenuous Activities 2.75 3.35 
Everyday Tasks 1.25 2.00 
Pain 2.00 2.50 
Fatigue 2.80 3.40 
Impact on Activities 2.75 3.25 
Emotional Distress (MHI-5) 2.08 2.49 
Body Image 2.00 3.00 
Sex Life 3.00 4.00 
 
4.5.6.2 Minimally important differences (MIDs) 
 
Mean score differences corresponding to small, medium and large effect sizes (d=0.2, 
0.5 and 0.8 respectively) were calculated by scaling the standard deviation (s) of each 
scale by the effect size. 
The standard error of the mean (SEM) is calculated as a function of the standard 
deviation of the sample scores and reliability (α) of each subscale. (SEM = s (1 - )). 
The SEM gives an indication of the expected range of a patient’s true score (Crosby et 
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al., 2003). Low levels of SEM indicate high levels of score accuracy and conversely, 
high levels of SEM indicate low levels of score accuracy. The thresholds of 1.0 SEM 
(68% confidence interval) and the more conservative 1.96 SEMs (95% confidence 
interval) are reported. 
Quality of Life data is expected to be positively skewed with the majority of patients 
being well. In order to make estimates of the changes in quality of life more meaningful 
for these patients, MIDs was calculated as above using the variability of the total 
sample as well as the 75% best scoring sub-sample. The result of this analysis is 
shown in Table 4.18. 
 
Table 4.18 Distribution based estimates of Minimally Important Differences 
Subscale   MID for Total 
Sample 
MID adjusted for 75% best scoring 
sample* 
Strenuous 
Activities 
d=0.2 .17 .10 
d=0.5 .43 .25 
d=0.8 .69 .39 
   
1.00 * 
SEM 
.33 .19 
1.96 * 
SEM 
.64 .36 
Everyday Tasks d=0.2 .09 .02 
d=0.5 .23 .04 
d=0.8 .36 .06 
   
1.00 * 
SEM 
.19 .03 
1.96 * 
SEM 
.38 .06 
Pain d=0.2 14 .04 
d=0.5 .35 .11 
d=0.8 .56 .17 
   
1.00 * 
SEM 
.24 .08 
1.96 * 
SEM 
.47 .16 
Fatigue d=0.2 15 .09 
 d=0.5 .37 .22 
 d=0.8 .59 .35 
    
 1.00 * 
SEM 
.21 .12 
 1.96 * 
SEM 
.42 .25 
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Impact on activities d=0.2 .16 07 
 d=0.5 .40 .17 
 d=0.8 .64 .28 
    
 1.00 * 
SEM 
.29 .17 
 1.96 * 
SEM 
.57 .34 
Emotional distress d=0.2 .11 .06 
 d=0.5 .27 .15 
 d=0.8 .43 .24 
    
 1.00 * 
SEM 
.27 .15 
 1.96 * 
SEM 
.52 .29 
Body Image d=0.2 16 .09 
 d=0.5 .40 .24 
 d=0.8 .64 .28 
    
 1.00 * 
SEM 
.29 .10 
 1.96 * 
SEM 
.57 .20 
Impact on sex life d=0.2 25 .09 
 d=0.5 .62 .23 
 d=0.8 .98 .37 
    
 1.00 * 
SEM 
n/a n/a 
 1.96 * 
SEM 
n/a n/a 
* Number of patients may exceed stated percentile where more patients have the same scale score 
 
4.5.6.3 Anchor based methods 
Anchor selection 
Hospital Anxiety and Depression Scale (HADS), FACT-G, the Distress Thermometer 
and WHO Performance Status were used as anchors for the questionnaire subscales. 
Specific anchors were chosen a priori, based on which measures were expected to be 
related. 
Cut off scores derived from the developers of the instruments were available for the 
Hospital Anxiety and Depression Scale (Snaith and Zigmond, 1994) and the Distress 
Thermometer (Jacobsen et al., 2005). Razavi et al investigated the use of HADS 
specifically as a tool to screen for depressive disorders in cancer population (Razavi et 
al., 1990). They have proposed a slightly different cur off scores compared to Snaith 
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and Zigmond, whose study sample consisted of patients in general medical out-patient 
clinics. Therefore, both sets of cut off scores were examined.  
Table 4.19 Chosen anchors and cut points 
 Approximate Impairment Categories 
 Non-Case Case 
 Normal Mild  Moderate  Severe  
HADS Total
1
 
 
 
0 - 7 
0 - 7 
8 - 10 
8 - 10 
11 - 15 
11 - 18 
16 – 42* 
19 – 42** 
HADS Anxiety
1
 
 
0 - 7 8 - 10 11 - 21 
HADS Depression
1
 
 
0 - 7 8 - 10 11 - 21 
WHO Performance 
Status
2
 
 
1 - 2 3 - 5 
FACT-G Total
2
 
 
108 - 65 64 - 55 54 - 0 
FACT-G PWB
2
 
 
28 - 18 17 - 13 12 - 0 
FACT-G EWB
2
 
 
24 - 14 13 - 10 9 - 0 
FACT-G SFWB
2
 
 
28 - 19 18 - 15 14 - 0 
FACT-G FWB
2
 
 
28 - 12 11 - 8 7 - 0 
FACT-G Fatigue Item
2
 
 
0 - 2 3 4 
FACT-G Pain Item
2
 
 
0 - 0 1 - 2 3 - 4 
FACT-G Sex Item
2
 
 
0 - 3 4 - 4 
Distress Thermometer
1
 0 - 3 4 - 10 
1 
Published cut points available (* scores based on Zigmond and Snaith, ** scores based on Razavi et al) 
2 
No published cut points available. Worst scoring 25% and 10% chosen as approximates for moderate 
and severe cases respectively. Where both scores are equivalent, only a moderate cut point is specified. 
PWB: Physical well-being, EWB: Emotional well-being, SFWB: Social/Family well-being, FWB: Functional 
well-being 
 
For FACT-G and WHO performance status, Worst scoring 25% and 10% chosen as 
approximates for moderate and severe cases respectively. For WHO performance 
status, scale of 1-5 was used rather than 0-4, to avoid null values. Table 4.19 illustrates 
the chosen anchors and approximate impairment categories and their respective 
questionnaire/item scores. 
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Anchor-based measures require them to be least moderately correlated with the 
instrument being explored. Pearson correlation coefficients were examined between 
the anchor measures and the respective subscales. As all data originated from the 
same source, correlations between all measures were only used to assess the 
suitability of the chosen anchors, but not to select them. Table 4.20 illustrates the 
correlation between the anchor measures and the QuEST-Cr subscales. This showed 
that the FACT-G Social/Family well-being scale did not correlate well with the subscale 
“Impact on activities”.   
Table 4.20 Pearson’s Correlation Coefficients with Chosen Anchors 
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Strenuous 
Activities 
   .583  -.538        
Everyday 
Tasks 
   .489 
 
 -.470 
 
       
Pain          .821 
 
   
Fatigue          . 
 
.783 
 
  
Impact on 
Activities* 
       -.255 
 
-.696 
 
    
Emotional 
Distress 
(MHI-5) 
.752 
 
.658 
 
.677 
 
   -.416 
 
     .561 
 
Body Image              
Impact on 
Sex Life 
           -.394 
 
 
r: Pearson correlation coefficient, PS: performance status 
* Due to low correlations, FACTG-SFWB will not be used as an anchor for Impact on Activities 
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4.5.6.4 Linear regression 
 
Each of the chosen anchors was used to predict the questionnaire subscale in question 
using linear regression. The regression formula was then applied to calculate 
equivalent cut-off scores (where equivalent values before and at the cut point were 
more than one decimal apart, the mean was taken as the new cut point) and the 
accuracy of such groupings was assessed. Table 4.21 summarizes the cut off score 
analysis by linear regression. 
 
Table 4.21 Cut-offs predicted by Linear Regression 
 Matched Cut-Offs Under-
estimate  
Correct 
Assignment 
Over-
estimate 
Positive Predictive 
Value 
Moderate Severe 
Strenuous Activities   
WHO PS 1-2 - 3-5 -      
Strenuous 
Activities 
1.0-2.2 
 
 2.3-4.0 
 
 24 (15.5%) 
 
105 (67.7%) 
 
26 (16.8%) 
 
57.4% 
 
 
 
FACT-PWB 28-18 - 17-13 12-0      
Strenuous 
Activities 
1.0-2.4 
 
 2.5-2.9 
 
3.0-4.0 
 
7 (4.5%) 
 
108 (69.7%) 
 
40 (25.8%) 
 
48.1% 
 
16.7% 
 
Everyday Tasks   
WHO PS. 1-2 - 3-5 -      
Everyday Tasks 1.0-1.2 
 
 1.3-4.0 
 
 35 (22.6%) 
 
104 (67.1%) 
 
16 (10.3%) 
 
60.0% 
 
 
FACT-PWB 28-18 - 17-13 12-0      
Everyday Tasks 1.0-1.3 
 
 1.5-1.6 
 
1.7-4.0 
 
18 (11.6%) 
 
121 (78.1%) 
 
16 (10.3%) 
 
62.5% 
 
22.2% 
 
Pain   
FACTG Pain 0 - 1-2 3-4      
Pain 1.0-1.4 
 
 1.4-2.5 
 
2.6-4.0 
 
15 (9.7%) 
 
129 (83.8%) 
 
10 (6.5%) 
 
86.6% 
 
83.3% 
 
Fatigue   
FACTG Fatigue 0-2 - 3 4      
Fatigue 1.0-2.5 
 
 2.6-3.0 
 
3.1-4.0 
 
14 (9.1%) 
 
118 (76.6%) 
 
22 (14.3%) 
 
72.5% 
 
58.3% 
 
Impact on Activities   
FACTG FWB 28-12 - 11-8 7-0      
Impact on 
Activities 
1.0-2.6 
 
 2.7-3.0 
 
3.1-4.0 
 
7 (4.5%) 
 
121 (78.1%) 
 
27 (17.4%) 
 
53.3% 
 
34.6% 
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Emotional Distress (MHI-5)   
HADS Total (1) 0-7 8-10 11-15 16-42      
Emotional 
Distress 
1.0-
1.6 
 
1.7-
1.8 
 
1.9-
2.1 
 
2.2-
4.0 
 
24 (15.6%) 
 
100 (64.9%) 
 
30 (19.5%) 
 
72.7% 
 
60.5% 
 
HADS Total (2) 0-7 8-10 11-18 19-42      
Emotional 
Distress 
1.0-
1.6 
 
1.7-
1.8 
 
1.9-
2.3 
 
2.4-
4.0 
 
24 (15.6%) 
 
96 (62.3%) 
 
34 (22.1%) 
 
72.7% 
 
35.0% 
 
HADS Anxiety 0-7 8-10 11-21 -      
Emotional 
Distress 
1.0-
2.0 
 
2.1-
2.3 
 
2.4-
4.0 
 
 11 (7.1%) 
 
114 (74.0%) 
 
29 (18.8%) 
 
46.5% 
 
30.0% 
 
HADS 
Depression 
0-7 8-10 11-21 -      
Emotional 
Distress 
1.0-
2.0 
 
2.1-
2.3 
 
2.4-
4.0 
 
 14 (9.0%) 
 
112 (72.3%) 
 
29 (18.7%) 
 
38.6% 
 
35.0% 
 
FACTG EWB 24-14 - 13-10 9-0      
Emotional 
Distress 
1.0-
1.9 
 
 2.0-
2.1 
 
2.2-
4.0 
 
11 (7.1%) 
 
95 (61.3%) 
 
49 (31.6%) 
 
28.6% 
 
13.2% 
 
Distress Therm. 0-3 - 4-10 -      
Emotional 
Distress 
1.0-
1.9 
 
 2.0-
4.0 
 
 11 (7.1%) 
 
114 (73.5%) 
 
30 (19.4%) 
 
46.4% 
 
 
Impact on Sex Life   
FACTG Sex 
Life 
0-3 - 4 -      
Impact on Sex 
Life 
1.0-
2.3 
 
 2.4-
4.0 
 
 20 (22.2%) 
 
32 (35.6%) 
 
38 (42.2%) 
 
7.3% 
 
 
 
 
4.5.6.5 Receiver Operating Characteristic Curves 
 
Cut off scores were further explored using the Receiver Characteristic Operating 
(ROC) curves using the same anchor measures. ROC curves compare sensitivity 
versus specificity across a range of values for the ability to predict a dichotomous 
outcome and provide another measure of test performance.  
The anchor measures were converted into dichotomous variables according to the cut 
off scores outlined previously in order to perform the analysis using SPSS. 
Cut off scores were chosen based on the score which provided sensitivity greater than 
or nearest to 0.8 with best specificity. Positive predictive value for the cut off score 
identified was also calculated for each subscale. Table 4.22 summarizes the ROC 
curve analysis performed.  
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Table 4.22 ROC curve analysis 
 Anchor positive 
case 
n 
AUC* 
(standard 
error) 
p 
p Best 
Cut-
off 
 
Sensitivity 
above 0.8 
or nearest 
Specificity Positive 
Predictive 
Value 
Strenuous 
Activities 
WHO PS ≥ 3 59 .758 
(.039) 
.000 1.6 
 
81.4% 
 
51.0% 50.5% 
FACTG- 
PWB 
≤ 
17 
31 
 
..839 
(.036) 
.000 2.4 
 
80.6% 
 
78.2% 
 
48.1% 
 
 ≤ 
12 
7 
 
.875 
(.038) 
.001 2.9 
 
85.7% 
 
79.7% 
 
16.7% 
 
Everyday 
Tasks 
WHO PS ≥ 3 59 
 
.720 
(.044) 
.000 1.1 
 
66.1% 
 
78.1% 
 
65.0% 
 
FACTG- 
PWB 
≤ 
17 
31 
 
.777 
(.051) 
.000 1.1 
 
64.5% 
 
71.0% 
 
40.0% 
 
 ≤ 
12 
7 
 
.910 
(.039) 
.000 1.5 
 
85.7% 
 
87.8% 
 
25.0% 
 
Pain FACTG Pain ≥ 1 70 
 
.879 
(.031) 
.000 1.3 
 
82.9% 
 
89.3% 
 
86.6% 
 
 ≥ 3 14 
 
.930 
(.050) 
.000 1.8 
 
92.9% 
 
81.4% 
 
33.3% 
 
Fatigue FACTG 
Fatigue 
≥ 3 46 
 
.925 
(.022) 
.000 2.5 
 
80.4% 
 
87.0% 
 
72.5% 
 
 ≥ 4 20 
 
.935 
(.021) 
.000 2.9 
 
85.0% 
 
86.6% 
 
48.6% 
 
Impact on 
Activities 
FACTG FWB ≤ 
11 
31 .869 
(.034) 
.000 2.4 839% 72.6% 43.3% 
 
 ≤ 7 12 
 
.845 
(.065) 
.000 2.1 
 
83.3% 
 
54.5% 
 
13.3% 
 
Emotional 
Distress 
(MHI-5) 
HADS-T  ≥ 8 70 
 
.859 
(.030) 
.000 1.7 
 
81.4% 
 
77.4% 
 
75.0% 
 
 ≥ 
11 
53 
 
.884 
(.027) 
.000 1.8 
 
84.9% 
 
78.2% 
 
67.2% 
 ≥ 
16 
29 
 
.921 
(.023) 
.000 1.9 
 
89.7% 
 
76.8% 
 
47.3% 
 
 ≥ 
19 
11 
 
.915 
(.039) 
.000 2.1 
 
90.9% 
 
80.4% 
 
26.3% 
 
HADS 
Anxiety 
≥ 8 29 
 
.857 
(.033) 
.000 1.8 
 
86.2% 
 
66.4% 
 
37.3% 
 
 ≥ 
11 
8 
 
.935 
(.027) 
.000 2.1 
 
100.0% 
 
79.5% 
 
21.1% 
 
HADS 
Depression  
≥ 8 25 
 
.853 
(.035) 
.000 1.9 
 
84.0% 
 
73.1% 
 
37.5% 
 ≥ 
11 
15 
 
.881 
(.038) 
.000 2.1 
 
80.0% 
 
81.4% 
 
31.6% 
 
FACTG EWB ≤ 
13 
27 
 
.738 
(.049) 
.000 1.5 
 
85.2% 
 
46.9% 
 
25.3% 
 
 ≤ 9 7 
 
.801 
(.084) 
.007 1.5 
 
100.0% 
 
43.2% 
 
7.7% 
 
Distress 
Thermometer  
≥ 4 37 
 
.784 
(.046) 
.000 1.8 
 
81.1% 
 
67.8% 
 
44.1% 
 
Impact on 
Sex Life 
FACTG Sex 
Life 
≥ 4 60 
 
.301 
(.047) 
.000 1.5 
 
41.7% 
 
26.9% 
 
33.8% 
 
*AUC: Area under the curve, PS: performance status 
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4.5.6.6 Scale Representation 
 
Prior to decisions being made on the cut off scores for the respective subscales, it was 
necessary to determine the smallest feasible difference between two scores for each 
subscale. Table 4.23 illustrates the relationship between the number of scale items and 
response options together with minimal possible increment for each subscale.  The 
table also illustrates the frequency of scores obtained from the study population from 
the Questionnaire Validation Study. 
 
Table 4.23 Response Options and Minimal Possible Increment 
Scale 
Items 
Number of 
possible 
responses 
Range Minimum 
Possible 
Increment 
Response Frequencies 
1 4 1 - 4 
 
1.00 
 
Impact on Sex Life 
 
2 7 1 - 4 
 
0.50 
 
Pain 
 
3 10 1 - 4 
 
0.33 
 
Body Image 
 
0
20
40
60
1.00 2.00 3.00 4.00
0
20
40
60
80
100
1.00 1.50 2.00 2.50 3.00 3.50 4.00
0
20
40
60
1.00 1.33 1.67 2.00 2.33 2.67 3.00 3.33 3.67 4.00
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Scale 
Items 
Number of 
possible 
responses 
Range Minimum 
Possible 
Increment 
Response Frequencies 
4 13 1 - 4 
 
0.25 
 
Strenuous Activities 
 
    Impact on Activities 
 
5 16 1 - 4 
 
0.20 
 
Everyday Tasks 
 
 
    Fatigue 
 
5 26 1 - 4 
 
0.12 
 
Emotional Functioning (MHI-5) 
 
 
  
0
10
20
30
1 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
0
5
10
15
20
25
1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00
0
50
100
1
.0
0
1
.2
0
1
.4
0
1
.6
0
1
.8
0
2
.0
0
2
.2
0
2
.4
0
2
.6
0
2
.8
0
3
.0
0
3
.2
0
3
.4
0
3
.6
0
3
.8
0
4
.0
0
0
10
20
30
40
1
.0
0
1
.2
0
1
.4
0
1
.6
0
1
.8
0
2
.0
0
2
.2
0
2
.2
5
2
.4
0
2
.6
0
2
.8
0
3
.0
0
3
.2
0
3
.4
0
3
.6
0
3
.8
0
4
.0
0
0
5
10
15
20
1.
00
1.
12
1.
24
1.
36
1.
48
1.
60
1.
72
1.
84
1.
96
2.
08
2.
20
2.
32
2.
44
2.
56
2.
68
2.
80
2.
92
3.
04
3.
16
3.
28
3.
40
3.
52
3.
64
3.
76
3.
88
4.
00
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4.5.6.7 Summary of the cut off score analysis 
 
All of the analyses performed for exploring the optimal cut off score for the subscales 
within QuEST-Cr are summarised in Table 4.24. 
The cut off scores for the “moderate impairment” for respective subscales obtained 
from the above analyses with the highest positive predictive value have been 
highlighted in red font within Table 4.24. The actual cut off score for the moderate 
impairment category used will be the closest score that can be obtained within the 
subscale. The cut off for the severe impairment category will be cut off for the moderate 
impairment category plus the minimally important difference for the medium effect size 
of the total population derived from the validation study. 
  
 
1
6
0
 
Table 4.24 Summary of Results and Cut Point Decisions (preferred options marked in red) 
Scale 
Smallest 
possible 
change 
Source / Anchor r Analysis 
PPV % for 
Moderate 
Cut-Off 
Estimated Cut-Offs 
MIDs Best 
Moderate 
Cut-off for 
scale 
Best 
Severe 
Cut-off for 
scale 
Effect Size total population  
(75% most well population) 
Mild Mod Severe Small Med Large 
Strenuous 
Activities 
.25 Distribution  Top 25/10%   2.8 3.4 
.17 
(.10) 
.43 
(.25) 
.69 
(.39) 
2.25 2.75 
 WHO Perf. Stat .583 Regression 57.4  2.3  
   ROC 50.5  1.6  
 FACT-G PWB -.538 Regression 48.1  2.5 3.0 
   ROC 48.1  2.4 2.9 
Everyday Tasks .20 Distribution  Top 25/10%   1.4 2.0 
.09 
(.02) 
.23 
(.04) 
.36 
(.06) 
1.20 1.40 
  WHO Perf. Stat .489 Regression 60.0  1.3  
    ROC 65.0  1.1  
  FACT-G PWB -.470 Regression 62.5  1.5 1.7 
    ROC 45.5  1.1 1.5 
Pain .50 Distribution  Top 25/10%   2.0 2.5 
.14 
(.04) 
.35 
(.11) 
.56 
(.17) 
1.50 2.00   FACTG Pain .821 Regression 86.6  1.4 2.6 
    ROC 86.6  1.3 1.8 
Fatigue .20 Distribution  Top 25/10%   2.8 3.4 
.15 
(.09) 
.37 
(.22) 
.59 
(.35) 
2.60 3.00   FACTG Fatigue .783 Regression 72.5  2.6 3.1 
   ROC 72.5  2.5 2.9 
Impact on 
Activities 
.25 Distribution  Top 25/10%   2.8 3.3 
.16 
(.07) 
.40 
(.17) 
.64 
(.28) 
2.75 3.00  FACTG FWB -.696 Regression 53.3  2.7 3.1 
 ROC 43.3  2.4 2.1 
Emotional 
Distress 
.12 Distribution  Top 25/10%   2.1 2.5 
.11 
(.06) 
.27 
(.15) 
.43 
(.24) 
1.96 2.20 
 HADS-T .752 Regression 72.7 1.7 1.9 2.2/2.4 
   ROC 67.2 1.7 1.8 1.9/2.1 
 HADS-Anx .658 Regression 46.5 2.1 2.4  
   ROC 37.3 1.8 2.1  
 HADS-Dep .677 Regression 38.6 2.1 2.4  
   ROC 37.5 1.9 2.1  
 FACT EWB -.416 Regression 28.6  2.0 2.2 
   ROC 25.3  1.5 1.5 
 Dist. Thermometer .561 Regression 46.4  2.0  
   ROC 44.1  1.8  
Body Image .33 Distribution  Top 25/10%   2.0 3.0 .16 
(.09) 
.40 
(.24) 
.64 
(.28) 
2.00 2.33 
Impact on Sex 
Life 
1.00 Distribution  Top 25/10%   3.0 4.0 
.25 
(.09) 
.62 
(.23) 
.98 
(.37) 
2.00 3.00  FACTG Sex -.623 Regression 7.3  2.4  
   ROC 33.8  1.5  
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4.6 Discussion 
 
This study has allowed exploration of 155 CRC patients’ experience of going though 
chemotherapy treatment for their underlying cancer.  Majority of patients were receiving 
palliative treatment for their underlying disease.  The results of the questionnaires 
indicate that these patients were physically functioning well with reasonable 
performance status.  This is not unexpected as they need to have reasonable reserve 
to be deemed fit to have chemotherapy treatment.  The findings from the questionnaire 
suggest cancer and treatment have varied impact on their symptoms and functions.  
The most prevalent symptom was fatigue in this population. 
 
The exploratory factor analysis identified 7 subscales which were common to the three 
disease groups investigated as part of this study.  These are strenuous activities, 
everyday tasks, pain, fatigue, impact on activities, emotional distress and body image. 
The subscales contain between 2 and 5 items. All had good internal consistency 
(Cronbach alpha >0.7). . QuEST-Cr also contains 16 single items which address 
symptoms patients may experience as a result of their underlying cancer or from their 
treatment.  
 
Findings from previous research suggested that the EORTC QLQ-C30 physical 
functioning scale would benefit from adjustment in order to make the scale more 
suitable for clinical practice.  The two physical function scales, everyday tasks and 
strenuous activities, separated basic activities of daily living and more strenuous 
activities which may be useful in better defining different groups of patients with varied 
physical capabilities. The everyday tasks scale reflects activities of daily living (ADL) for 
self care activities; for example, eating, washing and dressing.  The strenuous activities 
scale reflects instrumental activities of daily living (IADL) which represents activities 
that allow individuals to live independently within a community, such as housework, 
and shopping.  It would be expected that a patient undergoing chemotherapy would 
have good levels of basic physical functioning; however, it would be relevant for the 
clinicians to monitor this, particularly with patients with colorectal cancer, as they are 
often elderly patients.   
 
The EORTC QLQ-C30 (Aaronson et al., 1993) includes two items on role and 2 items 
of social functioning.  The role functioning questions explore patients’ perception of 
their limitations to work, perform daily activities and limitations in pursuing hobbies and 
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leisure time activities.  The social functioning questions explore patients’ perceptions of 
how their disease or treatment has interfered with their family life or social activities. 
Patients and clinicians may interpret “hobbies”, “leisure time activities” and “social 
activities” as very similar concepts and clinicians in particular, may have difficulty in 
differentiating between the two subscales. Within the above factor analysis, the four 
role and social items converged into one factor, with good levels of reliability, 
suggesting that these issues are actually underpinned by one concept; assessing the 
impact of disease and/or treatment on various activities patients may engage with. It is 
likely that this description of the scale would assist clinicians to better understand what 
this scale is trying to measure.  
 
Selecting the most suitable set of items for Emotional Function was difficult.  It was felt 
that retaining the scales form original questionnaires was the most sensible approach.  
It was decided that the MHI-5 subscale would be retained for all three disease groups 
as there was evidence from a previous study which had indicated MHI-5 to be a useful 
tool for step wise screening for emotional distress in oncology practice (Cull et al., 
2001).  In addition, oncologists and patients expressed their unease about some of the 
wording in the EORTC QLQ-C30 items.  However, the adaptation of the MHI-5 time 
frame from “during the past month” to “during the past week” may be a limitation, as we 
are yet to explore how this change may impact on the validity of patient responses. 
 
Sexual function and stoma function items were retained within the questionnaire as 
they were considered important topics to address in the questionnaire from the 
previous interview studies with oncologists and patients.   83.2% of patients responded 
to the initial sexual function question.  42% of those patients who responded to this 
question stated that they had not experienced negative impact on their sex life and 
would have been screened from the remaining sexual function items. It may be that the 
first question about general sexual function may be used as a screening question to 
prompt a discussion where needed.  The additional items may help facilitate discussion 
about specific problems experienced by the patients.  No changes were made to these 
items as more data is required to evaluate these items. Similarly, items relating to 
stoma function require further data to evaluate the utility of these items. 
 
Known group differences were explored to see if QuEST-Cr was able to distinguish 
between different characteristics; this analysis illustrated that the QuEST-Cr 
questionnaire distinguished relevant groups based on HADS and FACT-G total scores. 
Female patients reported more problems with strenuous activities than male patients 
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and younger patients reported more issues with their body image. Overall, QuEST-Cr 
did not perform well based on patients’ age, gender and disease stage, however, 
majority of patients (71%) in this study had metastatic disease with only 11 patients 
with stage 1 or 2 disease.   
 
There are a number of limitations to the study. Although, the validation study managed 
to recruit more than the target patient population sample overall, it was still a relatively 
small sample of patients, all recruited in a single cancer centre.  As the study 
participation was optional, it may have biased more patients with better performance 
status to be included in the study compared to the general oncology population. 
Patients completed the questionnaire only once during the study; therefore there is no 
data on how the questionnaire may perform over a period of time or to ensure test-
retest reliability.  More data is needed to further validate the shortened QuEST-Cr and 
examine the psychometric properties, and the cut off scores.  
 
Rigorous developmental processes involving mixed qualitative and quantitative 
methods have been pursued in the development of the QuEST-Cr questionnaire. 
These involved review of discussion topics within routine oncology out-patient clinics; 
review of literature; interviews with both oncologists specialising in the treatment of 
colorectal cancer and their patients; assessment of individual item performance, 
exploratory factor analysis; internal consistency reliability, multi-trait scaling and cut off 
score analysis. The focus was always on developing an instrument specifically for use 
within clinical practice to provide means of assessing patients’ health related quality of 
life.  Qualitative data from the interview studies helped to ensure the questionnaire to 
be clinically relevant and provide clinimetric perspective to the questionnaire 
development. 
 
The processes undertaken thus far have resulted in a formation of a colorectal cancer 
specific questionnaire, QuEST-Cr, which is clinically relevant with acceptable 
psychometric properties. The questionnaire needs to be utilized in oncology clinics to 
further explore its psychometric performance, but more importantly, to assess its’ utility 
in clinical practice and patient care. 
 
 The cut off scores aim to assist the clinicians to act upon the questionnaire results 
during their clinic encounter with their patients. The cut off scores are expected to 
serve an important function to assist oncologists to use the data from QuEST-Cr as 
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part of patient management.  Future studies will investigate how this questionnaire 
might impact on patient – doctor communication and decision making. 
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Chapter 5 Longitudinal Analysis of Patient-Physician 
Communication 
 
5.1 Introduction 
 
The aim of this exploratory analysis was to investigate the impact the patient reported 
HRQoL data had on the patient-doctor communication and to see whether the repeated 
intervention had an impact over time. I particularly wanted to explore whether the 
intervention made the doctors enquire more about patients’ symptoms and problems 
and to investigate whether scores of the questionnaires made doctors act upon them 
The purpose of this exploratory analysis was also to glean from the results whether 
there were any specific aspects that may help to increase the utility of the patient 
reported data. 
 
5.2 Randomized controlled study conducted by POCPRG 
 
The analyses were performed on a data set from a study previously conducted by the 
Leeds POCPRG (Velikova et al., 2004).  This was a randomized controlled prospective 
longitudinal study with repeated measures, investigating the impact of patients 
completing health related quality of life (HRQoL) questionnaires as part of their routine 
oncology care.  Eligible patients were those attending the Medical Oncology Out-
Patient clinics at St. James’s University Hospital, Leeds, who were starting cytotoxic 
chemotherapy or biological therapy for their underlying cancer diagnosis; who were 
expected to attend the clinic for review for at least four times.  Other eligibility criteria 
included those who were able to read and understand English and able to provide 
written informed consent.  Out-patient clinics were delivered by team approach 
whereby patients saw a variety of different doctors working within teams.  Therefore, all 
Consultant Medical Oncologists and Specialist Registrars working within the Medical 
Oncology Department during the study period took part in the study.  The study was 
approved by the Institutional Ethics Committee.  Written informed consent was 
obtained from participating patients and physicians. 
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286 patients and 28 physicians took part in this study.  The patients were randomly 
assigned to one of three arms; 1) Intervention, 2) Attention Control and 3) Control.  All 
patients had a baseline consultation followed by three study consultations.  Patients in 
the Intervention Arm were asked to complete EORTC QLQ-C30 (Aaronson et al., 1993) 
and HADS (Zigmond and Snaith, 1983) prior to their consultation on a touch-screen 
computer.  The results of the questionnaires were tabulated in real time and presented 
in a graphical format to the physicians so that they were available during their clinic 
encounter with the patient.  Patients in the Attention Control Arm were asked to 
complete the same questionnaires but the results were not fed back to the physicians.  
Patients in the Control Arm received standard care (i.e. no questionnaire intervention).  
All consultations were audio-recorded. 
All oncologists received individual one to one meeting/training with the members of the 
POCPRG prior to the study commencement.  They were provided with explanation for 
the questionnaire scoring and graphical output. They were also given a manual 
containing information about the questionnaires which were made readily available in 
their consultation rooms.  Oncologists were asked to use the data provided by the 
questionnaires where applicable without any further instructions as to how they might 
use the patient reported HRQoL data in their clinic consultation. The clinical utility of 
patient reported data include detection of problems which would not otherwise be 
identified.  Other ways in which the patient reported information might help doctors 
would be to allow the consultation to be focused around problems reported by patients 
and use the patient data to structure the consultation accordingly.  However, such 
information was not provided. 
The study had predetermined outcomes for which audio-recordings of the clinic 
consultations at specified time points were analysed using a study specific checklist 
developed by the POCPRG to analyse the content of the consultations.  This content 
analysis checklist noted discussions of symptoms/psychosocial functioning covered in 
the EORTC QLQ-C30 and HADS.  Symptoms covered in EORTC QLQ-C30 are 
Fatigue, Dyspnoea (shortness of breath), Insomnia, Pain, Nausea and Vomiting, Bowel 
Function (Constipation and Diarrhoea) and appetite. Functions covered in QLQ-C30 
are Physical, Social, Role, Emotional (also covered by HADS) and Cognitive functions.  
Any other symptoms or issues raised were also noted. The person (patient/relative or 
oncologists) initiating the discussion of each topic was documented.  Content analysis 
was performed directly from the audio-recordings.  Each consultation was coded by 
two raters.  Weekly meetings were held to achieve consensus. 
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Basic demographic data were collected from both patients and oncologists as part of 
the study.  This included age, gender, diagnosis, extent of disease, performance status 
for patients and age, gender, grade (consultants/specialist registrars) for oncologists. 
Following the publication of the above study, further work was performed to code all of 
the 4 consecutive clinic consultation audio-recordings collected during this study, which 
has resulted in the formation of a rich database of consecutive real life oncology clinic 
consultations of patients undergoing cancer therapy.  This provided longitudinal 
database of consultations which took place within a defined period of time. 
All of the content analyses were performed by the members of the Leeds POCPRG. 
However, I performed all of the exploratory statistical analyses with guidance from the 
Leeds POCPRG statistician. 
 
5.3 Analysis planning 
 
The randomized study had indicated that patients completing the questionnaires and 
feeding back the result to the oncologists had contributed to improvements in patient 
well being.  The mechanism by which this intervention resulted in improvement in 
patient well being remains uncertain.  There was, however, some evidence that the 
intervention had an impact on patient-doctor communication.  
This analysis aimed to investigate the impact on the use of the patient reported 
measures/questionnaires and the feedback of the results to the physicians on the clinic 
consultations. It may be anticipated that patients’ well being may be linked with 
improvement in patients’ health-related quality of life (HRQoL).  If the questionnaire or 
patient reported outcome intervention had contributed to improvement in patients’ 
HRQoL then it would be anticipated that such issues may have be brought to the 
consultation for discussion.   Therefore, analysis of communication between 
oncologists and patients and how this was impacted by the questionnaire feedback 
were considered important.  Particular attention was given to the communication on the 
issues that were specifically covered in the questionnaires to assess the impact of the 
intervention and whether the scores from the patient reported HRQoL had any 
relationship as to whether these issues were, in fact, raised during the consultation.  In 
addition, the longitudinal nature of the consultation database allowed exploration of the 
intervention impact over time. 
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5.4 Aims and hypotheses 
 
The aims and hypotheses for these analyses were 
1. To investigate whether repeated collection of patient reported outcomes of 
HRQoL and feedback of the results to the oncologists in clinic consultations had 
an impact on patient-physician communication over time.   
 
It was hypothesized that collecting patient reported HRQoL and feeding back 
the results to the oncologists would lead to increased discussion of patients’ 
HRQoL issues.  It was also hypothesized that repeated intervention would help 
maintain the level of discussion of such issues at subsequent clinic 
consultations. 
 
2. To investigate whether feedback of patient reported HRQoL had an impact on 
oncologists to initiate the discussion of highlighted HRQoL issues.   
 
The hypothesis was that feedback of the patient reported HRQoL may have an 
impact on the dynamics of the patient-physician communication and prompt 
oncologists to initiate discussions about problems patients have highlighted in 
the questionnaire. 
 
3. To investigate the relationship between the severity of the problems reported by 
patients and the content of the clinic consultation discussion. 
It was hypothesized that clinic discussion will be reflected by the severity of the 
problems reported by patients through the questionnaire and that feedback of 
the results to the oncologists would prevent important issues being missed (i.e. 
any severe problems would be noticed by the oncologists and therefore 
discussed during the clinic encounter). 
4. To identify elements within the intervention that may enhance the impact of 
patient reported outcome intervention to inform the content of the doctor training 
programme. 
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5.5 Methods 
 
5.5.1 Data preparation 
 
The content analyses performed on the audio-recording of clinic consultations were 
stored on Microsoft Access database.  Data necessary for the analysis was extracted 
from this database and exported to excel file.  The information extracted is shown in 
table 5.1.  In order to perform an analysis which took effect of time into consideration, it 
was felt that data from all four clinic consultations (baseline plus three study 
consultations) were necessary.  Therefore patients who did not have complete dataset 
from all four consultations were excluded.  In addition, patients whose audio-recordings 
were of poor quality, thus limiting the quality of the content analysis was also excluded. 
Final dataset was imported on SPSS for analysis.   
Table 5.1 Data extracted for analysis 
Patient details 
1. Study ID 
2. Study Arm 
3. Age 
4. Gender 
5. Disease site 
6. Extent of disease 
7. Performance status 
8. Date of diagnosis 
9. Response at 3 months 
Physician details 
1. Study ID 
2. Age 
3. Gender 
4. Grade (consultant or specialist registrars) 
Consultation details 
1. Dates 
2. QLQ-C30 and HADS scores from each clinic visit where applicable 
3. Topics of clinic consultation discussion 
4. Person initiating the discussion of a certain topic/symptom (oncologist or 
patient/relatives) 
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5.6 Analyses 
 
5.6.1 Longitudinal impact of study intervention 
 
Mixed effects models were employed to assess whether number of 
symptoms/functions discussed differed between study arms over time.  This model 
requires the outcome variable to be an ordinal data.  Therefore a summated score was 
calculated for the total number of symptoms (0-7) and functions (0-5) discussed at 
each consultation.  Potential covariates (age, gender, diagnosis, response at 3 months, 
performance status, extent of disease, time in study, months since diagnosis and a 
measure of extent to which patients have seen the same oncologist) were identified by 
univariate regression (the number of issues discussed at first consultation as the 
outcome variable and each covariate as the predictor, controlling for baseline).  
Covariates meeting the inclusion criterion (p<0.1) were entered in multivariate mixed 
effects models.   
The models’ outcome variable was the number of symptoms/functions discussed. 
Fixed effects were the number of symptoms/functions discussed at baseline, study 
arm, time (consultation 1, 2 or 3), arm by time interaction (only retained in the final 
model if significant) and any identified covariates. Patients were entered as a random 
effect. A significance level of p<0.05 was used for this primary hypothesis testing 
analysis. 
 
5.6.2 Dynamics of communication between patients and oncologists 
 
Descriptive statistics were used to analyse the proportion of clinic consultations in 
which topics from EORTC QLQ-C30/HADS were raised, and who initiated the 
discussion. 
Multivariate logistic regression was used to explore predictors for who initiated 
discussions of symptoms /functions (oncologists versus patients/relatives).  
In order to identify potential covariates for inclusion into the multivariate regression 
models, univariate regression analyses were performed for each symptom and function 
for each visit; the person initiating the discussion (oncologists or patients/relatives) as 
the outcome and potential covariate (patients’ gender, age, diagnosis, performance 
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status, extent of disease, oncologists’ gender and oncologists’ grade) as single 
explanatory variable. It was planned that covariates which met significance level of 
p<0.1 at least on two out of the three study visits would be entered in the multivariate 
analysis. 
In the multivariate regression model, the outcome variable was the person initiating the 
discussion at each visit, and the independent variables were study arm and significant 
covariates.  This was repeated for all symptoms and functions. 
The significance level was set at p<0.01 for the multivariate analysis to take into 
account for multiple tests. 
 
5.6.3 Relationship between the severity of patient-reported symptoms and 
functions and content of the clinic discussions 
 
Subgroup analyses were performed on the data from patients in the Intervention and 
Attention-Control arms of the study who completed the two questionnaires (n=146).  
Multivariate logistic regression was again used to investigate the relationship between 
the severity of patients’ symptoms/functions as determined by the questionnaire scores 
and the content of the clinic discussions.  
Potential covariates (patients’ gender, age, diagnosis, performance status, extent of 
disease, discussion of respective symptom/function at baseline, oncologists’ gender 
and oncologists’ grade) were determined by univariate regression, with a particular 
symptom or function discussed or not as the outcome variable.  This was repeated for 
each symptom/function at each of the three study visits. 
In the multivariate regression model, the outcome variable was whether a 
symptom/function was discussed or not and the independent variables were 
questionnaire score for the relevant symptom/function, study arm and significant 
covariates. Covariates which met significance level of p<0.1 at least on two out of the 
three study visits were planned to be included in the multivariate analysis. 
Analyses were repeated for all symptoms and functions at each consultation. A 
significance level of p<0.01 was again used to adjust for multiple testing. 
Statistical analysis for the mixed effects model was assisted by the POCPRG 
statistician, Miss Ada Keding. I performed all the regression analysis under her 
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supervision. All statistical analyses were carried out using SPSS (PASW Statistics 17 
for Windows, IBM Corporation, NY, USA). 
 
5.7 Results 
 
5.7.1 Patient population 
 
286 patients participated in the study.  Of these, 222 patients completed the planned 
four consecutive clinic consultations within the study.  7 patients withdrew consent after 
the baseline consultation and 57 patients dropped out during the study at various time 
points.  More male patients (p=0.002) and those with poorer performance status 
(p=0.003) failed to complete the study.   
After review of the content analysis of the clinic consultations, further 24 patients were 
excluded because of poor quality of audio recordings, resulting in 198 patients with 
complete data set. The characteristics of these 198 patients are shown in Table 5.2. 
Table 5.2 Patient characteristics 
  
Study Arm 
 Intervention Attention Control Control 
n = 100 n = 46 n = 52 
Age (years)    
Median  56 56 56 
Range 23-85 27-78 23-75 
    
Gender    
Female, n (%) 78 (78) 37 (80) 41 (79) 
    
Diagnosis    
Gynaecological Cancer 37 21 20 
Breast Cancer 20 9 11 
Renal Cancer 17 6 9 
Bladder Cancer 5 2 2 
Sarcoma 9 3 3 
Melanoma 6 3 3 
Other 6 2 4 
    
Extent of disease, n (%)    
Disease free/localised 20 (20) 12 (26) 6 (12) 
Metastatic 80 (80) 34 (74) 46 (88) 
    
Performance Status    
0+1 71 (71) 23 (50) 32 (61) 
2+3 29 (29) 23 (50) 20 (39) 
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5.7.2 Oncologist population 
 
All 28 oncologists working in the Medical Oncology Department at St. James’s 
University Hospital at the time of the study participated.  There were 17 male and 11 
female oncologists with median age of 33.5 years (range, 26 to 51 years).  6 were 
consultants and 22 were specialist registrars, with varied oncology experience (range, 
0 to 24 years).   
 
5.8 Longitudinal analysis 
 
Table 5.3 presents the results of the mixed effects models for number of symptoms and 
functions discussed. A time by arm interaction was not significant for either model. 
Patients in the intervention arm discussed more symptoms during consultations than 
those in the Attention-Control (p=0.008) and Control arms (p=0.040). There was also a 
significant effect of time with fewer symptoms being discussed between the first and 
third consultations (p=0.004).  The results of the univariate regression analysis to 
identify potential covariates are shown in Appendix 3.  
Figure 5.1 graphically represents the change in number of issues discussed compared 
to baseline, at first, second and third consultations. The increase in symptoms 
discussions was largest the first time PROs were provided to the physicians and was 
maintained over time.  There were no differences between arms for the discussion of 
functions and no time effect. Of the identified covariates only diagnosis remained 
significant in the functions model. In particular, melanoma patients discussed more and 
bladder cancer patients discussed fewer functional issues than patients in other 
disease groups.  However, the numbers of patients with these cancers were small. 
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Table 5.3 Mixed effects model results 
Variables Estimate 
of effect 
Standard 
error 
95% Confidence 
Interval 
p 
Number of symptoms discussed       
   Intercept 2.57 (0.437)     
   Discussion at baseline 0.26 (0.048) 0.16 - 0.35 <0.001 
   Arm      0.014 
      Intervention v Control  -0.41 (0.197) -0.79 - -0.02 0.040 
      Intervention v Attention Control  -0.55 (0.207) -0.96 - -0.14 0.008 
   Time        0.016 
      Consultation 1 v Consultation 3 0.40 (0.140) 0.13  0.68 0.004 
      Consultation 2 v Consultation 3 0.22 (0.140) -0.05 - 0.50 0.113 
   Gender -0.16 (0.277) -0.71 - 0.38 0.562 
   Diagnosis*      0.880 
   Response at 3 months*      0.851 
       
Number of functions discussed       
   Intercept 1.09 (0.339)     
   Discussion at baseline 0.16 (0.041) 0.08 - 0.24 <0.001 
   Arm      0.172 
      Intervention v Control  -0.22 (0.125) -0.46 - 0.03 0.084 
      Intervention v Attention Control  -0.16 (0.130) -0.42 - 0.09 0.210 
   Time        0.547 
      Consultation 1 v Consultation 3 0.05 (0.106) -0.16 - 0.25 0.670 
      Consultation 2 v Consultation 3 0.12 (0.106) -0.09 - 0.33 0.276 
   Diagnosis*      0.001 
   Extent of Disease 0.02 (0.137) -0.25 - 0.29 0.873 
   Time Since Diagnosis -0.002 (0.002) -0.01 - 0.001 0.261 
   Time on Study 0.002 (0.001) -0.0006 - 0.004 0.154 
 
*
Only p value of overall F test is given for categorical covariates with more than two levels 
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Figure 5-1 Change in the number of issues discussed compared to baseline 
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5.9 Dynamics of communication 
 
The discussion frequency of symptoms and functions at each consultation, together 
with person initiating the topic (oncologists or patients/relatives) are shown in Table 5.4 
a-c.   
Frequencies of symptom discussion were similar at all three time points; 26% to 63% at 
first consultation, 27% to 59% at second consultation and 27% to 59% at third 
consultation.  Discussions about pain, fatigue, nausea and vomiting were common at 
all three consultations. 
Frequencies of function discussion were less than symptom discussions; ranging 4% to 
41%, 6% to 42% and 6% to 37% at first, second and third consultations respectively.  
Most commonly discussed function was physical function at all three time points. 
 
Table 5.4 (a-c) Person initiating discussions of symptoms/functions 
Table 5.4 a Person Initiating Discussion of Symptoms/Functions During First Consultation 
 
 No. of consultations in 
which issue was 
discussed (n=198) 
Oncologist initiating Patient initiating 
 No. % No. % No. % 
Symptom       
   Fatigue 117 59 26 22 91 78 
   Dyspnoea 52 26 36 69 16 31 
   Insomnia 64 32 22 34 42 66 
   Pain 125 63 46 37 79 63 
   Nausea/Vomiting 108 55 40 37 68 63 
   Bowels 98 49 64 65 34 35 
   Appetite 94 47 40 43 54 57 
Function       
   Physical 81 41 24 30 57 70 
   Social 70 35 16 23 54 77 
   Role 52 26 13 25 39 75 
   Emotional 74 37 25 34 49 66 
   Cognitive 8 4 1 13 7 88 
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Table 5.4 b Person Initiating Discussion of Symptoms/Functions During Second Consultation 
 
 No. of consultations in 
which issue was 
discussed (n=198) 
Oncologist initiating Patient initiating 
 No. % No. % No. % 
Symptom       
   Fatigue 111 56 24 22 87 78 
   Dyspnoea 53 27 36 68 17 32 
   Insomnia 71 36 24 34 47 66 
   Pain 116 59 37 32 79 68 
   Nausea/Vomiting 106 54 39 37 67 63 
   Bowels 94 47 59 63 35 37 
   Appetite 80 40 38 48 42 53 
Function       
   Physical 83 42 27 33 56 67 
   Social 75 38 15 20 60 80 
   Role 52 26 12 23 40 77 
   Emotional 78 39 38 49 40 51 
   Cognitive 11 6 3 27 8 73 
       
 
Table 5.4 c Person Initiating Discussion of Symptoms/Functions During Third Consultation 
 
 No. of consultations in 
which issue was 
discussed (n=198) 
Oncologist initiating Patient initiating 
 No. % No. % No. % 
Symptom       
   Fatigue 100 51 33 33 67 67 
   Dyspnoea 54 27 34 63 20 37 
   Insomnia 53 27 23 43 30 57 
   Pain 117 59 44 38 73 62 
   Nausea/Vomiting 101 51 30 30 71 70 
   Bowels 88 44 44 50 44 50 
   Appetite 75 38 35 47 40 53 
Function       
   Physical 73 37 16 22 57 78 
   Social 70 35 10 14 60 86 
   Role 46 23 13 28 33 72 
   Emotional 76 38 30 39 46 61 
   Cognitive 11 6 3 27 8 73 
       
 
 
5.10 Regression analyses 
 
Discussion of symptoms and functions were predominantly initiated by 
patients/relatives with the exception of dyspnoea and bowel function. 
Results (p values) from univariate logistic regression analyses to identify potential 
covariate for the multivariate analyses are shown in Appendix 4.   
178 
 
 
Variables which were significant at minimum of two time points were planned to be 
included in the multivariate model.  However, no variable fulfilled this criterion for this 
model.  Therefore only univariate logistic regression was applied. Table 5.5 a and b 
illustrate the results of the analyses of the communication dynamics concerning 
discussion of symptoms and functions at three time points. 
Table 5.5 (a-b) Regression analysis of dynamics of communication of symptoms and 
functions 
a). Symptom Consultation 1 Consultation 2 Consultation 3 
 p p p 
Fatigue 0.474 0.387 0.551 
Dyspnoea 0.468 0.315 0.444 
Insomnia 0.354 0.43 0.395 
Pain 0.654 0.437 0.29 
Nausea + Vomiting 0.416 0.003 0.136 
Bowels 0.605 0.912 0.605 
Anorexia 0.9 0.566 0.282 
 
b). Function Consultation 1 Consultation 2 Consultation 3 
 p p p 
Physical 0.234 0.599 0.893 
Social 0.519 0.571 0.768 
Role 0.769 0.269 0.348 
Emotional 0.219 0.35 0.982 
Cognitive* NA NA NA 
*There were too few discussions of cognitive function for analysis 
 
Study arm effect was not observed in the above analyses, indicating that feedback of 
the questionnaire results to the oncologists did not increase inquiry about patients’ 
problems by the oncologists at all three time points in the study. 
 
  
179 
 
 
5.10.1 Association between severity of patient reported symptoms/ 
functions and content of clinic discussion 
 
Analyses were performed on patients in the Intervention and Attention Control arms, in 
which patients were asked to complete the two study questionnaires (n=146). 
For illustrative purposes, the EORTC QLQ-C30 scores were divided into four groups.  
In this questionnaire, higher scores represent better functioning but worse symptoms.   
For symptoms, three equally spaced score ranges (1 to 33.3, 33.4 to 66.7 and 66.8 to 
100) were categorised as “mild”, “moderate” and “severe” respectively.  For those 
patients scoring zero were grouped separately as having “no symptom”.  Similarly for 
functions,  three equally spaced score ranges (0 to 33.3, 33.4 to 66.7 and 66.8 to 99.9) 
were categorised as “poor”, “moderate” and “good” respectively.  Patients scoring 100 
was grouped separately as having “excellent functioning”.  HADS scores were also 
categorised into four groups, using cut off scores suggested by HADS developers.  
Score 0 as “no anxiety/depression”, scores 1 to 7 as “mild”, scores 8 to 10 as 
“moderate” and scores 11 or above as “severe” anxiety/depression (Zigmond and 
Snaith, 1983). 
The figures below (Fig 5.2 a-c) illustrate the prevalence and severity of symptoms and 
functions reported by this subgroup of patients at the first consultation.  Results for the 
second and third consultations are shown in Appendix 5. 
With the exception of fatigue, a large proportion of patients denied the presence of the 
symptoms listed (32% to 73%).  Where present, symptoms were generally mild with 
only a minority of patients reporting severe symptoms (3% to 9%).  Fatigue, on the 
other hand was very common, with 21% of patients reporting severe fatigue.   
A substantial proportion of patients reported poor role and social functioning (40% and 
32% respectively).  However, physical and cognitive functioning was generally good 
with poor functioning reported only by 12% and 4 % respectively.   
Although 9% of patients reported poor emotional functioning on EORTC QLQ-C30, 
“severe” anxiety and depression were reported on HADS by 16% and 13% of patients 
respectively. 
Similar results were seen at subsequent consultations. 
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Figure 5-2 (a-c) Prevalence and Severity of Symptoms and Functions Reported by 
Patients (at first consultation) 
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5.10.2 Association between questionnaire results and clinic discussion 
 
In the multivariate regression analyses, symptom and function discussions were 
predicted by relevant questionnaire score, study arm and significant covariates.   
Results (p values) from univariate logistic regression analyses to identify potential 
covariate for the multivariate analyses are shown in Appendix 6. 
The analyses indicated that patients reporting severe symptoms were more likely to 
have a discussion about those symptoms during their clinic consultation (Fig. 5.3). 
Severity was predictive of discussion about shortness of breath, and pain at all three 
clinic encounters.  Severity of fatigue, nausea and vomiting, anorexia and insomnia 
were significant predictors for discussion at two out of the three clinic encounters.  
Severity of constipation was a significant predictor for discussion of bowel function at 
first consultation, however, there was a positive trend at second and third consultations 
(p=0.015 and p=0.030 respectively).  There was no significant impact of the study arm 
on whether a specific symptom was discussed; indicating that the feedback of the 
questionnaire results to the oncologists did not influence the discussion of patients’ 
symptoms. 
In contrast to the symptoms, there was no clear relationship between severity of 
patients’ functional impairment and clinic discussions (Fig 5.3). The frequency of 
discussion about cognitive function was too small for multivariate analysis.  Study arm 
effect was again not observed. 
Similar results were observed in the second and third consultations (Appendix 7) 
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Figure 5-3 Relationship between Severity of Symptoms/Functions and Clinic Discussion 
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5.11 Discussion 
 
The findings from these analyses have highlighted the differences in the 
communication of symptoms and functions in oncology clinics.  The discussions during 
consultations seemed to focus on patient symptoms rather than how the symptoms and 
their underlying cancer may impact on patients’ functioning.   
The intervention of patients regularly completing HRQoL questionnaires and feeding 
the results back to the oncologists had an impact on the range of symptoms being 
discussed during the clinic consultations.  This effect was maintained over time.  It is 
not clear from these analyses how the intervention impacted on the communication of 
patients’ symptoms in this way. The analysis illustrated that discussions about 
symptoms were predominantly initiated by patients (or by their relatives) and not by the 
oncologists, irrespective of whether the patients completed the questionnaires or 
whether the results were fed back to the oncologists.  Discussions of symptoms were 
appropriate to the severity of the problems experienced by the patients; patients 
experiencing severe symptoms were more likely to have such issues discussed during 
their clinic consultations.  The feedback of the results to the oncologists did not 
influence the discussion of these symptoms but the main trigger seemed to be the 
severity of the problems experienced by the patients. 
The patients in this study were undergoing cytotoxic chemotherapy or biological 
therapy for their underlying cancer; therefore, the discussion topics during clinic 
consultations would have naturally focused on how the patients were tolerating their 
treatment.  Assessment of toxicity would have been expected to be one of the primary 
purposes of these clinic consultations.  It is therefore not surprising that the 
consultations were more focused on patients’ symptoms for this reason. It is possible 
that the for those patients who completed the questionnaire and the results given to 
their oncologist, the physical presence of the questionnaire results being available 
during their consultation may have acted as a prompt for both patients and oncologists, 
resulting in a more thorough discussion of patients’ symptoms.  However, the 
mechanism by which the questionnaire feedback impacted on the symptom discussion 
in the clinic consultation in these analyses remains speculative. 
In contrast, the patient reported outcome intervention had no impact on the 
communication of patients’ functions.  Similar to the symptom discussions, patients 
were more likely to raise these issues during the consultations themselves.  However, 
there was no clear relationship between the severity of their problems reported on the 
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questionnaires and the content of the clinic consultations, indicating that patients were 
possibly held back from raising such issues during the consultations.  Furthermore, the 
analyses indicated that oncologists failed to explore these issues even when the 
questionnaire results demonstrating poor functioning were presented to them.  
Discussions of social and role functions were particularly low with respect to the 
proportion of patients reporting poor functioning.   
It was anticipated that feedback of the questionnaire results to the oncologists may 
influence the dynamic of the communication between patients and oncologists by 
increasing exploration of both symptoms and functions initiated by the oncologists.  
This did not appear to be the case from these analyses, which indicated that the 
structure of a standard medical interview was affected very little by the patient reported 
outcome intervention.  The clinicians are trained to encourage patients to report their 
problems/concerns through open questions.  These would usually be followed by more 
specific or closed questions from the clinicians to delineate the problem in order to 
formulate differential diagnoses and management plan for the problems reported.  
However, it appears that patients reporting poor functioning on their questionnaires 
were not enough to prompt the oncologists to make further enquiries of these issues 
with their patients. 
In order to investigate how doctors use the patient reported HRQoL information in the 
consultation and to examine the effective use of this patient reported data, 
conversation analysis of previously recorded and transcribed consultations has been 
carried out. This project was guided by a theoretical framework which attempts to 
explain mechanisms underlying the impact of HRQoL intervention on patient well-being 
(Greenhalgh et al., 2013)  Findings indicate that 
 The way clinicians referred to the HRQoL data had implications for further 
discussion about symptoms.  
 The data appeared to play an important role in orienting the patient to a 
discussion about symptoms and providing structure to the consultation. 
 The HRQoL data were most commonly used to identify patient problems.  
 Patients participated most in the consultation when doctors referred to the 
HRQoL data to not only allow patients to confirm or contradict the presence of 
the problem, but also to enable patients to explain the problem further to the 
doctor.  
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 Establishing patient burden, offering treatment, advice or referral and exploring 
patient views on management options were identified as key behaviours in 
responding to the HRQoL issues.  
This work has provided helpful information on how patient-reported data can be 
effectively integrated into routine clinical practice.   
These analyses have highlighted and reconfirmed that cancer and cancer therapy have 
impact on many aspects of patients’ health related quality of life.  There is high 
prevalence of unmet psychological, supportive and information needs among cancer 
patients (Cella and Cherin, 1988) and there is increasing recognition and expectations 
that communications during oncology consultations should encompass patients’ 
psychosocial functioning in addition to cancer and treatment issues (Fayers, 2007, 
Department of Health, 2007). Asking patients to report their HRQoL concerns through 
questionnaires can be a way of drawing attention to any needs they may have.  
However, the above analysis indicates that simply asking the patients to complete 
HRQoL questionnaires alone is not enough to help address their psychosocial 
problems or meet their needs. 
The previous interview study with the oncologists has indicated their concerns about 
use of HRQoL questionnaires routinely in clinics in this way.  Their concerns were 
mainly around what they should do if patients report problems they feel they are ill 
equipped in managing or they had little advice to offer to the patients, indicating that 
not all oncologists are comfortable in discussing psychosocial issues. Clearly, 
oncologists have varied levels experience in managing and discussing such topics with 
their patients.  The interview study also raised their concerns about the impact of 
launching into discussions about such issues in busy clinics where they are constantly 
faced with time constraints. In addition, some oncologists felt that there were inevitable 
consequences of cancer and cancer treatment for which there were no obvious 
solutions and that repeatedly asking about such issues may have a negative impact on 
patients’ well being.   It was clear that oncologists were naturally keen to offer some 
kind of a solution or treatment where a problem is identified.  This is undoubtedly more 
complex for psychosocial issues compared to managing treatment side effects where 
they are able to provide patients with a prescription for a supportive medication.   
These are clear barriers which may be preventing important psychosocial issues being 
raised in clinic consultations.  These are reasons/barriers recognized by other 
investigators preventing psychosocial issues being discussed in clinic consultations 
(Frost et al., 2007) and it is quite possible that they were some of the reasons/barriers 
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for the limited discussion of patients’ functions in the consultations in the above 
analyses.   
These analyses support the need for additional training and support for the oncologists, 
if the patient reported outcome intervention is to become more effective in addressing 
patients’ psychosocial problems.  The training and support will require several facets 
including better understanding and familiarisation of the questionnaires; guidelines for 
managing some of the psychosocial issues such as emotional distress; linking with 
supportive services (Clinical Nurse Specialist where available or Psycho-Oncology 
Service, Social Services) so that oncologists are able to provide information and sign 
posts for patients to  seek further advice.  Assisting oncologists in this way may 
increase their confidence in discussing psychosocial issues with their patients to help 
to prevent important issues for patients being missed or ignored.  Training process may 
also help engage with the oncologists who may perhaps be more sceptical about using 
patient reported outcome measures in this manner. 
There are a number of limitations to these analyses.  The trial was conducted in a 
single centre with study population predominantly of women.  They were relatively 
young and with good performance status.  Therefore, the true impact of cancer and its 
treatment on patients’ HRQoL among wider patient population may be underestimated.  
In addition, the unit of randomization within the trial was patients.  Therefore, 
oncologists taking part in the study will have encountered patients in all three study 
arms which may have cause contamination. Furthermore, the study population did not 
include patients with colorectal cancer, which is my population of interest.  This is 
because colorectal cancer patients received their treatment in another hospital in 
Leeds at the time when this trial was conducted.  Nevertheless, the analyses have 
been performed on a relatively large sample of real life oncology consultations of 
patients, many of whom were receiving palliative treatment for advanced incurable 
cancer.  It has helped to highlight the differences in the communication of symptoms 
and psychosocial functioning during oncology clinic consultations and the findings 
appear to echo the concerns raised by the oncologists regarding the use of patient 
reported outcome measures. 
However, another limitation to the study is the way the consultations were analysed.  
The content analysis does not allow any assessment on the quality of the 
communication between the oncologists and the patients. The content analysis noted 
whether a particular issue was raised during the consultation. This is clearly an 
important initial step for any problems/concerns to be addressed.  However, it is not an 
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assessment of how the problems raised have been dealt with.  This is an important 
consideration for future analyses of clinic consultations.  The analyses of clinic 
consultations will need be able to evaluate whether any problems highlighted has been 
addressed and be able to make an assessment of how the patient reported outcome 
feedback may have contributed to the consultation. This would be of particular 
importance in evaluating the impact of any training for oncologists that may be 
implemented. 
 
5.12 Conclusions 
 
These analyses have highlighted that communication of patients’ psychosocial 
functioning is less prevalent compared to that of symptoms, despite patient reported 
outcome feedback, indicating the presence of barriers restricting discussion of such 
issues.   
These barriers may be explained by some of the concerns raised by the oncologists 
during the interview study.  These barriers need to be overcome in order to facilitate 
discussions of patients’ psychosocial functioning.  
Consideration needs to be given to how clinic consultations may be analysed in the 
future in order to better capture the impact of patient reported outcome intervention and 
to evaluate how problems reported by patients are being addressed. 
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Chapter 6 Training programme for integration of patient 
reported HRQoL in routine consultations 
 
6.1 Introduction 
 
Training has been identified as one of the ways which may help to overcome some of 
the healthcare professional related barriers to successful integration of HRQoL 
assessment in routine clinical practice (Luckett et al., 2009).  These barriers include: 
1. Healthcare professionals’ lack of familiarity or experience with routine HRQoL 
assessments (Morris et al., 1998b) 
2. Healthcare professionals’ ability to interpret the patient reported data and use the 
information to assist decision making about patient care/management in the way they 
use laboratory and radiological investigation results (Sutherland and Till, 1993, Giesler, 
2000). 
3. Healthcare professionals’ concerns that HRQoL assessment would unearth multiple 
problems and impact on the duration of consultation (Luckett et al., 2009). 
4. Healthcare professionals’ concerns about HRQoL assessments revealing problems 
for which there are no straight forward solutions to be offered to the patient 
(Donaldson, 2004) 
In order for the assessment of patient’s HRQoL to become integrated in clinical 
practice, these barriers need to be addressed. 
Descriptions about training for the recipients of patient reported HRQoL data within 
published studies have been brief, where this has been provided (Greenhalgh and 
Meadows, 1999).  They seem to focus on the HRQoL instruments used in the study 
and how they are scored (Detmar et al., 2002, Velikova et al., 2004). There was no 
indication about specific guidance as to how the healthcare professionals should 
manage patients in relation to the scores derived from the questionnaires. 
For example, Detmar et al (Detmar et al., 2002) described training provided to 
physicians as half an hour meeting with the individual oncologist specifically about the 
instruments they used in their study (EORTC QLQ-C30 (Aaronson et al., 1993)) but no 
further guidance as to how the data may be used in the consultation was provided.  
Similarly,  in the study by Velikova et al (Velikova et al., 2004), the training given to 
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oncologists included face to face meeting with each of the participating oncologists 
about the instruments used (EORTC QLQ-C30 (Aaronson et al., 1993) and Hospital 
Anxiety and Depression Scale (Zigmond and Snaith, 1983)), descriptions of items 
within the questionnaires which formed some of the functional scales  and how they 
were scored.  The oncologists were provided with a manual about the questionnaires 
which were available in the consultation rooms during the study period.  The 
oncologists were asked to use the data obtained from the patients but again, no further 
specific instructions were provided as to how the oncologists may use the data during 
their consultations.  
Interpretation of instruments used is clearly an important component of the training as it 
is essential for the recipient of the patient reported data to be able to make sense of the 
information derived from questionnaires.  However, these scores need to have a 
meaning on which the healthcare professional can act upon, just as the laboratory tests 
have a meaning to them in terms of what’s normal and what is abnormal and whether 
anything needs to be done about any of the abnormal results. 
The training therefore needs to expand in facilitating the patient reported HRQoL data 
to be incorporated into the management of patients along with laboratory and 
radiological investigations to assist in clinical decision making.  Training also needs to 
provide opportunities to engage with the healthcare professionals and present 
evidence of how patient reported data can help make consultations more efficient by 
focusing and prioritizing the discussions on areas which are concerning for the patients 
(Luckett et al., 2009).  
Patient reported HRQoL information has been shown to influence communication 
between patients and physicians during clinic consultations but the impact this has on 
distal patient outcomes such as improved patient outcomes and satisfaction have not 
been shown consistently.  Longitudinal analysis of the data of the previous randomized 
controlled study (Velikova et al., 2004) conducted by the Leeds POCPRG have shown 
that oncologists readily discussed some of the symptom issues reported by the 
patients.  However, despite patients’ data indicating significant problems with some of 
their function domains, these issues were often not discussed during the consultations 
(Chapter 5), suggesting that perhaps they felt unequipped or uncomfortable in 
discussing these issues.  The training therefore needs to address this barrier by 
provision of management guidelines to enable healthcare professionals to raise such 
problems reported by the patients.  Such guidelines may help healthcare professionals 
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to make decisions about referring patients to appropriate supportive care services 
(Frost et al., 2007).    
Training, therefore, needs to function in many ways to influence the mindset and 
attitudes of the health professionals so that the value of routine assessment of HRQoL 
can be realised.  This in turn may assist patient reported HRQoL being incorporated 
into the clinical practice and decision making process between patients and doctors, 
thus leading to the intervention having impact on the more distal patient outcomes.  
This chapter describes the ground work in the development of a training programme to 
facilitate the use of patient reported data in clinical practice. 
 
6.2 Theories of knowledge acquisition and learning styles 
 
Training is a form of education that helps develop a person’s abilities to gain new 
knowledge, acquire new skills and employ creative methods of problem-solving 
(Patrick, 1992).  In order to develop an effective training programme, it is helpful to 
understand how adults learn. 
Many adult learning theories have been described; however, most of these are based 
on the work by Malcolm Knowles who attempted to develop a conceptual basis for 
adult education and learning through the notion of andragogy.  He defined andragogy 
as “art and science of helping adults learn” (Knowles, 1980), in an attempt to 
differentiate learning in childhood from learning in adulthood.  
Knowles’ concept of andragogy is built on two major attributes; first is the idea that 
adult learners are self-directed and autonomous; and second idea that the role of the 
teacher as facilitators of learning rather than deliverer of content (Pratt, 1998). Knowles 
proposed a number of assumptions about the characteristics of adult learners and how 
these assumptions may impact on the process elements of adult education.   
The characteristics of adult learners proposed by Knowles are: 
1. Self-concept: As people mature they become internally motivated and self-
directed 
2. Experience: As people mature, they bring their life experiences and knowledge 
to their learning experiences. 
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3. Readiness to learn: As people mature, they are more interested in learning 
subjects that have immediate relevance to their work or their personal lives. 
4. Orientation to learning: As people mature, their time perspective changes from 
acquiring knowledge for future use to immediate application of knowledge.  
Therefore, adult learners become more problem-centered rather than focusing 
on the actual subject. 
5. Motivation to learn: As people mature, they become more motivated by internal 
incentives such as desire to achieve and satisfaction of accomplishment. 
6. Relevance: As people mature, they need to know why they need to learn 
something. 
 
Knowles proposed to adult educators to employ a seven step process in the delivery of 
teaching in order to implement and to make the most of the assumptions made of the 
adult learners.  These steps include: 
1. Creating a co-operative learning environment 
2. Planning goals of learning mutually 
3. Indentify the needs and interests of the adult learner  
4. Help them formulate learning objectives based on their needs and interests 
5. Design sequential activities in order to achieve these objectives 
6. Carry out the design to meet the objectives with selected methods, materials 
and resources 
7. Evaluate the quality of the learning experience for the learner that included 
reassessing the needs for continued learning.  
 
Another learning theory often referred in medical education is Kolb’s Learning Cycle 
(Kolb, 1984). It is based on experiential learning theory, which has been defined as “the 
process whereby knowledge is created through the transformation of experience. 
Knowledge results from the combination of grasping and transforming experience” 
(Kolb, 1984). 
 
Kolb was influential in describing how learning takes place and helping to understand 
the learning process.  His learning cycle as shown in Fig 6.1 below, illustrates the idea 
of learning as experiential (learning by doing or learning by observation). Experiential 
learning is relevant in medical education, particularly in clinical teaching which often 
involves seeking out opportunities for learners to practice clinical skills ranging from 
simple procedures to much more complex skills such as breaking bad news or carrying 
out an operation.  
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Figure 6-1 Kolb's learning cycle 
 
The Kolb’s learning cycle consists of 4 stages of learning from experience.   These 
stages are  
1. Concrete experience – learners becomes actively involved in new experiences.  This 
may be reading, attending a course, trying out a skill. 
2. Reflective observation – learners review and reflect on the experience from different 
perspectives.  Reflections may be through discussions with mentors and talking to 
peers. 
3. Abstract conceptualization – learners form and process ideas and integrate them 
into logical theories. This may involve reading new ideas and information, reflecting on 
actions and considering how things may be done differently. 
4. Active experimentation – learner use the skills and knowledge again but with the 
benefit of prior experience and reflection along with new and revised ideas and input. 
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Kolb suggests that learning is an integrated process with each stage being mutually 
supportive of and feeding into the next.  He therefore suggested that effective learning 
occurs when a learner is able to complete all four stages of the model. 
Kolb’s learning theory sets out four distinct learning styles or preferences based on his 
four stage learning cycle (Kolb and Fry, 1974).  Kolb suggests that different people 
naturally have preference for a certain type of learning style, which may be influenced 
by the learner’s social environment, educational background and their ability to process 
information. Kolb posited that there were two continuums involved in the learning cycle 
(Fig 6.1). In the vertical perception dimension, people will have preference along the 
continuum between Concrete Experience and Abstract Conceptualisation. In the 
horizontal processing dimension, people will, take the results of their perception and 
process it in preferred ways along the continuum between Active Experimentation and 
Reflective Observation. The two axis forms a quadrant, which provides characteristics 
of the learning styles or preferences which Kolb described as Diverging, Assimilating, 
Converging and Accommodating (Kolb and Kolb, 2005).  Descriptions of each learning 
style are given in Table 6.1. 
Table 6.1 Kolb’s learning styles 
Learning Style Dominant 
Learning 
Abilities 
Characteristics 
Diverging CE/RO Views situation from different points of view. 
Good at generating ideas 
Imaginative and emotional 
Prefers collaborative work 
Likes personalised feedback 
Assimilating AC/RO Good at understanding broad-ranging information and 
translating into concise, logical form 
Less interested in people 
Needs time to consider things 
Converging AC/AE Good at finding practical uses for ideas and theories 
Good at problem solving 
Learns through experimentation, simulation and practical work 
Accommodating CE/AE Learn from “hand-on” experience. 
Enjoy carrying out plans and new experiences 
Act on “gut feeling” over logic 
Rely on people for information for problem solving 
CE: Concrete experience 
RO: Reflective observation 
AC: Abstract conceptualisation 
AE: Active experimentation 
 
Based on Kolb, AY and Kolb, D. Learning Styles and Learning Spaces (Kolb and Kolb, 2005) 
 
Learning is a highly individualised process.  However, these conceptual models of 
knowledge acquisition and learning styles can provide practical applications when 
designing learning activities as they can be transferred into concrete teaching actions.  
They help teachers realise that learners have different ways and approaches in how 
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they acquire new knowledge and skills. Therefore, application of multiple teaching 
methods is necessary to enhance effectiveness of both teaching and learning. 
 
6.3 Types of teaching formats 
 
Many teaching situations involve a group of one size or another. Elton proposed a 
model in classifying teaching and learning into three broad categories based on the 
side of the group of learners (Elton, 1993):  
 Mass instruction 
 Individual Instruction 
 Group learning 
 
Elton’s classification has been used to describe the types of instructional materials that 
may be useful, and the role of the teacher in each of the categories. Table 6.2 
illustrates examples for each of the types of Elton’s teaching categories. 
 
Table 6.2 Elton's teaching categories 
Type of Techniques Examples Role of teacher/trainer 
Mass instruction Conventional lecture 
Expository lessons 
Film presentations 
Educational broadcasts 
Expository role 
Individualised instruction Directed study of materials in 
textbooks 
Computer/web based learning 
Individual assignments 
One to one teaching 
Producer of learning 
resources 
Tutor 
Group learning Tutorials 
Seminars 
Group exercises/projects 
Simulations 
Discussions 
Organiser and facilitator 
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Mass instruction techniques, such as lectures, are effective in the transmission of 
information for recall as knowledge.  However, group learning and small group work 
can facilitate development of higher level skills.  Effective teaching strategies can be 
created considering strength of each type of teaching methods.   
Small group teaching is considered to be highly relevant in adult learners and to clinical 
situations, as learning in a small group facilitates learning through discussion, active 
participation, feedback and reflection. Small group environment also allows 
opportunities co-operative behavior such as group problem solving (Fisher and Ellis, 
1990). For this reason, there has been a gradual shift towards group based learning 
strategies being increasingly adopted in medical education. 
 
6.4 Communication skills training in oncology 
 
As the intervention of colleting patient reported HRQoL data in routine oncology 
practice aims to impact on doctor – patient communication in the way that it changes 
the behavior of healthcare professionals and patients, reviewing the training methods 
used in advanced communication skills training for oncologists was considered useful. 
The efficacy of Communication Skills Training (CST) in improving communication skills 
of healthcare professionals involved in cancer patients have been demonstrated 
through a number of randomized controlled studies (Fallowfield et al., 2002, Delvaux et 
al., 2005, Wilkinson et al., 2008, Lienard et al., 2010).  CST has been shown to 
increase more patient-centred communication with healthcare professionals 
demonstrating empathic responses to patient cues (Delvaux et al., 2005, Fallowfield et 
al., 2002). In addition, CST has also been shown to increase confidence in healthcare 
professionals communicating with their patients by providing them with necessary skills 
to achieve this (Wilkinson et al., 2008, Butow et al., 2008).  The aims of the CST 
include provision of support for the healthcare professionals in structuring the medical 
consultation, exchanging information effectively, building a working relationship with the 
patient and responding their emotions. These attributes are all relevant to the use of 
patient reported data in clinical practice as the intervention aims to highlight any 
problems patients may be experiencing and for the healthcare professionals to be able 
to communicate effectively in managing these issues. 
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6.4.1 Types of teaching interventions used during CST 
 
Most of the studies that evaluated the CST specified use of learner–centred, 
experiential, adult learning methods grounded on the conceptual models for adult 
learning, with training facilitated by experienced facilitators (Moore et al., 2013). 
Studies generally utilized multi-faceted approach with different components within the 
training.  In many of the CST, participants were provided with written material 
describing key studies and articles from the communication skills literature to provide 
evidence base for the CST with short didactic lectures (Moore et al., 2013). Actual skills 
training took place in small groups with experiential learning opportunities provided 
through role–play, which were either with peers or with simulated/standardised 
patients.  The scenarios for the role-play (for example, breaking bad news, 
communicating transfer of care from active treatment to best supportive care and 
handling difficult emotions)  were often learner generated to make the training relevant 
to their own learning needs (Fallowfield et al., 2002, Delvaux et al., 2005, Finset et al., 
2003).  The small group teaching environment allowed discussions among the peers 
and verbal feedback to be given immediately from the facilitators, peers and from 
simulated patients in many of the CST evaluated (Moore et al., 2013). Fallowfield 
emphasized that provision of constructive feedback, both positive and negative, played 
a key role in the effectiveness of the CST (Fallowfield, 2005).   Delvaux et al (Delvaux 
et al., 2005) found use of learner generated peer role – plays with immediate feedback 
showed increased use of eliciting and clarifying psychological concerns directed 
towards patients, with an increase in patients’ global satisfaction with the interview. 
 
6.4.2 Evaluation of training 
 
Most of the studies evaluated outcomes before and after the CST (or no CST).  
Changes in the behavior of the healthcare professionals were measured through 
interviews either with real patients or standardised patients which were audio-recorded 
or videoed (Moore et al., 2013). What was actually measured differed from one study to 
another with different scales being used to evaluate healthcare professionals’ 
communication skills such as information gathering, clarifying or summarising, eliciting 
concerns, appropriate information giving and negotiating (Moore et al., 2013).  
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Other outcomes relating to the healthcare professionals included their health status 
and their perception of their attitude change. Outcomes relating to patients included 
their health status and their perception of or satisfaction with the interview. 
In summary, communication skills training employ a variety of teaching methods which 
provides diverse stimulus for learners with different learning styles.  Many of the 
training described included experiential component within the training in the form of 
role-play, with participants often enacting scenarios chosen by them so that teaching 
was directly relevant to their own learning needs. The teaching was often conducted in 
the small group environment to facilitate discussion, active participation and reflection. 
Having reviewed the theories of adult learning and how they can be applied to teaching 
communication skill in oncology, I decided to consider the following key aspects when 
developing the oncologist training. Different types of teaching materials are needed to 
cater for individuals who have different learning needs and styles.  The training needs 
to contain some evidence behind the intervention or skill that needs to be taught and 
why the learners might need those skills.  Experiential learning is a key component in 
clinical skills teaching and the doctor training programme would need to consider how 
best to achieve this. In addition, I have attended one of the Cancer Action Advanced 
Communication Skills Training which was facilitated by Professor Fallowfield.  I was 
fortunate enough to attend the course with her to try and gain the necessary facilitation 
skills in such a training programme. 
 
6.5 Development of the training programme to facilitate integration 
of patient reported HRQoL in clinical practice 
 
The purpose of the training programme within the Cancer Research UK funded project 
undertaken by the Leeds POCPRG was to address how the patient reported HRQoL 
data may be integrated into the clinic consultation effectively in order to influence the 
behavior of the healthcare professionals and the patients.  The training had to serve a 
specific role in relation to the patient reported data and illustrate how this information 
can help assist healthcare professionals in managing their patients, rather than 
providing training on generic communication skills. However, the training strategies 
used in the communication skills training provided useful framework to build on the 
training for integrating patient reported data. 
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Use of various teaching methods (didactic lectures, written references, small group 
discussions, role–play with feedback and reflection) to stimulate learners with different 
learning styles and to create simultaneous rather than sequential skills development 
and to stimulate knowledge acquisition are all highly relevant to this training. However, 
the training needed to focus and tailored on a very specific aspect of patient-doctor 
communication. 
The length of communication skills training varied widely; from 1 day course to 3 day 
courses with various follow up training (Moore et al., 2013). It was necessary to 
consider the time required for this training focused on the use of patient reported data.  
I took a practical approach in suggesting the length first, rather than driven by content 
of the training, as organising several oncologists with busy clinical commitments to 
meet at the same time was going to be difficult.  Half day session was considered to be 
the most feasible duration for the training at this stage, with a view to reviewing this 
later if necessary. 
Once the time frame for the training was decided, the content and the structure of the 
training could be explored.  Clear objectives of the training needed to be established, 
which were mainly around addressing healthcare professional related barriers to 
routine collection of patient reported HRQoL described earlier. The training needed to 
illustrate the potential benefits of the intervention and by doing so, engaging with the 
oncologists in the process. As with CST, different types of teaching methods were 
needed to address these objectives.  
Experiential learning is highly valued in skills training and role-play featured heavily in 
many of the CST described (Moore et al., 2013). Role-plays are resource intensive and 
time consuming therefore considered to be unfeasible in a short half day training 
session.  However, some form of training material which provided experiential learning 
component was considered necessary. 
Jenkins et al (Jenkins et al., 2005) devised a training programme for oncologists and 
research nurses, specifically concerning communication around randomized controlled 
trials in cancer. In their study, they used a variety of training methods, including didactic 
lectures/presentations, interactive exercises and discussions around videotaped 
scenarios of oncologists conducting interviews with simulated patients discussing 
various types of randomized controlled trials in cancer. They also produced other video 
based materials for their modules, each module describing a specific challenge/ 
situation healthcare professionals may be faced with when communicating randomized 
controlled trials with their patients. These “trigger” films or tapes were utilized to 
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stimulate constructive discussions among the group. Their main positive outcomes of 
the training were participants reporting increased confidence about recruiting patients 
into trials and behavioural changes in the style and content of the participants’ 
discussions about randomized trials. This training has now been adopted by the 
National Institute for Health Research Clinical Research Network and is widely 
accessible throughout the network.  I considered that “trigger” tapes used in a similar 
manner could provide valuable teaching material within the training programme for 
patient reported HRQoL intervention. 
The training also needed a way to evaluate its’ impact.  The primary outcomes would 
be how the training changed the way oncologists used the patient reported HRQoL 
data, before and after the training, through evaluation of clinic consultations using a 
pilot study.  It was anticipated that the pilot study would utilize the cancer site specific 
questionnaires which were being developed simultaneously with the development of 
this training programme.  Secondary outcomes would include changes in oncologists’ 
views and attitudes towards patient reported HRQoL intervention, before and after the 
training. 
In summary, teaching strategies and structures of CST can be transferred to the 
training programme for patient reported HRQoL intervention but the content needed to 
be focused on this specific aspect. Trigger tapes were considered to provide different 
but valuable experiential learning strategy compared to role-play, and serve an 
important role in facilitating small group discussions. 
 
6.6 Development of trigger tapes 
 
Trigger tapes, or trigger videos are brief clips that are used to provoke reflection, 
stimulate discussion and help learners confront their feelings (Fisch, 1972). In the 
context of healthcare, the trigger tape can be a short scene depicting a typical clinical 
situation with a patient and a doctor, which can be used to trigger discussions of the 
issues and circumstances raised in the film (Ber and Alroy, 2001).  Trigger tapes have 
been used successfully as facilitation tool in education in a variety of settings for many 
years, including in communication skills training in cancer (Fallowfield et al., 1998, 
Fleissig et al., 2001, Jenkins et al., 2005).  Trigger tapes can provide enduring teaching 
material particularly when the films are based on “real life” situations, (for example, 
interactions between a patient and a doctor), although the discussion points may 
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change over time (Ber and Alroy, 2001). The film provides an experiential learning 
opportunity to learn through observations (Kolb, 1984).  
I considered trigger tapes to be useful training material for the training programme.  
Trigger tapes can illustrate how the patient reported HRQoL information may be 
integrated and used during the consultations and help to stimulate discussions within 
the group.  These discussions may provide ideas for the participants about how they 
might use the patient reported data.  In addition, these trigger tapes provide 
opportunities to learn and acquire skills through observing their peers. 
 
6.6.1 Scenario development 
6.6.1.1 Methods 
 
Clinical scenarios were necessary to enact the consultations to be made into trigger 
tapes.  The scenarios needed to illustrate examples of patients or situations where 
patient reported HRQoL information can be expected to play a significant role in the 
management of the patient or contribute to the decision making.  The scenarios also 
needed to depict patients whose HRQoL scores may present challenges for the 
oncologists receiving the information so that discussions may take place as to how best 
manage these patients.   
In order to identify these patient characteristics and situations, transcripts from the 
interviews with oncologists (Chapter 3) were reviewed for comments made by the 
oncologists about the kind of patients (as depicted by their HRQoL scores) who they 
expressed concerns, in terms of how they might manage the patient or the situation.  In 
addition, I explored the literature for other situations where utility of patient reported 
data may be demonstrated. 
Once these patient characteristics for the scenarios were determined, data from the 
previous randomized study (Velikova et al., 2004) conducted by the Leeds POCPRG 
were reviewed to identify real patients on which the scenarios may be based on, as 
determined by their HRQoL scores. Using data from this study was considered helpful 
in making the cases more realistic and relevant as they came from real patients.   
The scores from the HRQoL instruments obtained from patients who were randomized 
to the intervention arm of this trial were examined to identify patients with HRQoL 
scores that reflected relevant cases for the scenarios.  Once the candidate patients 
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were identified, their clinic consultation audio-recordings were examined to see what 
actually happened when oncologists were presented with their HRQoL scores during 
the study. Those clinic consultations where oncologists actually referred to the 
questionnaire data were selected and examined to see how they used the information 
and whether this patient reported data had an impact on the consultation in reality.   
 
6.6.2 Results 
 
6.6.2.1 Review of the interviews with oncologists and literature 
 
There were two aspects of the patient reported HRQoL intervention which the clinical 
scenarios needed to illustrate.  One aspect was for the scenarios to portray patients, 
characteristics of whom the oncologists had concerns.  The other aspect was the 
positive utility of the intervention and how healthcare professionals’ anxieties about the 
intervention may be alleviated through the scenario. 
Oncologists were generally comfortable in discussing most of the symptoms and 
treatment side effects.  Their concerns were around patients who may report multiple 
problems and what they should do when there are time constraints in busy clinics 
(Chapter 3). However, there is evidence to suggest that this intervention does not 
necessarily increase the duration of consultations (McLachlan et al., 2001, Detmar et 
al., 2002, Velikova et al., 2004) and that HRQoL data actually can help to focus on the 
patient problem and make the consultation more efficient (Newell et al., 1997).  
Oncologists’ other concerns included patient reported HRQoL raising issues which they 
felt poorly equipped in dealing with themselves, such as emotional distress, and 
welcomed guidelines in how to manage such issues and providing a prompt for when 
action was actually needed (Chapter 3).  These concerns are echoed by other 
healthcare professionals in the literature (Donaldson, 2004).  
One of the utility of patient reported HRQoL often described is to help unearth patients’ 
problems which may otherwise go undetected (Higginson and Carr, 2001) and to 
provide means of monitoring patients over time through patients’ own assessment of 
their HRQoL (Asay et al.). One of the oncologists stated that patient reported HRQoL 
would support in making decisions about treatment, particularly when other standard 
investigations show results that are not clear cut (Chapter 3). 
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6.6.2.2 Generating ideas for scenario cases 
 
From the above results, I came up with ideas for the characteristics of patients for the 
scenarios.  These are listed below: 
1. Patient with HRQoL scores indicating poor emotional functioning:  This scenario 
could raise discussions about how such results may be brought into the consultation 
and how the patient may be managed.  This scenario would also provide opportunity to 
integrate locally developed guidelines for managing emotional distress. 
2. Patient whose HRQoL indicating they are coping well with minimal issues reported 
on their HRQoL: This scenario could help to demonstrate how consultations may be 
made efficient. 
3. Patient with multiple problems reported on their HRQoL questionnaires: This 
scenario could illustrate how such situation may be managed and to discuss how the 
HRQoL data may help to structure the consultation by helping the doctor and the 
patient to prioritise issues.  
4. Patient indicating some functional issues on their HRQoL: This scenario could 
illustrate how a doctor may explore these issues with the patient to investigate what 
may be accounting for their poor functioning. 
5. Patient whose HRQoL scores have shown steady improvement over the course of 
treatment period: This scenario could highlight use of HRQoL in monitoring patients 
over time. 
 
6.6.2.3 Data from the randomized controlled trial 
 
144 patients were assigned to the intervention arm of this trial.  Patients in this arm of 
the study completed the EORTC QLQ-C30 and Hospital Anxiety and Depression Scale 
with feedback of the results to the oncologists at each study visit.  113 patients 
completed the planned 3 study consultations.  HRQoL outcomes were available from 
97 of these patients (Velikova et al., 2004). HRQoL scores from these 97 patients were 
visually scanned to identify patients whose scores represented characteristics of 
patients for the scenarios as described above. 
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Two or three possible patients were identified for each scenario cases to narrow the 
search.  Audio-recording from these patients’ consultations were then examined to see 
whether and how the patient reported HRQoL data was used in these consultations.  
Following this, one patient for each scenario was chosen. 
The randomized controlled trial did not include patients with colorectal cancer as all 
colorectal cancer patients were treated in another hospital within Leeds which was not 
a study site for the trial.  As I was developing colorectal cancer specific questionnaire 
for my thesis and the pilot study to examine the impact of the doctor training was 
planned to involve patients with colorectal cancer, one of the scenario was changed to 
represent a case of colorectal cancer patient, although the nature of the case remained 
as the original patient. 
 
6.6.2.4 Operationalisation of the cases into scenarios 
 
Once the patients were selected, clinical scenarios for the patients were written, 
building on the basic information already collected as part of the study (primary cancer 
diagnosis, demographic information and type of treatment they were receiving for their 
cancer).  
Each scenario needed two versions; one for the oncologist and the other for the 
patient.  The scenarios were supplemented by additional hypothetical information in 
order to provide the patient with necessary background information which may be 
useful when it came to enacting these scenarios. The versions for the oncologists had 
to contain relevant clinical information concerning the case including any information 
about radiological or laboratory investigation results to mirror real life situations.  The 
scenarios for patients contained some background information in order to provide some 
social context for the patient, such as their marital status, family circumstances and 
employment details. The versions for the patients were also supplemented with 
explanation about the disease process and details about the cancer treatment the 
patient would have been receiving so that the person enacting the role would have 
better understanding about the diagnosis and side effects of treatment.   
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6.6.2.5 Questionnaire Output 
 
The result from HRQoL instruments (EORTC QLQ-C30 (Aaronson et al., 1993) and 
Hospital Anxiety Depression Scale (Zigmond and Snaith, 1983)), obtained from the 
patients on whom the scenario cases were based on, were presented in a graphical 
format, similar to how the results were presented to the oncologists within the original 
randomized study (Velikova et al., 2004).  In order to assist the oncologists to use the 
patient reported data, traffic light coding was applied to the graphs to highlight scores 
from the HRQoL instruments indicating presence of significant symptom issues or poor 
functioning.  
  
6.6.2.6 Medical Education Department at University of Leeds 
 
In order to produce the trigger tapes, access to audio-visual equipment was necessary. 
In addition, people to enact the patient roles were needed.  Leeds POCPRG had 
established a collaborative working with the Medical Education Department at 
University of Leeds.  They have facilities for video-recording of the consultations and 
access to a group of standardised patients or simulated patients who regularly took 
part in communication skills teaching and in Objective Structured Clinical Examination 
(OSCE) for medical examinations. 
Standardised patient (SP) is an umbrella term used to describe both a simulated 
patient (a well person trained to simulate a patient's illness in a standardised way) and 
an actual patient (who is trained to present his or her own illness in a standardized 
way) (Barrows, 1993).  They have been used in medical education and clinical skills 
assessment and evaluation for many years.  
The standardised patient is trained using a scenario based on a real patient case. Well-
prepared SPs are virtually indistinguishable from the real patients.  SPs can realistically 
convey an illness to a student and perform in a consistent and measurable way. There 
are a number of advantages in using standardised patients.  They are generally well 
people who are not necessarily worried about their medical care.  Therefore they can 
focus on the teaching and evaluation of the task in question.  They can provide a “safe” 
environment for the learner to practice their skills without worries over potentially 
upsetting a “real” patient. Standardised patients are also trained in providing feedback 
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to the learners in terms of their professional manner, attitudes and interpersonal skills 
(Good, 2003).  
 
6.6.2.7 Matching the scenario with suitable standardised patient 
 
The scenarios were presented to the team within the Medical Education Department 
(Dr Robert Lane and Miss Jools Symons) who facilitated in selecting the most 
appropriate standardised patient for each scenario.  Individual meetings took place with 
the relevant standardised patient so that the scenarios would be reviewed with them. 
Some modifications were implemented according to suggestions made by the 
standardised patient and by the education facilitators from the Medical Education 
Department.  
Final versions of the scenarios, together with respective questionnaire output can be 
found in Appendix 8. Brief synopses of the cases are shown in Table 6.3 below. 
Table 6.3 Synopsis of clinical scenarios 
Scenario  Brief synopsis 
 
Issues highlighted 
A A 51 year old woman with advanced breast cancer on 
palliative chemotherapy.   
She is tolerating treatment well with signs of response but 
developing depressive symptoms (insomnia, anorexia and 
high depression score on HADS) 
 
Screening for emotional 
distress/depression 
 
B A 63 year old man with metastatic leiomyosarcoma on 
palliative chemotherapy.  He is tolerating treatment well.  
This is reflected in the questionnaire scores showing very 
few problems. 
 
Questionnaire may help to 
make consultation more 
efficient 
 
 
C A 70 year old lady with advanced ovarian cancer.  She has 
undergone bowel surgery which has resulted in a formation 
of a stoma.  She has multiple symptoms and problems and 
this is manifested in the questionnaire scores. 
Questionnaire may help to 
structure the consultations by 
prioritising important issues. 
 
 
D A 45 year old woman with advanced breast cancer who 
has recently started on third line chemotherapy.  She has 
symptoms which limit her physically.  She is unable to work 
resulting in financial concerns, poor social and role 
functioning.  
 
Questionnaire to help detect 
problems 
 
 
E A 68 year old woman with advanced bowel cancer.  She 
has completed a 3 months of palliative chemotherapy 
during which she has had significant improvement in her 
symptoms.  Her restaging CT scan has shown that the 
appearance of her cancer has not changed very much 
(stable disease). 
 
Monitoring and assessing 
treatment effect 
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6.6.2.8 Matching the scenarios with the oncologists 
 
The scenarios consisted of patients with different primary cancer sites.  Therefore, five 
oncologists with expertise in relevant cancer site were invited to take part in this trigger 
tape production. In order to simulate a real clinic situation, the clinical scenario was 
presented to the relevant consultant immediately prior to filming.  They were presented 
with “mock” case notes of the patient with relevant clinical details and investigation 
results filed within them.  Oncologists were also presented with the questionnaire 
output from the HRQoL instruments together with copies of the instruments so that they 
were aware of the questions behind the functional scales.  
 
6.6.2.9 Filming of the scenarios 
 
The filming for all the scenarios took place in a studio within the Medical Education 
Department at University of Leeds. There were three stages in the filming of all the 
consultation scenarios.  Initially, the doctor was presented with the mock case notes of 
the simulated patient they were about meet.  This included results of relevant 
investigations and clinical correspondence normally found in real case notes.  The 
doctor was asked to read through the notes and describe what kind of a patient he or 
she might meet and any particular topic they might raise depending on the content of 
the previous consultation records. The doctors were then presented with the graphical 
output of the patient reported outcome information derived from the questionnaires. 
They were then asked how this information impacted on their expectation about the 
patient and how this might influence their consultation they were about to have. The 
second stage was the filming of the consultation with the simulated patient. The third 
and final stage was the feedback session; both the doctor and the simulated patient(s) 
were able to provide comments about the consultation they have just had. The focus of 
the discussion particularly centred on the role of the patient reported information during 
the consultation. Discussion sessions were facilitated by Dr Robert Lane and Miss 
Jools Symons from the Medical Education Department.  
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6.6.2.10 Production of trigger tapes 
 
All the recordings of the simulated consultations, including the pre and post 
consultation discussions, were transcribed verbatim. The transcripts were then studied 
alongside the video recordings to examine how doctors interpreted and used the 
patient reported data and the role this information played during the consultations. The 
different ways by which doctors introduced the information during their consultations 
were also examined. The transcripts were scrutinized for any sections where patient 
reported information played an important role during the consultations.  
Sections of videos were subsequently edited from the original recordings in order to 
create the “trigger tapes” which were short clips of video with specific relevance to the 
utility of the patient reported data. Editing of the video clips was performed by Mr 
Richard Garry, a member of the Leeds POCPRG.  
Transcripts of selected “trigger tapes” are shown in Table 6.4. 
 
Table 6.4 Selection of transcripts from "trigger tapes" 
Example of pre-consultation discussion 
 
Fac:       Having been through the questionnaire results, do you think that’ll help you approach the 
consultation in any way different to usual? 
 
Doc: Okay.  I think the results are interesting, actually. I think I was already mentally prepared for 
somebody who might not be so well from the story that I’d heard already but I was quite struck by 
these scores. The physical functioning and the emotional functioning and indeed role and social 
functioning which are extremely low. So clearly this woman is you know, not operating in anything 
like her normal capacity or how she might describe herself as a normal person or her normal self. 
So those are quite striking I think, really. And you know, significant level of impairment and 
physically not functioning well at all and although I would have asked about that I’m really quite 
struck by how apparent degree of that. And also some of these aspects seem to have got worse 
with the chemotherapy whereas I would have been hoping and actually statistically slightly 
expecting her to be getting better. But perhaps she isn’t. And that’s what I would say from the 
functional impairment scores. ….. 
             
             The symptom scores which I realise is the reverse she’s got some very significant symptoms, 
she’s short of breath which wasn’t something which came out of the history so she would have 
had to have volunteered that to me unless I’d noticed it myself…... Poor sleep, which we don’t 
often ask about I must say, err and then she’s clearly got very bad diarrhoea which I’m sure we 
would have covered but that is a very striking problem and then there’s this enormous score, you 
know, on financial concerns which I have to say I wouldn’t routinely ask about ……..if there was 
time I would try to avoid ignoring that because that’s clearly a key issue. 
 
Fac:       Do you think that would change how you structure the consultation? 
 
Doc: It might somewhat. I think the cognitive function is interesting because sometimes you’re 
establishing a rapport with a patient; you’re assessing how much they understand about things, 
you’re quite quickly working out if they know what’s happening.  And you tailor what you do 
according to that.  But this suggests that she is thinking very straight and all these things are 
major problem for her. So I might …. I might say to her that “Look, I can see from the scores and 
what I know already from the letters that you know, you’re having a very rough time at the 
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moment and these things are very difficult”. And you know shall we go through these things…… 
 
Fac: Perhaps a quicker way into…. 
 
Doc: … a quicker way into some of these issues, exactly.  Whereas you might have looked for a longer 
rapport building for permission to raise them so I think it might be quicker…. 
 
Example of how the patient reported data is introduced during the consultation 
 
 
Doc: Are there other things that the disease and the treatment are interfering with?  Your job and your 
money and ….  
SP: Well, I just don’t … I’m just not quite the same.  I sort of…I don’t go out as much.  Don’t see 
people as much.  Don’t get as much fresh air as …well, you know?  I can’t just go for a walk.  
Well, walking is free isn’t it?  
Doc: True 
SP: It clears your mind. 
Doc: umm. Ok. 
SP: I can’t…. it just hurts a bit.  I mean it’s “uncomfy” 
Doc: Is that getting you down? 
SP: Umm……….  Yeah. 
Doc: OK. There seems to be a kind of…. a number of related issues here.  There’re issues about your 
money and your finance.  You’re not sleeping very well.  Cos you’re obviously anxious about the 
situation that you’re in.  And you’re quite …. Well, not very depressed but it looks as though you 
are a bit depressed from the scores that are coming out on ….. (pointing at the questionnaire 
output) 
SP: Yeah, yeah.  I didn’t know quite what to say with that thing because people sort of use depression 
as a word don’t they? 
Doc: They do. 
SP: You know?  But I suppose I am a bit, yeah.  I mean you’d have to be wouldn’t you …. 
Doc: Well, I mean some of this….some of this of course is completely natural reaction to the situation 
that you’re in.  
SP: Yeah.  That’s what I mean. 
Doc: And the issue really is how we best support you through that.  Make you feel as though you’ve 
got some help and support.  That people are listening to you. 
SP: Umm 
Doc: Um and try and get you through it as best we can.   
 
Example of post-consultation discussion 
 
 
Fac: What do you feel went well in that consultation? 
 
Doc: It feels as though we’ve covered quite a lot of ground.  I mean I ….as presented, you were 
coming to me for a discussion about your next course of chemotherapy and it would have been 
very easy just to focus on what the side effects of the your last treatment, what do we need to 
change, you’re coming in next week and you’re coming back in 3 weeks….. I could have done 
that in 20 seconds or so.  I think having the information on these sheets it kind of immediately 
gave me a red alert to a number of issues.  Financial issue I think was a very obvious a trigger in 
that scenario that I wouldn’t have gone into I don’t think without the information on the sheet.  But 
actually that was a way into to a whole load of other things, wasn’t it?.... in fact. 
 Um, I think we did explore quite a lot of …quite a lot of issues.  I wondered whether it might be 
about your job but actually it was more about your family and your daughter and ur … your 
uncertainties for the future. So I was pleased to be able to explore some of those issues, which I 
don’t think I would have done …otherwise. 
 
Fac: Faciliator 
Doc: Doctor 
SP: Simulated patient 
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6.7 Doctor Training Programme 
 
The objectives of the training were to highlight the utility of patient reported HRQoL 
information in clinic consultations and to illustrate different ways in which this 
information may be used to aid/support clinical decision making.  
The length of the training was decided to be half day session to fit in with clinicians’ 
busy schedules. The training needed to incorporate different components to 
accommodate different learning styles people may have.  
The training consisted of a didactic component detailing the available evidence base 
for patient reported HRQoL assessment with feedback to oncologists and the role of 
such intervention within clinical practice. The training also highlighted the findings from 
the longitudinal analysis of the previous randomized controlled study (Chapter 5), 
indicating that psychosocial issues are often ignored even when the patients have 
reported problems.  
The interactive or experiential component of the training was provided by the trigger 
tapes produced; illustrating how different doctors have used the patient reported 
information in different clinical situations. These trigger tapes were used to promote 
small group discussions amongst the participants.  
The training programme also incorporated guidelines developed by the Leeds 
POCPRG for managing emotional distress and fatigue, which mapped onto existing 
supportive services available locally in Leeds.  These guidelines were produced in such 
a way that it can be used as a template which can easily be adapted according to 
locally available resources in any hospital, so that the doctor training can be tested in 
other institutions in the future.  
Participating doctors were asked to complete a questionnaire before and after the 
training session, concerning use of patient reported HRQoL information in clinical 
practice as part of the evaluation process. The components of the training programme 
were brought together with Dr Absolom and Prof Velikova.  The trainers’ manual 
developed for the training programme is shown in Appendix 9. 
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6.8 Summary 
 
This chapter has described the processes undertaken to formulate the framework for 
the doctor training programme aimed at increasing the utility and integration of patient 
reported HRQoL information in clinic consultations.  
As the patient reported HRQoL aims to influence communication between patients and 
healthcare professionals, training methods used in advance communication skills 
training were reviewed to inform the structure for the training programme for patient 
reported HRQoL intervention. Conceptual models of adult learning and learning styles 
have helped to better understand how adults learn and provided better appreciation of 
the strategies used in the communication skills training; these strategies were 
considered relevant to training doctors in using patient reported HRQoL data. 
I have developed trigger tapes which illustrates different ways patient reported data can 
be used.  These video clips offer learners opportunities for experiential learning through 
peer observation and provide ideas for how they may use the patient reported data. 
Trigger tapes can also help to make the training more stimulating for the learners and 
hopefully help generate small group discussions about utility of patient reported HRQoL 
data. 
The final half day doctor training programme included a didactic component to provide 
evidence base for the use of patient reported HRQoL information in clinical practice. 
The programme also offered a platform to integrate clinical guidelines for the 
management of emotional distress and fatigue to help doctors discuss these issues 
more readily with their patients. 
The next stage was to test the impact of the training programme in pre and post test 
pilot study to examine the impact of the training on how doctors use the patient 
reported data in their consultation. This pilot study also provided the opportunity to test 
the tumour site specific questionnaires (Chapters 3 and 4). The design and set up of 
the study is described in Chapter 7. 
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Chapter 7 Doctor training pilot study 
  
7.1 Introduction 
 
This chapter describes the methodology of a pilot study designed to assess the impact 
of the doctor training programme described in chapter 6.  
The study aimed to provide an estimate of the impact of the doctor training on utilising 
patient reported outcome data on patient-doctor communication in routine 
chemotherapy review consultation. The results could then be used to contribute to the 
preparation and sample size calculation for future studies planned as part of the wider 
programme of research by the Leeds POCPRG. 
The study protocol was written and submitted to the Local NHS Ethics committee for 
ethical approval by myself. The training session was led by Prof Velikova and Dr 
Absolom but I attended and took part in facilitating the training session. The recruitment 
and analysis of the study took place outside the timeframe of my doctorate degree. 
 
7.2 Measure of impact of doctor training 
 
It was necessary to consider how the physician training programme and the patient 
reported outcome intervention as a whole would be evaluated.   
Leeds POCPRG have collected and analysed a large number of oncology clinic 
consultations (over 1500 consultations from over 400 patients) as part of their studies.  
The consultations were analysed using content analysis as previously described in 
Chapter 2.   
It was necessary to expand this content analysis to provide a better measure of the 
impact of doctors’ training programme.  This developmental work was based on the 
theoretical framework of “patient centred communication”.  Definition of patient centred 
communication includes 1) eliciting and understanding the patient’s perspective, 2) 
understanding the patient within his or her psychosocial context, 3) finding common 
ground and 4) assist patients to share control and allow involvement in decision making 
to the degree they wish (Epstein et al., 2005).  These concepts fit well with the aims of 
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the patient reported outcomes intervention research, and provide the theoretical 
framework for the development and evaluation of the training programme. 
A review of coding systems used to analyse doctor-patient communication in oncology 
has revealed the majority of these systems to be based on interaction process analysis 
with focus on coding “utterances” and evaluating general communication skills 
(Fallowfield et al., 2002, Razavi et al., 2003, Roter et al., 2004) (e.g. breaking bad 
news, empathic communication).  These skills are undoubtedly important and 
necessary and advanced communication skills training is now an essential component 
of training for all oncologists.  However, it was felt that these systems were not wholly 
suitable for evaluating a training programme specifically on the utility of patient reported 
HRQoL information.  
Several instruments have been developed with the aim of measuring patient centred 
communication (Mead and Bower, 2000, Elwyn et al., 2000, Shields et al., 2005, Brown 
et al., 2001a).  Of these, the Measure of Patient Centred Communication (MPCC) 
(Brown et al., 2001a) was considered to be the most appropriate as it is the only 
instrument which focuses on clinician response to patient issues and incorporates 
assessment of shared decision making.  The MPCC was developed with the Patient 
Perception of Patient Centredness (PPPC) questionnaire (Stewart et al., 2004).  This 
questionnaire aims to capture patients’ views on how patient centred their consultations 
are.  Although this framework was developed specifically for consultations within the 
primary care setting, its’ fundamental principals are applicable to any clinical 
consultations, including oncology clinic consultations in hospitals.   
In anticipation of this pilot study and for future studies investigating the impact of 
patient reported outcomes intervention, Leeds POCPRG are evaluating the feasibility 
of applying MPCC consultation coding to oncology consultations. 
 
7.3 Method 
 
7.3.1 Study design 
 
This was a quasi experimental (before and after) study.  The study schema is shown in 
Fig 7.1. The participating oncologists attended the training programme half way 
through the study.  Individual meetings were arranged with the participating oncologists 
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prior to study commencement in order to provide them with basic information about the 
HRQoL instrument (QuEST questionnaires) used in the pilot study. 
The impact of this training will be assessed by comparing study measures obtained 
from both patients and physicians, along with content of clinic consultations before and 
after the training.   
Informed consent was obtained from both patients and oncologists taking part in the 
study.  
 
Figure 7-1 Study schema for pilot study of doctor training 
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7.3.2 Study sample 
 
7.3.2.1 Oncologists 
 
Three oncologists involved in the management of patients with breast, colorectal and 
gynaecological cancer respectively, who had no prior experience of patient reported 
outcome intervention, were invited to take part in the study. Consultants and specialist 
registrars/clinical fellows were invited to take part in this pilot study as the training will 
be delivered to doctors with varied oncology experiences in future studies. 
 
7.3.2.2 Patients 
 
Patients undergoing anti-cancer chemotherapy for advanced breast, colorectal and 
gynaecological cancers, who were attending the oncology out-patient clinics for review 
at the Leeds Cancer Centre, were invited to take part. Patients needed to be over the 
age of 18 years and be able to read and understand English. Patients exhibiting 
psychopathology or those with significant cognitive impairment which would prevent 
them from being able to provide informed consent were excluded. In addition, those 
patients who were considered too ill by the clinic staff were excluded from the study. 
 
7.3.2.3 Sample size 
Analysis of previous studies conducted by Leeds POCPRG showed that non-specific 
symptoms and functional issues were discussed on average in 30% of outpatient 
consultations. The observed increase in discussion of symptoms or functioning when 
patient reported HRQoL data was measured and fed back to the oncologists was of the 
order of 10-15%. Therefore, for a comparison of proportions in before-after design, 
based on wanting to detect an improvement from 30% to 45%, 3 oncologists with 10 
patients before training and 10 patients after training were planned to be recruited into 
the study.  This assumed the common variability in percentage before and after could 
be up to 12%.   
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7.3.2.4 Study measures 
 
Both patients and physicians were participants in this study.  Consenting patients were 
asked to complete the relevant cancer site specific QuEST questionnaire on touch 
screen computer immediately prior to their planned clinic consultation. The results of 
these questionnaires were automatically scored and presented in a graphical format 
within the patient’s electronic notes in real time so that they were available for their 
oncologists to review and use during the consultation. The scores were given colour 
coding (“traffic light system”) depending on the severity of the symptom or functional 
concerns.  The colour coding was performed in reference to the cut off points derived 
from distribution and anchor based methods (Chapter 4).  
 
Patient characteristics 
Clinical information including the site of primary cancer, stage of disease and the 
chemotherapy regimen patient was receiving were recorded from medical notes at 
study entry.  In addition, patients’ age, gender, marital status, level education and 
employment status were obtained through a demographic survey. 
 
Oncologist characteristics 
Oncologists’ age, gender, qualification level, number of years practicing in medicine 
and in oncology was recorded from demographic survey completed by the oncologists.  
 
7.3.2.5 Outcome measures and analysis 
 
The Patient Perception of Patient-Centredness questionnaire (PPPC) 
 
The Patient Perception of Patient-Centredness questionnaire (PPPC) (Stewart et al., 
2004) has 9 items and the score ranges from 1-4, with a higher score indicating more 
positive patient perceptions (Appendix 10). The internal consistency of the 
questionnaire (Cronbach’s alpha) is 0.80 (n=85). Validity of the questionnaire was 
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based on the origin of the items, Measure of Patient Centred Communication (MPCC), 
with all items being significantly related to the MPCC (Stewart et al., 2004). 
Descriptive statistics (mean and standard deviation) will be calculated for the PPPC 
questionnaire scores.  The scores will be correlated with the analysis of the audio-
recording of consultations (see below).   
 
Patient doctor communication 
 
Content analysis of consultation 
 
A study specific checklist will be used to note whether HRQoL issues included in the 
QuEST questionnaires are discussed and who (doctor or patient) initiates the 
discussion.  Symptoms and functions mentioned during the consultation will be 
recorded, along with any other problems or concerns reported by patients.  
Medical decision and non-medical actions taken in response to patients’ problems will 
also be recorded.  Medical decisions are defined as decisions on cancer treatment, 
symptomatic/supportive treatment, investigations and referrals. Non-medical actions 
include advice on lifestyle, coping, and reassurance.   
The content of communication will be presented as a list of binary variables (topics 
discussed or not) and descriptive statistics will be calculated showing the proportion of 
consultations when symptoms or functional issues are discussed. Medical and non-
medical actions taken in response to patient problems will also be analysed 
descriptively.  
 
Measure of Patient-Centred Communication (MPCC) 
 
All audio-recordings of the clinic consultation will be subjected to an analysis, using the 
coding framework outlined in the MPCC (Brown et al., 2001a).  There are three 
components to the coding framework.  These are: 
Component 1: Exploring both the disease and the illness experience,  
Component 2: Understanding of the whole person 
Component 3: Finding common ground 
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Descriptive statistics will be calculated for scores from each component (mean and 
standard deviation).  The scores derived from this analysis will also be correlated with 
the PPPC scores.   
Comparative analysis will be performed on outcome measures obtained before and 
after the training to examine its’ impact.   
 
Oncologist questionnaires 
 
Oncologist checklist 
 
Following every consultation with a patient participating in the study, the oncologist 
were asked to complete a brief checklist regarding the use of patient reported HRQoL 
in the consultation and its’ impact.   Oncologists’ perception of the usefulness of patient 
reported symptoms and HRQoL and their impact on the consultation will be analysed 
descriptively from the checklist. 
 
Oncologist self assessment questionnaire 
 
Oncologists were also asked to complete a self assessment/feedback questionnaire 
relating to patient-doctor communication after each study consultation.  This is the 
physicians’ version of the PPPC questionnaire; results from this questionnaire will be 
correlated with the results from PPPC questionnaire.    
 
Exit interviews with physicians 
 
Interviews were held with the participating physicians at the end of the study to explore 
their views on their experience of patient reported HRQoL intervention before and after 
the training programme.  Oncologists were asked to provide their opinions on the 
training programme, having used the patient reported information during the study. The 
interviews were audio-recorded, transcribed and will be analysed using framework 
analysis (Ritchie et al., 1994). The result from this analysis will assist in tailoring the 
content of the training programme for future studies.    
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7.4 Preliminary results 
 
The study was conducted by the Leeds POCPRG between August 2011 and January 
2013.  
3 oncologists (one Consultant Clinical Oncologist, one Clinical Fellow and one 
Specialist Registrar in Medical Oncology specialising in the treatment of breast, 
colorectal and gynaecological cancer respectively) were invited and consented to take 
part in the study.    
When the study began, there was another specialist registrar working with the 
gynaecological cancer team who initially took part in the study and had consultations 
with six patients. However, he had to rotate to another team during the study period 
and therefore these six patients were excluded from the analysis as this doctor did not 
attend the training session.  
Total of 251 patients were approached to take part in the study. 73 patients (29%) 
consented, of which 69 patients completed the study. 4 patients could not complete the 
study due to mainly timing issues. 178 patients declined or did not enter the study. For 
those patients who gave a reason for non participation, many stated that they would 
prefer to see another member of the team (59 patients). There were also patients who 
became ineligible due to their treatment being stopped or changed to something other 
than chemotherapy after the initial contact with the patient to introduce the study. 
Patients were initially approached by the clinic nurses before the researcher could 
discuss the study in detail. This multi-stage patient approach may have had some 
impact on the recruitment figures.  
6 patients’ consultations were excluded from analysis for reasons given above 
regarding the doctor rotating to another team during the study period. This left 21 
patients from each disease group who took part in the study and completed the 
measures as described above for analysis. There were 10 patients in the pre-training 
phase and 11 patients in post training phase in the breast group; 11 patients in the pre-
training phase and 10 patients in the post training phase in the colorectal and 
gynaecological cancer groups. There were 50 female and 13 male participants, with 
mean age of 63 years (range 33 – 84 years, SD 9.6). 81% of patients were receiving 
cytotoxic chemotherapy, 9.5% were on biological/antibody therapy and 9.5% were on 
endocrine therapy. Majority of patients were receiving palliative treatment for metastatic 
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disease (95% of breast cancer patients, 50% of gynaecological cancer patients and 
100% of colorectal cancer patients).  
The oncologists attended the doctor training after the pre-training phase recruitment 
had completed for each disease group.  The training was arranged so that all three 
oncologists within the study could attend at the same time, in order to create a small 
group teaching environment.  I took part in the training session as a facilitator, along 
with Dr Absolom and Prof Velikova. Once the training had taken place, post training 
phase of the study resumed.   
The analysis of the pilot study is being undertaken by the Leeds POCPRG, in order to 
gain an estimate of the impact of the doctor training. 61 patients’ consultation audio 
recordings were available for analysis (31 pre-training and 30 post-training) due to two 
audio-files being partially complete. 
The preliminary findings suggest interactive training sessions appear to be associated 
with some improvements on discussion/communication between patients and doctors.  
The study analysis indicated that patient reported HRQoL data were explicitly referred 
to in significantly more consultations in the post training phase (48.4 % vs 76.7 %, 
p<0.05). Although the mean number of common cancer symptoms being raised in the 
consultation did not differ pre and post training phase (3.81 vs 4.27, p = 0.24), the 
mean number of functions discussed were significantly higher post training (2.23 vs 
2.90, p<0.05).  In particular, physical functioning was raised more frequently in the 
post-training consultations (61.3 % vs 86.7 %, p<0.05) as was pain (51.6 % vs 86.7 %, 
p<0.05) (Absolom et al., 2014).  
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Chapter 8 Discussion 
 
The overarching hypothesis of this thesis is that patient self reported HRQoL 
instruments specifically developed for colorectal cancer patients to be used in routine 
clinical practice would play several important functions; improving patient-doctor 
communication, highlighting areas of unmet needs and providing a method of 
monitoring patients’ symptoms and side effects  over time. An instrument with such 
specific purpose may be built on existing questionnaires, by adapting them through 
processes involving both patients and healthcare professionals to ensure its’ clinical 
utility and relevance to the specific group of patients. In addition, training healthcare 
professionals on how to respond to and integrate patient reported HRQoL data during 
consultations would further enhance the intervention by assisting them to incorporate 
patient data in clinical decision making process. 
 
My expectations were that a questionnaire developed for patients with colorectal 
cancer specifically for use in clinical practice, together with training for the healthcare 
professionals would serve the following functions: 
 
1. Enhance patient-doctor communication, by allowing patients’ views to be actively 
presented and facilitate collaborative working relationship between the two parties. 
2. Provide a reliable assessment of colorectal cancer specific physical symptoms and 
treatment toxicities and thus provide a way of monitoring treatment response and 
symptoms over time and help support clinical decision making. 
3. Screen for and identify problems which are not always addressed, such as emotional 
distress, impact of disease and treatment on daily activities and physical function, and 
impact on family/personal relationships.  Doctors can raise and encourage patients to 
discuss these issues and, where necessary, refer for supportive care services. 
 
Patient reported outcome intervention is a complex intervention.  It requires multiple 
components to come together and ultimately change the behaviour of both patients and 
healthcare providers.  Evaluating the role of PROMs in clinical practice is equally 
challenging. Medical Research Council (MRC) has given a guidance on developing and 
evaluating complex interventions (Craig et al., 2008).   Emphasis is given on 
indentifying active components of the intervention and developing/piloting each 
component to assess its’ impact on the outcomes before definitive evaluation of the 
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intervention as a whole.  This framework fits well with the development and evaluation 
of PROMs intervention. 
 
The objectives of the thesis outlined in Chapter 1 can broadly be divided under two 
main themes. Below I summarise my key results and achievements in each theme: 
1. Enhancing the clinical practice through the development of colorectal cancer specific 
HRQoL questionnaire 
I have reviewed discussion topics from routine oncology consultations among 
colorectal cancer patients and reviewed the relevant literature to identify relevant 
HRQoL topics concerning patients with colorectal cancer. I have successfully 
conducted semi-structured interviews with 7 oncologists and 10 patients to explore and 
highlight these issues further to ensure the topics relevant in routine clinical practice 
were selected. The questionnaire was validated in a sample of 155 colorectal cancer 
patients but also by 448 patients overall as part of the wider research being undertaken 
by the Leeds POCPRG.  
2. Exploring the ways in which patient reported information may be incorporated into 
the routine practice, thus overcoming some of barriers for its successful 
implementation. 
I have performed secondary analyses of communication and use of HRQoL data during 
oncology consultations, using the rich dataset from the randomized controlled study 
previously conducted by POCPRG. These analyses highlighted that repeated patient 
reported outcomes intervention can have an impact on patient-doctor communication 
over time but this finding was only limited to discussion of physical symptoms.  
Patients’ psychosocial issues remained largely unaddressed, despite patients reporting 
significant problems.  Doctors may not necessarily have the tacit knowledge of what 
the HRQoL scores indicate. Within clinical practice, doctors rely on normal parameters 
on laboratory tests gage their clinical decisions as to whether they need to act on the 
results.  The cut off score analysis of the QuEST-Cr questionnaire will help provide 
clinicians an idea of a parameter which may in turn help them use the information to 
make clinical decisions where indicated. These findings have informed the content of 
the doctor training programme. 
Using theory of adult learning and the model of communication skills training, and 
through collaborative working with University of Leeds Medical Education Unit and 
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oncology colleagues, I developed and recorded scenarios for trigger tapes which can 
be used as part of the doctor training to provide a valuable experiential learning 
opportunity.  I designed and implemented these components within a training 
programme for oncologists, with the aim of enabling them to use patient reported 
HRQoL data more effectively during clinic consultations.  This training programme has 
been tested within a pilot study, to examine its’ impact of the utility of patient reported 
HRQoL information. 
 
8.1 Enhancing the clinical practice through the development of 
colorectal cancer specific HRQoL questionnaire 
 
QuEST-Cr is a 55 item questionnaire which has been developed specifically for 
colorectal cancer patients for use in routine clinical practice. As colorectal cancer can 
affect both men and women, there are gender specific questions concerning sexual 
function.  It also includes items specific to patients with a stoma.   
The processes undertaken for the development of QuEST-Cr have incorporated both 
clinimetric (Feinstein, 1983) and psychometric approach.  The combination of EORTC 
QLQ-C30 (Aaronson et al., 1993) and EORTC QLQ-CR29 (Whistance et al., 2009) was 
found to provide best coverage of topics raised in routine colorectal cancer patients’ 
clinic consultations and was used as the basis for adaptation.  It is noteworthy that the 
adaptation process has not increased the number of items contained in the 
questionnaire as brevity of instruments is an important factor for use in clinical practice 
to ensure patients are able to complete the questionnaire and for the healthcare 
professional to be able to interpret the data efficiently. 
QuEST-Cr provides assessment of commonly reported symptoms and side effects of 
colorectal cancer treatments, which are essential to oncologist supervising their 
patients’ treatment course.  QuEST-Cr provides a way of monitoring these symptoms 
over time. QuEST-Cr includes a more detailed assessment of physical activity 
compared to the EORTC instruments; a function considered important by the 
oncologists.  Similarly, there are more items addressing fatigue as this was one of the 
commonly reported symptom by patients but often poorly managed within the oncology 
practice in general (Borneman et al., 2007); improved assessment may play a role in 
increased recognition and treatment of the condition.  Variety of questions was 
explored for the assessment of emotional distress.  Both patients and oncologists 
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expressed concerns for the word “depressed” within the question.  MHI-5 (Berwick et 
al., 1991) was considered the most appropriate as the items contained both positive 
and negatively worded questions but also used language which patients could relate to.  
In addition, based on the work by Cull et al (Cull et al., 2001), MHI-5 can be used as 
part of a step-wise screening process in conjunction with the HADS (Zigmond and 
Snaith, 1983), providing a method of identifying patients who may warrant referral to 
supportive care services .  
I felt it was important to include questions concerning stoma within this questionnaire 
as having a stoma has an enormous impact on patients, both physically and 
psychologically (Brown and Randle, 2005). Many of the existing questionnaires asks 
patients predominantly about their bowel function when addressing issues relating to 
their stoma, which often overlaps with other bowel related questions.  Therefore, items 
were chosen which would address practical issues relating to the stoma and the 
psychosocial impact patients may experience because of the stoma. 
There were mixed views about inclusion of questions concerning body image and 
sexual function from both patients and oncologists.  However, these are issues relevant 
to patients with colorectal cancer (Bullen et al., 2012, Traa et al., 2012)  and as one of 
the aims of the questionnaire is to help raise issues which are often ignored, it was 
considered necessary to  include items addressing these issues within the 
questionnaire, but provide patients with options to skip the items if they did not wish to 
answer. 
The questionnaire has undergone psychometric testing in a sample of 155 colorectal 
cancer patients plus amongst nearly 450 wider cancer patient patients to test the 
reliability of the subscales which have been identified through exploratory factor 
analysis. 
In summary, the QuEST-Cr provides a comprehensive assessment of colorectal cancer 
patients with particular focus on those undergoing chemotherapy treatments; the 
questionnaire addresses disease and treatment related symptoms but also general 
HRQoL issues which may affect these patients.  The questionnaire allows patients to 
report problems which they may find otherwise difficult to raise during the consultation 
(such as sexual issues).  It may also assist in detection of important issues which may 
be amenable to further treatment, such as emotional distress.  
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8.2 Exploring the ways in which patient reported information may be 
incorporated into the routine clinical practice 
 
Exploratory work around the development of doctor training programme has indicated 
that psychosocial and other functional issues are rarely discussed in routine oncology 
consultations.  Although many consultation models have been developed over the last 
four decades, highlighting the importance of holistic approach to patient management, 
the clinic consultations were often doctor led with discussion topics centred on physical 
symptoms.  Even when patients reported significant problems with their psychosocial 
functioning, doctors often failed to raise these issues with their patients.  I have 
published this observation identified through the exploratory analysis of longitudinal 
data from the previous randomized controlled study, conducted by the Leeds POCPRG 
in Journal of Clinical Oncology (Takeuchi et al., 2011). This was the first attempt being 
made linking the questionnaire scores and content of patient-doctor communication. 
It is necessary for doctors to be able to respond to patient reported information so that 
patients’ problems are not left unaddressed (Velikova et al., 2004, Detmar et al., 2002); 
analysis described above indicates the need to identify ways to assist doctors in how to 
respond to patient reported HRQoL information.   
Details about training given to healthcare professionals receiving patient reported 
information have been sparse, even where there was indication of such training being 
provided.  They generally focused on the HRQoL instruments used but not how the 
healthcare professionals might use the information.   
Interviews with oncologists, as part of the questionnaire development, highlighted many 
of the recognised barriers (Deyo and Patrick, 1989) to the implementation of patient 
reported HRQoL assessments.  These were time constraints, lack of familiarity with 
HRQoL instruments in general, and their ability to deal with a wide range of problems 
which patients may report.  However, involving the healthcare professionals in the 
development of QuEST-Cr has helped to gain their interest in the intervention and their 
engagement with the process, which is one of the key factors needed for patient 
reported HRQoL to be adopted in clinical practice (Locklear et al., 2014).   
Although training clinicians has been suggested as a way of overcoming these barriers, 
there was no specific guidance on how such training may look like.  It was helpful to 
look at the conceptual models of adult learning and learning styles together with 
teaching methodologies in identifying the components necessary in the training 
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programme.  I used the teaching strategies used in advanced communication skills 
training as the model for the training programme for patient reported HRQoL 
intervention as the content of the communication skills training incorporate key 
elements of the adult learning theory. 
I identified that there needs to be a didactic component to highlight the evidence for the 
utility of patient reported HRQoL information, how such information may assist them 
during clinic consultations and alleviate their fears and concerns about patient reported 
data. Experiential learning is an important strategy in clinical skills training, including 
communication skills, where role-play feature heavily as a method to acquire new skills. 
As the training programme for patient reported HRQoL intervention had to be relatively 
short in order to fit in with doctors’ demanding clinical schedules, it was necessary to 
consider options on how experiential learning can be included in the training. Trigger 
tapes have been used successfully in clinical skills training for many years, including 
communication skills training. I felt this was the most appropriate tool to illustrate how 
patient reported data can be used, facilitate discussions among the participants and 
provide them with ideas on how they might use the patient reported data and act on it.  
The specific content and components of the training programme has been brought 
together with Dr Absolom and Prof Velikova.  The training programme has also 
incorporated locally produced guidelines on the management of emotional distress and 
fatigue, in order to facilitate oncologists to discuss these issues with the patients where 
indicated.  The approach taken for the development of this training programme 
contributes to the description and practical ideas on how to design and implement a 
training programme of this kind.  
This study highlights the need for the training to be specifically tailored to the specific 
nature of the patient reported outcome instruments being used in the intervention, as 
well as having an understanding of the training needs among the healthcare 
professionals.  Different training methodologies may be necessary to cater for the 
specific situation in which the patient reported outcome intervention is being carried 
out.  The importance of this tailored approach is highlighted in a study by Santana and 
her colleagues (Santana et al., 2015).  Although the training may take different formats 
and may utilize different resources, the need for an experiential learning opportunity is 
emphasized in order to facilitate clinicians to acquire new skills. 
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8.3 Methodological issues 
 
8.3.1 Strengths 
 
8.3.1.1 Questionnaire development/adaptation 
 
The questionnaire development used mixed methods approach, using both qualitative 
and quantitative methodologies. The processes undertaken for the development of 
QuEST-Cr are comparable to published guidelines on the development of HRQoL 
instruments (Johnson et al., 2011), which included interviews with both patients and 
healthcare professionals and review of literature.  However, rather than using the 
interviews with patients and healthcare professionals to generate a list of topics to be 
included in the questionnaire, I used the consultation data from real oncology clinics 
involving colorectal cancer patients to ensure relevant topics were included. 
The questionnaire items were refined using both psychometric and clinimetric 
approach.  Psychometric approaches used in the study were well established 
traditional questionnaire development methodologies.  The clinimetric approach was 
used to ensure clinical utility of the questionnaire.  This has lead to the creation of 
QuEST-Cr, an instrument for use in clinical practice specifically for patients with 
colorectal cancer. 
 
8.3.1.2 Doctor training 
 
The longitudinal analysis of the previous randomized controlled study allowed 
exploration of a very rich longitudinal database of real life oncology consultations, 
where patient reported HRQoL information was used. The analysis indicated that the 
intervention of collecting patient reported HRQoL with feedback to the oncologists 
helps to maintain discussions over time, albeit mainly about physical symptoms. This 
study highlighted the need to improve discussions about patients’ psychosocial 
concerns. 
There was no guidance available on how to construct a training programme to assist 
oncologists in how to use patient reported HRQoL information.  I examined the 
conceptual models of adult learning and learning styles to inform the type of teaching 
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interventions that were required and used the communication skills training 
methodology as a guide to developing the training.  I felt communication skills training 
was particularly relevant, as patient reported HRQoL intervention ultimately aims to 
impact on doctor-patient communication as a first step in changing the behaviour of 
doctors and patients.  
The development of trigger tapes was guided by existing literature.  The strength of my 
trigger tapes is that they are based on real patient consultations and their HRQoL 
scores, ensuring clinical relevance. 
 
8.3.1.3 Limitations 
 
There are a number of limitations in the methodologies applied in this thesis.  
The consultation data from colorectal cancer patients used in the initial phase of the 
questionnaire development came from a randomized controlled study, called the 
Attention Control Study (Velikova et al., 2008), which looked at the impact of patients 
completing the HRQoL questionnaires without feedback to the oncologists.  Completion 
of HRQoL alone may have had an impact on the discussion topics raised by the 
patients during these recorded consultations. 
In addition, there are concerns about the sample size for each of the elements of this 
thesis.  The colorectal cancer patient sample in the Attention Control Study was only 
17, providing 68 consultations between them from four consecutive clinic visits.  Some 
of the issues raised during these consultations may have been recurring issues for the 
sample population, thus giving an overestimate of the frequency at which these topics 
were raised.  
During the interview stages of the questionnaire development, only 7 oncologists and 
10 patients were interviewed.  The colorectal cancer practice in Leeds Cancer Centre 
does not have a clinical nurse specialist within their team, who would routinely attend 
oncology clinics to review patients.  They are mainly based with the surgical teams but 
are able to provide support if patients are having problems such as stoma related 
issues. I therefore interviewed all oncologists, who routinely prescribed chemotherapy 
treatment for colorectal cancer patients, who were based at the Leeds Cancer Centre. 
The number of patients interviewed is in keeping with the EORTC questionnaire 
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development guidelines.  At the end of both sets of interviews, similar issues and 
problems were emerging. 
The sample size for the questionnaire validation study was calculated for all three 
disease groups for which the questionnaire was being developed as part of the CRUK 
funded programme of research by the Leeds POCPRG (i.e. colorectal, breast and 
gynaecological cancers) rather than for the colorectal cancer questionnaire alone.  
Therefore, the sample size used may be considered suboptimal, particularly for items 
which are only included in the colorectal cancer questionnaire. As stoma related items 
were branching items, only relevant to a small proportion of patients, these items and 
the sexual function items were excluded from the factor analysis. Further research is 
necessary to test the QuEST-Cr for its reliability and validity. As there is currently no 
standard HRQoL instrument for measuring HRQoL in clinical practice, it may be difficult 
to make a comparison with other HRQoL instruments.   
 
8.4 Future Directions 
 
8.4.1 QuEST-Cr 
 
8.4.1.1 Further validation of QuEST-Cr 
 
QuEST-Cr was validated in a relatively small sample of colorectal cancer patients from 
single institution.  In addition, the questionnaire was only administered to patients once; 
hence test-retest data was not available to assess the stability of scoring among the 
study population and how the questionnaire performs over time.  Therefore, QuEST-Cr 
may be improved further by testing its psychometric properties in a larger group of 
patients and to administer the questionnaire repeatedly. The most efficient way of 
collecting this data would be to administer the questionnaire in routine clinical practice.  
Validating a questionnaire intended to make an assessment of individual patients also 
require careful consideration as to how it may be validated, not just at group level but 
also at individual level.  As there is no gold standard questionnaire available which can 
be used to compare against the QuEST-Cr, other strategies may need to be explored.  
Kocks et al (Kocks et al., 2010) used in-depth semi-structured interviews with individual 
patients to assess the individual validity of a health status questionnaire used among 
patients with chronic obstructive airways disease (COPD) called Clinical COPD 
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Questionnaire (CCQ). They found that the outcomes from CCQ from individual patients 
showed good agreement from that obtained through the interviews.  However, such a 
method is time consuming and can only realistically be applied for short questionnaires 
addressing a specific topic within a defined clinical setting. Alternatively, patients may 
be asked to undergo several different assessments to evaluate various domains 
included in the QuEST-Cr (for example, physical function and psychosocial needs); 
however, this will again require large patient sample and may increase patient burden.   
 
8.4.1.2 Further refinement of QuEST-Cr 
 
Item response theory is concerned with accurate test scoring and development of test 
items.  Item response theory models, such as the Rasch model, may allow reduction in 
the number of items within a scale without compromising the measurement accuracy.  
This may help reduce patient burden in completing the questionnaire. 
One of the limitations of QuEST-Cr approach is that the questionnaire aims to capture 
most of the experiences of patients with colorectal cancer. However, patients differ in 
their symptom experience and level of health.  Therefore, the questionnaire may 
contain items which may be irrelevant for a particular patient.  
Item response theory provides basis for the computer adaptive testing (CAT) (Gershon, 
2005), which is a form of computer based test that adapts to the ability of the person 
taking the test. CAT is particularly appealing within the clinical context (Walker et al., 
2010), as the questionnaire is tailored to the individual patients.  However, CAT 
requires a large item bank to test each domain (such as physical function) and large 
sample size for validation.  As one of the utilities of QuEST-Cr is to function as a 
screening tool for a number of domains of HRQoL, CAT may not be the most suitable 
approach. 
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8.5 Implementing QuEST-Cr into clinical practice 
 
8.5.1 Doctor training 
8.5.1.1 Pilot study 
 
The doctor training programme has been tested in a pilot study as described in Chapter 
7. The study was carried out by the Leeds POCPRG and patients were recruited 
between August 2011 and January 2013. The aim of the pilot study was to provide an 
estimate of the impact of the training on patient-doctor communication. This will inform 
requirements of future studies to evaluate the complex intervention of using the cancer 
site specific questionnaires together with doctor training programme. 
The pilot study utilized a quasi-experimental design (before and after); 3 oncologists 
and 73 of their patients from colorectal, breast and gynaecological cancer practices 
respectively consented to take part. Of these 73 patients, 69 patients completed the 
study. Consultation data from 61 patients (31 from pre-training and 30 from post-
training) were available for analysis.  Preliminary results have shown that the training 
has had an impact on patient doctor communication with more oncologists specifically 
referring to the patient reported data and increase in discussion of symptoms.  These 
findings will inform future study plans to evaluate the training and also the QuEST 
questionnaires. 
 
8.5.1.2 Provision of management guidelines 
 
Interviews with the oncologists have highlighted the need for information provision and 
management guidelines for issues which may be reported by patients through the 
HRQoL instrument, such as emotional distress, body image and sexual function issues. 
Managing emotional distress was a particular priority and Leeds Psychosocial 
Oncology Group have developed guidelines in association with the Psycho-Oncology 
and Liaison Psychiatry teams, based around services which are available locally, using 
the recommendations set out by National Institute for Health and Clinical Excellence 
(NICE) guidance (National Institute for Clinical Excellence, 2004). This guideline will be 
incorporated into the training. 
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Issues about body image and sexual functions raised concerns from the oncologists in 
terms of how they might help their patients if they reported problems in this area. 
Oncologists suggested that guidelines and specific referral pathway would help them in 
raising these issues with their patients.  However, the prevalence of these issues 
among patients with advanced colorectal cancer is largely unknown and warrant further 
investigation.  This would help inform development of supportive services to meet the 
needs. 
 
8.5.1.3 Measure of impact of doctor training 
 
It is necessary to consider how the doctor training programme and the patient reported 
HRQoL intervention as a whole will be evaluated.  Leeds POCPRG have collected and 
analysed a large number of oncology clinic consultations.  These consultations were 
analysed using basic content analysis using a study specific checklist to note whether 
issues covered in the HRQoL questionnaires were discussed during the consultation, 
who (doctor or patient/relative) initiated the discussion and the actions that followed. 
Any other concerns or issues raised by the patients were also noted.  
As the training aims to incorporate patient views actively into the consultation 
discussions, the measure of the impact of training should also aim to assess how well 
the communication between doctors and patients have centred around patient reported 
issues.  In order to capture whether the consultation have been “patient centred”, it is 
necessary to expand the content analysis to provide a better measure of the impact of 
doctor training. There are plans for the consultations from the pilot study to be analysed 
using the Measure of Patient Centred Communication framework (MPCC) (Brown et 
al., 2001a).  This work was outside the scope of the thesis, however, MPCC 
consultation analysis tool will be used alongside the content analysis to evaluate the 
impact of doctor training. .   
 
8.6 Implementing QuEST-Cr and doctor training 
 
I have developed a colorectal cancer specific HRQoL questionnaire for clinical practice 
to allow patients to report relevant symptoms, side effects of treatment and 
psychosocial issues.  I have also developed a training programme for oncologists to 
assist them in using the patient reported information as part of their decision making 
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process, with the aim of improving patient outcomes such as patient well-being and 
satisfaction with their care. 
It is therefore necessary to bring the two elements together to test the impact of these 
interventions within the clinical practice. The pilot study using before-after study design 
was aiming to provide the initial experience with the doctor training and early estimates 
of potential impact and its effect size.  The effectiveness of this intervention should be 
tested prospectively in a randomized controlled trial.  
The design of the randomized study will require careful consideration to minimize 
contamination effect, which may obscure the true impact of the intervention. This is 
particularly relevant in studies where traditional two arm study design was used in 
which doctors saw patients in both the intervention and control arms. Alternative study 
designs may be more favourable, such as cluster randomized studies where the 
doctor, a particular clinic or hospital is the unit of randomization.  However, this 
approach will require large numbers of clusters and likely to need multi-centre 
involvement.   
Employing traditional experimental study designs to evaluate such intervention is 
resource intensive.  The studies require time, skilled investigators and their research 
team (consisting of research assistants, data managers and statisticians among others) 
and adequate funding. 
Alternative evaluation methods which may be considered include quasi-experimental or 
continuous quality improvement designs and methods.  Such evaluation methods can 
provide evidence of effectiveness of the intervention, may be cheaper to conduct and it 
can be built on quality improvement programmes which may already exist within the 
health institutions (Snyder et al., 2012).  For example, continuous quality improvement 
design aims to make small changes incrementally with regular evaluation and 
modifications, such as in the plan-do-study-act (PDSA) cycles (Langley et al., 2009). 
PDSA cycle provides a framework for developing, testing and implementing changes 
leading to improvement.  
Disadvantage of such an approach includes risk for bias and low internal validity due to 
lack of experimental control.  However, these methods allow qualitative assessment of 
the mechanism of patient reported HRQoL intervention (how the data is used by the 
patients and clinicians and how it is integrated into the routine workflow) and describe 
the local conditions that have influenced the outcome of the intervention (Berwick, 
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2008).  Such analyses can help to identify aspects of the intervention that may be 
generalisable to other contexts and inform how effective changes can be implemented.  
 
8.7 Future directions 
 
We now have sophisticated electronic patient health records, which are increasingly 
being adopted within the NHS.  This move towards increased use of technology has 
been associated with move towards patient portals allowing patients to access their 
own health records.  Patient reported outcomes can be integrated in electronic notes 
system, as already demonstrated in the work described in this thesis and in wider 
literature.  
With the development of reliable mobile technology and availability/wider use of 
internet can allow online and mobile patient reporting to be feasible.  Patient reported 
data can be incorporated in to their electronic records in real time.  This approach of 
collecting patient reported outcomes can permit remote monitoring of symptoms and 
follow up. 
However, the key issues of choosing an instrument best suited to fulfill the necessary 
function and training of healthcare professionals remain critical in the successful 
application of such an intervention.  My work in this thesis informs these current 
developments being made. 
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Appendices 
Appendix 1 Healthcare professional interview questions (Chapter 3) 
 
Table 1 Physical Functions (Healthcare professionals were asked to comment about the three physical function assessments below) 
EORTC QLQ-C30 Rotterdam Symptom Check List  WHO PS 
 
 Do you have any trouble doing strenuous 
activities, like carrying a heavy shopping bag 
or a suitcase? 
 Do you have any trouble taking a long walk? 
 Do you have any trouble taking a short walk 
outside of the house? 
 Do you need to stay in bed or a chair during 
the day? 
 Do you need help with eating, dressing, 
washing yourself or using the toilet? 
 
 
 
 
Responses:  
not at all 
a little 
quite a bit 
very much 
 
A number of activities are listed below.  We do 
not want to know whether you actually do these, 
but only whether you are able to perform them 
presently.  Would you please mark the answer 
that applies most to your condition of the past 
week? 
 
Care for myself 
Walk about the house 
Light housework/household jobs 
Climb stairs 
Heavy housework/household jobs 
Walk out of doors 
Go shopping 
Go to work 
 
Responses:  
unable 
only with help 
without help with difficulty  
without help 
 
Please select one of the following items that best 
describes your current level of physical ability 
 
0 -  I am fully active and more or less as I was before 
my illness 
1 – I cannot carry out heavy physical work, but can 
do anything else 
2 – I am up and about more than half the day; I can 
look after myself, but not well enough to work  
3 – I am in bed or sitting in a chair for more than half 
the day; I need some help in self care 
4 – I am in bed or a chair all the time and need a lot 
of looking after 
 
Modified from Cancer Research UK Cancer Help 
website 
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Table 2A List of symptoms and toxicities 
Questions Useful Somewhat 
Useful 
Not  
useful 
Instructions for patients:  
Please answer the following questions by telling us how you 
have felt since your last cycle of chemotherapy 
Response options: not at all, a little, quite a bit, very much 
   
    
Infection    
1. Have you had any infection since your last cycle of 
chemotherapy? 
   
2. Have you been bothered by fevers or chills?    
Gastrointestinal symptoms    
3. Have you had sore mouth or tongue?    
4. Have you had dry mouth?    
5. Have you had problems with sense of taste?     
6. Did food and drink taste different from usual?    
7. Have you lacked appetite?    
8. Have you had trouble with eating?    
9. Have you felt full up too quickly after beginning to 
eat? 
   
10. Have you worried about losing weight?    
11. Have you had indigestion or heartburn?    
12. Have you felt nauseated?    
13. Have you vomited?    
14. Have you been constipated?    
15. Did you have bloated feeling in your abdomen?    
16. Were you troubled by passing wind/gas/flatulence?    
17. Have you had diarrhoea?    
18. Have you blood in your stools?    
19. Have you had mucus in your stools?    
20. Have your skin or eyes been yellow (jaundiced)?    
Skin    
21. Have you had soreness or redness of your hands or 
feet? 
   
22. Have you had any other skin problems (e.g. itching, 
dryness, sensitivity to sun)? 
   
Sensory Neuropathy    
23. Have you had tingling or numbness in your hands or 
feet? 
   
24. Are you concerned by any changes in your hearing?    
Alopecia    
25. Have you lost your hair as a result of your 
treatment? 
   
26. Have you been upset by hair loss?    
Fatigue    
27. Have you had trouble sleeping?    
28. Did you need to rest?    
29. Have you felt weak?    
30. Were you tired?    
31. Have you been less active than you would like to 
be? 
   
32. Have you felt slowed down?    
33. Have you felt lacking in energy?    
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Questions Useful Somewhat 
Useful 
Not  
useful 
Pain    
34. Have you had pain?    
35. Did pain interfere with your daily activities?    
36. Did you have abdominal pain?    
37. Have you had pain in your stomach area?    
38. Have you had discomfort in your stomach area?    
39. Did you have pain in your buttocks/anal 
area/rectum? 
   
40. Have you had pain in your back?    
Urinary symptoms    
41. Did you urinate frequently during the day?    
42. Did you urinate frequently during the night?    
43. Have you had any unintentional release (leakage) of 
urine? 
   
44. Did you have pain when you urinated?    
Other symptoms    
45. Were you short of breath?    
46. Were your eyes painful, irritated or watery?    
47. Did you feel ill or unwell?    
Emotional /Cognitive Functioning    
48. Have you had difficulty in concentrating on things, 
like reading the newspaper or watching television? 
   
49. Did you feel tense?    
50. Did you worry?    
51. Did you feel irritable?    
52. Did you feel depressed?    
53. Have you had difficulty remembering things?    
54. Have you had trouble talking about your feelings to 
your family and friends? 
   
55. Have you felt stressed?    
56. Have you felt less able to enjoy yourself?    
Body image     
57. Have you felt physically less attractive as a result of 
your disease or your treatment? 
   
58. Have you been feeling less feminine/masculine as a 
result of your disease or your treatment? 
   
59. Have you been dissatisfied with your body?    
Sexual Functioning    
60. Has the disease or treatment affected your sex life 
(for the worse)? 
   
For men only    
61. To what extent were you interested in sex?    
62. Did you have difficulty getting or maintaining an 
erection? 
   
For women only    
63. To what extent were you interested in sex?    
64. Did you have pain or discomfort during intercourse?    
  
262 
 
 
Questions Useful Somewhat 
Useful 
Not  
useful 
Coping during treatment    
65. How much has your disease been a burden to you?    
66. How much has your treatment been a burden to 
you? 
   
67. How much has your chemotherapy treatment 
interfered with your normal daily activities? 
   
68. Have you worried about your health in the future?    
69. Were your worried about your family in the future?    
70. Did you feel uncertain about the future?    
71. Were the side effects of treatment worse than you 
expected? 
   
72. Were you concerned about disruption of family life?    
Role and Social Functioning    
73. Were you limited in doing either your work or other 
daily activities? 
   
74. Were you limited in pursuing your hobbies or other 
leisure time activities? 
   
75. Has your physical condition or medical treatment 
interfered with your family life? 
   
76. Has your physical condition or medical treatment 
interfered with your social life? 
   
77. Has your physical condition or medical treatment 
caused you financial difficulties? 
   
78. Have you had trouble having social contact with 
friends? 
   
Treatment worth    
79. Since you started chemotherapy, how worthwhile do 
you think your treatment has been? 
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Table 2B Stoma function (Healthcare professionals were asked to comment about the four stoma function assessments below) 
FOCUS 2  EORTC QLQ-CR38 EORTC QLQ-CR29 FACT-C 
Do you have a stoma?  
 Yes      No 
 
If yes, have you had any 
problems with it (for example 
soreness of skin, increased 
frequency, leakage)? 
Do you have a stoma? 
 Yes      No 
 
Only for patients WITHOUT a stoma 
Did you have frequent bowel movements during the 
day? 
Did you have frequent bowel movements during the 
night? 
Did you feel the urge to move your bowel 
movements without actually producing any stools? 
Have you had any unintentional release of stools? 
Have you had any blood in your stools? 
Have you had any difficulty in moving your stools? 
Have your bowel movements been painful? 
 
Only for patients WITH a stoma 
Were you afraid that other people would be able to 
hear your stoma? 
Were you afraid that other people would be able to 
smell your stoma? 
Were you worried about possible leakage from the 
stoma? 
Did you have problems caring for your stoma? 
Was your skin around the stoma irritated? 
Did you feel embarrassed because of your stoma? 
Did you feel less complete because of your stoma? 
 
Do you have a stoma bag (colostomy/ ileostomy)? 
Please circle the correct answer. 
 Yes      No 
 
Answer these questions ONLY IF YOU HAVE A 
STOMA BAG 
Have you had unintentional release of 
gas/flatulence from your stoma bag? 
Have you had leakage of stools from your stoma 
bag? 
Have you had sore skin around your stoma? 
Did frequent bag change occur during the day? 
Did frequent bag change occur during the night? 
Did you feel embarrassed because of your stoma? 
Did you have problems caring for your stoma? 
 
Answer these questions ONLY IF YOU DO NOT 
HAVE A STOMA BAG 
Have you had unintentional release of 
gas/flatulence from your back passage? 
Have you had leakage of stools from your back 
passage? 
Have you had sore skin around your anal area? 
Did frequent bowel movements occur during the 
day? 
Did frequent bowel movements occur during the 
night? 
Did you feel embarrassed because of your bowel 
movement? 
Do you have an ostomy 
appliance? 
 Yes      No 
 
If yes, please answer the next 
two items: 
I am embarrassed by my 
ostomy appliance 
 
Caring for my ostomy 
appliance is difficult 
 
Not at all 
A little 
Quite a bit 
Very much 
 
Not at all 
A little 
Quite a bit 
Very much 
 
Not at all 
A little 
Quite a bit 
Very much 
Not at all 
A little 
Somewhat 
Quite a bit 
Very much 
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Appendix 2 QuEST-Cr item origin and references 
 
Abbreviated 
name Full name and reference 
FACT-C Functional Assessment of Cancer Therapy-Colorectal (Ward et al., 1999) 
FOCUS2 Item from FOCUS2 trial (Seymour et al., 2011) 
QLQ-BN20 EORTC QLQ-BN20, Brain cancer module (Taphoorn et al., 2010) 
QLQ-Br23 EORTC QLQ-Br23, Breast cancer module (Sprangers et al., 1996) 
QLQ-C30 EORTC QLQ-C30, Core quality of life questionnaire (Aaronson et al., 1993) 
QLQ-CR29 EORTC QLQ-CR29, Colorectal cancer module 29 items (Whistance et al., 2009) 
QLQ-CR38 EORTC QLQ-CR38, Colorectal cancer module 38 items (Sprangers et al., 1999) 
QLQ-HDC29 EORTC QLQ-HDC29, High dose chemotherapy module (Velikova et al., 2007b) 
QLQ-LMC21 EORTC QLQ-LMC21, Colorectal liver metastasis module (Blazeby et al., 2009) 
QLQ-OV28 EORTC QLQ-OV28, Ovarian cancer module (Greimel et al., 2003) 
RSCL Rotterdam Symptom Checklist (de Haes et al., 1990) 
WHO PS WHO performance status (World Health Organization, 1979) 
QLQ-HDC45 under development 
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Appendix 3 Longitudinal impact analysis – Mixed effects model 
(Chapter 5) 
 
Method 
A summated score was calculated for the total number of symptoms (0-7) and 
functions (0-5) discussed at each consultation.  Mixed effects models were employed 
to assess whether number of symptoms/functions discussed differed between study 
arms over time.  Potential covariates (age, gender, diagnosis, response at 3 months, 
performance status, extent of disease, time in study, months since diagnosis and a 
measure of extent to which patients have seen the same oncologist) were identified by 
univariate regression (the number of issues discussed at first consultation as the 
outcome variable and each covariate as the predictor, controlling for baseline).  
Covariates meeting the inclusion criterion (p<0.1) were entered in multivariate mixed 
effects models. 
 
p values following univariate regressions  
(Significant covariates have been highlighted by bold text) 
 
 Symptoms Functions 
Age .815 .451 
Gender .046 .766 
Diagnosis .006 .047 
Response at 3 months .080 .674 
Performance status .262 .660 
Extent of disease .213 .076 
Time in study .848 .051 
Months since diagnosis .843 .045 
K Index .991 .338 
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Appendix 4 Dynamic of communication analysis (Chapter 5) 
 
Method 
Multivariate logistic regression was employed to explore predictors for who initiated 
discussions of symptoms/functions (oncologist vs patient/relatives).    To identify 
covariates for inclusion, univariate regression models for each symptom/function at 
each visit were fitted with the person initiating discussion as the outcome and the 
potential covariate (gender, age, diagnosis, performance status, extent of disease, 
oncologist gender and grade [consultant or specialist registrar]) as single explanatory 
variable.   In the multivariate regression model, outcome variable was person initiating 
discussion at each visit and independent variables were study arm and significant 
covariates (p<0.1). This was repeated for all symptoms and functions.  A significance 
level was set at p<0.01 for the multivariate analysis to adjust for multiple tests. 
 
p values following univariate regression 
(Variables which were significant at minimum of two time points were planned to be 
included in the multivariate model.  No variable fulfilled this criterion for this model.) 
 
Fatigue 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.474 0.387 0.551 
    
Patient gender 0.528 0.686 0.151 
Age 0.123 0.051 0.461 
Diagnosis 0.185 0.639 0.451 
Performance Status 0.056 0.138 0.584 
Extent of disease 0.526 0.27 0.458 
Oncologist gender 0.429 0.755 0.169 
Oncologist grade 0.528 0.094 0.647 
 
Dyspnoea 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.468 0.315 0.444 
    
Patient gender 0.12 0.372 0.169 
Age 0.54 0.64 0.355 
Diagnosis 0.991 0.964 0.814 
Performance Status 0.677 0.443 0.182 
Extent of disease 0.655 0.722 0.859 
Oncologist gender 0.771 0.549 0.388 
Oncologist grade 0.355 0.744 0.077 
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Insomnia 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.354 0.43 0.395 
    
Patient gender 0.327 0.656 0.557 
Age 0.482 0.524 0.689 
Diagnosis 0.968 0.853 0.967 
Performance Status 0.427 0.252 0.546 
Extent of disease 0.139 0.371 0.766 
Oncologist gender 0.295 0.149 0.099 
Oncologist grade 0.635 0.212 0.134 
 
Pain 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.654 0.437 0.29 
    
Patient gender 0.729 0.178 0.064 
Age 0.924 0.294 0.34 
Diagnosis 0.963 0.256 0.635 
Performance Status 0.143 0.271 0.94 
Extent of disease 0.583 0.91 0.743 
Oncologist gender 0.501 0.403 0.507 
Oncologist grade 0.652 0.198 0.741 
 
Nausea + Vomiting 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.416 0.003 0.136 
    
Patient gender 0.789 0.206 0.873 
Age 0.334 0.767 0.403 
Diagnosis 0.675 0.521 0.413 
Performance Status 0.492 0.81 0.537 
Extent of disease 0.99 0.957 0.72 
Oncologist gender 0.113 0.758 0.224 
Oncologist grade 0.007 0.187 0.195 
 
Bowels 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.605 0.912 0.605 
    
Patient gender 0.49 0.531 0.036 
Age 0.655 0.86 0.812 
Diagnosis 0.745 0.457 0.839 
Performance Status 0.541 0.386 0.319 
Extent of disease 0.281 0.043 0.349 
Oncologist gender 0.986 0.227 0.662 
Oncologist grade 0.054 0.115 0.154 
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Anorexia 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.9 0.566 0.282 
    
Patient gender 0.98 0.632 0.052 
Age 0.785 0.144 0.921 
Diagnosis 0.900 0.802 0.991 
Performance Status 0.476 0.145 0.582 
Extent of disease 0.382 0.405 0.828 
Oncologist gender 0.212 0.173 0.772 
Oncologist grade 0.055 0.943 0.564 
 
Physical Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.234 0.599 0.893 
    
Patient gender 0.846 0.611 0.828 
Age 0.154 0.443 0.057 
Diagnosis 0.421 0.755 0.982 
Performance Status 0.711 0.424 0.583 
Extent of disease 0.239 0.045 0.124 
Oncologist gender 0.483 0.844 0.615 
Oncologist grade 0.081 0.694 0.460 
 
Social Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.519 0.571 0.768 
    
Patient gender 0.167 0.868 0.905 
Age 0.209 0.479 0.253 
Diagnosis 0.478 0.665 0.903 
Performance Status 0.771 0.828 0.685 
Extent of disease 0.261 0.279 0.596 
Oncologist gender 0.454 0.421 0.840 
Oncologist grade 0.657 0.888 0.489 
 
Role Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.769 0.269 0.348 
    
Patient gender 0.087 0.452 0.974 
Age 0.073 0.648 0.649 
Diagnosis 0.984 0.838 0.987 
Performance Status 0.45 0.369 0.105 
Extent of disease 0.452 0.565 0.188 
Oncologist gender 0.870 0.879 0.468 
Oncologist grade 0.081 0.694 0.460 
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Emotional Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study Arm 0.219 0.35 0.982 
    
Patient gender 0.53 0.629 0.178 
Age 0.192 0.152 0.799 
Diagnosis 0.737 0.407 0.696 
Performance Status 0.911 0.424 0.202 
Extent of disease 0.552 0.471 0.089 
Oncologist gender 0.043 0.485 0.111 
Oncologist grade 0.570 0.159 0.190 
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Appendix 5 Prevalence and Severity of Symptoms and Functions 
Reported by Patients 
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Appendix 6 Association between severity of patient reported 
symptoms/functions and clinic discussion  
 
Method 
 
Subgroup analyses were performed on patients in Intervention and Attention-Control 
arms (n=146). Multivariate logistic regression was used to investigate the association 
between severity of problems and the clinic discussion content.  Potential covariates 
(age, gender, diagnosis, performance status, extent of disease, discussion of 
respective symptom/function at baseline, oncologist gender and grade) were identified 
by univariate regression, with particular symptom/function discussed or not as the 
outcome variable.   
 
In the multivariate regression model, outcome variable was whether a 
symptom/function was discussed or not and the independent variables were 
questionnaire score for relevant symptom/function, study arm and significant covariates 
(p<0.1). Variables which were significant at minimum of two time points were planned 
to be included in the multivariate model. These variables have been highlighted by 
bold text. Analysis was repeated for all symptoms and functions at each consultation.   
 
A significance level of p<0.01 was used in the multivariate analysis to adjust for 
multiple tests.  Variables which were significant at minimum of two time points have 
again been highlighted by bold text in the multivariate models. 
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Univariate analysis 
 
Fatigue 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.1 0.037 0.067 
Age 0.347 0.430 0.606 
Diagnosis 0.477 0.934 0.331 
Performance status 0.924 0.958 0.787 
Extent of disease 0.08 0.921 0.717 
Baseline fatigue 
discussed 
0.002 0.041 0.029 
Oncologist gender 0.079 0.010 0.228 
Oncologist grade 0.200 0.107 0.949 
 
Results of multivariate analysis 
Fatigue 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.466 0.781 0.051 
Fatigue score 0.239 0.002 0.003 
Gender 0.343 0.125 0.272 
Baseline fatigue 
discussed 
0.008 0.062 0.092 
Oncologist gender 0.111 0.003 0.816 
 
Univariate analysis 
Dyspnoea 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.228 0.898 0.668 
Age 0.550 0.048 0.530 
Diagnosis 0.826 0.410 0.800 
Performance status 0.040 0.111 0.174 
Extent of disease 0.661 0.485 0.136 
Baseline dyspnoea 
discussed 
0.003 0.024 0.153 
Oncologist gender 0.008 0.246 0.962 
Oncologist grade 0.747 0.050 0.946 
 
Results of multivariate analysis 
Dyspnoea 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.008 0.753 0.413 
Dyspnoea score 0.01 0.001 0.001 
Baseline dyspnoea 
discussed 
0.011 0.092 0.434 
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Univariate analysis 
Insomnia 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.078 0.110 0.561 
Age 0.939 0.047 0.877 
Diagnosis 0.649 0.894 0.364 
Performance status 0.753 0.737 0.169 
Extent of disease 0.565 0.910 0.183 
Emotional function 
score 
0.055 0.037 0.242 
Anxiety score 0.153 0.004 0.461 
Depression score 0.01 0.013 0.643 
Baseline insomnia 
discussed 
0.051 0.002 0.014 
Oncologist gender 0.839 0.357 0.961 
Oncologist grade 0.041 0.475 0.270 
 
Results of multivariate analysis 
Insomnia 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.642 0.560 0.002 
Insomnia score 0.002 0.002 0.512 
Emotional function 
score 
0.410 0.825 0.207 
Depression score 0.136 0.431 0.624 
Baseline insomnia 
discussed 
0.171 0.007 0.004 
 
Univariate analysis 
Pain 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.304 0.878 0.432 
Age 0.994 0.270 0.807 
Diagnosis 0.641 0.173 0.108 
Performance status 0.527 0.878 0.062 
Extent of disease 0.087 0.093 0.068 
BL pain m/d 0.639 0.009 0.521 
Oncologist gender 0.703 0.522 0.151 
Oncologist grade 0.622 0.063 0.192 
 
Results of multivariate analysis 
Pain 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.901 0.626 0.836 
Pain score <0.0001 0.001 <0.0001 
Extent of disease 0.125 0.152 0.137 
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Univariate analysis  
Nausea + Vomiting 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.420 0.160 0.097 
Age 0.828 0.383 0.814 
Diagnosis 0.086 0.762 0.644 
Performance status 0.864 0.490 0.747 
Ext of disease 0.556 0.689 0.591 
Baseline nausea 
discussed 
0.0005 0.0005 0.035 
Oncologist gender 0.906 0.246 0.024 
Oncologist grade 0.447 0.534 0.368 
 
Results of multivariate analysis 
Nausea + Vomiting 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.142 0.519 0.578 
Nausea + vomiting 
score 
0.056 0.006 0.004 
Baseline nausea 
discussed 
0.004 <0.0001 0.074 
 
Univariate analysis  
Bowels 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.274 0.367 0.166 
Age 0.285 0.321 0.381 
Diagnosis 0.472 0.132 0.226 
Performance status 0.110 0.153 0.537 
Ext of disease 0.477 0.598 0.121 
Baseline bowels 
discussed 
0.003 0.007 0.001 
Oncologist gender 0.624 0.115 0.635 
Oncologist grade 0.614 0.128 0.949 
 
Results of multivariate analysis 
Bowels 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.885 0.752 0.137 
Diarrhoea score 0.055 0.044 0.076 
Constipation score 0.001 0.015 0.030 
Baseline bowels 
discussed 
0.023 0.023 0.006 
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Univariate analysis  
Anorexia 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.075 0.946 0.946 
Age 0.161 0.005 0.061 
Diagnosis 0.519 0.732 0.155 
Performance status 0.020 0.748 0.705 
Extent of disease 0.660 0.331 0.331 
Baseline anorexia 
discussed 
0.011 0.013 0.070 
Oncologist gender 0.895 0.392 0.518 
Oncologist grade 0.883 0.895 0.176 
 
Results of multivariate analysis 
Anorexia 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.619 0.687 0.171 
Anorexia score <0.0001 0.753 0.01 
Age 0.228 0.015 0.141 
Baseline anorexia 
discussed 
0.394 0.069 0.187 
 
Univariate analysis  
Physical Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Patient gender 0.619 0.414 0.777 
Age 0.416 0.848 0.015 
Diagnosis 0.938 0.677 0.682 
Performance status 0.153 0.864 0.390 
Extent of disease 0.086 0.538 0.423 
Baseline physical 
function discussed 
0.459 0.025 0.055 
Oncologist gender 0.665 0.125 0.166 
Oncologist grade 1.0 0.206 0.848 
 
Results of multivariate analysis 
Physical Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.704 0.684 0.704 
Physical function score 0.085 0.622 0.003 
Baseline physical 
function discussed 
0.734 0.037 0.223 
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Univariate analysis  
Social Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.495 0.155 0.598 
Age 0.498 0.013 0.266 
Diagnosis 0.167 0.499 0.875 
Performance status 0.370 0.159 0.965 
Extent of disease 0.912 0.704 0.502 
Baseline social 
function discussed 
0.008 0.032 0.012 
Oncologist gender 0.382 0.754 0.274 
Oncologist grade 0.653 0.906 0.008 
 
Results of multivariate analysis 
Social Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.971 0.208 0.808 
Social function score 0.91 0.306 0.644 
Baseline social function 
discussed 
0.01 0.05 0.013 
 
Univariate analysis  
Role Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.751 0.818 0.997 
Age 0.036 0.102 0.772 
Diagnosis 0.092 0.129 0.533 
Performance status 0.034 0.211 0.182 
Extent of disease 0.652 0.581 0.714 
Baseline role function 
discussed 
0.055 0.764 0.883 
Oncologist gender 0.051 0.614 0.932 
Oncologist grade 0.104 0.075 0.281 
 
Results of multivariate analysis 
Role Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.022 0.578 0.799 
Role function score 0.224 0.756 0.672 
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Univariate analysis  
Emotional Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Gender 0.377 0.345 0.032 
Age 0.210 0.738 0.490 
Diagnosis 0.997 0.689 0.874 
Performance status 0.705 0.302 0.239 
Extent of disease 0.077 0.502 0.906 
Baseline emotional 
function discussed 
0.002 0.08 0.685 
Oncologist gender 0.339 0.037 0.484 
Oncologist grade 0.650 0.644 0.630 
 
Discussion of Emotional functioning was linked to the EORTC QLQ-C30 emotional 
functioning score, HADS anxiety and HADS depression scores.  As these are expected 
to be highly correlated, we examined three multivariate models with each variable as 
predictor. 
Results of multivariate analysis (EORTC QLQ-C30 Emotional Function score) 
Emotional Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.658 0.199 0.643 
Emotional function 
score 
0.023 0.394 0.410 
Baseline emotional 
function discussed 
0.011 0.095 0.778 
 
Results of multivariate analysis (HADS Anxiety score) 
Emotional Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.425 0.140 0.597 
Anxiety score 0.003 0.053 0.273 
Baseline emotional 
function discussed 
0.009 0.141 0.818 
 
Results of multivariate analysis (HADS Depression score) 
Emotional Function 
 Consultation 1 Consultation 2 Consultation 3 
 p p p 
Study arm 0.475 0.160 0.682 
Depression score 0.023 0.526 0.602 
Baseline emotional 
function discussed 
0.01 0.077 0.646 
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Appendix 7 Graphical representation of the relationship between 
severity of symptoms and clinic discussions at second and third 
consultations 
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Appendix 8 Clinical scenarios for trigger DVDs 
 
Scenario A 
Mary Taylor 51 year old lady with metastatic breast cancer 
Information given to doctor: 
 
Breast Cancer History 
 
1. Diagnosed at the age of 45 with ductal carcinoma of left breast.   
T1 (19mm) G3 N2 (4/16) ER Positive HER2 Negative. 
 
2. Underwent left mastectomy with immediate reconstruction. 
 
3. Adjuvant chemotherapy with FEC x 6 cycles 
 
4. Adjuvant hormone therapy with Tamoxifen for 5 years. 
 
5. Metastatic disease diagnosed 12 months ago – Developed left sided SCF nodes 
which were biopsy positive.  Restaging CT and bone scan revealed lung mets.  No 
other visceral or bone disease. 
 
6. Started on Arimidex with initial response which was clinically assessable with the left 
SCF nodes and with regular CXR.   
 
7. Clinical disease progression was evident after 9 months.  Restaging CT scan did not 
reveal new sites of disease.  She had shortness of breath and cough which was 
thought to be due to the lung mets. 
 
8. Started on Docetaxel 6 weeks ago.  Attends for review prior to cycle 3.   
 
 
Social Background 
 
Used to work as a practice nurse in a GP surgery 
Never married.  No children.  Next of kin is an aunt living in Scotland. 
Socially quite isolated 
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Information given to simulated patient: 
 
You are Miss Mary Taylor, a 51 year old lady with advanced breast cancer.  You work 
part time as a practice nurse at a GP surgery.  Recently you have been on sick leave.   
 
Your breast cancer was originally diagnosed 6 and half years ago, when you noticed a 
lump in your left breast whilst in the shower.  After the biopsy, confirming the cancer 
diagnosis, you had your left breast surgically removed (mastectomy) and had 
reconstruction at the same time.   
 
After the operation, you were told the cancer had spread to the lymph nodes in your 
arm pit (axilla) with 4 of the 16 lymph nodes removed being positive for cancer cells 
and you were recommended to have chemotherapy to try and reduce the risk of the 
cancer coming back.   
 
You received 6 cycles of chemotherapy with 3 agents (5FU, Epirubicin and 
Cyclophosphamide) abbreviated to FEC.  These were given as injections into the vein 
every 3 weeks.  You recall that chemotherapy made you slightly sickly and tired but 
you got through the treatment without any other major problems.  You were then given 
a hormone tablet called Tamoxifen, which you took every day for 5 years.   
 
You were very relieved when you completed your treatment.  You were discharged 
from routine follow up thereafter. 
 
About a year ago, you noticed a hard pea sized lump on the left side of your neck, just 
behind your collar bone, which grew in size over a period of few weeks.  Your GP sent 
you to an ENT (Ear Nose and Throat) surgeon urgently and he arranged for you to 
have a biopsy of this lump.  This was actually an enlarged lymph node and the result 
came back showing that the breast cancer had come back.   
 
You were then referred back to the cancer specialist, who had discharged you after you 
completed the Tamoxifen.  He organised a CT scan and bone scan and this came back 
showing that there was cancer recurrence within your chest (lungs) also.  You had 
some cough at the time and this was the likely cause for your symptoms.  
 
You were told by the doctor that they cannot cure you but they can give you treatment 
which can control the cancer. 
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The news of cancer recurrence left you feeling anxious and overwhelmed, you had 
many concerns about how you would cope both physically and emotionally but felt that 
you could not verbalise them with the doctors or nurses. 
 
You started on a hormone treatment called “Arimidex”, a tablet form of treatment which 
you had to take once a day.  This worked well for about 9 months with obvious 
shrinkage of the lymph node but you noticed that your lymph node was getting bigger 
again.  Around the same time, you were starting to feel more breathless and you 
started to have trouble with dry cough.  This was reflected on your chest x ray which 
showed that your lung disease was deteriorating. You found this very frightening and at 
first tried to tell yourself that it wasn’t really happening and that the lymph node had not 
increased in size however eventually you had to admit to yourself that it was getting 
bigger and that you were less well. 
 
You had a CT scan to confirm the above finding.  You could not sleep during the week 
leading up to the CT scan dreading that it would confirm bad news. This did not show 
any new sites of disease but confirmed your worst fears that things were deteriorating. 
 
You were recommended to have some chemotherapy and were started on a drug 
called “Taxotere”.  This was decided after you had a long discussion with the cancer 
specialist who thought that chemotherapy was likely to work quicker and hopefully 
alleviate some of your symptoms quicker compared to trying a different hormone tablet. 
 
You have now had 2 cycles of this treatment and tolerated it reasonably well.  You 
have had some minor discomfort in your joints for a few days after the chemotherapy 
but this has now subsided. You have sometimes had a throbbing sensation in your 
lymph node in your neck but you have noticed that the node is shrinking in size; you 
look at this as a good sign but you cannot get the doctors statement that your disease 
is not curable out of your mind. 
 
You used to work as a practice nurse at a GP surgery.  You have been working part 
time after your breast cancer recurrence was diagnosed whilst you were on your 
Arimidex tablets but have been on sick leave since you have started on chemotherapy. 
During your professional life you have seen a number of patients die from cancer and 
keep thinking that this is your fate. You recall patients who have died with severe pain. 
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You were never married and live alone in a flat.  You have no children and your closest 
relative is an aunt living in Scotland, she is in her 70s and you feel it would be wrong to 
burden her with your problems.   
 
You are somewhat socially isolated, and this has worsened since you have stopped 
working and started chemotherapy.  
 
Your mood is low; you are getting very little enjoyment from anything, including 
television programmes you always enjoyed (e.g. soaps).  You find that you cannot look 
forward to things any more (e.g. visits from work colleagues which you have actually 
discouraged). Previously you took pride in your appearance but recently making the 
effort has all been too much and you have not worn makeup for several weeks. Your 
sleep has deteriorated; you get off to sleep but wake in the early hours and cannot get 
back to sleep again. You find your thoughts frightening being unable to take your mind 
off memories of patients you have known with cancer who died and all the problems 
they faced. You keep returning to things in your life where you feel you have failed – 
you blame yourself for all the failed relationships in your life and don’t believe you are 
worth knowing. You have thought about your own death and found this very frightening 
– both in terms of how you might die but also what being dead actually means. Part of 
you thinks it might be better to get it all over with and die soon but you have not had 
any thoughts about harming yourself. 
 
Current List of Medications 
 
 Paracetamol 500mg tablets 2 tablets as required up to 4 times/day 
(Pain killer) 
 
 Ibuprofen 200mg tablets 2 tablets as required up to 3 times/day 
(Pain killer for joint pains) 
 
 Domperidone 10mg tablets  1 tablet as required up to 4 times/day 
(Anti-sickness - You have not needed to take this very often) 
 
 Mouth wash 1 capful 4 times/day 
 
 Dexamethasone 2mg tablets 4 tablets twice a day for 3 days 
 
(Steroid tablets as part of the chemotherapy treatment - Taken twice a day starting the 
day before the chemotherapy for 3 days) 
  
287 
 
 
Scenario A Questionnaire Output 
 
 
 Mild      66.8 - 100            Moderate       33.4 – 66.7       Severe       0 – 33.3 
 
 Mild       0 – 33.3           Moderate       33.4 – 66.7       Severe       66.8 – 100 
 
Functioning Impairment: higher scores mean better functioning
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Pre cycle 1 41.7 16.7 50 66.7 16.7 16.7
Pre cycle 2 41.7 16.7 41.7 66.7 16.7 16.7
Pre cycle 3 33.3 1 41.7 50 16.7 1
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Role 
Functioning
Emotional 
Functioning
Cognitive 
Functioning
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Global QoL
Symptom Scores: Higher scores mean worse symptoms
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Pre cycle 1 66.7 1 16.7 100 66.7 66.7 1 0 1
Pre cycle 2 88.9 66.7 16.7 100 66.7 100 1 66.7 1
Pre cycle 3 100 33.3 16.7 66.7 100 100 1 66.7 1
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Nausea+Vo
miting
Pain SOB Sleep Appetite Constipation Diarrhoea Finance
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 Mild 0 – 7       Moderate  8 – 10   Severe          >11 
 
  
HADS
0
5
10
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20
Pre cycle 1 4 10
Pre cycle 2 5 11
Pre cycle 3 4 13
Anxiety Depression
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Scenario B 
 
James Kitching 63 year old man with metastatic leiomyosarcoma 
 
Information given to the doctor: 
 
Sarcoma History 
 
1. Diagnosed with T1b (40mm) G3 (stage II) leiomyosarcoma arising from left thigh 18 
months ago.   
 
2. Underwent excision followed by adjuvant radiotherapy. 
 
3. Asymptomatic lung mets diagnosed through routine CXR about 2 months ago, which 
was arranged by the GP as the patient has developed sinus symptoms 
 
4. Restaging CT scan shows no disease outside of the lungs. 
 
5. He has been commenced on palliative chemotherapy with single agent Doxorubicin 
3 weeks ago. 
 
6. Attends for review prior to 2nd cycle of chemotherapy 
 
 
Social background 
 
Very fit man who enjoyed many sports throughout his life.   
Took early retirement after diagnosis of cancer 
Married and lives with his wife.  
He has 3 children all living in Yorkshire. 
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Information given to simulated patient number 1 (Mr Kitching): 
 
You are Mr. James Kitching, a 63 year old retired postman.  You noticed a lump on 
your inner left thigh about 18 months ago.  You went to see your GP straight away as it 
was rubbing on your bicycle seat when you were doing your post delivery and it caused 
you discomfort. 
 
The doctor looked rather worried when he saw the lump as it was very hard and you 
were referred to an orthopaedic surgeon fairly promptly.   
 
After you saw the surgeon, he organised for you to have a scan called a Magnetic 
Resonance Scan.  This was a very noisy scan in which you had to lie still for about 30 
minutes.  You then went onto have a biopsy of the lump, which confirmed that it was 
cancerous. 
 
You then went on to have a big operation to remove the lump, which was about a size 
of a golf ball by the time you had it removed.  You were told that the cancer had arisen 
from your muscle in your thigh and it was called Leiomyosarcoma. 
 
After the operation, you had radiotherapy to try and reduce the risk of the cancer 
coming back in the same place. 
 
You recovered from this operation well and tolerated the radiotherapy afterwards but 
you decided to take early retirement thereafter. 
 
You developed some symptoms of sinus irritation associated with a bit of a cough and 
went to see your GP about 6 weeks ago.  Your GP was quite thorough and suggested 
that you have a routine chest x ray. 
 
Unfortunately, this revealed that the cancer had come back in your lungs and your 
follow up appointment with the cancer specialist was brought forward.  You underwent 
a CT scan and this did not show any disease outside of your lungs. 
 
You were rather baffled as you felt very well.  Antibiotics soon sorted out the sinus 
problems and the cough also stopped. 
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You have been started on chemotherapy with a drug called Doxorubicin and you have 
completed your first cycle.  Doxorubicin is given as an injection into the vein by the 
chemotherapy nurse over about 10 minutes and is administered as an out-patient.  The 
drug is red in colour and can sometimes stain your body fluid (for example, urine).  You 
are due to attend for a review prior to your 2nd cycle. 
 
You had read the information about this drug, telling you all sorts of possible side 
effects but you have actually had no major problems at all.  You did have some sickly 
feeling for a few days but you were not sick.  You have felt a little off food and noticed 
some changes in the way it tasted.  You are slightly bothered by the fact that your hair 
is thinning.  You had a moustache which you were quite proud of but you decided to 
shave it off when you started the treatment as you were told that chemotherapy would 
affect your facial hair. 
 
You have always been a very fit man, who enjoyed many sports throughout your life.  
You were able to play football with your grandchildren every week but you have felt a 
little more tired since the chemotherapy and have not been as active. 
 
You are married and have 3 children (2 sons, Daniel and Andrew and a daughter Ruth) 
all living close by.   
 
You had been worried about how chemotherapy may affect you but having had the first 
cycle and managed it reasonably well you are feeling quite relieved.  However, at the 
same time, the enormity of your current situation (recurrence of cancer) is beginning to 
sink in.   
 
At the time of recurrence you remember being told that the cancer could not be cured 
but did not wish, at that time, to know more. 
 
Your daughter is getting married in 9 months time and you have been wondering as to 
how you might be physically then.  You feel that you need to concentrate on the 
treatment at the moment but this is something that you have on the back of your mind. 
 
Now you feel that a more in-depth discussion would be helpful as there are decisions to 
be made about your will, a family holiday and how you no longer being around will 
impact on others, particularly your children.  
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Current Medication 
 
 Domperidone 10mg (Anti-sickness tablets) 1 tablet to be taken when required up to 4 
times a day 
 
(You were advised to take these tablets for the first 24 hours after the chemotherapy 
but you have not needed to take them regularly thereafter) 
 
 
Information given to simulated patient number 2 (Mrs Kitching): 
 
You are Elaine Kitching, wife of James Kitching. 
 
Your husband, James, was diagnosed with a type of cancer called Leiomyosarcoma 
about 18 months ago.   
 
You remember him complaining of a lump on the inner left thigh which was rubbing on 
his bicycle seat when he was doing the post delivery round. 
 
James had arranged to see a doctor straight away, who quickly referred him to an 
orthopaedic surgeon.  He underwent various tests which confirmed that this lump in his 
thigh was a cancerous lump. 
 
The diagnosis came as a shock to both James and yourself.  However, it seemed as 
though James’ cancer was caught at relatively early stage and the doctors seemed 
optimistic that James will do well. 
 
You were shocked when you heard that James was diagnosed with recurrence of his 
sarcoma, particularly because he had been very well with no warning signs 
whatsoever.  You were devastated when you were told by the doctor that his condition 
was not curable and that treatment was mainly to try and control the behaviour of the 
cancer and hopefully buy James “some time”. 
 
You are still coming to terms with the fact that James has incurable cancer but you find 
this very hard to believe as James remains very well.  You were naturally very pleased 
to see how well James has tolerated the first cycle of chemotherapy, having read all 
the possible things that could happen to him.  You had been anxious as to how you 
might cope yourself if he had become poorly after the chemotherapy.   
 
You were very upset when he shaved off his moustache as this was his characteristic 
feature and this reminded you that he was on chemotherapy. 
 
Your daughter, Ruth is getting married in 9 months time.  Although you try and remain 
optimistic and strong, you are anxious as to how James might be then.  You have had 
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awful thoughts cross your mind that James might not be alive to see Ruth get married.   
You are also scared of losing him. 
 
James’s Current Medication 
 
 Domperidone 10 mgs (Anti-sickness tablets) 1 tablet to be taken when required up to 
4 times a day 
 
(He was advised to take these tablets for the first 24 hours after the chemotherapy but 
he has not needed to take them regularly thereafter) 
 
Scenario B Questionnaire Output 
 
Mild      66.8 - 100             Moderate       33.4 – 66.7       Severe       0 – 33.3 
 
 
Functioning Impairment: Higher scores mean better 
functioning
0
10
20
30
40
50
60
70
80
90
100
Pre cycle 2 100 100 75 100 100 83.3
Physical 
Functioning
Role 
Functioning
Emotional 
Functioning
Cognitive 
Functioning
Social 
Functioning
Global QoL
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 Mild       0 – 33.3           Moderate       33.4 – 66.7       Severe       66.8 – 100 
 
 
 
 Mild 0 – 7     Moderate 8 – 10   Severe          >11  
Symptom Scores: Higher scores mean worse symptoms
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Scenario C 
 
Pauline Barker 70 year old lady with advanced ovarian cancer 
 
Information given to doctor: 
 
Ovarian cancer history 
 
1. Admitted via A+E with subacute bowel obstruction.  Found to have pelvic mass 
with omental disease.  CA125 >3000 
 
2. Primary surgery unsuccessful due to tumour causing frozen pelvis – 
defunctioning ileostomy formation 
 
3. Problems with high output stoma 
 
4. Started on single agent Carboplatin 
 
5. Attends for review prior to cycle 3 
 
Social Background 
Lives with elderly husband, who is also recovering from recent abdominal surgery.  
Mrs. Barker was his main carer. 
3 children all living outside of Yorkshire – one lives in Manchester 
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Information given to simulated patient: 
 
You are a 70 year old lady called Mrs Pauline Barker who has been diagnosed with 
advanced stage ovarian cancer.   
 
You were initially admitted via the accident and emergency department 10 weeks ago, 
when you developed pain in your tummy area with vomiting for 3 days.   
 
You had several tests after you were admitted under the General Surgical doctors, 
including a CT scan.  This revealed that you had a tumour in your right ovary with 
evidence of spread within your abdomen.  You were told at this stage that this was 
likely to be advanced ovarian cancer and you were subsequently referred to the 
gynaecology surgeons. 
 
You were very shocked to hear this news.  In hindsight, you have had vague tummy 
discomfort for 6 months or so but you thought this was due to the fact that you had 
been going through stressful time with your husband also being unwell and requiring 
surgery.  He has history of gall stones, which caused pancreatitis (significant 
inflammation of the pancreas) and he was in a lot of pain.  He was on various drips in 
the hospital.  He developed complication from his pancreatitis which required surgery.  
All this had made your husband very weak and dependent on your help. 
 
You had a discussion with the gynaecology surgeon and it was suggested that the best 
approach would be an operation because the bowel had become twisted and this was 
causing your pain and vomiting.  He painted a reasonably optimistic picture that the 
operation will help with your symptoms and that they will probably be able to take most 
of the cancer away. 
 
Although you were warned of the possibility of a stoma (bag attached through your skin 
directly to your bowel to collect its contents, which is worn under your clothes, you were 
devastated to see the stoma when you woke up from the anaesthetic after the 
operation.  To make the situation worse, you were told by the surgeon that the cancer 
had caused everything to stick together and that they actually could not remove any of 
the cancer.  So you were left with a stoma, which was producing very watery green 
stools, and none of the cancer being removed from your body. 
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After the operation, you struggled to come to terms with your stoma.  It was producing 
large volume of watery stools and you needed to change the bag almost every hour.  
You were seen by the stoma nurse regularly to try and deal with this but you became 
naturally very distressed when the stoma leaked.  Even by the time you were 
discharged from hospital, you were not really confident about dealing with the stoma 
yourself. You feel that people will know you have a stoma and be able to smell it; this 
makes you reluctant to socialise. You also found it very difficult to look at your body in a 
mirror. 
 
You were referred to one of the cancer specialists (oncologist) who talked about giving 
chemotherapy to try and shrink the cancer.  You were told that the cancer was not 
curable.  Although you knew this, it was nevertheless painful to hear it again.   
 
You were told that you had a reasonable chance of response to the chemotherapy and 
that if you respond well then there might be a possibility that the stoma could be 
reversed and joined up.  
 
You were given information about a drug called Carboplatin, which is a drug given via 
the drip over 30 minutes.  You were told that the side effects from this chemotherapy 
were reasonably manageable and that you weren’t going to lose your hair. 
 
You were also told that the dose of this drug depended on your kidney function and 
because the doctors were worried about the volume of fluid you were passing through 
the stoma each day and the possible impact it may have on your kidney function, they 
decided to do a special kidney function test which required you to come into the 
hospital for a day and have 3 blood tests.   
 
You were also asked to go to your doctors’ surgery 10 days after each cycle of 
chemotherapy to check your kidney function and your blood counts to make sure that 
your body was handling the chemotherapy drug ok. 
 
You have now had 2 cycles of chemotherapy.  You have tolerated the chemotherapy 
reasonably well with little in the way of side effects but you are struggling with the 
watery stools from your stoma.   
 
The bags fill up quite quickly over night and you are up couple times during the night to 
change the bag.  This is making you feel very tired.  You have started to sleep in a 
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separate bedroom from your husband as you are concerned that you would disturb his 
sleep also.   
 
You have also noticed that you are becoming breathless, especially on walking, even 
after short distance in the house. 
 
You feel embarrassed and afraid that people could smell your stools when you are out.  
You had had problems with it leaking few times.  You have now become quite 
withdrawn and fears whenever you need to go out.  You are becoming increasingly 
dependent on your husband, who is also recovering from surgery himself. 
 
Your son, who lives in Manchester, has been arranging your grocery shopping on the 
internet, which has helped to some extent.   
 
You have stopped seeing your friends.    
 
You have been told by the doctors that you must try and drink plenty but you find this 
quite difficult because you feel the more you drink, the more watery stool you will pass. 
 
You are clinging on the hope that this stoma can be reversed and desperate that the 
chemotherapy is working. 
 
Current Medication 
 
 Codeine Phosphate 30 mg tablets  2 tablets four times/day 
(These are pain killers but one of their side effects is constipation.  You have been 
given these to try and slow down your bowel movement) 
 
 Imodium 2mg tablets 1 tablet 4 times/day 
(These are tablets for diarrhoea.  You have been given these to slow down your bowel 
movement) 
 
 Cyclizine 50 mg tablets 1 tablet up to 3 times/day when needed 
(These are anti-sickness tablets given with your chemotherapy.  You have not needed 
to take many of these tablets) 
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Scenario C Questionnaire Output 
 
 Mild      66.8 - 100           Moderate       33.4 – 66.7       Severe       0 – 33.3 
 
 
 Mild       0 – 33.3         Moderate       33.4 – 66.7       Severe       66.8 – 100 
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 Mild       0 – 7  Moderate 8 – 10   Severe          >11 
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Pre cycle 2 13 11
Pre cycle 3 13 13
Anxiety Depression
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Scenario D 
 
Janet Roberts, 45 year old lady with metastatic breast cancer 
 
Information given to doctor: 
 
Breast cancer history 
 
1. Diagnosed with metastatic breast cancer 2 years ago.  Triple receptor negative 
disease. 
 
2. Has received 2 lines of palliative chemotherapy so far. 
 
3. Presented with discomfort in right hip.  Restaging revealed progressive bone 
disease.  Started on further palliative chemotherapy with ECF. 
 
4. Attends for review prior to second cycle of chemotherapy 
 
Social Background 
 
Single parent.  Has a daughter currently studying for A-levels. 
 
Had been working as a part time dinner lady in a primary school  
 
On sick leave since starting ECF chemotherapy. 
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Information given to simulated patient: 
 
You are Miss Janet Roberts.  You are 45 years of age and a single parent with a 
teenage daughter, Anne, who is currently studying for her A-Levels. 
You were diagnosed just over 2 years ago (October 2007) with advanced breast 
cancer which had spread to your liver and bones.   
You developed some right sided tummy/stomach pains and your GP organised for you 
to have an ultra sound scan (like what the pregnant ladies have) which showed that 
there were secondary cancers within the liver.  You were referred to a specialist who 
examined you and found a lump in your left breast.  A biopsy from this showed that you 
had breast cancer.  You had other investigations (scans) which showed that the cancer 
had also spread to the bones. 
You were told at that your cancer was treatable but not curable. 
You have previously had 2 courses of chemotherapy in the past.  First was a 
combination of 2 drugs called Epirubicin and Cyclophosphamide and the second 
course was with a drug called Taxotere.   
 
Rough dates 
Nov 07 – Mar 08: Epirubicin and Cyclophosphamide 
Jan 09 – Apr 09: Taxotere 
 
You have been reasonably well up until 6 weeks ago when you started to have 
increasing discomfort in your right hip.  This has led to further tests (CT scan and bone 
scan) which have shown that your cancer in the bones has got worse particularly in the 
right pelvis, which was thought to be the cause of your discomfort.  The disease in your 
liver had not changed. 
You were not surprised about the result of the scan but was very disappointed as it has 
only been about 5 months since you had completed previous course of chemotherapy.  
You had hoped that the cancer would be controlled for longer. 
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You have been started on a combination of chemotherapy with Epirubicin, Cisplatin 
and 5-FU.  You were told that this was going to be more complicated than your 
previous chemotherapy treatments.   
 
You were told you needed a heart scan before the treatment was started.  This showed 
that your heart was completely normal. 
 
In order to start this chemotherapy, you also had to have a special tube inserted 
through your chest into one of the big veins near your heart called a Hickman Line.  
You have to be admitted to hospital for the first 2 days of the 3 weekly cycle and you 
are connected to a 5FU pump which needed changing every week, which meant that 
you needed to visit the hospital every week.   
 
You have tolerated the chemotherapy reasonably well, although you did have some 
sickness for few days after the chemotherapy.  You have not been sick.  Your hair is 
starting to come out.   
 
The main problem you have at present is the “ache” in your right hip.  This is limiting 
your mobility and hence affecting many aspects of your activities of daily living.  The 
discomfort sometimes makes you feel nauseous and is generally making you feel 
miserable. 
 
You perceive this as an “ache” rather than “pain” and therefore have not been reaching 
out for pain killers (as you don’t really like taking tablets anyway).  You feel that there 
will come a time when you will have “pain” and you don’t want to take the pain killers 
until such time for fear that they will become less effective later on, although this 
“discomfort” is actually causing quite a lot of problems. 
 
Your daughter Anne is 17 and she is studying for her A-levels.  Her father is not on the 
scene but provides a small maintenance.  She is reasonably self sufficient but you 
have good friends who can see to her if needed.   
 
You have been working at a primary school as a dinner lady 3 days a week.  Since 
starting this ECF chemotherapy you have been unable to work and had to go on sick 
leave.  This has led to some financial difficulties.  (Food costs, bus fares to hospital, 
Anne’s Geography field trip etc) 
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You are generally anxious about the future; about what the future holds for you and the 
welfare of your daughter. You want to live for as long as possible and would like to see 
your daughter go to university and even get married and have children. You are able to 
hold these positive thoughts most of the time (often telling yourself that it is possible to 
live for many years with breast cancer – look at Jane Tomlinson) but sometimes at 
night doubts creep in and you worry that your daughter will have to find her own way in 
life and that it is extremely unlikely that you will see your grandchildren. 
 
Current Medication 
 
 Domperidone 10 mg Tablets 1 tablet when needed up to 4 times a day 
(These are anti-sickness tablets, which you have taken occasionally when you felt sick 
with the discomfort in your hip) 
 
 Paracetamol 500 mg Tablets 2 tablets when needed up to 4 times a day 
(These are pain killers.  You have not taken these as you have “discomfort” rather than 
“pain”.  You feel that there will come a time when you will need to take pain killers in 
the future and want to try without them as long as possible)  
 
 Chlorhexidine mouthwash capful up to 4 times a day as required 
(This is mouthwash for when your mouth gets sore during chemotherapy) 
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Scenario D Questionnaire Output 
 
 Mild      66.8 - 100              Moderate       33.4 – 66.7       Severe       0 – 33.3 
 
 
 Mild       0 – 33.3           Moderate       33.4 – 66.7       Severe       66.8 – 100 
 
Functional Impairment: Higher scores means better functioning
0
10
20
30
40
50
60
70
80
90
100
Pre cycle2 33.3 33.3 83.3 83.3 16.7 33.3
Physical 
Functioning
Role 
Functioning
Emotional 
Functioning
Cognitive 
Functioning
Social 
Functioning
Global QoL
Symptom scores:Higher scores mean worse symptoms
0
10
20
30
40
50
60
70
80
90
100
Pre cycle2 55.6 16.7 33.3 33.3 66.7 1 33.3 1 100
Fatigue
Nausea+
Vomiting
Pain SOB Sleep Appetite
Constipa
tion
Diarrhoe
a
Finance
306 
 
 
 
 Mild 0 – 7       Moderate  8 – 10   Severe          >11 
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Scenario E 
 
Mrs Sheila Parker, 68 year old lady with advanced bowel cancer 
 
Information given to the doctor: 
 
Bowel cancer history 
 
1. Presented to GP in July with weight loss and upper abdominal discomfort.  
Found to have hepatomegaly.  Referred to GI surgeon. 
 
2. CT scan showed thickening of Sigmoid colon with evidence of multiple liver and 
peritoneal metastases 
 
3. Referred to Medical Oncology for palliative chemotherapy 
 
4. Completed 6 cycles of chemotherapy with OxaliCap 
 
5. Attends for review with CT scan report. 
 
Social Background 
 
Widow.  Husband died following CVA 12 months ago.  Daughter (Mary Robinson) lives 
about 10 minutes away. 
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Information given to simulated patient number 1 (Mrs Sheila Parker): 
 
You are Mrs. Sheila Parker, a 68 year old woman with advanced bowel cancer.   
 
You initially visited your GP approximately 5 months ago, as your daughter was 
concerned that your appetite was diminishing and you were losing weight.  You also 
started to get some discomfort in your upper abdomen with indigestion, which were all 
new symptoms for you.  In hind sight, you probably also had a change in your bowel 
habits for about 6 months prior to this, with intermittent episodes of diarrhoea and 
constipation for no apparent reason.  You thought this was related to the bereavement 
after your husband Peter passed away, rather unexpectedly, after suffering a stroke.   
 
When you were seen by your GP, she was very worried as she was able to feel your 
enlarged liver. 
 
Your GP sent you to see a surgeon, Mr. Jayne, who arranged various tests, which 
included a CT scan and a colonoscopy (camera in the back passage), following which 
you were told you had advanced bowel cancer, which had spread to the liver and to the 
lining of the bowel called peritoneum.   
 
You were advised to see a cancer specialist (oncologist) who talked to you about 
chemotherapy.  You were told that your condition was not curable.  The aim of the 
treatment would be to try and control the cancer, shrink the disease and hopefully this 
will translate to better outcome overall, i.e. better symptom control and may be prolong 
your life.     
 
You found the diagnosis very hard to take on board, particularly without your husband, 
Peter, by your side.  Although you were scared about having chemotherapy, you 
wanted the best possible treatment to try and prolong your life, so that you might have 
the chance to see your grand children grow up. 
 
You were recommended combination chemotherapy with Oxaliplatin and Capecitabine.  
Oxaliplatin was given via a drip every 2 weeks and Capecitabine, a tablet form of 
chemotherapy you took twice a day by mouth every day. 
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After starting the chemotherapy, you felt very tired, partly because you were not 
sleeping very well.  You were very anxious about all the possible side effects you had 
been warned about.     
 
Starting chemotherapy has impacted significantly on your daily routine as you have had 
to visit the hospital twice every 2 weeks.  First visit to have a blood test to make sure 
you could have the chemotherapy and to see the doctor and the second visit to actually 
receive the treatment. 
 
Chemotherapy was not all that pleasant.  It made you feel rather sickly and gave you 
worsening of the indigestion and diarrhoea.  You got into the routine of taking the 
Imodium tablets as soon as your tummy started to grumble and you seemed to get on 
top of things.  You also had trouble with tingling sensation affecting your fingers and 
toes, especially in the first week after Oxaliplatin. This made things like doing up 
buttons more difficult. Your skin on the palms of your hands was becoming quite dry 
and sore at times. 
 
Despite all the side effects of the treatment, you started to feel better in yourself.  This 
was particularly noticeable after the first 3 cycles of chemotherapy.  Over time, you 
were feeling stronger and your appetite started to return.  Your weight also seemed to 
level out and you were starting to regain the weight you had lost. 
 
You felt you had a little more energy to do things you used enjoy, like going out for a 
walk. 
 
You are anxious about getting the results of the CT scan you had last week to assess 
how well the chemotherapy has worked.  However, you have little doubt that the 
chemotherapy has helped you because you feel much better in yourself. 
 
You were told at the start that you will be given chemotherapy for 3 months, which you 
have now completed and stop thereafter. You are worried as to what’s going to happen 
now.  What the future holds and whether you would be able to have more treatment in 
the future.  
 
Your daughter Mary has invited you on a trip to Northumberland with her family in few 
months time and you are hopeful that you will be well enough to go with them.  
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Current Medication 
 
 Bendrofluazide 2.5 mg tablets 1 tablet once a day  
(This medication is for high blood pressure which you have been taking for many 
years)  
 
 Domperidone 10 mg tablets 1 tablet up to 4 times a day 
(This is anti-sickness medication, given with chemotherapy but you have not needed to 
take them very often) 
 
 Pyridoxine 50mg tablets 1 tablet taken three times a day 
(These are Vitamin tablets, given to you when you started having some soreness in 
your fingers, which you were told was due to the Capecitabine chemotherapy tablets.  
You have been on them for about 4 weeks) 
 
Information given to simulated patient number 2 (Mrs Mary Robinson) 
 
You are Mrs. Mary Robinson, daughter of Mrs. Sheila Parker.  You live about 10 
minutes drive away from your mother.  You are married to John and have 2 children, 
aged 12 and 10. 
 
Your mother was diagnosed with advanced bowel cancer about 5 months ago but you 
recall that she had not been quite right for few months before she was diagnosed 
(going off food, losing weight and complaining of discomfort in his tummy).  You 
encouraged her to seek medical attention after these symptoms persisted for few 
months. 
 
You had general concerns over her health particularly after your father, Peter, passed 
away rather unexpectedly after suffering a stroke.  Your father’s death had impacted on 
the whole family but particularly on your mother.  They had been married for over 45 
years.  You felt that some of the symptoms might be due to bereavement process but 
you had become more concerned when her weight loss became more apparent and 
she started to complain of tummy pains. 
 
You were devastated when your mother was diagnosed with advanced bowel cancer 
and was told by the doctor that her condition was not curable.  You bitterly regretted 
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about not encouraging her to seek medical attention sooner.  The news was also 
extremely upsetting, particularly so soon after the death of your father. 
 
Your mother rarely talked about her illness at home and you could see that she was 
trying to carry on with her usual routine as much as possible.  You know this was partly 
not to make you worry and partly because she was trying to maintain some form of 
normality.  
 
Starting chemotherapy made a significant impact on your lives, however, with 2 visits to 
the hospital every 2 weeks.  One visit for blood tests and a consultation with the doctor, 
and the another visit for the treatment. These visits have been physically challenging 
for your mother and for you in terms of adjusting your working hours so that you were 
able to accompany her to the hospital.  Your husband John has been very supportive. 
 
Although the chemotherapy made your mother rather tired, you started to notice that 
she was eating more and looking a little brighter after 2-3 cycles of chemotherapy. You 
have noticed ongoing improvement particularly over the course of last 3 weeks.  
 
You are hopeful that the CT scan your mother had last week will show good results.  
You and your husband are keen to take her on a short trip to Northumberland during 
your children’s school holidays in couple of month’s time and you are hoping that the 
doctor will say it would not be a problem for your mother to go. 
 
Current Medication Mrs. Sheila Parker is taking 
 
 Bendrofluazide 2.5 mg tablets 1 tablet once a day  
(This medication is for high blood pressure which you have been taking for many 
years)  
 
 Domperidone 10 mg tablets 1 tablet up to 4 times a day 
(This is anti-sickness medication, given with chemotherapy but you have not needed to 
take them very often) 
 
 Pyridoxine 50mg tablets 1 tablet taken three times a day 
(These are Vitamin tablets, given to you when you started having some soreness in 
your fingers, which you were told was due to the Capecitabine chemotherapy tablets.  
You have been on them for about 4 weeks) 
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Scenario E Questionnaire Output 
 
 Mild     66.8 - 100            Moderate      33.4 – 66.7       Severe    0 – 33.3 
 
 
 Mild     0 – 33.3            Moderate      33.4 – 66.7       Severe    66.8 – 100 
Functional Impairment: Higher scores mean betetr functioning
0
10
20
30
40
50
60
70
80
90
100
pre cycle 5 60 50 66.7 66.7 50 66.7
pre cycle 6 73.3 66.7 75 83.3 66.7 75
post cycle 6 93 83 83 100 83.3 91.7
Physical 
Functioning
Role 
Functioning
Emotional 
Functioning
Cognitive 
Functioning
Social 
Functioning
Global QoL
Symptom Scores: Higher scores mean worse symptoms
0
10
20
30
40
50
60
70
80
90
100
pre cycle 5 66.7 33.33 16.7 33.33 66.7 33.33 1 66.7 1
pre cycle 6 33.3 16.7 16.7 1 33.3 1 1 33.3 1
post cycle 6 22 1 1 1 33.3 1 1 1 1
Fatigue
Nausea 
+Vomiting
Pain
Shortness 
of breath
Sleep Appetite Constipation Diarrhoea Finance
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 Mild     0 - 7                 Moderate      8 - 10          Severe     >11 
  
HADS
0
5
10
15
20
pre cycle 5 8 7
pre cycle 6 6 4
post cycle 6 8 1
Anxiety Depression
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Appendix 9 Doctor Training Programme Manual 
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Appendix 10 Patient Perception of Patient Centredness 
Questionnaire 
 
Patient-Perception of Patient-Centredness Questionnaire 
 
1.  To what extent was your main problem(s) discussed today? 
      Completely  □     Mostly  □          A little  □       Not at all  □ 
 
2.  How satisfied were you with the discussion of your problem (s)? 
       Very satisfied  □    Satisfied  □     Somewhat satisfied  □      Not satisfied  □ 
 
3.  To what extent did the doctor listen to what you had to say? 
      Completely  □     Mostly  □          A little  □       Not at all  □ 
 
4.  To what extent did the doctor explain things to you? 
      Completely  □     Mostly  □          A little  □       Not at all  □ 
 
5.  To what extent did you and the doctor discuss your respective roles? (Who is responsible 
for making decisions   and who is responsible for what aspects of your care?) 
      Completely  □     Mostly  □          A little  □       Not discussed  □ 
 
6.  To what extent did the doctor explain treatment? 
       Very well  □     Well  □      Somewhat  □     Not at all  □      
 
7.  To what extent did the doctor explore how manageable this (treatment) would be for you? 
He/she explored this 
       Completely  □     Mostly  □          A little  □       Not at all  □ 
 
8.   How well do you think your doctor understood you today? 
       Very well  □     Well  □      Somewhat  □     Not at all  □    
 
9.  To what extent did the doctor discuss personal or family issues that might affect your 
health? 
       Completely  □     Mostly  □          A little  □       Not at all  □ 
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